Projects A-Z - Clinical Trials Arena

<!doctype html> <html lang="en-US"> <head> <script async src='https://securepubads.g.doubleclick.net/tag/js/gpt.js'></script> <style> .login-button a { display: block; width: 100%; height: 100%; } .login-button.logout-button i { font-size: 25px; margin-left: 0.6em; } .login-button.logout-button{ background: none !important; text-indent: 0 !important; } </style> <script> </script> <link href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,600;1,400;1,600&display=swap" rel="stylesheet"> <link rel='preload' id='fonts' href='https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/scss/fonts.css' media='all' as="style" onload="this.rel='stylesheet'"> <meta charset="UTF-8"> <meta http-equiv="x-ua-compatible" content="ie=edge" /><script type="text/javascript">(window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"1385880850",accountID:"3318845",trustKey:"66686",xpid:"VwUGWV5XDRABVlRSBAgPU1EE",licenseKey:"NRJS-7b82eb47d05ddffd6c6",applicationID:"1250398555"};;/*! For license information please see nr-loader-spa-1.281.0.min.js.LICENSE.txt */ (()=>{var e,t,r={8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{if(null===e[a]){r[a]=null;continue}Array.isArray(e[a])&&Array.isArray(t[a])?r[a]=Array.from(new Set([...e[a],...t[a]])):"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},2555:(e,t,r)=>{"use strict";r.d(t,{Vp:()=>c,fn:()=>s,x1:()=>u});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){try{const t=c(e);return!!t.licenseKey&&!!t.errorBeacon&&!!t.applicationID}catch(e){return!1}}function c(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function u(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.a)(t,o);const r=(0,n.nY)(e);r&&(r.info=a[e])}},9417:(e,t,r)=>{"use strict";r.d(t,{D0:()=>p,gD:()=>m,xN:()=>g});var n=r(3333),i=r(993);const o=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var a=r(2614),s=r(944),c=r(384),u=r(8122);const d="[data-nr-mask]",l=()=>{const e={feature_flags:[],experimental:{marks:!1,measures:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0,level:i.p_.INFO},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{get capture_marks(){return e.feature_flags.includes(n.$v.MARKS)||e.experimental.marks},set capture_marks(t){e.experimental.marks=t},get capture_measures(){return e.feature_flags.includes(n.$v.MEASURES)||e.experimental.measures},set capture_measures(t){e.experimental.measures=t},capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(n.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:a.wk,inactiveMs:a.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){o(t)?e.mask_selector="".concat(t,",").concat(d):""===t||null===t?e.mask_selector=d:(0,s.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){o(t)?e.block_selector+=",".concat(t):""!==t&&(0,s.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,s.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}},f={},h="All configuration objects require an agent identifier!";function p(e){if(!e)throw new Error(h);if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function g(e,t){if(!e)throw new Error(h);f[e]=(0,u.a)(t,l());const r=(0,c.nY)(e);r&&(r.init=f[e])}function m(e,t){if(!e)throw new Error(h);var r=p(e);if(r){for(var n=t.split("."),i=0;i<n.length-1;i++)if("object"!=typeof(r=r[n[i]]))return;r=r[n[n.length-1]]}return r}},5603:(e,t,r)=>{"use strict";r.d(t,{a:()=>c,o:()=>s});var n=r(384),i=r(8122);const o={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},a={};function s(e){if(!e)throw new Error("All loader-config objects require an agent identifier!");if(!a[e])throw new Error("LoaderConfig for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All loader-config objects require an agent identifier!");a[e]=(0,i.a)(t,o);const r=(0,n.nY)(e);r&&(r.loader_config=a[e])}},3371:(e,t,r)=>{"use strict";r.d(t,{V:()=>f,f:()=>l});var n=r(8122),i=r(384),o=r(6154),a=r(9324);let s=0;const c={buildEnv:a.F3,distMethod:a.Xs,version:a.xv,originTime:o.WN},u={customTransaction:void 0,disabled:!1,isolatedBacklog:!1,loaderType:void 0,maxBytes:3e4,onerror:void 0,ptid:void 0,releaseIds:{},appMetadata:{},session:void 0,denyList:void 0,timeKeeper:void 0,obfuscator:void 0,harvester:void 0},d={};function l(e){if(!e)throw new Error("All runtime objects require an agent identifier!");if(!d[e])throw new Error("Runtime for ".concat(e," was never set"));return d[e]}function f(e,t){if(!e)throw new Error("All runtime objects require an agent identifier!");d[e]={...(0,n.a)(t,u),...c},Object.hasOwnProperty.call(d[e],"harvestCount")||Object.defineProperty(d[e],"harvestCount",{get:()=>++s});const r=(0,i.nY)(e);r&&(r.runtime=d[e])}},9324:(e,t,r)=>{"use strict";r.d(t,{F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.281.0",i="PROD",o="CDN",a="^2.0.0-alpha.17"},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>s,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>a,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),a=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),s="complete"===a?.document?.readyState,c=Boolean("hidden"===a?.document?.visibilityState),u=""+a?.location,d=/iPad|iPhone|iPod/.test(a.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=a.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>a,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(s(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function a(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,a;i>0?(o=r.substring(0,i),a=r.substring(i)):(o=r,a="");let[s]=o.split(":");n.push({hostname:s,pathname:a})}}function s(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>c,Ze:()=>l,x3:()=>u});var n=r(7836),i=r(3606),o=r(860),a=r(2646);const s={};function c(e,t){const r={staged:!1,priority:o.P3[t]||0};d(e),s[e].get(t)||s[e].set(t,r)}function u(e,t){e&&s[e]&&(s[e].get(t)&&s[e].delete(t),h(e,t,!1),s[e].size&&f(e))}function d(e){if(!e)throw new Error("agentIdentifier required");s[e]||(s[e]=new Map)}function l(e="",t="feature",r=!1){if(d(e),!e||!s[e].get(t)||r)return h(e,t);s[e].get(t).staged=!0,f(e)}function f(e){const t=Array.from(s[e]);t.every((([e,t])=>t.staged))&&(t.sort(((e,t)=>e[1].priority-t[1].priority)),t.forEach((([t])=>{s[e].delete(t),h(e,t)})))}function h(e,t,r=!0){const o=e?n.ee.get(e):n.ee,s=i.i.handlers;if(!o.aborted&&o.backlog&&s){if(r){const e=o.backlog[t],r=s[t];if(r){for(let t=0;e&&t<e.length;++t)p(e[t],r);Object.entries(r).forEach((([e,t])=>{Object.values(t||{}).forEach((t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])}))}))}}o.isolatedBacklog||delete s[t],o.backlog[t]=null,o.emit("drain-"+t,[])}}function p(e,t){var r=e[1];Object.values(t[r]||{}).forEach((t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}}))}},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>c,ee:()=>u});var n=r(384),i=r(8990),o=r(3371),a=r(2646),s=r(5607);const c="nr@context:".concat(s.W),u=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&(0,o.f)(r).isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(u.aborted&&!i)return;t&&o&&t.emit(e,r,n);for(var a=h(n),c=g(e),d=c.length,l=0;l<d;l++)c[l].apply(a,r);var p=v()[s[e]];p&&p.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach((([e,n])=>{s[n]=t,t in r||(r[t]=[])}))},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach((e=>{delete f.backlog[e]}))},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof a.y?e:e?(0,i.I)(e,c,(()=>new a.y(c))):new a.y(c)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),d=(0,n.Zm)();d.ee||(d.ee=u)},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.d,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>s,ZF:()=>c,bz:()=>a,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map((e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const a=[];for(var s=0;s<e;s++)a.push(o(r,i++).toString(16));return a.join("")}function c(){return s(16)}function u(){return s(32)}},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>a,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>s,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,a=18e5,s={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},944:(e,t,r)=>{"use strict";function n(e,t){"function"==typeof console.debug&&console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t)}r.d(t,{R:()=>n})},5284:(e,t,r)=>{"use strict";r.d(t,{t:()=>c,B:()=>s});var n=r(7836),i=r(6154);const o="newrelic";const a=new Set,s={};function c(e,t){const r=n.ee.get(t);s[t]??={},e&&"object"==typeof e&&(a.has(t)||(r.emit("rumresp",[e]),s[t]=e,a.add(t),function(e={}){try{i.gm.dispatchEvent(new CustomEvent(o,{detail:e}))}catch(e){}}({loaded:!0})))}},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout((()=>{i=clearTimeout(i)}),t)),n||(clearTimeout(i),i=setTimeout((()=>{e.apply(this,r)}),t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,sB:()=>a});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function a(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}},384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>o,US:()=>d,Zm:()=>a,bQ:()=>c,dV:()=>s,nY:()=>u,pV:()=>l});var n=r(6154),i=r(1863);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function s(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket}),e}function c(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function u(e){let t=a();return t.initializedAgents?.[e]}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",(function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)}),r,i)}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),a=r(6154);const s={},c=a.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(s[t.debugId]++)return t;s[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(a.RI&&h(document,f),c&&h(c.prototype,f),h(a.gm,f)),t.on(u+"-start",(function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var i=(0,o.I)(n,l,(function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n}));this.wrapped=e[1]=i}})),t.on(d+"-start",(function(e){e[1]=this.wrapped||e[1]})),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>c});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W);var a=Object.prototype.hasOwnProperty,s=!1;function c(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const a="-"===n.charAt(0);for(let s=0;s<t.length;s++){const c=t[s],u=e[c];d(u)||(e[c]=r(u,a?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,s,c){return d(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach((function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})})),t}catch(e){u([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,d,l;try{a=this,o=[...arguments],d="function"==typeof n?n(o,a):n||{}}catch(t){u([t,"",[o,a,s],d],e)}i(r+"start",[o,a,s],d,c);try{return l=t.apply(a,o)}catch(e){throw i(r+"err",[o,a,e],d,c),e}finally{i(r+"end",[o,a,l],d,c)}}}function i(r,n,i,o){if(!s||t){var a=s;s=!0;try{e.emit(r,n,i,t,o)}catch(t){u([t,r,n,i],e)}s=a}}}function u(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function d(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>u,TZ:()=>n,Zp:()=>i,kd:()=>c,mq:()=>s,nf:()=>a,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],a=4,s=1e3,c=["PageAction","UserAction","BrowserPerformance"],u={MARKS:"experimental.marks",MEASURES:"experimental.measures",RESOURCES:"experimental.resources"}},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},993:(e,t,r)=>{"use strict";r.d(t,{ET:()=>o,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o="log",a=n.K7.logging},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),a=r(3969),s=r(993);function c(e,t,r={},c=s.p_.INFO){(0,n.p)(a.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(s.ET,[(0,i.t)(),t,r,c],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(s.p_).some((t=>t===e.toUpperCase().trim()))}},3969:(e,t,r)=>{"use strict";r.d(t,{TZ:()=>n,XG:()=>s,rs:()=>i,xV:()=>a,z_:()=>o});const n=r(860).K7.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,G4:()=>o,Qb:()=>l,TZ:()=>i,Ug:()=>a,_s:()=>s,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o={RECORD:"recordReplay",PAUSE:"pauseReplay",REPLAY_RUNNING:"replayRunning",ERROR_DURING_REPLAY:"errorDuringReplay"},a=.12,s={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api"}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>c,CT:()=>u,SR:()=>s});var n=r(384),i=r(9417),o=r(7767),a=r(6154);function s(e){return!!(0,n.dV)().o.MO&&(0,o.V)(e)&&!0===(0,i.gD)(e,"session_trace.enabled")}function c(e){return!0===(0,i.gD)(e,"session_replay.preload")&&s(e)}function u(e,t){const r=t.correctAbsoluteTimestamp(e);return{originalTimestamp:e,correctedTimestamp:r,timestampDiff:e-r,originTime:a.WN,correctedOriginTime:t.correctedOriginTime,originTimeDiff:Math.floor(a.WN-t.correctedOriginTime)}}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>s,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>a,jx:()=>l,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState",l=1e3},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>o,O2:()=>c,Qu:()=>u,TZ:()=>s,ih:()=>d,pP:()=>a,tC:()=>i});var n=r(860);const i=["click","keydown","submit","popstate"],o="api",a="initialPageLoad",s=n.K7.softNav,c={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},u={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},d={IP:"in progress",FIN:"finished",CAN:"cancelled"}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>T,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>s,wW:()=>E,xq:()=>a});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",E="cb"+R,T="jsTime",A="fetch"},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>o});var n=r(9417),i=r(6154);const o=e=>i.RI&&!0===(0,n.gD)(e,"privacy.cookies_enabled")},425:(e,t,r)=>{"use strict";r.d(t,{j:()=>j});var n=r(860),i=r(2555),o=r(3371),a=r(9908),s=r(7836),c=r(1687),u=r(5289),d=r(6154),l=r(944),f=r(3969),h=r(384),p=r(6344);const g=["setErrorHandler","finished","addToTrace","addRelease","recordCustomEvent","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId","setApplicationVersion","start",p.G4.RECORD,p.G4.PAUSE,"log","wrapLogger"],m=["setErrorHandler","finished","addToTrace","addRelease"];var v=r(1863),b=r(2614),y=r(993),w=r(3785),R=r(2646),x=r(3434);const E=new Map;function T(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||s.ee).get("logger")}(e),o=(0,x.YM)(i),a=new R.y(s.P);a.level=n.level,a.customAttributes=n.customAttributes;const c=t[r]?.[x.Jt]||t[r];return E.set(c,a),o.inPlace(t,[r],"wrap-logger-",(()=>E.get(c))),i}function A(){const e=(0,h.pV)();g.forEach((t=>{e[t]=(...r)=>function(t,...r){let n=[];return Object.values(e.initializedAgents).forEach((e=>{e&&e.api?e.exposed&&e.api[t]&&n.push(e.api[t](...r)):(0,l.R)(38,t)})),n.length>1?n:n[0]}(t,...r)}))}const S={};var N=r(9417),_=r(5603),O=r(5284);const I=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};let P=!1;function j(e,t={},g,R){let{init:x,info:E,loader_config:j,runtime:C={},exposed:k=!0}=t;C.loaderType=g;const L=(0,h.pV)();E||(x=L.init,E=L.info,j=L.loader_config),(0,N.xN)(e.agentIdentifier,x||{}),(0,_.a)(e.agentIdentifier,j||{}),E.jsAttributes??={},d.bv&&(E.jsAttributes.isWorker=!0),(0,i.x1)(e.agentIdentifier,E);const H=(0,N.D0)(e.agentIdentifier),M=[E.beacon,E.errorBeacon];P||(H.proxy.assets&&(I(H.proxy.assets),M.push(H.proxy.assets)),H.proxy.beacon&&M.push(H.proxy.beacon),A(),(0,h.US)("activatedFeatures",O.B),e.runSoftNavOverSpa&&=!0===H.soft_navigations.enabled&&H.feature_flags.includes("soft_nav")),C.denyList=[...H.ajax.deny_list||[],...H.ajax.block_internal?M:[]],C.ptid=e.agentIdentifier,(0,o.V)(e.agentIdentifier,C),e.ee=s.ee.get(e.agentIdentifier),void 0===e.api&&(e.api=function(e,t,h=!1){t||(0,c.Ak)(e,"api");const g={};var R=s.ee.get(e),x=R.get("tracer");S[e]=b.g.OFF,R.on(p.G4.REPLAY_RUNNING,(t=>{S[e]=t}));var E="api-",A=E+"ixn-";function N(t,r,n,o){const a=(0,i.Vp)(e);return null===r?delete a.jsAttributes[t]:(0,i.x1)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),I(E,n,!0,o||null===r?"session":void 0)(t,r)}function _(){}g.log=function(e,{customAttributes:t={},level:r=y.p_.INFO}={}){(0,a.p)(f.xV,["API/log/called"],void 0,n.K7.metrics,R),(0,w.R)(R,e,t,r)},g.wrapLogger=(e,t,{customAttributes:r={},level:i=y.p_.INFO}={})=>{(0,a.p)(f.xV,["API/wrapLogger/called"],void 0,n.K7.metrics,R),T(R,e,t,{customAttributes:r,level:i})},m.forEach((e=>{g[e]=I(E,e,!0,"api")})),g.addPageAction=I(E,"addPageAction",!0,n.K7.genericEvents),g.recordCustomEvent=I(E,"recordCustomEvent",!0,n.K7.genericEvents),g.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,o.f)(e).customTransaction=(r||"http://custom.transaction")+t,I(E,"setPageViewName",!0)()},g.setCustomAttribute=function(e,t,r=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof t)||null===t)return N(e,t,"setCustomAttribute",r);(0,l.R)(40,typeof t)}else(0,l.R)(39,typeof e)},g.setUserId=function(e){if("string"==typeof e||null===e)return N("enduser.id",e,"setUserId",!0);(0,l.R)(41,typeof e)},g.setApplicationVersion=function(e){if("string"==typeof e||null===e)return N("application.version",e,"setApplicationVersion",!1);(0,l.R)(42,typeof e)},g.start=()=>{try{(0,a.p)(f.xV,["API/start/called"],void 0,n.K7.metrics,R),R.emit("manual-start-all")}catch(e){(0,l.R)(23,e)}},g[p.G4.RECORD]=function(){(0,a.p)(f.xV,["API/recordReplay/called"],void 0,n.K7.metrics,R),(0,a.p)(p.G4.RECORD,[],void 0,n.K7.sessionReplay,R)},g[p.G4.PAUSE]=function(){(0,a.p)(f.xV,["API/pauseReplay/called"],void 0,n.K7.metrics,R),(0,a.p)(p.G4.PAUSE,[],void 0,n.K7.sessionReplay,R)},g.interaction=function(e){return(new _).get("object"==typeof e?e:{})};const O=_.prototype={createTracer:function(e,t){var r={},i=this,o="function"==typeof t;return(0,a.p)(f.xV,["API/createTracer/called"],void 0,n.K7.metrics,R),h||(0,a.p)(A+"tracer",[(0,v.t)(),e,r],i,n.K7.spa,R),function(){if(x.emit((o?"":"no-")+"fn-start",[(0,v.t)(),i,o],r),o)try{return t.apply(this,arguments)}catch(e){const t="string"==typeof e?new Error(e):e;throw x.emit("fn-err",[arguments,this,t],r),t}finally{x.emit("fn-end",[(0,v.t)()],r)}}}};function I(e,t,r,i){return function(){return(0,a.p)(f.xV,["API/"+t+"/called"],void 0,n.K7.metrics,R),i&&(0,a.p)(e+t,[r?(0,v.t)():performance.now(),...arguments],r?null:this,i,R),r?void 0:this}}function P(){r.e(478).then(r.bind(r,8778)).then((({setAPI:t})=>{t(e),(0,c.Ze)(e,"api")})).catch((e=>{(0,l.R)(27,e),R.abort()}))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{O[e]=I(A,e,void 0,h?n.K7.softNav:n.K7.spa)})),g.setCurrentRouteName=h?I(A,"routeName",void 0,n.K7.softNav):I(E,"routeName",!0,n.K7.spa),g.noticeError=function(t,r){"string"==typeof t&&(t=new Error(t)),(0,a.p)(f.xV,["API/noticeError/called"],void 0,n.K7.metrics,R),(0,a.p)("err",[t,(0,v.t)(),!1,r,!!S[e]],void 0,n.K7.jserrors,R)},d.RI?(0,u.GG)((()=>P()),!0):P(),g}(e.agentIdentifier,R,e.runSoftNavOverSpa)),void 0===e.exposed&&(e.exposed=k),P=!0}},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>u,K7:()=>s,P3:()=>c,XX:()=>i,qY:()=>n,v4:()=>a});const n="events",i="jserrors",o="browser/blobs",a="rum",s={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},c={[s.pageViewEvent]:1,[s.pageViewTiming]:2,[s.metrics]:3,[s.jserrors]:4,[s.spa]:5,[s.ajax]:6,[s.sessionTrace]:7,[s.softNav]:8,[s.sessionReplay]:9,[s.logging]:10,[s.genericEvents]:11},u={[s.pageViewEvent]:a,[s.pageViewTiming]:n,[s.ajax]:n,[s.spa]:n,[s.softNav]:n,[s.metrics]:i,[s.jserrors]:i,[s.sessionTrace]:o,[s.sessionReplay]:o,[s.logging]:"browser/logs",[s.genericEvents]:"ins"}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.281.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.281.0.PROD:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){s=l;break}}if(!s){c=!0;var f={478:"sha512-jmvAlmjCn64ans8tLueqHRlBI/iWekylsDWb94A77CG0ukSriVDvgD3dThx+XjUSBBBMYhFn8B1a18fViyBPEQ==",249:"sha512-ICY/ZrcytM/86t5KFy+9OAWVYmNNJy10EBtxoSUGjQWuZx53p/eLo+L8HfrGjvHuRHRnutqLTGSnvNttffJkaA==",212:"sha512-pQSn+X/RfBOvx/49HvlghaiXMLhhDQXTi13n1N2XMpDquWJgs9U0pbqE3RbAnYC9nsdaTu/RVGvneEPv1fpCxA=="};(s=document.createElement("script")).charset="utf-8",s.timeout=120,i.nc&&s.setAttribute("nonce",i.nc),s.setAttribute("data-webpack",t+o),s.src=r,0!==s.src.indexOf(window.location.origin+"/")&&(s.crossOrigin="anonymous"),f[a]&&(s.integrity=f[a])}e[r]=[n];var h=(t,n)=>{s.onerror=s.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=h.bind(null,s.onerror),s.onload=h.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u<a.length;u++)o=a[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.281.0.PROD"]=self["webpackChunk:NRBA-1.281.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(944),t=i(6344),r=i(9566);class n{agentIdentifier;constructor(){this.agentIdentifier=(0,r.LA)(16)}#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}addPageAction(e,t){return this.#e("addPageAction",e,t)}recordCustomEvent(e,t){return this.#e("recordCustomEvent",e,t)}setPageViewName(e,t){return this.#e("setPageViewName",e,t)}setCustomAttribute(e,t,r){return this.#e("setCustomAttribute",e,t,r)}noticeError(e,t){return this.#e("noticeError",e,t)}setUserId(e){return this.#e("setUserId",e)}setApplicationVersion(e){return this.#e("setApplicationVersion",e)}setErrorHandler(e){return this.#e("setErrorHandler",e)}addRelease(e,t){return this.#e("addRelease",e,t)}log(e,t){return this.#e("log",e,t)}}class o extends n{#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}start(){return this.#e("start")}finished(e){return this.#e("finished",e)}recordReplay(){return this.#e(t.G4.RECORD)}pauseReplay(){return this.#e(t.G4.PAUSE)}addToTrace(e){return this.#e("addToTrace",e)}setCurrentRouteName(e){return this.#e("setCurrentRouteName",e)}interaction(){return this.#e("interaction")}wrapLogger(e,t,r){return this.#e("wrapLogger",e,t,r)}}var a=i(860),s=i(9417);const c=Object.values(a.K7);function u(e){const t={};return c.forEach((r=>{t[r]=function(e,t){return!0===(0,s.gD)(t,"".concat(e,".enabled"))}(r,e)})),t}var d=i(425);var l=i(1687),f=i(4234),h=i(5289),p=i(6154),g=i(5270),m=i(7767),v=i(6389);class b extends f.W{constructor(e,t,r=!0){super(e.agentIdentifier,t),this.auto=r,this.abortHandler=void 0,this.featAggregate=void 0,this.onAggregateImported=void 0,!1===e.init[this.featureName].autoStart&&(this.auto=!1),this.auto?(0,l.Ak)(e.agentIdentifier,t):this.ee.on("manual-start-all",(0,v.J)((()=>{(0,l.Ak)(e.agentIdentifier,this.featureName),this.auto=!0,this.importAggregator(e)})))}importAggregator(t,r={}){if(this.featAggregate||!this.auto)return;let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let o;try{if((0,m.V)(this.agentIdentifier)){const{setupAgentSession:e}=await i.e(478).then(i.bind(i,6526));o=e(t)}}catch(t){(0,e.R)(20,t),this.ee.emit("internal-error",[t]),this.featureName===a.K7.sessionReplay&&this.abortHandler?.()}try{if(!this.#t(this.featureName,o))return(0,l.Ze)(this.agentIdentifier,this.featureName),void n(!1);const{lazyFeatureLoader:e}=await i.e(478).then(i.bind(i,6103)),{Aggregate:a}=await e(this.featureName,"aggregate");this.featAggregate=new a(t,r),t.runtime.harvester.initializedAggregates.push(this.featAggregate),n(!0)}catch(t){(0,e.R)(34,t),this.abortHandler?.(),(0,l.Ze)(this.agentIdentifier,this.featureName,!0),n(!1),this.ee&&this.ee.abort()}};p.RI?(0,h.GG)((()=>o()),!0):o()}#t(e,t){switch(e){case a.K7.sessionReplay:return(0,g.SR)(this.agentIdentifier)&&!!t;case a.K7.sessionTrace:return!!t;default:return!0}}}var y=i(6630);class w extends b{static featureName=y.T;constructor(e,t=!0){super(e,y.T,t),this.importAggregator(e)}}var R=i(384);var x=i(9908),E=i(2843),T=i(3878),A=i(782),S=i(1863);class N extends b{static featureName=A.T;constructor(e,t=!0){super(e,A.T,t),p.RI&&((0,E.u)((()=>(0,x.p)("docHidden",[(0,S.t)()],void 0,A.T,this.ee)),!0),(0,T.sp)("pagehide",(()=>(0,x.p)("winPagehide",[(0,S.t)()],void 0,A.T,this.ee))),this.importAggregator(e))}}var _=i(3969);class O extends b{static featureName=_.TZ;constructor(e,t=!0){super(e,_.TZ,t),this.importAggregator(e)}}var I=i(6774),P=i(3304);class j{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,P.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function C(e){return H(e)?e:new j(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic)}function k(e){const t="Unhandled Promise Rejection";if(!e?.reason)return;if(H(e.reason))try{return e.reason.message=t+": "+e.reason.message,C(e.reason)}catch(t){return C(e.reason)}const r=C(e.reason);return r.message=t+": "+r?.message,r}function L(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new j(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic);return t.name=SyntaxError.name,t}return H(e.error)?e.error:C(e)}function H(e){return e instanceof Error&&!!e.stack}class M extends b{static featureName=I.T;#r=!1;constructor(e,r=!0){super(e,I.T,r);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",((e,t)=>{this.abortHandler&&(0,x.p)("ierr",[C(e),(0,S.t)(),!0,{},this.#r,t],void 0,this.featureName,this.ee)})),this.ee.on(t.G4.REPLAY_RUNNING,(e=>{this.#r=e})),p.gm.addEventListener("unhandledrejection",(e=>{this.abortHandler&&(0,x.p)("err",[k(e),(0,S.t)(),!1,{unhandledPromiseRejection:1},this.#r],void 0,this.featureName,this.ee)}),(0,T.jT)(!1,this.removeOnAbort?.signal)),p.gm.addEventListener("error",(e=>{this.abortHandler&&(0,x.p)("err",[L(e),(0,S.t)(),!1,{},this.#r],void 0,this.featureName,this.ee)}),(0,T.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e)}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var D=i(8990);let K=1;const U="nr@id";function V(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===p.gm?0:(0,D.I)(e,U,(function(){return K++}))}function G(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,P.A)(e).length}catch(e){return}}}var F=i(8139),B=i(7836),W=i(3434);const z={},q=["open","send"];function Z(t){var r=t||B.ee;const n=function(e){return(e||B.ee).get("xhr")}(r);if(void 0===p.gm.XMLHttpRequest)return n;if(z[n.debugId]++)return n;z[n.debugId]=1,(0,F.u)(r);var i=(0,W.YM)(n),o=p.gm.XMLHttpRequest,a=p.gm.MutationObserver,s=p.gm.Promise,c=p.gm.setInterval,u="readystatechange",d=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],l=[],f=p.gm.XMLHttpRequest=function(t){const r=new o(t),a=n.context(r);try{n.emit("new-xhr",[r],a),r.addEventListener(u,(s=a,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,n.emit("xhr-resolved",[],e)),i.inPlace(e,d,"fn-",y)}),(0,T.jT)(!1))}catch(t){(0,e.R)(15,t);try{n.emit("internal-error",[t])}catch(e){}}var s;return r};function h(e,t){i.inPlace(t,["onreadystatechange"],"fn-",y)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,f),f.prototype=o.prototype,i.inPlace(f.prototype,q,"-xhr-",y),n.on("send-xhr-start",(function(e,t){h(e,t),function(e){l.push(e),a&&(g?g.then(b):c?c(b):(m=-m,v.data=m))}(t)})),n.on("open-xhr-start",h),a){var g=s&&s.resolve();if(!c&&!s){var m=1,v=document.createTextNode(m);new a(b).observe(v,{characterData:!0})}}else r.on("fn-end",(function(e){e[0]&&e[0].type===u||b()}));function b(){for(var e=0;e<l.length;e++)h(0,l[e]);l.length&&(l=[])}function y(e,t){return t}return n}var Y="fetch-",X=Y+"body-",J=["arrayBuffer","blob","json","text","formData"],Q=p.gm.Request,ee=p.gm.Response,te="prototype";const re={};function ne(e){const t=function(e){return(e||B.ee).get("fetch")}(e);if(!(Q&&ee&&p.gm.fetch))return t;if(re[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[B.P]&&o[B.P].dt&&(e=o[B.P].dt);var a=i.apply(this,r);return t.emit(n+"start",[r,e],a),a.then((function(e){return t.emit(n+"end",[null,e],a),e}),(function(e){throw t.emit(n+"end",[e],a),e}))})}return re[t.debugId]=1,J.forEach((e=>{r(Q[te],e,X),r(ee[te],e,X)})),r(p.gm,"fetch",Y),t.on(Y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(Y+"done",[null,r],n)}else t.emit(Y+"done",[e],n)})),t}var ie=i(7485),oe=i(5603);class ae{constructor(e){this.agentIdentifier=e}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var t=(0,oe.o)(this.agentIdentifier);if(!t)return null;var n=(t.accountID||"").toString()||null,i=(t.agentID||"").toString()||null,o=(t.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,r.ZF)(),s=(0,r.el)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof p.gm?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,P.A)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1,r={};if((0,s.gD)(this.agentIdentifier,"distributed_tracing")&&(r=(0,s.D0)(this.agentIdentifier).distributed_tracing),e.sameOrigin)t=!0;else if(r.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ie.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}isDtEnabled(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.enabled}excludeNewrelicHeader(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.cors_use_tracecontext_headers}}var se=i(9300),ce=i(7295),ue=["load","error","abort","timeout"],de=ue.length,le=(0,R.dV)().o.REQ,fe=(0,R.dV)().o.XHR;class he extends b{static featureName=se.T;constructor(e,t=!0){super(e,se.T,t),this.dt=new ae(e.agentIdentifier),this.handler=(e,t,r,n)=>(0,x.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};p.gm?.performance?.getEntriesByType("resource").forEach((t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},n={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};pe(r,t.name),this.handler("xhr",[r,n,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,a.K7.ajax)}}))}catch(e){}ne(this.ee),Z(this.ee),function(e,t,r,n){function i(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=R,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){E(t,e)}),(0,T.jT)(!1)),p.lR||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,T.jT)(!1))}function o(e){this.params={method:e[0]},pe(this,e[1]),this.metrics={}}function s(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var i=n.generateTracePayload(this.parsedOrigin);if(i){var o=!1;i.newrelicHeader&&(r.setRequestHeader("newrelic",i.newrelicHeader),o=!0),i.traceContextParentHeader&&(r.setRequestHeader("traceparent",i.traceContextParentHeader),i.traceContextStateHeader&&r.setRequestHeader("tracestate",i.traceContextStateHeader),o=!0),o&&(this.dt=i)}}function c(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var a=G(i);a&&(n.txSize=a)}this.startTime=(0,S.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var s=0;s<de;s++)r.addEventListener(ue[s],this.listener,(0,T.jT)(!1))}function u(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function d(e,t){var r=""+V(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function l(e,t){var r=""+V(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function f(){this.endTime=(0,S.t)()}function h(e,r){r instanceof fe&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function g(e,r){r instanceof fe&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function m(e,t,r){t instanceof fe&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,S.t)()))}function v(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,S.t)()-this.xhrCbStart,this.onload,r],r)}function b(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&p.RI&&(t=""+p.gm.location.href):e[0]&&e[0].url?t=e[0].url:p.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ie.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var i=n.generateTracePayload(this.parsedOrigin);if(i&&(i.newrelicHeader||i.traceContextParentHeader))if(e[0]&&e[0].headers)s(e[0].headers,i)&&(this.dt=i);else{var o={};for(var a in r)o[a]=r[a];o.headers=new Headers(r.headers||{}),s(o.headers,i)&&(this.dt=i),e.length>1?e[1]=o:e.push(o)}}function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function y(e,t){this.params={},this.metrics={},this.startTime=(0,S.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof le?r=i.url:p.gm?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),pe(this,r);var o=(""+(i&&i instanceof le&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.body=n.body,this.txSize=G(n.body)||0}function w(e,t){if(this.endTime=(0,S.t)(),this.params||(this.params={}),(0,ce.iW)(this.params))return;let n;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);const i={txSize:this.txSize,rxSize:n,duration:(0,S.t)()-this.startTime};r("xhr",[this.params,i,this.startTime,this.endTime,"fetch"],this,a.K7.ajax)}function R(e){const t=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<de;t++)e.removeEventListener(ue[t],this.listener,!1);t.aborted||(0,ce.iW)(t)||(n.duration=(0,S.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):E(this,e),n.cbTime=this.cbTime,r("xhr",[t,n,this.startTime,this.endTime,"xhr"],this,a.K7.ajax))}}function E(e,r){e.params.status=r.status;var n=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?G(e.response):"text"===r||""===r||void 0===r?G(e.responseText):void 0}(r,e.lastSize);if(n&&(e.metrics.rxSize=n),e.sameOrigin){var i=r.getResponseHeader("X-NewRelic-App-Data");i&&((0,x.p)(_.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,a.K7.metrics,t),e.params.cat=i.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",i),t.on("open-xhr-start",o),t.on("open-xhr-end",s),t.on("send-xhr-start",c),t.on("xhr-cb-time",u),t.on("xhr-load-added",d),t.on("xhr-load-removed",l),t.on("xhr-resolved",f),t.on("addEventListener-end",h),t.on("removeEventListener-end",g),t.on("fn-end",v),t.on("fetch-before-start",b),t.on("fetch-start",y),t.on("fn-start",m),t.on("fetch-done",w)}(e,this.ee,this.handler,this.dt),this.importAggregator(e)}}function pe(e,t){var r=(0,ie.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const ge={},me=["pushState","replaceState"];function ve(e){const t=function(e){return(e||B.ee).get("history")}(e);return!p.RI||ge[t.debugId]++||(ge[t.debugId]=1,(0,W.YM)(t).inPlace(window.history,me,"-")),t}var be=i(3738);const{He:ye,bD:we,d3:Re,Kp:xe,TZ:Ee,Lc:Te,uP:Ae,Rz:Se}=be;class Ne extends b{static featureName=Ee;constructor(e,t=!0){super(e,Ee,t);if(!(0,m.V)(this.agentIdentifier))return void this.deregisterDrain();const r=this.ee;let n;ve(r),this.eventsEE=(0,F.u)(r),this.eventsEE.on(Ae,(function(e,t){this.bstStart=(0,S.t)()})),this.eventsEE.on(Te,(function(e,t){(0,x.p)("bst",[e[0],t,this.bstStart,(0,S.t)()],void 0,a.K7.sessionTrace,r)})),r.on(Se+Re,(function(e){this.time=(0,S.t)(),this.startPath=location.pathname+location.hash})),r.on(Se+xe,(function(e){(0,x.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,a.K7.sessionTrace,r)}));try{n=new PerformanceObserver((e=>{const t=e.getEntries();(0,x.p)(ye,[t],void 0,a.K7.sessionTrace,r)})),n.observe({type:we,buffered:!0})}catch(e){}this.importAggregator(e,{resourceObserver:n})}}var _e=i(2614);class Oe extends b{static featureName=t.TZ;#i;#o;constructor(e,r=!0){let n;super(e,t.TZ,r),this.replayRunning=!1,this.#o=e;try{n=JSON.parse(localStorage.getItem("".concat(_e.H3,"_").concat(_e.uh)))}catch(e){}(0,g.SR)(e.agentIdentifier)&&this.ee.on(t.G4.RECORD,(()=>this.#a())),this.#s(n)?(this.#i=n?.sessionReplayMode,this.#c()):this.importAggregator(e),this.ee.on("err",(e=>{this.replayRunning&&(this.errorNoticed=!0,(0,x.p)(t.G4.ERROR_DURING_REPLAY,[e],void 0,this.featureName,this.ee))})),this.ee.on(t.G4.REPLAY_RUNNING,(e=>{this.replayRunning=e}))}#s(e){return e&&(e.sessionReplayMode===_e.g.FULL||e.sessionReplayMode===_e.g.ERROR)||(0,g.Aw)(this.agentIdentifier)}#u=!1;async#c(e){if(!this.#u){this.#u=!0;try{const{Recorder:t}=await Promise.all([i.e(478),i.e(249)]).then(i.bind(i,8589));this.recorder??=new t({mode:this.#i,agentIdentifier:this.agentIdentifier,trigger:e,ee:this.ee,agentRef:this.#o}),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording}catch(e){}this.importAggregator(this.#o,{recorder:this.recorder,errorNoticed:this.errorNoticed})}}#a(){this.featAggregate?this.featAggregate.mode!==_e.g.FULL&&this.featAggregate.initializeRecording(_e.g.FULL,!0):(this.#i=_e.g.FULL,this.#c(t.Qb.API),this.recorder&&this.recorder.parent.mode!==_e.g.FULL&&(this.recorder.parent.mode=_e.g.FULL,this.recorder.stopRecording(),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording))}}var Ie=i(3962);class Pe extends b{static featureName=Ie.TZ;constructor(e,t=!0){if(super(e,Ie.TZ,t),!p.RI||!(0,R.dV)().o.MO)return;const r=ve(this.ee);Ie.tC.forEach((e=>{(0,T.sp)(e,(e=>{a(e)}),!0)}));const n=()=>(0,x.p)("newURL",[(0,S.t)(),""+window.location],void 0,this.featureName,this.ee);r.on("pushState-end",n),r.on("replaceState-end",n);try{this.removeOnAbort=new AbortController}catch(e){}(0,T.sp)("popstate",(e=>(0,x.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)),!0,this.removeOnAbort?.signal);let i=!1;const o=new((0,R.dV)().o.MO)(((e,t)=>{i||(i=!0,requestAnimationFrame((()=>{(0,x.p)("newDom",[(0,S.t)()],void 0,this.featureName,this.ee),i=!1})))})),a=(0,v.s)((e=>{(0,x.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})}),100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,{domObserver:o})}}var je=i(7378);const Ce={},ke=["appendChild","insertBefore","replaceChild"];function Le(e){const t=function(e){return(e||B.ee).get("jsonp")}(e);if(!p.RI||Ce[t.debugId])return t;Ce[t.debugId]=!0;var r=(0,W.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function a(e,t){if(!e)return t;const r=e.match(o),n=r[1];return a(r[3],t[n])}return r.inPlace(Node.prototype,ke,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(s=e.src,c=s.match(n),c?c[1]:null);var s,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:a(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,T.jT)(!1)),e.removeEventListener("error",f,(0,T.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,T.jT)(!1)),e.removeEventListener("error",f,(0,T.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,T.jT)(!1)),e.addEventListener("error",f,(0,T.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}const He={};function Me(e){const t=function(e){return(e||B.ee).get("promise")}(e);if(He[t.debugId])return t;He[t.debugId]=!0;var r=t.context,n=(0,W.YM)(t),i=p.gm.Promise;return i&&function(){function e(r){var o=t.context(),a=n(r,"executor-",o,null,!1);const s=Reflect.construct(i,[a],e);return t.context(s).getCtx=function(){return o},s}p.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach((function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,a=r(i);a.promise=i,e[0]=n(e[0],"cb-",a,null,!1),e[1]=n(e[1],"cb-",a,null,!1);const s=o.apply(this,e);return a.nextPromise=s,t.emit("propagate",[i,!0],s,!1,!1),s},i.prototype.then[W.Jt]=o,t.on("executor-start",(function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)})),t.on("executor-err",(function(e,t,r){e[1](r)})),t.on("cb-end",(function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)})),t.on("propagate",(function(e,r,n){this.getCtx&&!r||(this.getCtx=function(){if(e instanceof Promise)var r=t.context(e);return r&&r.getCtx?r.getCtx():this})}))}(),t}const De={},Ke="setTimeout",Ue="setInterval",Ve="clearTimeout",Ge="-start",Fe=[Ke,"setImmediate",Ue,Ve,"clearImmediate"];function Be(e){const t=function(e){return(e||B.ee).get("timer")}(e);if(De[t.debugId]++)return t;De[t.debugId]=1;var r=(0,W.YM)(t);return r.inPlace(p.gm,Fe.slice(0,2),Ke+"-"),r.inPlace(p.gm,Fe.slice(2,3),Ue+"-"),r.inPlace(p.gm,Fe.slice(3),Ve+"-"),t.on(Ue+Ge,(function(e,t,n){e[0]=r(e[0],"fn-",null,n)})),t.on(Ke+Ge,(function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)})),t}const We={};function ze(e){const t=function(e){return(e||B.ee).get("mutation")}(e);if(!p.RI||We[t.debugId])return t;We[t.debugId]=!0;var r=(0,W.YM)(t),n=p.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:qe,d3:Ze,Kp:Ye,$p:Xe,wW:$e,e5:Je,tH:Qe,uP:et,rw:tt,Lc:rt}=je;class nt extends b{static featureName=qe;constructor(e,t=!0){if(super(e,qe,t),!p.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let r,n=0;const i=this.ee.get("tracer"),o=Le(this.ee),a=Me(this.ee),s=Be(this.ee),c=Z(this.ee),u=this.ee.get("events"),d=ne(this.ee),l=ve(this.ee),f=ze(this.ee);function h(e,t){l.emit("newURL",[""+window.location,t])}function g(){n++,r=window.location.hash,this[et]=(0,S.t)()}function m(){n--,window.location.hash!==r&&h(0,!0);var e=(0,S.t)();this[Je]=~~this[Je]+e-this[et],this[rt]=e}function v(e,t){e.on(t,(function(){this[t]=(0,S.t)()}))}this.ee.on(et,g),a.on(tt,g),o.on(tt,g),this.ee.on(rt,m),a.on($e,m),o.on($e,m),this.ee.on("fn-err",((...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,x.p)("function-err",[...t],void 0,this.featureName,this.ee)})),this.ee.buffer([et,rt,"xhr-resolved"],this.featureName),u.buffer([et],this.featureName),s.buffer(["setTimeout"+Ye,"clearTimeout"+Ze,et],this.featureName),c.buffer([et,"new-xhr","send-xhr"+Ze],this.featureName),d.buffer([Qe+Ze,Qe+"-done",Qe+Xe+Ze,Qe+Xe+Ye],this.featureName),l.buffer(["newURL"],this.featureName),f.buffer([et],this.featureName),a.buffer(["propagate",tt,$e,"executor-err","resolve"+Ze],this.featureName),i.buffer([et,"no-"+et],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),v(d,Qe+Ze),v(d,Qe+"-done"),v(o,"new-jsonp"),v(o,"jsonp-end"),v(o,"cb-start"),l.on("pushState-end",h),l.on("replaceState-end",h),window.addEventListener("hashchange",h,(0,T.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",h,(0,T.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){h(0,n>1)}),(0,T.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e)}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var it=i(3333);class ot extends b{static featureName=it.TZ;constructor(e,t=!0){super(e,it.TZ,t);const r=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];if(p.RI&&(e.init.user_actions.enabled&&(it.Zp.forEach((e=>(0,T.sp)(e,(e=>(0,x.p)("ua",[e],void 0,this.featureName,this.ee)),!0))),it.qN.forEach((e=>{const t=(0,v.s)((e=>{(0,x.p)("ua",[e],void 0,this.featureName,this.ee)}),500,{leading:!0});(0,T.sp)(e,t)}))),e.init.performance.resources.enabled&&p.gm.PerformanceObserver?.supportedEntryTypes.includes("resource"))){new PerformanceObserver((e=>{e.getEntries().forEach((e=>{(0,x.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)}))})).observe({type:"resource",buffered:!0})}r.some((e=>e))?this.importAggregator(e):this.deregisterDrain()}}var at=i(993),st=i(3785);class ct extends b{static featureName=at.TZ;constructor(e,t=!0){super(e,at.TZ,t);const r=this.ee;this.ee.on("wrap-logger-end",(function([e]){const{level:t,customAttributes:n}=this;(0,st.R)(r,e,n,t)})),this.importAggregator(e)}}new class extends o{constructor(t){super(),p.gm?(this.features={},(0,R.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(t.features||[]),this.desiredFeatures.add(w),this.runSoftNavOverSpa=[...this.desiredFeatures].some((e=>e.featureName===a.K7.softNav)),(0,d.j)(this,t,t.loaderType||"agent"),this.run()):(0,e.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}run(){try{const t=u(this.agentIdentifier),r=[...this.desiredFeatures];r.sort(((e,t)=>a.P3[e.featureName]-a.P3[t.featureName])),r.forEach((r=>{if(!t[r.featureName]&&r.featureName!==a.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&r.featureName===a.K7.spa)return;if(!this.runSoftNavOverSpa&&r.featureName===a.K7.softNav)return;const n=function(e){switch(e){case a.K7.ajax:return[a.K7.jserrors];case a.K7.sessionTrace:return[a.K7.ajax,a.K7.pageViewEvent];case a.K7.sessionReplay:return[a.K7.sessionTrace];case a.K7.pageViewTiming:return[a.K7.pageViewEvent];default:return[]}}(r.featureName).filter((e=>!(e in this.features)));n.length>0&&(0,e.R)(36,{targetFeature:r.featureName,missingDependencies:n}),this.features[r.featureName]=new r(this)}))}catch(t){(0,e.R)(22,t);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,R.Zm)();delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return r.ee.get(this.agentIdentifier).abort(),!1}}}({features:[he,w,N,Ne,Oe,O,M,ot,ct,Pe,nt],loaderType:"spa"})})()})();</script> <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=1"> <meta name="pocket-site-verification" content="" /> <script> (function (html) { html.className = html.className.replace(/\bno-js\b/, 'js'); })(document.documentElement); </script> <link rel="profile" href="https://gmpg.org/xfn/11"> <link rel="pingback" href="https://www.clinicaltrialsarena.com/xmlrpc.php"> <link rel="icon" href=""> <link rel="icon" href="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-32x32.png" sizes="32x32" /> <link rel="icon" href="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-192x192.png" sizes="192x192" /> <link rel="apple-touch-icon" href="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-180x180.png" /> <meta name="msapplication-TileImage" content="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-270x270.png" /> <meta name='robots' content='index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1' /> <style>img:is([sizes="auto" i], [sizes^="auto," i]) { contain-intrinsic-size: 3000px 1500px }</style>  <script src="https://cdn-ukwest.onetrust.com/scripttemplates/otSDKStub.js" type="text/javascript" charset="UTF-8" data-domain-script="1a37fe17-d133-4d2b-89bc-011d0af997c5" ></script> <script type="text/javascript"> function OptanonWrapper() { } </script>   <title>Projects A-Z - Clinical Trials Arena</title> <link rel="canonical" href="https://www.clinicaltrialsarena.com/projects-a-z/" /> <meta property="og:locale" content="en_US" /> <meta property="og:type" content="article" /> <meta property="og:title" content="Projects A-Z" /> <meta property="og:url" content="https://www.clinicaltrialsarena.com/projects-a-z/" /> <meta property="og:site_name" content="Clinical Trials Arena" /> <meta property="article:modified_time" content="2023-01-11T08:02:26+00:00" /> <meta name="twitter:card" content="summary_large_image" /> <script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebPage","@id":"https://www.clinicaltrialsarena.com/projects-a-z/","url":"https://www.clinicaltrialsarena.com/projects-a-z/","name":"Projects A-Z - Clinical Trials Arena","isPartOf":{"@id":"https://www.clinicaltrialsarena.com/#website"},"datePublished":"2021-12-28T08:08:57+00:00","dateModified":"2023-01-11T08:02:26+00:00","breadcrumb":{"@id":"https://www.clinicaltrialsarena.com/projects-a-z/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https://www.clinicaltrialsarena.com/projects-a-z/"]}]},{"@type":"BreadcrumbList","@id":"https://www.clinicaltrialsarena.com/projects-a-z/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.clinicaltrialsarena.com/"},{"@type":"ListItem","position":2,"name":"Projects A-Z"}]},{"@type":"WebSite","@id":"https://www.clinicaltrialsarena.com/#website","url":"https://www.clinicaltrialsarena.com/","name":"Clinical Trials Arena","description":"Hard data and deep insights on clinical trials strategy & operations","publisher":{"@id":"https://www.clinicaltrialsarena.com/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://www.clinicaltrialsarena.com/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https://www.clinicaltrialsarena.com/#organization","name":"Clinical Trials Arena","url":"https://www.clinicaltrialsarena.com/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://www.clinicaltrialsarena.com/#/schema/logo/image/","url":"https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/clinical_trials_arena_logo-1.png","contentUrl":"https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/clinical_trials_arena_logo-1.png","width":448,"height":96,"caption":"Clinical Trials Arena"},"image":{"@id":"https://www.clinicaltrialsarena.com/#/schema/logo/image/"}}]}</script>  <link rel='dns-prefetch' href='//www.clinicaltrialsarena.com' /> <link rel='dns-prefetch' href='//cdn.permutive.com' /> <link rel='dns-prefetch' href='//www.google.com' /> <link rel='dns-prefetch' href='//cdn.jsdelivr.net' /> <link rel='dns-prefetch' href='//cdn.plyr.io' /> <link rel='dns-prefetch' href='//fonts.googleapis.com' /> <link rel="alternate" type="application/rss+xml" title="Clinical Trials Arena » Feed" href="https://www.clinicaltrialsarena.com/feed/" /> <link rel="alternate" type="application/rss+xml" title="Clinical Trials Arena » Comments Feed" href="https://www.clinicaltrialsarena.com/comments/feed/" /> <style id='wp-emoji-styles-inline-css' type='text/css'> img.wp-smiley, img.emoji { display: inline !important; border: none !important; box-shadow: none !important; height: 1em !important; width: 1em !important; margin: 0 0.07em !important; vertical-align: -0.1em !important; background: none !important; padding: 0 !important; } </style> <link rel='stylesheet' id='wp-block-library-css' href='https://www.clinicaltrialsarena.com/wp-includes/css/dist/block-library/style.min.css?ver=6.7.1' type='text/css' media='all' /> <style id='classic-theme-styles-inline-css' type='text/css'> /*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} </style> <style id='global-styles-inline-css' type='text/css'> :root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--color--thb-accent: #f74a2e;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;} :where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;} :where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;} :root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;} </style> <link rel='stylesheet' id='gd-banner-css' href='https://www.clinicaltrialsarena.com/wp-content/plugins/all-newsletters/assets/css/gd-banners.css?ver=6.7.1' type='text/css' media='all' /> <link rel='stylesheet' id='project_NS-css-css' href='https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/scss/projects.css?ver=1.7.5' type='text/css' media='all' /> <link rel='stylesheet' id='main_NS-css-css' href='https://www.clinicaltrialsarena.com/wp-content/plugins/storefronts-gd/assets/css/main_NS.css?ver=1.7.5' type='text/css' media='all' /> <link rel='stylesheet' id='Swiper-css-css' href='https://www.clinicaltrialsarena.com/wp-content/plugins/storefronts-gd/assets/vendor/swiper/swiper.css?ver=6.8.3' type='text/css' media='all' /> <link rel='stylesheet' id='font-lora-css' href='https://fonts.googleapis.com/css2?family=Lora%3Aital%2Cwght%400%2C400%3B0%2C500%3B0%2C600%3B0%2C700%3B1%2C400%3B1%2C500%3B1%2C600%3B1%2C700&display=swap&ver=1' type='text/css' media='all' /> <link rel='stylesheet' id='Swiper-css' href='https://cdn.jsdelivr.net/npm/swiper@8/swiper-bundle.min.css?ver=6.7.1' type='text/css' media='all' /> <link rel='stylesheet' id='gdm-b2b-main-css' href='https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/scss/main.css?ver=2.36' type='text/css' media='all' /> <link rel='stylesheet' id='thb-fa-css' href='https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp/assets/css/font-awesome.min.css?ver=4.7.0' type='text/css' media='all' /> <link rel='stylesheet' id='style-css' href='https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/style.css?ver=4.6.0' type='text/css' media='all' /> <link rel='stylesheet' id='tablepress-default-css' href='https://www.clinicaltrialsarena.com/wp-content/plugins/tablepress/css/default.min.css?ver=1.13' type='text/css' media='all' /> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-includes/js/jquery/jquery.min.js?ver=3.7.1" id="jquery-core-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=3.4.1" id="jquery-migrate-js"></script> <script type="text/javascript" id="crb-google-tagmanager-js-extra"> /* <![CDATA[ */ var crbTracker = {"googleTagManager":{"id":"GTM-NKVVKWM"}}; /* ]]> */ </script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/plugins/verdict-tracking//js/googleTagManager.js?ver=1739771389" id="crb-google-tagmanager-js"></script> <script type="text/javascript" async src="https://cdn.permutive.com/e82dc6a7-79a5-49b7-b1ed-a89a37f2fe8b-web.js?ver=6.7.1" id="crb-permutive-cdn-js"></script> <script type="text/javascript" id="crb-permutive-js-extra"> /* <![CDATA[ */ var crbTracker = {"permutive":{"workspaceID":"e82dc6a7-79a5-49b7-b1ed-a89a37f2fe8b","publicAPIKey":"62905692-4299-42af-951f-aa610546b2b1","postTitle":"Projects A-Z","postID":146828,"postType":"page","postDate":"December 28, 2021","postAuthor":"mallikarjuna","postTags":false,"postCategories":false,"collectDomains":"https:\/\/www.clinicaltrialsarena.com\/wp-content\/plugins\/verdict-tracking\/\/js\/pollsInFrame.js","pageViewEvent":[]}}; /* ]]> */ </script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/plugins/verdict-tracking//js/permutive.js?ver=1739771389" id="crb-permutive-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/plugins/gd-opensearch/public/js/gd-opensearch-public.js?ver=1739779008" id="gd-opensearch-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/foundation.min.js?ver=6.7.1" id="foundation-js"></script> <script type="text/javascript" id="loadmore_posts-js-extra"> /* <![CDATA[ */ var loadmore_params = {"ajaxurl":"https:\/\/www.clinicaltrialsarena.com\/wp-admin\/admin-ajax.php","posts":"{\"page\":0,\"pagename\":\"projects-a-z\",\"error\":\"\",\"m\":\"\",\"p\":0,\"post_parent\":\"\",\"subpost\":\"\",\"subpost_id\":\"\",\"attachment\":\"\",\"attachment_id\":0,\"name\":\"projects-a-z\",\"page_id\":0,\"second\":\"\",\"minute\":\"\",\"hour\":\"\",\"day\":0,\"monthnum\":0,\"year\":0,\"w\":0,\"category_name\":\"\",\"tag\":\"\",\"cat\":\"\",\"tag_id\":\"\",\"author\":\"\",\"author_name\":\"\",\"feed\":\"\",\"tb\":\"\",\"paged\":0,\"meta_key\":\"\",\"meta_value\":\"\",\"preview\":\"\",\"s\":\"\",\"sentence\":\"\",\"title\":\"\",\"fields\":\"\",\"menu_order\":\"\",\"embed\":\"\",\"category__in\":[],\"category__not_in\":[],\"category__and\":[],\"post__in\":[],\"post__not_in\":[],\"post_name__in\":[],\"tag__in\":[],\"tag__not_in\":[],\"tag__and\":[],\"tag_slug__in\":[],\"tag_slug__and\":[],\"post_parent__in\":[],\"post_parent__not_in\":[],\"author__in\":[],\"author__not_in\":[],\"search_columns\":[],\"ignore_sticky_posts\":false,\"suppress_filters\":false,\"cache_results\":true,\"update_post_term_cache\":true,\"update_menu_item_cache\":false,\"lazy_load_term_meta\":true,\"update_post_meta_cache\":true,\"post_type\":\"\",\"posts_per_page\":10,\"nopaging\":false,\"comments_per_page\":\"50\",\"no_found_rows\":false,\"order\":\"DESC\"}","current_page":"2","max_page":"0"}; /* ]]> */ </script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/loadmoreposts.js?ver=6.7.1" id="loadmore_posts-js"></script> <link rel="https://api.w.org/" href="https://www.clinicaltrialsarena.com/wp-json/" /><link rel="alternate" title="JSON" type="application/json" href="https://www.clinicaltrialsarena.com/wp-json/wp/v2/pages/146828" /><link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://www.clinicaltrialsarena.com/xmlrpc.php?rsd" /> <meta name="generator" content="WordPress 6.7.1" /> <link rel='shortlink' href='https://www.clinicaltrialsarena.com/?p=146828' /> <link rel="alternate" title="oEmbed (JSON)" type="application/json+oembed" href="https://www.clinicaltrialsarena.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.clinicaltrialsarena.com%2Fprojects-a-z%2F" /> <link rel="alternate" title="oEmbed (XML)" type="text/xml+oembed" href="https://www.clinicaltrialsarena.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.clinicaltrialsarena.com%2Fprojects-a-z%2F&format=xml" /> <style id="Sgpollscstyle">iframe[src^="https://www.surveygizmo.eu"]{display:block!important;height:auto!important;}</style> <script async src="https://www.googletagmanager.com/gtag/js?id=G-HFH8RPKJ6M"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-HFH8RPKJ6M'); </script> <script src="https://www.googleoptimize.com/optimize.js?id=OPT-5D7BSTZ"></script> <script> !function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}; if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0'; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)}(window, document,'script', 'https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1175064750058523'); fbq('track', 'PageView'); </script> <noscript> <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1175064750058523&ev=PageView&noscript=1"/> </noscript>   <script type="application/ld+json"> {"@context":"http:\/\/schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"http:\/\/www.clinicaltrialsarena.com\/projects-a-z\/"},"headline":"Projects A-Z","url":"http:\/\/www.clinicaltrialsarena.com\/projects-a-z\/","thumbnailUrl":"","image":{"@type":"ImageObject","url":""},"dateCreated":"2021-12-28T08:08:57Z","datePublished":"2021-12-28T08:08:57Z","dateModified":"2021-12-28T08:08:57Z","articleSection":"Uncategorized","author":[{"@type":"Person","name":"mallikarjuna"}],"creator":["mallikarjuna"],"publisher":{"@type":"Organization","name":"Clinical Trials Arena","logo":"https:\/\/www.clinicaltrialsarena.com\/wp-content\/uploads\/sites\/22\/2021\/12\/cropped-Clinical-Trials-Arena-Favicon.png"},"keywords":[]} </script>  <link rel="icon" href="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-32x32.png" sizes="32x32" /> <link rel="icon" href="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-192x192.png" sizes="192x192" /> <link rel="apple-touch-icon" href="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-180x180.png" /> <meta name="msapplication-TileImage" content="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-270x270.png" />  <script> (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m) })(window,document,'script','//www.google-analytics.com/analytics.js','ga'); ga('create', '', 'auto'); ga('send', 'pageview'); </script>  <script type="text/javascript"> piAId = '376012'; piCId = '71913'; piHostname = 'pi.pardot.com'; (function() { function async_load(){ var s = document.createElement('script'); s.type = 'text/javascript'; s.src = ('https:' == document.location.protocol ? 'https://pi' : 'http://cdn') + '.pardot.com/pd.js'; var c = document.getElementsByTagName('script')[0]; c.parentNode.insertBefore(s, c); } if(window.attachEvent) { window.attachEvent('onload', async_load); } else { window.addEventListener('load', async_load, false); } })(); </script>    <script> /* window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-3619893-46'); */ </script> </head> <body id="site-body" class="thb-boxed-off thb_ads_header_mobile_on thb-lightbox-on thb-capitalize-off thb-dark-mode-off thb-header-style1 thb-title-underline-hover" > <a href="#menu" class="screen-reader-text">Skip to site menu</a> <a href="#page-content" class="screen-reader-text">Skip to page content</a> <script src="https://cdnjs.cloudflare.com/ajax/libs/classie/1.0.1/classie.js"></script> <script src="https://cdnjs.cloudflare.com/ajax/libs/magnific-popup.js/1.1.0/jquery.magnific-popup.min.js"></script> <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/magnific-popup.js/1.1.0/magnific-popup.min.css" /> <link rel="stylesheet" type="text/css" href="//cdn.jsdelivr.net/jquery.slick/1.6.0/slick.css"/> <script type="text/javascript" src="//cdn.jsdelivr.net/jquery.slick/1.6.0/slick.min.js"></script>    <header class="site-header" id="top"> <div class="grid-container"> <div class="site-logo"> <a href="https://www.clinicaltrialsarena.com/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2018/06/CTA.png" alt="CTA"> </a> </div> <div class="initials"><a href="https://www.clinicaltrialsarena.com">CT</a></div> <div class="menu-button">Menu</div> <div class="search-button">Search</div> <form id="searchForm" action="https://www.clinicaltrialsarena.com/s" class="search-form laptop-search" method="get" role="search"> <input id="searchInput" type="text" name="search" value="" placeholder="Search" class="search-box" /> <input type="submit" class="search-submit"> <div id="messageBox" style="color: red; margin-top: 5px;"></div> </form>  <script> document.getElementById('searchForm').addEventListener('submit', function(e) { var input = document.getElementById('searchInput'); var messageBox = document.getElementById('messageBox'); var sanitizedInput = input.value.replace(/[^a-zA-Z0-9\s.']/g, ''); if (sanitizedInput !== input.value) { e.preventDefault(); // Prevent form submission input.value = sanitizedInput; // Update the input with sanitized value messageBox.textContent = 'Special characters have been removed from your search query.'; // Optionally, clear the message after a few seconds setTimeout(function() { messageBox.textContent = ''; }, 5000); // Clear after 5 seconds } else { messageBox.textContent = ''; // Clear any existing message } }); </script> </div>  <nav class="burger-menu"> <div class="scroll"> <form action="https://www.clinicaltrialsarena.com/s" class="search-form" method="get" role="search"> <input type="text" name="search" value="" placeholder="Search" class="search-box" /> <input type="submit" class="search-submit"> </form>  <section class="nav-block sections" id="menu"> <h2>Sections</h2> <div class="menu-burger-menu-container"><ul id="menu-burger-menu" class="menu"><li id="menu-item-168876" class="menu-itemmenu-item-168876"><a title="Home" href="https://www.clinicaltrialsarena.com/" class="c-nav-hamburger-menu__link">Home</a></li><li id="menu-item-168858" class="menu-itemmenu-item-168858"><a title="News" href="https://www.clinicaltrialsarena.com/news/" class="c-nav-hamburger-menu__link">News</a></li><li id="menu-item-168877" class="menu-item menu-item-has-children dropdown menu-item-168877"><a title="Analysis" href="https://www.clinicaltrialsarena.com/analysis/" data-toggle="dropdown" class="c-nav-hamburger-menu__link c-nav-hamburger-menu__link--has-children">Analysis</a><input type="checkbox" value="analysis" name="analysis"><ul role="menu" class=" dropdown-menu"><li id="menu-item-168883" class="menu-item menu-item-168883"><a title="Features" href="https://www.clinicaltrialsarena.com/features/" class="c-nav-hamburger-menu__link">Features</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168859" class="menu-item menu-item-168859"><a title="Comment & Opinion" href="https://www.clinicaltrialsarena.com/comment/" class="c-nav-hamburger-menu__link">Comment & Opinion</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168968" class="menu-item menu-item-168968"><a title="Projects" href="https://www.clinicaltrialsarena.com/projects/" class="c-nav-hamburger-menu__link">Projects</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168884" class="menu-item menu-item-168884"><a title="Data Insights" href="https://www.clinicaltrialsarena.com/data-insights/" class="c-nav-hamburger-menu__link">Data Insights</a><ul role="menu" class=" dropdown-menu"></ul></li></ul></li><li id="menu-item-168885" class="menu-item menu-item-has-children dropdown menu-item-168885"><a title="Sectors" href="https://www.clinicaltrialsarena.com/sector/clinical/" data-toggle="dropdown" class="c-nav-hamburger-menu__link c-nav-hamburger-menu__link--has-children">Sectors</a><input type="checkbox" value="analysis" name="analysis"><ul role="menu" class=" dropdown-menu"><li id="menu-item-168882" class="menu-item menu-item-168882"><a title="Clinical Trials" href="https://www.clinicaltrialsarena.com/sector/services/clinical-trials/" class="c-nav-hamburger-menu__link">Clinical Trials</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168881" class="menu-item menu-item-168881"><a title="Approvals" href="https://www.clinicaltrialsarena.com/sector/approvals/" class="c-nav-hamburger-menu__link">Approvals</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168860" class="menu-item menu-item-168860"><a title="Operations" href="https://www.clinicaltrialsarena.com/sector/operations/" class="c-nav-hamburger-menu__link">Operations</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168861" class="menu-item menu-item-168861"><a title="Outsourced Services" href="https://www.clinicaltrialsarena.com/sector/services/outsourced-services/" class="c-nav-hamburger-menu__link">Outsourced Services</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168878" class="menu-item menu-item-168878"><a title="Supply Chain" href="https://www.clinicaltrialsarena.com/sector/services/supply-chain/" class="c-nav-hamburger-menu__link">Supply Chain</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168879" class="menu-item menu-item-168879"><a title="Data Management" href="https://www.clinicaltrialsarena.com/sector/data-management/" class="c-nav-hamburger-menu__link">Data Management</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168880" class="menu-item menu-item-168880"><a title="Medical Devices" href="https://www.clinicaltrialsarena.com/sector/medical-devices/" class="c-nav-hamburger-menu__link">Medical Devices</a><ul role="menu" class=" dropdown-menu"></ul></li></ul></li><li id="menu-item-168886" class="menu-item menu-item-has-children dropdown menu-item-168886"><a title="Themes" href="https://www.clinicaltrialsarena.com/sector/theme/" data-toggle="dropdown" class="c-nav-hamburger-menu__link c-nav-hamburger-menu__link--has-children">Themes</a><input type="checkbox" value="analysis" name="analysis"><ul role="menu" class=" dropdown-menu"><li id="menu-item-168887" class="menu-item menu-item-168887"><a title="Artificial Intelligence" href="https://www.clinicaltrialsarena.com/sector/theme/technology/artificial-intelligence/" class="c-nav-hamburger-menu__link">Artificial Intelligence</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168888" class="menu-item menu-item-168888"><a title="Cloud" href="https://www.clinicaltrialsarena.com/sector/theme/technology/cloud/" class="c-nav-hamburger-menu__link">Cloud</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168889" class="menu-item menu-item-168889"><a title="Corporate Governance" href="https://www.clinicaltrialsarena.com/sector/theme/macro/esg/governance/" class="c-nav-hamburger-menu__link">Corporate Governance</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168890" class="menu-item menu-item-168890"><a title="Cybersecurity" href="https://www.clinicaltrialsarena.com/sector/theme/technology/cybersecurity/" class="c-nav-hamburger-menu__link">Cybersecurity</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168891" class="menu-item menu-item-168891"><a title="Environmental Sustainability" href="https://www.clinicaltrialsarena.com/sector/theme/macro/esg/environment/" class="c-nav-hamburger-menu__link">Environmental Sustainability</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168892" class="menu-item menu-item-168892"><a title="Internet of Things" href="https://www.clinicaltrialsarena.com/sector/theme/technology/internet-of-things/" class="c-nav-hamburger-menu__link">Internet of Things</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168893" class="menu-item menu-item-168893"><a title="Robotics" href="https://www.clinicaltrialsarena.com/sector/theme/technology/robotics/" class="c-nav-hamburger-menu__link">Robotics</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168894" class="menu-item menu-item-168894"><a title="Social Responsibility" href="https://www.clinicaltrialsarena.com/sector/theme/macro/esg/social/" class="c-nav-hamburger-menu__link">Social Responsibility</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168895" class="menu-item menu-item-168895"><a title="Covid-19" href="https://www.clinicaltrialsarena.com/sector/theme/macro/covid-19/" class="c-nav-hamburger-menu__link">Covid-19</a><ul role="menu" class=" dropdown-menu"></ul></li></ul></li><li id="menu-item-168911" class="menu-item menu-item-has-children dropdown menu-item-168911"><a title="Insights" href="https://www.clinicaltrialsarena.com/insights/" data-toggle="dropdown" class="c-nav-hamburger-menu__link c-nav-hamburger-menu__link--has-children">Insights</a><input type="checkbox" value="analysis" name="analysis"><ul role="menu" class=" dropdown-menu"><li id="menu-item-168896" class="menu-item menu-item-168896"><a title="Deals" href="https://www.clinicaltrialsarena.com/deals-dashboards/" class="c-nav-hamburger-menu__link">Deals</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168905" class="menu-item menu-item-168905"><a title="Jobs" href="https://www.clinicaltrialsarena.com/jobs/" class="c-nav-hamburger-menu__link">Jobs</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168904" class="menu-item menu-item-168904"><a title="Filings" href="https://www.clinicaltrialsarena.com/filings/" class="c-nav-hamburger-menu__link">Filings</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168906" class="menu-item menu-item-168906"><a title="Patents" href="https://www.clinicaltrialsarena.com/patents/" class="c-nav-hamburger-menu__link">Patents</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168907" class="menu-item menu-item-168907"><a title="Social Media" href="https://www.clinicaltrialsarena.com/influencers-dashboards/" class="c-nav-hamburger-menu__link">Social Media</a><ul role="menu" class=" dropdown-menu"></ul></li></ul></li><li id="menu-item-168897" class="menu-item menu-item-has-children dropdown menu-item-168897"><a title="Companies" href="#" data-toggle="dropdown" class="c-nav-hamburger-menu__link c-nav-hamburger-menu__link--has-children">Companies</a><input type="checkbox" value="analysis" name="analysis"><ul role="menu" class=" dropdown-menu"><li id="menu-item-168898" class="menu-item menu-item-168898"><a title="Company A-Z" href="https://www.clinicaltrialsarena.com/company-a-z/" class="c-nav-hamburger-menu__link">Company A-Z</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168908" class="menu-item menu-item-168908"><a title="Company Categories" href="https://www.clinicaltrialsarena.com/contractors/" class="c-nav-hamburger-menu__link">Company Categories</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-169033" class="menu-item menu-item-169033"><a title="Product & Services" href="https://www.clinicaltrialsarena.com/products/" class="c-nav-hamburger-menu__link">Product & Services</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-169034" class="menu-item menu-item-169034"><a title="Company Releases" href="https://www.clinicaltrialsarena.com/pressreleases/" class="c-nav-hamburger-menu__link">Company Releases</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-169036" class="menu-item menu-item-169036"><a title="White Papers" href="https://www.clinicaltrialsarena.com/whitepapers/" class="c-nav-hamburger-menu__link">White Papers</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-169035" class="menu-item menu-item-169035"><a title="Videos" href="https://www.clinicaltrialsarena.com/videos/" class="c-nav-hamburger-menu__link">Videos</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168909" class="menu-item menu-item-168909"><a title="Buyer's Guides" href="https://www.clinicaltrialsarena.com/buyers-guide/" class="c-nav-hamburger-menu__link">Buyer's Guides</a><ul role="menu" class=" dropdown-menu"></ul></li><li id="menu-item-168900" class="menu-item menu-item-168900"><a title="Partner Content" href="https://www.clinicaltrialsarena.com/sponsored/" class="c-nav-hamburger-menu__link">Partner Content</a><ul role="menu" class=" dropdown-menu"></ul></li></ul></li><li id="menu-item-169037" class="menu-itemmenu-item-169037"><a title="Events" href="https://www.clinicaltrialsarena.com/events/" class="c-nav-hamburger-menu__link">Events</a></li><li id="menu-item-187782" class="premium-insights-menu-link menu-itemmenu-item-187782"><a title="Buy Reports" href="https://www.clinicaltrialsarena.com/buy-reports/" class="c-nav-hamburger-menu__link">Buy Reports</a></li><li id="menu-item-168910" class="menu-itemmenu-item-168910"><a title="Excellence Awards" href="https://www.clinicaltrialsarena.com/excellence-awards/" class="c-nav-hamburger-menu__link">Excellence Awards</a></li><li id="menu-item-189758" class="menu-itemmenu-item-189758"><a title="Innovation Rankings" href="https://www.clinicaltrialsarena.com/innovation-ranking/" class="c-nav-hamburger-menu__link">Innovation Rankings</a></li><li id="menu-item-168899" class="menu-itemmenu-item-168899"><a title="Magazine" href="https://www.clinicaltrialsarena.com/magazine/" class="c-nav-hamburger-menu__link">Magazine</a></li><li id="menu-item-186175" class="menu-itemmenu-item-186175"><a title="Newsletters" href="https://www.clinicaltrialsarena.com/newsletters/" class="c-nav-hamburger-menu__link">Newsletters</a></li><ul></div> </section> <section class="nav-block globaldata"> <h2>GlobalData</h2> <div class="menu-globaldata-container"><ul id="menu-globaldata" class="menu"><li id="menu-item-168864" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-168864"><a href="https://www.clinicaltrialsarena.com/about-us-online/" class="c-nav-hamburger-menu__link">About Us</a></li> <li id="menu-item-168868" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-168868"><a href="https://www.clinicaltrialsarena.com/advertise-with-us/" class="c-nav-hamburger-menu__link">Advertise With Us</a></li> <li id="menu-item-168862" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-168862"><a href="https://www.clinicaltrialsarena.com/contact-us/" class="c-nav-hamburger-menu__link">Contact Us</a></li> <li id="menu-item-168867" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-168867"><a href="https://www.verdictmediastrategies.com/" class="c-nav-hamburger-menu__link">Our Marketing Solution</a></li> <li id="menu-item-168865" class="ext-link menu-item menu-item-type-custom menu-item-object-custom menu-item-168865"><a target="_blank" href="https://www.globaldata.com/store/" class="c-nav-hamburger-menu__link">GlobalData Reports</a></li> <li id="menu-item-168863" class="ext-link menu-item menu-item-type-custom menu-item-object-custom menu-item-168863"><a target="_blank" href="https://globaldata.com/" class="c-nav-hamburger-menu__link">Visit GlobalData</a></li> </ul></div> </section> <section class="nav-block from-our-partners"> <h2>From Our Partners</h2> <div class="menu-partners-container"><ul id="menu-partners" class="menu"><li id="menu-item-224993" class="menu-item menu-item-type-taxonomy menu-item-object-sector menu-item-224993"><a href="https://www.clinicaltrialsarena.com/sector/partners/control-and-confidence-in-clinical-data-management/" class="c-nav-hamburger-menu__link">Control and confidence in clinical data management</a></li> <li id="menu-item-199223" class="menu-item menu-item-type-taxonomy menu-item-object-sector menu-item-199223"><a href="https://www.clinicaltrialsarena.com/sector/partners/optimizing-cell-gene-therapy-processes/" class="c-nav-hamburger-menu__link">Optimizing Cell & Gene Therapy Processes</a></li> <li id="menu-item-168855" class="menu-item menu-item-type-taxonomy menu-item-object-sector menu-item-168855"><a href="https://www.clinicaltrialsarena.com/sector/partners/accelerating-clinical-trials/" class="c-nav-hamburger-menu__link">Accelerating Clinical Trials</a></li> <li id="menu-item-189234" class="menu-item menu-item-type-taxonomy menu-item-object-sector menu-item-189234"><a href="https://www.clinicaltrialsarena.com/sector/partners/improving-decentralized-trials-with-mobile-research-nursing/" class="c-nav-hamburger-menu__link">Improving decentralized trials with mobile research nursing</a></li> <li id="menu-item-168857" class="menu-item menu-item-type-taxonomy menu-item-object-sector menu-item-168857"><a href="https://www.clinicaltrialsarena.com/sector/partners/the-next-chapter-of-clinical-trial-services/" class="c-nav-hamburger-menu__link">The next chapter of clinical trial services</a></li> <li id="menu-item-209444" class="menu-item menu-item-type-taxonomy menu-item-object-sector menu-item-209444"><a href="https://www.clinicaltrialsarena.com/sector/partners/meet-critical-milestones/" class="c-nav-hamburger-menu__link">Meet critical milestones</a></li> </ul></div> </section> </div>  </nav>  <nav class="nav-bar"> <div class="grid-container"> <div class="menu-header-menu-container"><ul id="menu-header-menu" class="menu"><li id="menu-item-168919" class="menu-item menu-item-168919"><a title="News" href="https://www.clinicaltrialsarena.com/news/"><span>News</span></a></li><li id="menu-item-168921" class="menu-item menu-item-has-children has-sub menu-item-168921"><a title="Analysis" href="https://www.clinicaltrialsarena.com/analysis/"><span>Analysis</span></a><div class="mega"><section class="nav-block subcats"><h2>Sections</h2><ul role="menu" class=" dropdown-menu"><li id="menu-item-168920" class="menu-item menu-item-168920"><a title="Features" href="https://www.clinicaltrialsarena.com/features/" class=""><span>Features</span></a></li><li id="menu-item-168912" class="menu-item menu-item-168912"><a title="Comment & Opinion" href="https://www.clinicaltrialsarena.com/comment/" class=""><span>Comment & Opinion</span></a></li><li id="menu-item-171196" class="menu-item menu-item-171196"><a title="Projects" href="https://www.clinicaltrialsarena.com/projects-a-z/" class=""><span>Projects</span></a></li><li id="menu-item-168922" class="menu-item menu-item-168922"><a title="Data Insights" href="https://www.clinicaltrialsarena.com/data-insights/" class=""><span>Data Insights</span></a></li></ul></section><section class="nav-block most-read"><h2>Latest</h2><ul><li><a href="https://www.clinicaltrialsarena.com/features/trumps-tariffs-will-trickle-down-the-clinical-trial-chain/">Trump’s tariffs will trickle down the clinical trial chain</a></li><li><a href="https://www.clinicaltrialsarena.com/features/oct-medical-devices-2025-ai-value-appreciable-yet-human-touch-remains-key/">OCT Medical Devices 2025: AI’s value appreciable, yet human touch remains key</a></li><li><a href="https://www.clinicaltrialsarena.com/features/the-ai-advantage-in-discovering-new-medicines/">The AI advantage in discovering new medicines </a></li></ul></section></div></li><li id="menu-item-168929" class="menu-item menu-item-has-children has-sub menu-item-168929"><a title="Sectors" href="https://www.clinicaltrialsarena.com/sector/clinical/"><span>Sectors</span></a><div class="mega"><section class="nav-block subcats"><h2>Sections</h2><ul role="menu" class=" dropdown-menu"><li id="menu-item-168918" class="menu-item menu-item-168918"><a title="Clinical Trials" href="https://www.clinicaltrialsarena.com/sector/services/clinical-trials/" class=""><span>Clinical Trials</span></a></li><li id="menu-item-168931" class="menu-item menu-item-168931"><a title="Approvals" href="https://www.clinicaltrialsarena.com/sector/approvals/" class=""><span>Approvals</span></a></li><li id="menu-item-168915" class="menu-item menu-item-168915"><a title="Operations" href="https://www.clinicaltrialsarena.com/sector/operations/" class=""><span>Operations</span></a></li><li id="menu-item-168916" class="menu-item menu-item-168916"><a title="Outsourced Services" href="https://www.clinicaltrialsarena.com/sector/services/outsourced-services/" class=""><span>Outsourced Services</span></a></li><li id="menu-item-168917" class="menu-item menu-item-168917"><a title="Supply Chain" href="https://www.clinicaltrialsarena.com/sector/services/supply-chain/" class=""><span>Supply Chain</span></a></li><li id="menu-item-168913" class="menu-item menu-item-168913"><a title="Data Management" href="https://www.clinicaltrialsarena.com/sector/data-management/" class=""><span>Data Management</span></a></li><li id="menu-item-168914" class="menu-item menu-item-168914"><a title="Medical Devices" href="https://www.clinicaltrialsarena.com/sector/medical-devices/" class=""><span>Medical Devices</span></a></li></ul></section><section class="nav-block most-read"><h2>Latest</h2><ul><li><a href="https://www.clinicaltrialsarena.com/news/palvella-trial-gel/">Palvella to expand trial of microcystic LMs treatment gel to younger subjects</a></li><li><a href="https://www.clinicaltrialsarena.com/news/satellos-trial-sat-3247/">Satellos concludes MAD cohort enrolment for Phase I trial of SAT-3247</a></li><li><a href="https://www.clinicaltrialsarena.com/news/bms-trial-car-t/">BMS’ Phase II trial of CAR T cell therapy meets primary endpoint</a></li></ul></section></div></li><li id="menu-item-168935" class="menu-item menu-item-has-children has-sub menu-item-168935"><a title="Themes" href="https://www.clinicaltrialsarena.com/sector/theme/"><span>Themes</span></a><div class="mega"><section class="nav-block subcats"><h2>Sections</h2><ul role="menu" class=" dropdown-menu"><li id="menu-item-168936" class="menu-item menu-item-168936"><a title="Artificial Intelligence" href="https://www.clinicaltrialsarena.com/sector/theme/technology/artificial-intelligence/" class=""><span>Artificial Intelligence</span></a></li><li id="menu-item-168937" class="menu-item menu-item-168937"><a title="Cloud" href="https://www.clinicaltrialsarena.com/sector/theme/technology/cloud/" class=""><span>Cloud</span></a></li><li id="menu-item-168938" class="menu-item menu-item-168938"><a title="Corporate Governance" href="https://www.clinicaltrialsarena.com/sector/theme/macro/esg/governance/" class=""><span>Corporate Governance</span></a></li><li id="menu-item-168939" class="menu-item menu-item-168939"><a title="Cybersecurity" href="https://www.clinicaltrialsarena.com/sector/theme/technology/cybersecurity/" class=""><span>Cybersecurity</span></a></li><li id="menu-item-168940" class="menu-item menu-item-168940"><a title="Environmental Sustainability" href="https://www.clinicaltrialsarena.com/sector/theme/macro/esg/environment/" class=""><span>Environmental Sustainability</span></a></li><li id="menu-item-168941" class="menu-item menu-item-168941"><a title="Internet of Things" href="https://www.clinicaltrialsarena.com/sector/theme/technology/internet-of-things/" class=""><span>Internet of Things</span></a></li><li id="menu-item-168942" class="menu-item menu-item-168942"><a title="Robotics" href="https://www.clinicaltrialsarena.com/sector/theme/technology/robotics/" class=""><span>Robotics</span></a></li><li id="menu-item-168943" class="menu-item menu-item-168943"><a title="Social Responsibility" href="https://www.clinicaltrialsarena.com/sector/theme/macro/esg/social/" class=""><span>Social Responsibility</span></a></li><li id="menu-item-168944" class="menu-item menu-item-168944"><a title="Covid-19" href="https://www.clinicaltrialsarena.com/sector/theme/macro/covid-19/" class=""><span>Covid-19</span></a></li><li id="menu-item-203169" class="menu-item menu-item-203169"><a title="Foreign Direct Investment" href="https://www.clinicaltrialsarena.com/sector/fdi/" class=""><span>Foreign Direct Investment</span></a></li></ul></section><section class="nav-block most-read"><h2>Latest</h2><ul><li><a href="https://www.clinicaltrialsarena.com/features/the-ai-advantage-in-discovering-new-medicines/">The AI advantage in discovering new medicines </a></li><li><a href="https://www.clinicaltrialsarena.com/news/jp-morgan-2025-jazz-pharmaceuticals-focusing-on-oncology-pipeline/">JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline</a></li><li><a href="https://www.clinicaltrialsarena.com/news/hengrui-and-kailera-report-best-in-class-data-from-phase-ii-glp-1-gip-trial/">Hengrui and Kailera report best-in-class data from Phase II GLP-1/GIP trial</a></li></ul></section></div></li><li id="menu-item-168953" class="menu-item menu-item-has-children has-sub menu-item-168953"><a title="Insights" href="https://www.clinicaltrialsarena.com/insights/"><span>Insights</span></a><div class="mega"><section class="nav-block subcats"><h2>Sections</h2><ul role="menu" class=" dropdown-menu"><li id="menu-item-168945" class="menu-item menu-item-168945"><a title="Deals" href="https://www.clinicaltrialsarena.com/deals-dashboards/" class=""><span>Deals</span></a></li><li id="menu-item-168947" class="menu-item menu-item-168947"><a title="Jobs" href="https://www.clinicaltrialsarena.com/jobs/" class=""><span>Jobs</span></a></li><li id="menu-item-168946" class="menu-item menu-item-168946"><a title="Filings" href="https://www.clinicaltrialsarena.com/filings/" class=""><span>Filings</span></a></li><li id="menu-item-168948" class="menu-item menu-item-168948"><a title="Patents" href="https://www.clinicaltrialsarena.com/patents/" class=""><span>Patents</span></a></li><li id="menu-item-168949" class="menu-item menu-item-168949"><a title="Social Media" href="https://www.clinicaltrialsarena.com/influencers-dashboards/" class=""><span>Social Media</span></a></li></ul></section><section class="nav-block most-read"><h2>Latest</h2><ul><li><a href="https://www.clinicaltrialsarena.com/dashboards/jobs/q2-2024-update-social-responsibility-related-hiring-actvity-in-the-pharma-industry/">Q2 2024 update: social responsibility related hiring actvity in the pharma industry</a></li><li><a href="https://www.clinicaltrialsarena.com/dashboards/jobs/q2-2024-update-environmental-sustainability-related-hiring-actvity-in-the-pharma-industry/">Q2 2024 update: environmental sustainability related hiring actvity in the pharma industry</a></li><li><a href="https://www.clinicaltrialsarena.com/dashboards/jobs/q2-2024-update-cloud-related-hiring-actvity-in-the-pharma-industry/">Q2 2024 update: cloud related hiring actvity in the pharma industry</a></li></ul></section></div></li><li id="menu-item-168932" class="menu-item menu-item-has-children has-sub menu-item-168932"><a title="Companies" href="#"><span>Companies</span></a><div class="mega"><section class="nav-block subcats"><h2>Sections</h2><ul role="menu" class=" dropdown-menu"><li id="menu-item-168933" class="menu-item menu-item-168933"><a title="Company A-Z" href="https://www.clinicaltrialsarena.com/company-a-z/" class=""><span>Company A-Z</span></a></li><li id="menu-item-168934" class="menu-item menu-item-168934"><a title="Company Categories" href="https://www.clinicaltrialsarena.com/contractors/" class=""><span>Company Categories</span></a></li><li id="menu-item-169046" class="menu-item menu-item-169046"><a title="Products & Services" href="https://www.clinicaltrialsarena.com/products/" class=""><span>Products & Services</span></a></li><li id="menu-item-169047" class="menu-item menu-item-169047"><a title="Company Releases" href="https://www.clinicaltrialsarena.com/pressreleases/" class=""><span>Company Releases</span></a></li><li id="menu-item-169125" class="menu-item menu-item-169125"><a title="White Papers" href="https://www.clinicaltrialsarena.com/whitepapers/" class=""><span>White Papers</span></a></li><li id="menu-item-169126" class="menu-item menu-item-169126"><a title="Videos" href="https://www.clinicaltrialsarena.com/videos/" class=""><span>Videos</span></a></li><li id="menu-item-169127" class="menu-item menu-item-169127"><a title="Buyer's Guides" href="https://www.clinicaltrialsarena.com/buyers-guide/" class=""><span>Buyer's Guides</span></a></li><li id="menu-item-169128" class="menu-item menu-item-169128"><a title="Partner Content" href="https://www.clinicaltrialsarena.com/sponsored/" class=""><span>Partner Content</span></a></li></ul></section><section class="nav-block most-read"><h2>Latest</h2><ul><li><a href="https://www.clinicaltrialsarena.com/sponsored/43rd-annual-jp-morgan-healthcare-conference-2025/">43rd Annual JP Morgan Healthcare Conference 2025</a></li><li><a href="https://www.clinicaltrialsarena.com/sponsored/how-ai-is-streamlining-cell-and-gene-therapy-manufacturing/">How AI is streamlining cell and gene therapy manufacturing</a></li><li><a href="https://www.clinicaltrialsarena.com/sponsored/advancing-the-fight-against-parkinsons-disease-new-treatments-clinical-trials-and-future-innovations/">Advancing the fight against Parkinson’s disease: New treatments, clinical trials, and future innovations</a></li></ul></section></div></li><li id="menu-item-169050" class="menu-item menu-item-169050"><a title="Events" href="https://www.clinicaltrialsarena.com/events/"><span>Events</span></a></li><li id="menu-item-187783" class="premium-insights-menu-link menu-item menu-item-187783"><a title="Buy Reports" href="https://www.clinicaltrialsarena.com/buy-reports/"><span>Buy Reports</span></a></li><li id="menu-item-186173" class="menu-item menu-item-186173"><a title="Newsletters" href="https://www.clinicaltrialsarena.com/newsletters/"><span>Newsletters</span></a></li><ul></div> <div class="initials"><a href="https://www.clinicaltrialsarena.com">CT</a></div> </div> </nav> <nav class="sub-nav-bar"> <div class="grid-container"> <div class="sub-nav-inner"> <div class="breadcrumb"> <ul> <li class="current"><a href="https://www.clinicaltrialsarena.com/analysis/">Analysis</a></li> </ul> </div> <div class="subcategories"> <div class="arrow-left">Left</div> <div class="arrow-right">Right</div> <ul> <li class=""><a href="https://www.clinicaltrialsarena.com/features/">Features</a></li> <li class=""><a href="https://www.clinicaltrialsarena.com/comment/">Comment & Opinion</a></li> <li class="current"><a href="https://www.clinicaltrialsarena.com/projects-a-z/">Projects</a></li> <li class=""><a href="https://www.clinicaltrialsarena.com/data-insights/">Data Insights</a></li> </ul> </div> </div> </div> </nav> <div class="menu-bg"></div> </header> <main> <div class="grid-container"> <header class="header-category"> <h1>All Projects</h1> </header> </div> <section class="c-posts-grid u-mb-5 grid-container gdm-form gdm-filters"> <div class="grid-x grid-padding-x align-center"> <div class="cell xlarge-12 xxlarge-12"> <div class="grid-x grid-padding-x"> <div class="cell small-6 smedium-6 medium-6 text-left show-smed"> <label>Page Letter <select class="blc-rwslist"> <option value="">#</option> <option value="">A</option> <option value="">B</option> <option value="">C</option> <option value="">D</option> <option value="">E</option> <option value="">F</option> <option value="">G</option> <option value="">H</option> <option value="">I</option> <option value="">J</option> <option value="">K</option> <option value="">L</option> <option value="">M</option> <option value="">N</option> <option value="">O</option> <option value="">P</option> <option value="">Q</option> <option value="">R</option> <option value="">S</option> <option value="">T</option> <option value="">U</option> <option value="">V</option> <option value="">X</option> <option value="">Y</option> <option value="">Z</option> </select> </label> </div> </div> <div class="c-search-and-filters"> <div class="inline-filters c-search-and-filters__filters" id="cSearchAndFiltersFilters"> <div class="c-filters-bar"> <div class="grid-x inline-filters-box" id="modal-three"> <div class="mobile-filters-header"> <p>Filter projects</p> <span class="modal-exit">×</span> <button class=" button solid primary apply-filters" data-toggle="#cSearchAndFiltersFilters">Apply filters</button> </div> <div class="cell medium-3 line-search"> <div class="c-nav-search-content__form"> <label>Search:</label> <input class="c-nav-search-content__input s search-field myInput" id="myInput" name="s" type="text" placeholder="Search"> <button class="c-search__button" type="button"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" class="svg-icon-search"> <path fill="000" d="M14.3023,13.7518l-3.2047-3.4655a5.77,5.77,0,0,0,1.2755-3.6338A5.5541,5.5541,0,0,0,6.9365,1,5.5541,5.5541,0,0,0,1.5,6.6525,5.5541,5.5541,0,0,0,6.9365,12.305a5.2377,5.2377,0,0,0,3.1147-1.0229L13.28,14.7739a.69.69,0,0,0,1.0024.02A.7589.7589,0,0,0,14.3023,13.7518ZM6.9365,2.4746a4.105,4.105,0,0,1,4.0183,4.1779A4.105,4.105,0,0,1,6.9365,10.83,4.105,4.105,0,0,1,2.9182,6.6525,4.105,4.105,0,0,1,6.9365,2.4746Z"> </path> </svg> </button> <button class="btn-mobile-filters" data-modal="modal-three"> III </button> </div> </div> <div class="cell medium-3 line-filter" id="cSearchAndFiltersFilters"> <label>Geography</label> <select id="filter-region"> <option value="" selected="selected">Geography</option> <option value="asia-pacific"> Asia-Pacific</option> <option value="belgium"> Belgium</option> <option value="canada"> Canada</option> <option value="europe"> Europe</option> <option value="france"> France</option> <option value="germany"> Germany</option> <option value="global"> Global</option> <option value="india"> India</option> <option value="italy"> Italy</option> <option value="japan-2"> Japan</option> <option value="middle-east-africa"> Middle East & Africa</option> <option value="north-america"> North America</option> <option value="south-korea"> South Korea</option> <option value="united-kingdom"> United Kingdom</option> <option value="united-states"> United States</option> <option value="united-states-of-america"> United States of America</option> </select> </div> <div class="cell medium-3 line-filter"> <label>Sectors</label> <select id="filter-categories"> <option value="" class="c-select__label" selected="selected"> Sectors </option> <option value="api-manufacturers">API Manufacturers </option> <option value="approvals">Approvals </option> <option value="biopharmaceutical-industry">Biopharmaceutical Industry </option> <option value="cancer">Cancer </option> <option value="cardiovascular">Cardiovascular </option> <option value="central-nervous-system">Central Nervous System </option> <option value="clinical-trial-patient-recruitment">Clinical Trial Patient Recruitment </option> <option value="clinical-trials">Clinical Trials </option> <option value="clinical-trials-arena">Clinical Trials Arena </option> <option value="covid-19">Covid-19 </option> <option value="dermatology">Dermatology </option> <option value="drug-development">Drug Development </option> <option value="ear-nose-throat">Ear Nose Throat Disorders </option> <option value="gastrointestinal">Gastrointestinal </option> <option value="genetic-disorders">Genetic Disorders </option> <option value="genito-urinary">Genito Urinary System And Sex Hormones </option> <option value="genomics">Genomics </option> <option value="hematological-disorders">Hematological Disorders </option> <option value="immunology">Immunology </option> <option value="infectious-disease">Infectious Disease </option> <option value="manufacturing">Manufacturing </option> <option value="markets">Markets </option> <option value="medelpharm-wp">MEDELPHARM WP </option> <option value="metabolic-disorders">Metabolic Disorders </option> <option value="musculoskeletal-disorders">Musculoskeletal Disorders </option> <option value="neurology">Neurology </option> <option value="non-malignant-disorders">Non Malignant Disorders </option> <option value="nutritional-disorders">Nutritional Disorders </option> <option value="oncology">Oncology </option> <option value="oncology-immuno">Oncology </option> <option value="ophthalmology">Ophthalmology </option> <option value="oracle-nas-wp">Oracle NAS WP </option> <option value="other-diseases">Other Diseases </option> <option value="pall-wp">Pall WP </option> <option value="procaps-wp">Procaps WP </option> <option value="respiratory">Respiratory </option> <option value="technology">Technology </option> <option value="therapy-area">Therapy Area </option> <option value="toxicology">Toxicology </option> <option value="womens-health">Women's Health </option> </select> </div> <div class="cell medium-3 line-filter"> <label>Sort by</label> <select id="filter-sort-by"> <option value="" selected="selected">Sort by</option> <option class="level-0" value="alphabetical">Alphabetical</option> <option class="level-0" value="date">Recently Added</option> </select> </div> </div> </div> </div> </div> </div> </div> </section> <section class="grid-container"> <div id="project-az"> <div class="lsit-abtl-company"> <ul> <li> <a href="##" class=" #c-tabs-nav__tab--disabled ">#</a> </li> <li> <a href="#a" class=" a ">A</a> </li> <li> <a href="#b" class=" b ">B</a> </li> <li> <a href="#c" class=" c ">C</a> </li> <li> <a href="#d" class=" d ">D</a> </li> <li> <a href="#e" class=" e ">E</a> </li> <li> <a href="#f" class=" f ">F</a> </li> <li> <a href="#g" class=" g ">G</a> </li> <li> <a href="#h" class=" h ">H</a> </li> <li> <a href="#i" class=" i ">I</a> </li> <li> <a href="#j" class=" j ">J</a> </li> <li> <a href="#k" class=" k ">K</a> </li> <li> <a href="#l" class=" l ">L</a> </li> <li> <a href="#m" class=" m ">M</a> </li> <li> <a href="#n" class=" n ">N</a> </li> <li> <a href="#o" class=" o ">O</a> </li> <li> <a href="#p" class=" p ">P</a> </li> <li> <a href="#q" class=" q ">Q</a> </li> <li> <a href="#r" class=" r ">R</a> </li> <li> <a href="#s" class=" s ">S</a> </li> <li> <a href="#t" class=" t ">T</a> </li> <li> <a href="#u" class=" u ">U</a> </li> <li> <a href="#v" class=" v ">V</a> </li> <li> <a href="#w" class=" w ">W</a> </li> <li> <a href="#x" class=" x ">X</a> </li> <li> <a href="#y" class=" y ">Y</a> </li> <li> <a href="#z" class=" z ">Z</a> </li> </ul> </div> <section> <div class="ordered-article"> <div class="categories grid-x"> <div class="large-7 centered-content"> <section id="a" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>A</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/abaloparatide-sc-for-the-treatment-of-post-menopausal-osteoporosis/">Abaloparatide-SC for the Treatment of Post-menopausal Osteoporosis</a> </h3> <p>Abaloparatide-SC is an injectable formulation of abaloparatide developed by Radius Health for the treatment of osteoporosis in post-menopausal women.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/abaloparatide-sc-for-the-treatment-of-post-menopausal-osteoporosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-111.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/abatacept/">Abatacept (Orencia) – Treatment for Rheumatoid Arthritis (RA)</a> </h3> <p>Abatacept (Orencia) was developed by Bristol-Myers-Squibb for the treatment of rheumatoid arthritis (RA). It is a biologic drug which contains a selective co-stimulation modulator.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/abatacept/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image1-3.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/abecma-idecabtagene-vicleucel-multiple-myeloma/">Abecma (idecabtagene vicleucel) for the Treatment of Multiple Myeloma</a> </h3> <p>Abecma (idecabtagene vicleucel) is the first approved CAR T-cell immunotherapy for relapsed or refractory (r/r) multiple myeloma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/abecma-idecabtagene-vicleucel-multiple-myeloma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/03/Featured-Image-Abecma-idecabtagene-vicleucel.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/abilify-aripiprazole-digital-medicine-treatment-schizophrenia/">Abilify (aripiprazole) Digital Medicine for Treatment of Schizophrenia</a> </h3> <p>Abilify (aripiprazole), an orally administered dopamine partial agonist and a seratonin antagonist, was approved by US Food and Drug Administration (FDA) in November 2002 for the treatment of schizophrenia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/abilify-aripiprazole-digital-medicine-treatment-schizophrenia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-97.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/abraxane-treatment-late-stage-pancreatic-cancer/">Abraxane for the Treatment of Late-Stage Pancreatic Cancer</a> </h3> <p>Abraxane (albumin-bound paclitaxel for injectable suspension) is an intravenous injection indicated for the treatment of metastatic pancreatic cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/abraxane-treatment-late-stage-pancreatic-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/3l-image-38.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/abrysvo-vaccine-prevention-rsv-us/">Abrysvo Vaccine for the Prevention of Respiratory Syncytial Virus, US</a> </h3> <p>Abrysvo has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/abrysvo-vaccine-prevention-rsv-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/10/Featured-Image-Abrysvo-vaccine-to-prevent-RSV.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ace031forthetreatmen/">ACE-031 for the Treatment of Duchenne Muscular Dystrophy</a> </h3> <p>ACE-031 is an investigational protein therapeutic that is being developed by Acceleron Pharma for the treatment of Du</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ace031forthetreatmen/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-ace-031.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rimonabant/">Acomplia (Rimonabant) – Investigational Agent for the Management of Obesity</a> </h3> <p>Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rimonabant/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_Atherosclerotic_Artery.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/actemra/">Actemra – Biological Therapy for Rheumatoid Arthritis</a> </h3> <p>Roche Pharmaceuticals' Actemra (tocilizumab) was approved as a rheumatoid arthritis treatment in the EU in January 2009</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/actemra/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-roche-pharmaceuticals.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/actonel-osteoporosis-risedronate-sodium/">Actonel (Risedronate Sodium) – Treatment for Osteoporosis</a> </h3> <p>Actonel is targeted for the treatment of osteoporosis in postmenopausal women. It is also indicated for the treatment of osteoporosis in men, to improve BMD and Paget's disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/actonel-osteoporosis-risedronate-sodium/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-6.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/adcetris-brentuximab-hodgkins-lymphoma/">Adcetris (brentuximab vedotin) for the Treatment of Relapsed or Refractory Hodgkin’s Lymphoma</a> </h3> <p>Adcetris® (brentuximab vedotin) is a treatment for relapsed or refractory (r/r) Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/adcetris-brentuximab-hodgkins-lymphoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-adcetris-treatment.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/adempas-riociguat-treatment-pulmonary-hypertension/">Adempas (Riociguat) for Treatment of Pulmonary Hypertension</a> </h3> <p>Adempas (riociguat) is indicated for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/adempas-riociguat-treatment-pulmonary-hypertension/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/Image-1l.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/adlyxin-lixisenatide-for-the-treatment-of-type-2-diabetes/">Adlyxin (lixisenatide) for the Treatment of Type 2 Diabetes</a> </h3> <p>Adlyxin (lixisenatide) is an injectable solution developed by Sanofi for the treatment of type 2 diabetes in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/adlyxin-lixisenatide-for-the-treatment-of-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-31.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/admelog-insulin-lispro-treatment-type-1-type-2-diabetes/">Admelog (insulin lispro) for the Treatment of Type 1 and Type 2 Diabetes</a> </h3> <p>Admelog® (insulin lispro) is a rapid-acting human insulin analogue approved as a follow-on product to treat type 1 and type 2 diabetes in adults and paediatric patients aged three years and older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/admelog-insulin-lispro-treatment-type-1-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/aduhelm-aducanumab-avwa-alzheimers/">ADUHELM (aducanumab-avwa) for the Treatment of Alzheimer’s Disease</a> </h3> <p>ADUHELM™ (aducanumab-avwa) is a first-of-its-kind monoclonal antibody indicated for the treatment of Alzheimer’s disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/aduhelm-aducanumab-avwa-alzheimers/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/07/Featured-Image-ADUHELM.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/adynovi-treatment-adults-adolescents-haemophilia/">ADYNOVI for the Treatment of Adults and Adolescents with Haemophilia A</a> </h3> <p>ADYNOVI® is an intravenous infusion indicated for the treatment of adults and adolescents with haemophilia A.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/adynovi-treatment-adults-adolescents-haemophilia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/afamelanotide/">Afamelanotide, Photo-Protective Drug</a> </h3> <p>Afamelanotide is a photo-protective drug that increases melanin levels in the human skin to gain protection from ultraviolet radiation (UVR) and sunlight.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/afamelanotide/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-afamelanotide.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/afinitor-disperz-everolimus-treatment-tsc-associated-partial-onset-seizures/">Afinitor Disperz (everolimus) for the Treatment of TSC-Associated Partial-Onset Seizures</a> </h3> <p>Afinitor Disperz® (everolimus) is indicated for the treatment of tuberous sclerosis complex (TSC) associated partial-onset seizures in adult and paediatric patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/afinitor-disperz-everolimus-treatment-tsc-associated-partial-onset-seizures/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-images-Afinitor-Disperz.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/afluria-quadrivalent-for-prevention-of-infection-from-influenza-virus/">Afluria Quadrivalent for Prevention of Infection from Influenza Virus</a> </h3> <p>Afluria Quadrivalent is an inactivated influenza vaccine developed by Seqirus, which is developed to provide active immunisation against the disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/afluria-quadrivalent-for-prevention-of-infection-from-influenza-virus/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-124.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/afrezza-mealtime-insulin-therapy-diabetes/">Afrezza: Mealtime Insulin Therapy for Diabetes</a> </h3> <p>Afrezza is a rapid-acting insulin therapy indicated for controlling hyperglycaemia in adult patients with type 1 and type 2 diabetes mellitus.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/afrezza-mealtime-insulin-therapy-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-40.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/agamree-treatment-dmd-us/">Agamree for the Treatment of Duchenne Muscular Dystrophy, US</a> </h3> <p>The FDA approved Agamree for the treatment of DMD in October this year.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/agamree-treatment-dmd-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/11/Featured-Image-Agamree®-vamorolone-for-the-Treatment-of-Duchenne-Muscular-Dystrophy-US.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/aimovig-erenumab-treatment-episodic-migraine/">Aimovig (erenumab) for the Treatment of Episodic Migraine</a> </h3> <p>Aimovig™ (erenumab) is the first CGRP inhibitor approved for preventive treatment of migraine in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/aimovig-erenumab-treatment-episodic-migraine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/01/Featured-Image-Aimovig-erenumab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/alecensa-alectinib-for-treatment-of-alk-positive-non-small-cell-lung-cancer-nsclc/">Alecensa (alectinib) for the Treatment of ALK-positive Non-small Cell Lung Cancer (NSCLC)</a> </h3> <p>Alecensa (alectinib) is a kinase inhibitor intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/alecensa-alectinib-for-treatment-of-alk-positive-non-small-cell-lung-cancer-nsclc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-136.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/alemtuzumab/">Alemtuzumab – Potential in Multiple Sclerosis (MS)</a> </h3> <p>Alemtuzumab (marketed as Campath/MabCampath/Lemtrada) is an anti-CD52 monoclonal antibody (MAb) for which Bayer HealthCare holds exclusive global marketing rights. It was licensed in 2001 for the treatment of chronic lymphocytic leukaemia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/alemtuzumab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-neuron.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/aliqopa-copanlisib-treatment-relapsed-follicular-lymphoma/">Aliqopa (copanlisib) for the Treatment of Relapsed Follicular Lymphoma</a> </h3> <p>Aliqopa (copanlisib) is a novel intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/aliqopa-copanlisib-treatment-relapsed-follicular-lymphoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Aliqopa.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/almorexant/">Almorexant for Treatment of Primary Insomnia</a> </h3> <p>Almorexant is the first member of a new class of drugs called orexin receptor antagonists indicated for the treatment of</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/almorexant/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-hypothalamus.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/alofisel-darvadstrocel-treatment-complex-perianal-fistulas-crohns-disease/">Alofisel (darvadstrocel) for the Treatment of Complex Perianal Fistulas in Crohn’s Disease</a> </h3> <p>Alofisel® (formerly Cx601 / darvadstrocel) is the first allogeneic stem cell therapy to be approved for the treatment of complex perianal fistulas in adult patients with Crohn’s disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/alofisel-darvadstrocel-treatment-complex-perianal-fistulas-crohns-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Alofisel.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/alprolix-treatment-haemophilia-b/">Alprolix for the Treatment of Haemophilia B</a> </h3> <p>Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an intravenous injection indicated for the control and prevention of bleeding episodes, as well as routine prophylaxis in haemophilia B-affected adults and children aged 12 and above.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/alprolix-treatment-haemophilia-b/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-51.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/">Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)</a> </h3> <p>Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-144.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/am103/">AM103 Experimental Treatment for Respiratory Diseases</a> </h3> <p>Under development by Amira Pharmaceuticals, AM103 is a novel inhibitor of 5-lipoxygenase activating protein (FLAP) that</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/am103/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-respiratory-system-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/amglidia-glibenclamide/">Amglidia (glibenclamide) for the Treatment of Neonatal Diabetes</a> </h3> <p>Amglidia is a hybrid medicine indicated for the treatment of neonatal diabetes mellitus in newborns, infants, and children.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/amglidia-glibenclamide/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-Image-Amglidia.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/amondys-45-casimersen-dmd-treatment/">Amondys 45 (Casimersen) for the Treatment of Duchenne Muscular Dystrophy</a> </h3> <p>Amondys 45 (casimersen) injection is an antisense oligonucleotide indicated for the treatment of patients with Duchenne muscular dystrophy (DMD). It is the first US Food and Drug Administration (FDA)-approved treatment for patients with DMD with a mutation amenable to skipping exon 45.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/amondys-45-casimersen-dmd-treatment/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/04/Image-1-Amondys-45.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/amarinamr101/">AMR101 – Omega-3-Based Treatment for Hypertriglyceridaemia</a> </h3> <p>Under development by Amarin Corporation, AMR101 is a partially synthetic omega-3 fatty acid-based drug. It contains the</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/amarinamr101/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-amr101.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/amvuttra-vutrisiran-hattr-amyloidosis/">AMVUTTRA (vutrisiran) for the Treatment of Polyneuropathy of hATTR Amyloidosis, USA</a> </h3> <p>AMVUTTRA™ (vutrisiran) is the first FDA-approved drug to reverse neuropathy impairment in hATTR amyloidosis patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/amvuttra-vutrisiran-hattr-amyloidosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/07/Featured-Image_AMVUTTRA-vutrisiran-for-Treatment-of-hATTR-Amyloidosis-US-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/treatment-psoriasis/">AN2728 for the Treatment of Psoriasis</a> </h3> <p>AN2728 is an anti-inflammatory drug being developed by Anacor Pharmaceuticals as a treatment for psoriasis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/treatment-psoriasis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-treatment-psoriasis.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/anacetrapib-treatment-for-atherosclerosis/">Anacetrapib – Treatment for Atherosclerosis</a> </h3> <p>Anacetrapib (MK-0859) is an orally active cholesteryl ester transfer protein (CETP) inhibitor indicated for the treatment of atherosclerosis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/anacetrapib-treatment-for-atherosclerosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-formula-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/andexxa-andexanet-alfa-treatment-factor-xa-inhibitor-associated-acute-major-bleeding/">Andexxa (coagulation factor Xa recombinant, inactivated-zhzo) for the Treatment of Factor Xa Inhibitor-Associated Acute Major Bleeding</a> </h3> <p>Andexxa® (coagulation factor Xa recombinant, inactivated-zhzo) is an intravenous infusion indicated for the treatment of patients with factor Xa inhibitor-associated acute major bleeding.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/andexxa-andexanet-alfa-treatment-factor-xa-inhibitor-associated-acute-major-bleeding/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Andexxa-for-the-treatment-of-Acute-Major-Bleeding.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/anktiva-non-muscle-invasive-bladder-cancer/">ANKTIVA for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC), USA</a> </h3> <p>ANKTIVA® is a next-generation immunotherapy to treat BCG-unresponsive non-muscle invasive bladder cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/anktiva-non-muscle-invasive-bladder-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/05/Featured-Image-ANKTIVA-for-the-Treatment-of-Non-Muscle-Invasive-Bladder-Cancer-NMIBC.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/anoro-ellipta-treatment-chronic-obstructive-pulmonary-disease/">Anoro Ellipta for Treatment of Chronic Obstructive Pulmonary Disease</a> </h3> <p>Anoro ellipta (umeclidinium bromide / vilanterol) is a dry powder for inhalation, indicated for the treatment of airflow obstructions in patients suffering from chronic obstructive pulmonary disease (COPD) or emphysema.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/anoro-ellipta-treatment-chronic-obstructive-pulmonary-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-41.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/anthim-obiltoxaximab-injection-for-the-treatment-of-inhalational-anthrax/">Anthim (obiltoxaximab) Injection for the Treatment of Inhalational Anthrax</a> </h3> <p>Anthim (obiltoxaximab) is an injectable drug developed by Elusys Therapeutics for the treatment of inhalational anthrax caused by bacillus anthracis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/anthim-obiltoxaximab-injection-for-the-treatment-of-inhalational-anthrax/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-110.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/arena/">APD125 – Therapy for Insomnia</a> </h3> <p>Developed by Arena Pharmaceuticals, APD125 is an oral serotonin antagonist with potential for the treatment of insomnia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/arena/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-human-brain.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/aphexda-multiple-myeloma/">Aphexda (Motixafortide) for Stem Cell Mobilisation for Autologous Transplantation for Multiple Myeloma, USA</a> </h3> <p>Aphexda™ is a first-of-its-kind product approved for stem cell mobilisation for multiple myeloma in approximately ten years.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/aphexda-multiple-myeloma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/09/Featured-Image-Aphexda.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/apretude-cabotegravir-hiv-1-prep/">Apretude (cabotegravir) for the Treatment of HIV-1 Pre-Exposure Prevention (PrEP)</a> </h3> <p>Apretude (cabotegravir) is indicated for the treatment of HIV-1 PrEP to minimise the risk of HIV-1 infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/apretude-cabotegravir-hiv-1-prep/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/03/Featured-Image-Apretude-cabotegravir.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/aptiom-eslicarbazepine-acetate-for-the-treatment-of-partial-onset-seizures/">Aptiom® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures</a> </h3> <p>Aptiom (eslicarbazepine acetate) is a sodium channel inhibitor approved as an adjunctive treatment for partial-onset seizures in the US and Europe.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/aptiom-eslicarbazepine-acetate-for-the-treatment-of-partial-onset-seizures/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-small.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/arexvy-prevent-lower-respiratory-tract-disease/">Arexvy (RSV vaccine) to Prevent Lower Respiratory Tract Disease (LRTD), USA</a> </h3> <p>Arexvy is the world’s first respiratory syncytial virus vaccine to prevent lower respiratory tract disease in older adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/arexvy-prevent-lower-respiratory-tract-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/05/Featured-image_Arexvy-to-prevent-RSV.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ariflo/">Ariflo (Cilomilast) – Oral PDE-IV Inhibitor for</a> </h3> <p>Ariflo (cilomilast) is an oral selective phosphodiesterase (PDE) IV inhibitor under development by GlaxoSmithKline Pharm</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ariflo/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/image1-17.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/aristada-aripiprazole-lauroxil-for-the-treatment-of-schizophrenia/">Aristada™ (aripiprazole lauroxil) for the Treatment of Schizophrenia</a> </h3> <p>Aristada™ (aripiprazole lauroxil), discovered and developed by Alkermes, is an antipsychotic drug indicated for the treatment of schizophrenia in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/aristada-aripiprazole-lauroxil-for-the-treatment-of-schizophrenia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-93.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/artesunate-for-injection-for-the-treatment-of-severe-malaria/">Artesunate for Injection for the Treatment of Severe Malaria</a> </h3> <p>Artesunate for Injection is an antimalarial drug indicated for the initial treatment of severe malaria in adult and paediatric patients. It is the only drug in the US to treat the condition.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/artesunate-for-injection-for-the-treatment-of-severe-malaria/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/06/Image-1-Artesunte-for-Injection.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/arzerra-ofatumumab-treatment-chronic-lymphocytic-leukaemia-cll/">Arzerra (Ofatumumab) for the Treatment of Chronic Lymphocytic Leukaemia (CLL)</a> </h3> <p>Arzerra (ofatumumab) is the first-line drug approved for the treatment of chronic lymphocytic leukaemia (CLL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/arzerra-ofatumumab-treatment-chronic-lymphocytic-leukaemia-cll/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-57.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/antisomas/">ASA404 Vascular Disrupting Agent for Solid Tumours</a> </h3> <p>ASA404 is a vascular disrupting agent (VDA) that was being developed by Antisoma and Novartis as a treatment for a range</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/antisomas/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-respiratory-system.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/asp-1929-head-neck-carcinomas/">ASP-1929 for the Treatment of Head and Neck Squamous Cell Carcinomas</a> </h3> <p>ASP-1929 is a first-in-class therapy indicated for the treatment of head and neck squamous cell carcinomas (HNSCC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/asp-1929-head-neck-carcinomas/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-ASP-1929.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/brilinta-treatment/">AstraZeneca’s Brilinta – Treatment for Acute Coronary Syndrome</a> </h3> <p>Brilinta is an anti-platelet drug which decreases the platelet aggregation and prevents blood clots. It was developed by AstraZeneca for the treatment of acute coronary syndrome (ACS).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/brilinta-treatment/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-brilinta-treatment.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/abbvie-atogepant-migraine/">Atogepant for the Preventive Treatment of Migraine, US</a> </h3> <p>Atogepant binds to the CGRP receptor on the brain’s trigeminal nerve and blocks the activation of the migraine.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/abbvie-atogepant-migraine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/11/Clinical-Trial-Feat-Img.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/aubagio-teriflunomide-treatment-multiple-sclerosis-us/">Aubagio (Teriflunomide) for the Treatment of Multiple Sclerosis</a> </h3> <p>Aubagio (teriflunomide) is an immunomodulatory agent indicated for the treatment of relapsing forms of multiple sclerosis (MS). It was developed by Genzyme.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/aubagio-teriflunomide-treatment-multiple-sclerosis-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-14.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/austedo-treatment-chorea/">Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease</a> </h3> <p>Austedo™ (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT 2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/austedo-treatment-chorea/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-37.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/auvelity-dextromethorphan-and-bupropion-for-the-treatment-of-major-depressive-disorder-mdd-usa/">Auvelity (dextromethorphan and bupropion) for the Treatment of Major Depressive Disorder (MDD), USA</a> </h3> <p>Auvelity™ (dextromethorphan and bupropion) is the first and only oral rapid-acting antidepressant for major depressive disorder.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/auvelity-dextromethorphan-and-bupropion-for-the-treatment-of-major-depressive-disorder-mdd-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/04/Featured-Image-Auvelity.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/avastin/">Avastin (bevacizumab) – Angiogenesis Inhibitor and Cancer Therapy</a> </h3> <p>The product of a joint development programme between Genentech and Roche, Avastin (bevacizumab) is a humanised monoclonal antibody (MAb) directed against vascular endothelial growth factor (VEGF), a pro-angiogenesis factor.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/avastin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_liquid_dosage_production_.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/aveed-testosterone-undecanoate-treatment-men-hypogonadism/">Aveed (testosterone undecanoate) for the Treatment of Men with Hypogonadism</a> </h3> <p>Aveed (testosterone undecanoate) is a testosterone replacement therapy indicated for the treatment of hypogonadism in adult men who are associated with a deficiency or absence of the male hormone testosterone.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/aveed-testosterone-undecanoate-treatment-men-hypogonadism/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-49.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/axitinib-carcinoma/">Axitinib – Treatment for Advanced Renal Cell Carcinoma</a> </h3> <p>Inlyta (axitinib) was developed by Pfizer for treating advanced renal cell carcinoma (ARCC) and hepatocellular carcinoma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/axitinib-carcinoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-axitinib-carcinoma.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ayvakit-avapritinib/">AYVAKIT (avapritinib) for the Treatment of Gastrointestinal Stromal Tumours (GISTs)</a> </h3> <p>AYVAKIT™ (avapritinib) is the first precision therapy approved for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumours (GISTs) and advanced systemic mastocytosis (ASM).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ayvakit-avapritinib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/02/Image-1-AYVAKIT-avapritinib.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="b" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>B</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/balversa-erdafitinib/">BALVERSA for the Treatment of Urothelial Carcinoma, US</a> </h3> <p>BALVERSA is available as a round, biconvex, film-coated tablet in 3mg, 4mg, or 5mg strengths.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/balversa-erdafitinib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/09/Featured-Image-Balversa-erdafitinib-for-the-Treatment-of-Urothelial-Carcinoma-USA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/bamlanivimab-ly-cov555-for-the-treatment-of-covid-19/">Bamlanivimab (LY-Cov555) for the Treatment of Covid-19</a> </h3> <p>Bamlanivimab (LY-CoV555) is a neutralising monoclonal antibody intended for the treatment of mild to moderate COVID-19.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/bamlanivimab-ly-cov555-for-the-treatment-of-covid-19/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/11/Image-1-Bamlanivimab-LY-Cov555.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/banzel-treatment-for-linnaux-gastaut-syndrome/">Banzel – Treatment for Lennox-Gastaut syndrome</a> </h3> <p>Banzel (Rufinamide) was developed in 2004 by Novartis Pharma. It is being manufactured by Eisai in Europe. It is indicated for the treatment of epileptic seizures.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/banzel-treatment-for-linnaux-gastaut-syndrome/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Formula.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/avelumab-for-the-treatment-of-metastatic-merkel-cell-carcinoma/">Bavencio (avelumab) for the Treatment of Metastatic Merkel Cell Carcinoma</a> </h3> <p>Bavencio® (avelumab) is a human PD-L1 monoclonal antibody indicated for the treatment of metastatic Merkel-cell carcinoma (MCC). </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/avelumab-for-the-treatment-of-metastatic-merkel-cell-carcinoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-36.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/baxdela-delafloxacin-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections/">Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections</a> </h3> <p>Baxdela™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered and developed by Melinta Therapeutics in partnership with Ligand Pharmaceuticals.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/baxdela-delafloxacin-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-41.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/belinostat-pxd-101-for-the-treatment-of-peripheral-t-cell-lymphoma-ptcl/">Belinostat (PXD 101) for the Treatment of Peripheral T-Cell Lymphoma (PTCL)</a> </h3> <p>Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/belinostat-pxd-101-for-the-treatment-of-peripheral-t-cell-lymphoma-ptcl/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/2l-image-47.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/belsomra-suvorexant-treatment-insomnia/">Belsomra (suvorexant) for the Treatment of Insomnia</a> </h3> <p>Belsomra (suvorexant) is the only approved drug of its kind for treating adult patients suffering from insomnia characterised by difficulty with sleep onset or sleep maintenance. The drug was developed by Merck, Sharp & Dohme Corp.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/belsomra-suvorexant-treatment-insomnia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-43.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/benlysta-lupus/">Benlysta – Lupus Treatment</a> </h3> <p>Benlysta is an investigational human monoclonal antibody drug indicated for treating autoantibody-positive systemic lupu</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/benlysta-lupus/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-glaxosmithkline.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/beovu-brolucizumab/">Beovu® (Brolucizumab) for the Treatment of wet Age-related Macular Degeneration (AMD)</a> </h3> <p>Beovu® (brolucizumab) is an anti-vascular endothelial growth factor (anti-VEGF) drug indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/beovu-brolucizumab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/11/Image-1-BEOVU.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/besponsa-inotuzumab-ozogamicin-treatment-acute-lymphoblastic-leukaemia/">BESPONSA (inotuzumab ozogamicin) for the Treatment of Acute Lymphoblastic Leukaemia</a> </h3> <p>BESPONSA® is an intravenous infusion indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/besponsa-inotuzumab-ozogamicin-treatment-acute-lymphoblastic-leukaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-BESPONSA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/besremi-ropeginterferon-alfa-2b/">BESREMi (ropeginterferon alfa-2B) for the Treatment of Polycythaemia Vera, US</a> </h3> <p>BESREMi® (ropeginterferon alfa-2B) is a mono-pegylated proline interferon indicated for the treatment of polycythaemia vera.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/besremi-ropeginterferon-alfa-2b/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/03/Image-1-Besremi-ropeginterferon-alfa-2B.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/bevyxxa-betrixaban-treatment-venous-thromboembolism-vte-adults/">Bevyxxa (betrixaban) for the Treatment of Venous Thromboembolism (VTE) in Adults</a> </h3> <p>Bevyxxa (betrixaban) is a drug developed by Portola Pharmaceuticals that is indicated for the prevention and treatment of venous thromboembolism (VTE) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/bevyxxa-betrixaban-treatment-venous-thromboembolism-vte-adults/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/bexsero-multicomponent-meningococcal-serogroup-b-vaccine/">Bexsero – Treatment for Meningitis B (MenB) Disease</a> </h3> <p>Discovered and developed by Novartis, Bexsero is a vaccine indicated for the treatment of meningococcal group B (MenB) disease. It is the first and the only Men B vaccine for the protection of all age groups against the disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/bexsero-multicomponent-meningococcal-serogroup-b-vaccine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-bexsero.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/bifeprunox/">Bifeprunox – Atypical Antipsychotic Drug</a> </h3> <p>Bifeprunox mesilate was a novel atypical antipsychotic agent under development by Solvay Pharmaceuticals as a treatment</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/bifeprunox/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/solvay_hq.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/biktarvy-treatment-hiv/">Biktarvy for the Treatment of HIV-I</a> </h3> <p>Biktarvy® is a once-daily regimen indicated for the treatment of HIV-1 infection in adults that were previously not treated with anti-retroviral medicines.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/biktarvy-treatment-hiv/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Biktarvy.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/blincyto-blinatumomab-all/">Blincyto® (blinatumomab) for the Treatment of B-cell Precursor Acute Lymphoblastic Leukaemia</a> </h3> <p>Blincyto® (blinatumomab) is a monoclonal antibody indicated as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/blincyto-blinatumomab-all/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-blinatumomab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/bionomics-bnc105/">BNC105</a> </h3> <p>BNC105, being developed by Adelaide-based Bionomics, is a new kind of drug known as a vascular targeting agent (VDA). As</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/bionomics-bnc105/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-bnc105.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/boceprevir/">Boceprevir, Experimental Drug for Chronic Hepatitis C Infection by Schering-Plough</a> </h3> <p>Victrelis (boceprevir) is an oral HCV protease inhibitor indicated for the treatment of chronic infection with hepatitis</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/boceprevir/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-boceprevir.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/boostrix-vaccine-whooping-cough-tetanus-diphtheria/">Boostrix – Vaccine for Whooping Cough, Tetanus and Diphtheria</a> </h3> <p>Boostrix is a three-in-one vaccine administered to protect against whooping cough, tetanus and diphtheria. Vaccination is an effective way to protect against them.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/boostrix-vaccine-whooping-cough-tetanus-diphtheria/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-3.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/bosutinib-leukaemia/">Bosutinib – Chronic Myelogenous Leukaemia (CML) Treatment</a> </h3> <p>Bosutinib is an investigational drug indicated for treating Philadelphia chromosome positive Chronic Myelogenous Leuka</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/bosutinib-leukaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-pills-3.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/breo-ellipta-for-the-treatment-of-chronic-obstructive-pulmonary-disease-copd/">Breo Ellipta for Treatment of Chronic Obstructive Pulmonary Disease (COPD)</a> </h3> <p>Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) is a dry powder inhaler indicated for the long-term maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/breo-ellipta-for-the-treatment-of-chronic-obstructive-pulmonary-disease-copd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-31.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/brexafemme-ibrexafungerp/">Brexafemme (ibrexafungerp) for the Treatment of Vaginal Yeast Infection</a> </h3> <p>Brexafemme (ibrexafungerp) is the first FDA-approved oral non-azole treatment for vaginal yeast infections.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/brexafemme-ibrexafungerp/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/09/Featured-Image-BREXAFEMME-ibrexafungerp.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/breyanzi-for-the-treatment-of-large-b-cell-lymphoma-lbcl/">Breyanzi for the Treatment of Large B-cell Lymphoma, US</a> </h3> <p>Breyanzi is a gene-modified autologous therapy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/breyanzi-for-the-treatment-of-large-b-cell-lymphoma-lbcl/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/05/Featured-Image-Breyanzi-lisocabtagene-maraleucel-for-the-Treatment-of-Large-B-cell-lymphoma-LBCL-US.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/brintellix-vortioxetine-treatment-major-depressive-disorder/">Brintellix (Vortioxetine) for Treatment of Major Depressive Disorder (MDD)</a> </h3> <p>Brintellix (vortioxetine) is a new multimodal antidepressant indicated for the treatment major depressive disorder (MDD) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/brintellix-vortioxetine-treatment-major-depressive-disorder/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-44.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/briumvi-ublituximab-xiiy/">Briumvi (ublituximab-xiiy) for the Treatment of Multiple Sclerosis, USA</a> </h3> <p>Briumvi™ is the first and only approved anti-CD20 monoclonal antibody for treating relapsing forms of multiple sclerosis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/briumvi-ublituximab-xiiy/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/02/Featured-Image_Briumvi-ublituximab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/briviact-brivaracetam-treatment-partial-onset-seizures/">Briviact (brivaracetam) For the Treatment of Partial Onset Seizures</a> </h3> <p>Briviact (brivaracetam) was developed by UCB for the treatment of partial onset of seizures in epilepsy patients over the age of 16.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/briviact-brivaracetam-treatment-partial-onset-seizures/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-107.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/brukinsa-zanubrutinib-waldenstroms-macroglobulinaemia/">Brukinsa (zanubrutinib) for the Treatment of Waldenstrom’s Macroglobulinaemia, USA</a> </h3> <p>Brukinsa® (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor developed by BeiGene.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/brukinsa-zanubrutinib-waldenstroms-macroglobulinaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/09/Featured-Image-Brukinsa-zanubrutinib-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/bydureon-bcise-treatment-type-2-diabetes/">Bydureon® BCise™ for the Treatment of Type-2 Diabetes</a> </h3> <p>Bydureon® BCise™ (exenatide extended-release) is an injectable suspension containing a glucagon-like peptide-1 (GLP-1) receptor agonist. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/bydureon-bcise-treatment-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/Image-1-Bydureon-BCise.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/exenatide/">Byetta (exenatide) – First-in-Class Incretin Mimetic for Type 2 Diabetes</a> </h3> <p>Developed by Amylin Pharmaceuticals, Byetta (exenatide) is a synthetic exendin-4 agent indicated for the treatment of ty</p> </div> <div class="cell large-4"> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/bylvay-odevixibat-pfic/">Bylvay (odevixibat) for the Treatment of Pruritus, USA</a> </h3> <p>Bylvay™ is indicated to treat skin itching caused by certain inherited liver conditions, PFIC and Alagille syndrome.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/bylvay-odevixibat-pfic/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/08/Featured-Image-Bylvay.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="c" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>C</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cabenuva-cabotegravir-rilpivirine/">Cabenuva (cabotegravir and rilpivirine) for the Treatment of HIV-1 Infection, USA</a> </h3> <p>Cabenuva is the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cabenuva-cabotegravir-rilpivirine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/12/Image-2-Cabenuva.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cablivi-acquired-thrombotic-thrombocytopenic-purpura/">Cablivi (caplacizumab) for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura</a> </h3> <p>Cablivi™ (caplacizumab) is a bivalent anti-Von Willebrand factor (vWF) nanobody indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cablivi-acquired-thrombotic-thrombocytopenic-purpura/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Cablivi.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cabometyx-cabozantinib-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma/">Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma</a> </h3> <p>Cabometyx (cabozantinib) is used for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cabometyx-cabozantinib-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-115.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/calquence-acalabrutinib-treatment-mantle-cell-lymphoma/">Calquence (acalabrutinib) for the Treatment of Mantle Cell Lymphoma</a> </h3> <p>Calquence® (acalabrutinib) is a bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/calquence-acalabrutinib-treatment-mantle-cell-lymphoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/2l-image-Calquence.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/camzyos-mavacamten-symptomatic-obstructive-hcm/">Camzyos (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)</a> </h3> <p>Camzyos® (mavacamten) is the only FDA-approved cardiac myosin inhibitor that particularly targets the source of obstructive HCM.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/camzyos-mavacamten-symptomatic-obstructive-hcm/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/05/Featured-Image-Camzyos-mavacamten-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/capravirine/">Capravirine – Anti-Retroviral Drug</a> </h3> <p>Developed by Pfizer Global Research and Development, capravirine is a Non-Nuclesoide Reverse Transcriptase Inhibitor (NN</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/capravirine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_Aids_Virus.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/caprosinol/">Caprospinol, Therapy for Alzheimer’s Disease (AD)</a> </h3> <p>Samaritan Pharmaceuticals' caprospinol (SP-233) is an investigational<br /> agent under development for the treatment of Alzh</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/caprosinol/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-brain.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/carnexiv-carbamazepine-for-the-treatment-of-certain-seizure-types-in-adults/">Carnexiv (carbamazepine) for the Treatment of Certain Seizure Types in Adults</a> </h3> <p>Carnexiv (carbamazepine) is an injectable formulation developed by Lundbeck for partial, generalised tonic-clonic seizures in adult patients who are unable to temporarily take oral medication.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/carnexiv-carbamazepine-for-the-treatment-of-certain-seizure-types-in-adults/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-126.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/carvykti-ciltacabtagene-autoleucel/">Carvykti (ciltacabtagene autoleucel) for the Treatment of Multiple Myeloma</a> </h3> <p>Carvykti™ (ciltacabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory multiple myeloma (RRMM).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/carvykti-ciltacabtagene-autoleucel/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/04/Featured-Image-CARVYKTI-ciltacabtagene-autoleucel.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ceftazidime-avibactam-urinary-tract-intra-abdominal-infections/">Ceftazidime-Avibactam for Treatment of Complicated Urinary Tract and Intra-Abdominal Infections</a> </h3> <p>Ceftazidime-avibactam is an investigational antibiotic indicated for treatment of patients with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Actavis is jointly developing the drug in collaboration with AstraZeneca.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ceftazidime-avibactam-urinary-tract-intra-abdominal-infections/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-61.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ceftobiprole/">Ceftobiprole – Injectable Anti-MRSA Cephalosporin Antibiotic</a> </h3> <p>The product of a joint development programme between the Swiss pharmaceutical company Basilea Pharmaceutica AG and Cilag AG International (a Johnson & Johnson company), ceftobiprole medocaril (BAL5788) is a novel cephalosporin antibiotic indicated for the treatment of serious bacterial infections in hospitalised patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ceftobiprole/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/BAL5788.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/celvapan/">Celvapan – H1N1 Pandemic Influenza Vaccine</a> </h3> <p>The Celvapan pandemic vaccine is being developed by Baxter International. It was first developed as a mock-up vaccine co</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/celvapan/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-celvapan.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cepheidxpert/">Cepheid Xpert vanA Test Kit</a> </h3> <p>Xpert vanA is a new diagnostic test kit developed by California-based Cepheid for the early and easy detection of vancom</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cepheidxpert/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-vre.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cerovive/">Cerovive – Neuroprotectant for the</a> </h3> <p>Cerovive, a nitrone-based free radical scavenger indicated for the treatment of acute ischaemic stroke has been disconti</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cerovive/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_Brain_Cross_Section.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cervarix/">Cervarix, Cervical Cancer Vaccine by GlaxoSmithKline</a> </h3> <p>GlaxoSmithKline's (GSK) Cervarix is a prophylactic vaccine currently indicated for the prevention of precancerous cervic</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cervarix/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-risk-factors.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cetilistat/">Cetilistat – Investigational Drug for Obesity</a> </h3> <p>Developed by Alizyme, a specialist biopharmaceutical company in collaboration with Takeda Pharmaceutical, cetilistat (AT</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cetilistat/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_Metabolic_Syndrome.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ilumya-treatment-moderate-severe-plaque-psoriasis/">Chronic Plaque Psoriais Treatment with ILUMYA</a> </h3> <p>ILUMYA™ (tildrakizumab-asmn) is a subcutaneous infusion indicated for the treatment of adults with moderate-to-severe plaque psoriasis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ilumya-treatment-moderate-severe-plaque-psoriasis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/Image-1-Ilumya.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cibinqo-abrocitinib-atopic-dermatitis/">CIBINQO (abrocitinib) to Treat Moderate to Severe Atopic Dermatitis</a> </h3> <p>CIBINQO (abrocitinib) is a once-daily, oral, prescription medicine to treat moderate to severe atopic dermatitis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cibinqo-abrocitinib-atopic-dermatitis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/02/Featured-Image-CIBINQO-abrocitinib-to-Treat-Moderate-to-Severe-Atopic-Dermatitis.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cilanserton/">Cilansetron – New Treatment for IBS</a> </h3> <p>Developed by Solvay Pharmaceuticals, cilansetron is a 5-HT3 antagonist indicated for the treatment of diarrhoea-predomin</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cilanserton/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_solvay_headquarters.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cimzia-certolizumab-pegol-treatment-moderate-severe-plaque-psoriasis/">CIMZIA (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis</a> </h3> <p>CIMZIA® (certolizumab pegol) is a subcutaneous infusion indicated for the treatment of adults with moderate-to-severe plaque psoriasis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cimzia-certolizumab-pegol-treatment-moderate-severe-plaque-psoriasis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-CIMZIA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cinqair-reslizumab-injection-for-treatment-of-severe-asthma-and-an-eosinophilic-phenotype/">Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype</a> </h3> <p>Cinqair is an injectable formulation of reslizumab developed by Teva Pharmaceuticals for the treatment of severe asthma and eosinophilic phenotype in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cinqair-reslizumab-injection-for-treatment-of-severe-asthma-and-an-eosinophilic-phenotype/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-113.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cobenfy-for-treatment-schizophrenia-us/">COBENFY for the Treatment of Schizophrenia, US</a> </h3> <p>Schizophrenia is a chronic and debilitating mental disorder that impacts the way an individual thinks, feels, and acts.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cobenfy-for-treatment-schizophrenia-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/10/Featured-Image-COBENFY™-xanomeline-and-trospium-chloride-for-the-Treatment-of-Schizophrenia-USA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/columvi-treatment-lymphoma/">Columvi (Glofitamab-gxbm) for the Treatment of Diffuse Large B-Cell Lymphoma, USA</a> </h3> <p>Columvi is a bispecific antibody, fixed-duration treatment for relapsed or refractory diffuse large B-cell lymphoma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/columvi-treatment-lymphoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/09/Featured-Image-Columvi.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/contraveforthetreatm/">Contrave for the Treatment of Obesity</a> </h3> <p>Contrave (Bupropion / naltrexone) is a drug indicated for treating obesity. The drug was developed by Orexigen Therapeutics.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/contraveforthetreatm/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-10.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/copiktra-chronic-lymphocytic-leukaemia/">COPIKTRA (duvelisib) Indicated for chronic lymphocytic leukaemia</a> </h3> <p>COPIKTRA (duvelisib) is a dual phosphoinositide 3-kinase (PI3K) inhibitor indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) or follicular lymphoma (FL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/copiktra-chronic-lymphocytic-leukaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-COPIKTRA-duvelisib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/corifact-hemophilia/">Corifact – Treatment for Rare Form of Haemophilia</a> </h3> <p>Corifact is an intravenous drug indicated for the treatment of bleeding disorder in patients with factor XIII deficien</p> </div> <div class="cell large-4"> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/corlanor-ivabradine-treatment-heart-failure/">Corlanor (Ivabradine) for the Treatment of Heart Failure</a> </h3> <p>Corlanor (ivabradine) is an oral medication approved to reduce the risk of hospitalisation for worsening heart failure in patients facing chronic heart failure risk due to the lower-left part of the heart not contracting well.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/corlanor-ivabradine-treatment-heart-failure/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-77.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cosela-trilaciclib-for-the-treatment-of-chemotherapy-induced-myelosuppression-us/">COSELA™ (trilaciclib) for the Treatment of Chemotherapy-Induced Myelosuppression, US</a> </h3> <p>COSELA™ (trilaciclib) is the first approved myeloprotection therapy indicated to reduce the occurrence of chemotherapy-induced bone marrow suppression in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cosela-trilaciclib-for-the-treatment-of-chemotherapy-induced-myelosuppression-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/03/Image-1-COSELA™-trilaciclib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cosentyx-secukinumab/">Cosentyx (secukinumab) for Treatment of Plaque Psoriasis</a> </h3> <p>Cosentyx is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cosentyx-secukinumab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2015/02/Featured-Image-Cosentyx-to-treat-Plaque-Psoriasis-US.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/covaxin-bbv152-for-the-treatment-of-covid-19/">COVAXIN (BBV152) for the Treatment of Covid-19, India</a> </h3> <p>COVAXIN™ (BBV152) is the first Covid-19 vaccine developed completely in India.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/covaxin-bbv152-for-the-treatment-of-covid-19/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/02/Image-1-COVAXIN-BBV152-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cresemba-isavuconazonium-sulphate/">Cresemba® (isavuconazonium sulphate) for the Treatment of Invasive Aspergillosis and Mucormycosis</a> </h3> <p>Cresemba (isavuconazonium sulphate) is an antifungal drug indicated for the treatment of invasive aspergillosis and invasive mucormycosis, which is also known as zygomycosis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cresemba-isavuconazonium-sulphate/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-73.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/crysvita-burosumab-twza/">Crysvita (burosumab-twza) for Treating X–Linked Hypophosphatemia</a> </h3> <p>Crysvita® (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for the treatment of X-linked hypophosphatemia (XLH) in adults and children.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/crysvita-burosumab-twza/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Crysvita.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cuvposa-treatment/">Cuvposa – Treatment for Chronic Drooling</a> </h3> <p>Cuvposa (Glycopyrrolate) is the first and only approved drug for controlling drooling in patients aged between three</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cuvposa-treatment/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-cuvposa.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cxl1020treatmentforp/">CXL-1020 Treatment for Patients with Acute Decompensated Heart Failure (ADHF)</a> </h3> <p>CXL-1020 is an investigational therapeutic agent being developed for treating patients with acute decompensated heart fa</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cxl1020treatmentforp/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Pic-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cymbaltadloxetinehci/">Cymbalta (Duloxetine HCl) for Chronic Musculoskeletal Pain Management</a> </h3> <p>Cymbalta (Duloxetine hydrochloride) is indicated for treating chronic musculoskeletal pain as a result of osteoarthritis</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cymbaltadloxetinehci/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-1-Cymbalta-capsule.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cyramza-ramucirumab-for-the-treatment-of-gastric-cancer/">Cyramza (ramucirumab) for the Treatment of Gastric Cancer</a> </h3> <p>Cyramza (ramucirumab) is a human monoclonal antibody for the treatment of Gastric cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cyramza-ramucirumab-for-the-treatment-of-gastric-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-15.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cystaran-cysteamine-hydrochloride-for-treatment-of-cystinosis/">Cystaran (cysteamine hydrochloride) for Treatment of Cystinosis</a> </h3> <p>Cystaran (cysteamine hydrochloride) is a cystine-depleting agent indicated for the treatment of cystinosis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cystaran-cysteamine-hydrochloride-for-treatment-of-cystinosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-15.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cytalux-pafolacianine-for-identification-of-ovarian-cancer/">Cytalux (pafolacianine) for Identification of Ovarian Cancer</a> </h3> <p>Cytalux is the first intraoperative fluorescent imaging drug that helps in identifying ovarian cancer lesions during surgery.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cytalux-pafolacianine-for-identification-of-ovarian-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/Featured-Image-Cytalux-pafolacianine.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="d" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>D</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/daklinza-daclatasvir-for-the-treatment-of-chronic-hepatitis-c-genotype-3-infection/">Daklinza (daclatasvir) for the Treatment of Chronic Hepatitis C Genotype 3 Infection</a> </h3> <p>Daklinza (daclatasvir), an NS5A replication complex inhibitor, is the first 12-week, all-oral therapy indicated for use with sofosbuvir, for the treatment of hepatitis C (HCV) genotype 3 infections.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/daklinza-daclatasvir-for-the-treatment-of-chronic-hepatitis-c-genotype-3-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-88.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/daliresp-treatment/">Daliresp (Roflumilast), Treatment to Reduce COPD</a> </h3> <p>Daliresp (Roflumilast) is an oral tablet that is proved to reduce the risk of exacerbations in patients suffering from</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/daliresp-treatment/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-roflumilast.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/dalvabancin/">Dalvabancin – Second-Generation Glycopeptide for Serious Gram-Positive Infections</a> </h3> <p>Originally developed by Vicuron Pharmaceuticals (which was subsequently acquired by Pfizer and then Durata Therapeutics)</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/dalvabancin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-21.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/danyelza-naxitamab-neuroblastoma/">DANYELZA (naxitamab-gqgk) for the Treatment of Neuroblastoma</a> </h3> <p>DANYELZA® (naxitamab-gqgk) is a humanised immunotherapy indicated in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of high-risk neuroblastoma (HR-NB).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/danyelza-naxitamab-neuroblastoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/12/Image-1-DANYELZA-naxitamab-gqgk.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/darapladib/">Darapladib – Selective Lp-PLA2 Inhibitor for Prevention of Atherosclerosis</a> </h3> <p>Darapladib is a selective LpPLA2 inhibitor under development by GlaxoSmithKline (GSK). The drug is targeted at coronary</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/darapladib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-gsk-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/darzalex-daratumumab-treatment-multiple-myeloma/">Darzalex (daratumumab) for the Treatment of Multiple Myeloma</a> </h3> <p>Darzalex (daratumumab) is the world's first human anti-CD38 monoclonal antibody (mAb) approved for the treatment of patients with multiple myeloma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/darzalex-daratumumab-treatment-multiple-myeloma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-105.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-for-the-treatment-of-light-chain-al-amyloidosis/">DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the Treatment of Light Chain (AL) Amyloidosis</a> </h3> <p>DARZALEX FASPRO<sup>®</sup> (daratumumab and hyaluronidase-fihj) is the first subcutaneous therapy approved for the treatment of newly diagnosed light chain (AL) amyloidosis in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-for-the-treatment-of-light-chain-al-amyloidosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/02/Image-1-DARZALEX-FASPRO.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/dasatinib/">Dasatinib – Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML)</a> </h3> <p>Dasatinib is a new, oral small-molecule tyrosine kinase inhibitor (TKI) developed by Bristol Myers Squibb for the trea</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/dasatinib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-22.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/defitelio-defibrotide-sodium-for-the-treatment-of-hepatic-veno-occlusive-disease/">Defitelio (defibrotide sodium) for the Treatment of Hepatic Veno-Occlusive Disease</a> </h3> <p>Defitelio (defibrotide sodium) is an injectable drug developed by Jazz Pharmaceuticals, for the treatment of hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome, in adults and children with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/defitelio-defibrotide-sodium-for-the-treatment-of-hepatic-veno-occlusive-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-28.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/delstrigo/">Delstrigo for the Treatment of HIV-1 Infection</a> </h3> <p>Delstrigo™ is a fixed-dose combination tablet of antiretroviral drugs doravirine, lamivudine, and tenofovir disoproxil fumarate indicated for the treatment of human immunodeficiency virus (HIV) 1 infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/delstrigo/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-image-Delstrigo.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/descovy-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection/">Descovy (emtricitabine, tenofovir alafenamide) for the Treatment of HIV-1 Infection</a> </h3> <p>Descovy (emtricitabine200mg/tenofovir alafenamide25mg, F/TAF) is developed by Gilead sciences for the treatment of HIV-1 infection in adults and children above 12 years of age.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/descovy-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-27.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fidaxomicin/">Dificid (fidaxomicin) – Narrow-Spectrum Antibiotic for Clostridium Difficile Infection</a> </h3> <p>Dificid (fidaxomicin) is the first in a new class of antibiotics developed by Optimer Pharmaceuticals to treat Clostridi</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fidaxomicin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-fidaxomicin.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/dimebon/">Dimebon – Investigational Compound Indicated for the Treatment of Alzheimer’s and Huntington’s Disease</a> </h3> <p>Dimebon (latrepirdine) is an investigational compound indicated for the treatment of Alzheimer's and Huntington's diseas</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/dimebon/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-brain-scan.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/">Dinutuximab beta for the Treatment of Neuroblastoma</a> </h3> <p>Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-145.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/doptelet-avatrombopag-treatment-thrombocytopenia/">Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia</a> </h3> <p>Doptelet® (avatrombopag) is one of the first thrombopoietin (TPO) receptor agonists to be approved in the US for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/doptelet-avatrombopag-treatment-thrombocytopenia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Doptelet.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/doripenem/">Doripenem – A New Broad-Spectrum Carabapenem Antibiotic</a> </h3> <p>Doripenem is part of Johnson &' Johnson's anti-infective R&D portfolio following the acquisition of Peninsula Ph</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/doripenem/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-anibiotic-resistance-cycle.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/dovato-dolutegravir-lamivudine/">Dovato (dolutegravir/lamivudine) for the Treatment of HIV Infection</a> </h3> <p>Dovato® (dolutegravir/lamivudine) is a two-drug regimen indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/dovato-dolutegravir-lamivudine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/Image-1-Dovato-dolutegravirlamivudine.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/duaklir-genuair-treatment-copd/">Duaklir Genuair for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)</a> </h3> <p>Duaklir Genuair (aclidinium bromide / formoterol fumarate) is an inhalation powder indicated as a maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/duaklir-genuair-treatment-copd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-64.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/dulera-treatment-asthma/">Dulera (Mometasone Furoate and Formoterol Fumarate Dihydrate) – Treatment for Asthma</a> </h3> <p>Dulera (mometasone furoate and formoterol fumarate dihydrate) is a new fixed-dose combination inhaler for the treatment of asthma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/dulera-treatment-asthma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-3.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/dupixent-dupilumab-atopic-dermatitis/">Dupixent (dupilumab) for the Treatment of Atopic Dermatitis, US</a> </h3> <p>Dupixent (dupilumab) is the first targeted treatment for children as young as six months old with severe atopic dermatitis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/dupixent-dupilumab-atopic-dermatitis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/09/Featured-Image-Dupixent.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/durlaza-aspirin-reducing-risk-cardiovascular-events/">Durlaza (aspirin) for Reducing Risk of Cardiovascular Events</a> </h3> <p>Durlaza (aspirin) is a non steroidal anti-inflammatory drug indicated for the prevention of thrombotic events in patients with cardiovascular disease (CVD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/durlaza-aspirin-reducing-risk-cardiovascular-events/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-23.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/duvyzat-duchenne-muscular-dystrophy-usa/">Duvyzat (givinostat) for the Treatment of Duchenne Muscular Dystrophy (DMD), USA</a> </h3> <p>Duvyzat™ (givinostat) is the first non-steroidal drug approved to treat all genetic variants of Duchenne muscular dystrophy (DMD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/duvyzat-duchenne-muscular-dystrophy-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/06/Featured-Image-Duvyzat-givinostat-for-the-Treatment-of-Duchenne-muscular-dystrophy-shutterstock_1894082203.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/duzallo-allopurinol-and-lesinurad-for-the-treatment-of-hyperuricemia-associated-with-gout/">Duzallo (allopurinol and lesinurad) for the Treatment of Hyperuricemia Associated with Gout</a> </h3> <p>Duzallo (allopurinol and lesinurad) is indicated for the treatment of hyperuricemia associated with uncontrolled gout. It contains urate transporter-1 (URAT-1) inhibitor blended with xanthine oxidase inhibitor (XOI).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/duzallo-allopurinol-and-lesinurad-for-the-treatment-of-hyperuricemia-associated-with-gout/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-153.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/dysport-abobotulinumtoxina-for-the-treatment-of-lower-limb-spasticity-in-paediatric-patients/">Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Paediatric Patients</a> </h3> <p>Dysport (abobotulinumtoxinA) is an injectable formulation developed by Ipsen Biopharmaceuticals for the treatment of lower limb spasticity in paediatric patients aged two years or older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/dysport-abobotulinumtoxina-for-the-treatment-of-lower-limb-spasticity-in-paediatric-patients/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-30.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="e" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>E</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ebanga-ansuvimab-zykl/">Ebanga (ansuvimab-zykl) for the Treatment of Zaire Ebolavirus Infection</a> </h3> <p>Ebanga (ansuvimab-zykl) is a Zaire ebolavirus glycoprotein (EBOV GP)-directed human monoclonal antibody for the treatment of Zaire ebolavirus infection in adult and paediatric patients. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ebanga-ansuvimab-zykl/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/05/Image-1-Ebanga.jpeg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/edarbi-treatment/">Edarbi for the Treatment of Hypertension</a> </h3> <p>Edarbi (Azilsartan medoxomil) was developed by Takeda Pharmaceuticals for the treatment of hypertension in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/edarbi-treatment/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-edarbi-treatment.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/edoxabanoralanticoag/">Edoxaban, Oral Anticoagulant</a> </h3> <p>Lixiana (edoxaban) is an oral anticoagulant developed by Daiichi Sankyo, a pharmaceutical company based in Japan. It is</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/edoxabanoralanticoag/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-1-20.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/edurant-rilpivirine-for-the-treatment-of-hiv-1-infection/">Edurant (rilpivirine) for the Treatment of HIV-1 Infection</a> </h3> <p>Edurant (rilpivirine) is an antiviral drug indicated for treatment-naive adults with HIV-1 infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/edurant-rilpivirine-for-the-treatment-of-hiv-1-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-38.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/blacytarabinefortrea/">Elacytarabine (CP-4055) for Treatment of Acute Myeloid Leukaemia</a> </h3> <p>Elacytarabine (CP-4055) is a lipid-conjugated version of cytarabine, an anti-cancer agent drug approved for the treatmen</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/blacytarabinefortrea/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Diagram.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/elahere-for-treatment-of-ovarian-cancer-us/">ELAHERE for the Treatment of Ovarian Cancer, US</a> </h3> <p>AbbVie acquired ImmunoGen in February 2024, which added ELAHERE to its portfolio.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/elahere-for-treatment-of-ovarian-cancer-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/FEATUR1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/elelyso-taliglucerase-alfa-treatment-gaucher-disease/">Elelyso (Taliglucerase Alfa) for Treating Gaucher Disease</a> </h3> <p>Elelyso (taliglucerase alfa) is an intravenous drug indicated for the treatment of type one Gaucher disease. The drug was jointly developed by Protalix BioTherapeutics and Pfizer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/elelyso-taliglucerase-alfa-treatment-gaucher-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-27.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/elevidys-duchenne-muscular-dystrophy/">ELEVIDYS (delandistrogene moxeparvovec) for the Treatment of Duchenne Muscular Dystrophy, USA</a> </h3> <p>Elevidys (delandistrogene moxeparvovec) is the first gene therapy approved to treat Duchenne muscular dystrophy in children.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/elevidys-duchenne-muscular-dystrophy/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/01/Featured-Image-ELEVIDYS-delandistrogene-moxeparvovec-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/eliquis-apixaban-for-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-nvaf-patients/">Eliquis (apixaban) for Prevention of Stroke in Nonvalvular Atrial Fibrillation (NVAF) Patients</a> </h3> <p>Eliquis (apixaban) is an anticoagulant drug that was jointly developed by Bristol-Myers Squibb and Pfizer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/eliquis-apixaban-for-prevention-of-stroke-in-nonvalvular-atrial-fibrillation-nvaf-patients/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-20.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/eloctate-for-treatment-of-haemophilia-a/">Eloctate™ for the Treatment of Haemophilia A</a> </h3> <p>Eloctate is a drug approved for the control and prevention of bleeding episodes in children and adult haemophilia A patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/eloctate-for-treatment-of-haemophilia-a/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/Eloctate.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/elotuzumab/">Elotuzumab – Anti-CS1 Antibody for Multiple Myeloma</a> </h3> <p>Elotuzumab (HuLuc63) is an anti-CS1 humanised monoclonal antibody (MAb) developed by PDL Biopharma. In December 2008 PDL</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/elotuzumab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-blood-cells.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/elrexfio-elranatamab-multiple-myeloma-usa/">ELREXFIO (elranatamab) for the Treatment of Multiple Myeloma, USA</a> </h3> <p>ELREFXIO™ (elranatamab) is a targeted immunotherapy to treat adult patients with relapsed and refractory multiple myeloma (RRMM).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/elrexfio-elranatamab-multiple-myeloma-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/07/Featured-Image-ELREXFIO-elranatamab-shutterstock_1424208956.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/elzonris/">Elzonris (tagraxofusp-erzs) for the Treatment of BPDCN</a> </h3> <p>Elzonris™ (tagraxofusp-erzs) is an interleukin-3 receptor alpha chain (CD123) directed cytotoxin that is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and paediatric patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/elzonris/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/Image-1-Elzonris.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/emflaza-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy/">Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy</a> </h3> <p>Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for treatment of patients aged two years and older suffering from duchenne muscular dystrophy (DMD). </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/emflaza-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-134.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/empaveli-pegcetacoplan/">EMPAVELI (pegcetacoplan) for the Treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH)</a> </h3> <p>EMPAVELI™ (pegcetacoplan) is the first and only targeted complement component 3 (C3) therapy indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/empaveli-pegcetacoplan/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/06/Image-1-EMPAVELI-pegcetacoplan.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/empliciti-elotuzumab-treatment-multiple-myeloma/">Empliciti (elotuzumab) for the Treatment of Multiple Myeloma</a> </h3> <p>Empliciti (elotuzumab) is an immunostimulatory antibody indicated for the treatment of multiple myeloma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/empliciti-elotuzumab-treatment-multiple-myeloma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2015/12/1l-Image-Empliciti.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/enbrel/">Enbrel – Immunosuppressant for Treatment of Rheumatoid Arthritis</a> </h3> <p>Enbrel is an immunosuppressant that inhibits the production of tumour necrosis factor (TNF) in patients suffering from r</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/enbrel/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-hands-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/endari-for-the-treatment-of-sickle-cell-disease/">Endari for the Treatment of Sickle Cell Disease</a> </h3> <p>Endari™ is an orally administered powdered form of amino acid L-glutamine indicated for the treatment of sickle-cell disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/endari-for-the-treatment-of-sickle-cell-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-42.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/enhertu-her2-positive-advanced-gastric-cancer/">ENHERTU (fam-trastuzumab deruxtecan-nxki) for the Treatment of HER2 Positive Advanced Gastric Cancer</a> </h3> <p>Enhertu is a HER2-directed antibody-drug conjugate jointly developed by AstraZeneca and Daiichi Sankyo.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/enhertu-her2-positive-advanced-gastric-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/01/Image-1-ENHERTU-fam-trastuzumab-deruxtecan-nxki.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/enjaymo-sutimlimab-jome-cad/">Enjaymo (sutimlimab-jome) for the Treatment of Cold Agglutinin Disease (CAD)</a> </h3> <p>Enjaymo™ (sutimlimab-jome) is a classical complement inhibitor that works by inhibiting the haemolysis of red blood cells.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/enjaymo-sutimlimab-jome-cad/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/03/Featured-Image-Enjaymo-sutimlimab-jome.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/enspryng-satralizumab-mwge/">Enspryng (satralizumab-mwge) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)</a> </h3> <p>Enspryng™ (satralizumab-mwge) is the first and only US Food and Drug Administration (FDA)-approved subcutaneous therapy indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in anti-aquaporin-4 (AQP4) antibody-positive adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/enspryng-satralizumab-mwge/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/09/Image-1-Enspryng™-satralizumab-mwge.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/entecaviroralhepatit/">Entecavir (Baraclude) – Oral Antiviral Drug for Hepatitis-B Infection</a> </h3> <p>Discovered by Bristol-Myers Squibb (BMS), Entecavir / Baraclude is an antiviral drug for treating chronic Hepatitis B.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/entecaviroralhepatit/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-6.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/entresto-sacubitril-valsartan-heart-failure/">Entresto (Sacubitril / Valsartan) for the Treatment of Heart Failure</a> </h3> <p>Entresto (sacubitril/valsartan) is an angiotensin II receptor blocker indicated for the treatment of chronic heart failure.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/entresto-sacubitril-valsartan-heart-failure/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2015/07/Image-2-Entresto-Sacubitril-and-Valsartan.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/entyvio-treatment-uc-cd/">Entyvio for the Treatment of Ulcerative Colitis and Crohn’s Disease, US</a> </h3> <p>Positive clinical trail results for Entyvio have led to its approval in both the US and EU markets.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/entyvio-treatment-uc-cd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2014/06/Entyvio-CW-Feat-Img.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/epanova-for-the-treatment-of-hypertriglyceridemia/">Epanova for the Treatment of Hypertriglyceridemia</a> </h3> <p>Epanova (omega-3-carboxylic acids) is indicated for the treatment of adult patients with severe hypertriglyceridaemia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/epanova-for-the-treatment-of-hypertriglyceridemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-42.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/epclusa-sofosbuvir-velpatasvir-treatment-of-hepatitis-c/">Epclusa (Sofosbuvir/ Velpatasvir) for the Treatment of Hepatitis C</a> </h3> <p>Epclusa (Sofosbuvir/ Velpatasvir) is an oral formulation developed by Gilead Sciences for the treatment of 1-6 chronic hepatitis C virus (HCV) infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/epclusa-sofosbuvir-velpatasvir-treatment-of-hepatitis-c/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-121.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/epidiolex-cannabidiol-treatment-seizures-associated-lennox-gastaut-syndrome-dravet-syndrome/">EPIDIOLEX (cannabidiol) for Seizures Associated with Lennox-Gastaut and Dravet Syndromes</a> </h3> <p>EPIDIOLEX® is a cannabidiol (CBD) based drug indicated for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/epidiolex-cannabidiol-treatment-seizures-associated-lennox-gastaut-syndrome-dravet-syndrome/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-EPIDIOLEX-for-the-Treatment-of-Seizures.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/epkinly-treatment-diffuse-large-b-cell-lymphoma/">Epkinly (epcoritamab-bysp) for the Treatment of Diffuse Large B-Cell Lymphoma, USA</a> </h3> <p>Epkinly™ (epcoritamab-bysp) is the first bispecific antibody to treat adults with diffuse large B-cell lymphoma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/epkinly-treatment-diffuse-large-b-cell-lymphoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/08/Featured-Image-Epkinly.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/erbitux/">Erbitux (Cetuximab)</a> </h3> <p>Erbitux is a chimaeric monoclonal antibody (MAb) that is specific for the epidermal growth factor receptor (EGFR). A new</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/erbitux/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_0421-PH_EthicalsPrecl.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/erivedge-treatment-for-advanced-basal-cell-carcinoma/">Erivedge (vismodegib) – Treatment for Advanced Basal Cell Carcinoma</a> </h3> <p>Erivedge (vismodegib) is a Hedgehog pathway inhibitor indicated for the treatment of advanced basal cell carcinoma (BCC) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/erivedge-treatment-for-advanced-basal-cell-carcinoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/erleada-apalutamide-treatment-non-metastatic-castration-resistant-prostate-cancer/">Erleada (apalutamide) for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer</a> </h3> <p>Erleada™ (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/erleada-apalutamide-treatment-non-metastatic-castration-resistant-prostate-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Erleada.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/erwinaze-asparaginase-erwinia-chrysanthemi/">Erwinaze (Asparaginase Erwinia Chrysanthemi) – Treatment for ALL</a> </h3> <p>Erwinaze (asparaginase Erwinia chrysanthemi) is indicated for the treatment of acute lymphoblastic leukaemia (ALL). It is manufactured by EUSA Pharma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/erwinaze-asparaginase-erwinia-chrysanthemi/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/eskata-hydrogen-peroxide-treatment-raised-seborrheic-keratoses/">Eskata (hydrogen peroxide) for the Treatment of Raised Seborrheic Keratoses (SK), USA</a> </h3> <p>Eskata® (hydrogen peroxide) is a topical, non-invasive treatment for raised seborrheic keratoses (SK) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/eskata-hydrogen-peroxide-treatment-raised-seborrheic-keratoses/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Eskata.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/esperoct-turoctocog-alfa-pegol/">Esperoct (turoctocog alfa pegol) for the Treatment of Haemophilia A</a> </h3> <p>Esperoct® (turoctocog alfa pegol) is a recombinant factor indicated for the treatment of haemophilia A in adults and children.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/esperoct-turoctocog-alfa-pegol/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-Image-Esperoct.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/etc/">ETC-216 – Phospholipid</a> </h3> <p>Developed by US biopharmaceutical company Esperion Therapeutics, ETC-216 is a synthetic variant of high-density lipoprot</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/etc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/image_1-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/eviplera-treatment-hiv-pill/">Eviplera – Treatment for HIV</a> </h3> <p>Eviplera is a single-pill regimen targeted at human immunodeficiency virus-1 (HIV-1). It combines the active substances emtricitabine, rilpivirine and tenofovir disoproxil.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/eviplera-treatment-hiv-pill/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/evotaz-atazanavir-and-cobicistat-for-the-treatment-of-hiv-1-infection/">Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection</a> </h3> <p>Evotaz (atazanavir and cobicistat) is a protease inhibitor indicated for the treatment of HIV-1 infection in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/evotaz-atazanavir-and-cobicistat-for-the-treatment-of-hiv-1-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/2l-image-92.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/evrysdi-risdiplam/">Evrysdi for the Treatment of Spinal Muscular Atrophy, US</a> </h3> <p>Evrysdi is the first and only oral medication indicated for the treatment of SMA in patients. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/evrysdi-risdiplam/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/08/Evrysdi-Feat-Img.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/evusheld-tixagevimab-cilgavimab/">Evusheld (tixagevimab and cilgavimab) for the Prevention of Covid-19</a> </h3> <p>Evusheld is a long-acting antibody combination therapy for the pre-exposure prevention of Covid-19 in high-risk patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/evusheld-tixagevimab-cilgavimab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/03/Featured-Image-Evusheld.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/exanta/">Exanta – Oral Direct Thrombin Inhibitor for the</a> </h3> <p>Exanta (ximelagatran) is an oral Direct Thrombin Inhibitor (DTI) under development by AstraZeneca. As the first fixed-do</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/exanta/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/exanta1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/exjade-deferasirox-treatment-chronic-iron-overload-novartis/">Exjade (Deferasirox) for Treating Chronic Iron Overload, US</a> </h3> <p>Exjade (deferasirox) is an oral iron chelator developed and manufactured by Novartis. It is indicated for the treatment of iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/exjade-deferasirox-treatment-chronic-iron-overload-novartis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-17.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/exkivity-mobocertinib-nsclc/">Exkivity (mobocertinib) for the Treatment of Non-Small Cell Lung Cancer</a> </h3> <p>Exkivity is the first and only oral therapy indicated for non-small cell lung cancer with EGFR exon 20 insertion mutations.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/exkivity-mobocertinib-nsclc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/10/Featured-Image-Mobocertinib.jpeg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/exondys-51-eteplirsen-for-the-treatment-of-duchenne-muscular-dystrophy-dmd/">Exondys 51 (eteplirsen) for the Treatment of Duchenne Muscular Dystrophy (DMD)</a> </h3> <p>Exondys 51 (eteplirsen) is an injectable solution developed by Sarepta Therapeutics.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/exondys-51-eteplirsen-for-the-treatment-of-duchenne-muscular-dystrophy-dmd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-127.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/exparel-for-postsurgical-pain-relief/">Exparel for Postsurgical Pain Relief</a> </h3> <p>Exparel is a non-opioid analgesic, developed to provide postsurgical pain relief. It is a long acting liposome injection of bupivacaine, a drug widely used to treat postsurgical pain.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/exparel-for-postsurgical-pain-relief/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-bottle.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/exubera/">Exubera – Inhaled Insulin</a> </h3> <p>The product of a joint development programme between Aventis and Pfizer, Exubera is an inhaled short-acting insulin prep</p> </div> <div class="cell large-4"> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/eylea-aflibercept-for-the-treatment-of-wet-amd/">Eylea (Aflibercept) for Treatment for Wet AMD</a> </h3> <p>Eylea (aflibercept), a recombinant fusion protein, was developed for the treatment of patients with wet age-related macular degeneration (AMD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/eylea-aflibercept-for-the-treatment-of-wet-amd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-15.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="f" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>F</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fabhalta-iptacopan-paroxysmal-nocturnal-hemoglobinuria-us/">Fabhalta (iptacopan) for the Treatment of Paroxysmal Nocturnal Hemoglobinuria, USA</a> </h3> <p>Fabhalta (iptacopan) is the first oral monotherapy indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fabhalta-iptacopan-paroxysmal-nocturnal-hemoglobinuria-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/12/Featured-Image-Fabhalta-iptacopan-for-the-treatment-of-paroxysmal-nocturnal-hemoglobinuria-US.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lasofoxifene/">Fablyn (Lasofoxifene) – Investigational SERM</a> </h3> <p>The product of a joint development programme between Pfizer and Ligand Pharmaceuticals, Fablyn, formerly Oporia (lasofoxifene) is a selective oestrogen receptor modulator (SERM).</p> </div> <div class="cell large-4"> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fampridine/">Fampridine-SR – Treatment for Multiple Sclerosis</a> </h3> <p>Developed by Acorda Therapeutics and manufactured by Elan Corporation, fampridine-SR (now referred to as AMPYRA) is a se</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fampridine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-nerve-cells.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/farydak-panobinostat-treatment-multiple-myeloma/">Farydak® (panobinostat) for the Treatment of Multiple Myeloma</a> </h3> <p>Farydak (panobinostat, previously known as LBH589) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of patients with multiple myeloma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/farydak-panobinostat-treatment-multiple-myeloma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-75.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fasenra-benralizumab-treatment-asthma/">Fasenra (benralizumab) for the Treatment of Asthma</a> </h3> <p>Fasenra (benralizumab) is a monoclonal antibody (mAb) indicated for the treatment of severe eosinophilic asthma in patients aged 12 years and older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fasenra-benralizumab-treatment-asthma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Fasenra.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/faslodex-fulvestrant-treatment-advanced-breast-cancer/">Faslodex (fulvestrant) for the Treatment of Advanced Breast Cancer</a> </h3> <p>Faslodex (fulvestrant) is an oestrogen receptor antagonist indicated for the treatment of locally advanced or metastatic breast cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/faslodex-fulvestrant-treatment-advanced-breast-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Faslodex.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fetroja-cefiderocol/">FETROJA (cefiderocol) for the Treatment of Bacterial Pneumonia</a> </h3> <p>FETROJA® (cefiderocol) is the first approved siderophore cephalosporin antibacterial drug. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fetroja-cefiderocol/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/10/Image-1-FETROJA-cefiderocol.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fetzima-levomilnacipran-major-depressive-disorder/">Fetzima (Levomilnacipran) – Treatment for Major Depressive Disorder (MDD)</a> </h3> <p>Fetzima (levomilnacipran) is an antidepressant indicated for treatment of adult patients suffering from major depressive disorder (MDD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fetzima-levomilnacipran-major-depressive-disorder/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-34.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fiasp-insulin-aspart-treatment-type-1-type-2-diabetes-2/">Fiasp (insulin aspart) for the Treatment of Type 1 and Type 2 Diabetes</a> </h3> <p>Discovered and developed by Novo Nordisk, Fiasp® (insulin aspart) is a fast-acting insulin analogue indicated for the treatment of adults with Type 1 and Type 2 diabetes.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fiasp-insulin-aspart-treatment-type-1-type-2-diabetes-2/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-4.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/filspari-sparsentan-proteinuria-iga-nephropathy/">Filspari (sparsentan) for the Reduction of Proteinuria in IgA Nephropathy, USA</a> </h3> <p>Filspari (sparsentan) is the first approved non-immunosuppressive therapy for reducing proteinuria in IgA nephropathy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/filspari-sparsentan-proteinuria-iga-nephropathy/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/06/Featured-Image_Filspari-sparsentan.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fingolimod/">Fingolimod – Novel Therapy for Multiple Sclerosis</a> </h3> <p>Fingolimod (branded Gilenya) is an innovative treatment for multiple sclerosis (MS) under development by Novartis. The d</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fingolimod/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-multiple-sclerosis.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fintepla-fenfluramine-treatment-seizures-dravet-syndrome/">FINTEPLA (Fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome, USA</a> </h3> <p>FINTEPLA® (fenfluramine) is indicated to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fintepla-fenfluramine-treatment-seizures-dravet-syndrome/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/09/Featured-Image-FINTEPLA-fenfluramine-for-Treatment-of-Seizures.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/firazyr-treatment-for-hereditary-angioedema/">FIRAZYR – Treatment for Hereditary Angioedema</a> </h3> <p>FIRAZYR (Icatibant) is a drug developed and manufactured by Jerini, which was taken over by Shire Pharmaceuticals in 2008. The drug is indicated for the treatment of Hereditary Angioedema (HAE).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/firazyr-treatment-for-hereditary-angioedema/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-compound.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/firdapse-amifampridine-lems/">Firdapse (amifampridine) for Lambert-Eaton Myasthaenic Syndrome</a> </h3> <p>Firdapse® (amifampridine) is one of the first drugs to be approved for the treatment of Lambert-Eaton myasthaenic syndrome (LEMS) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/firdapse-amifampridine-lems/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Firdapse.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/florbetaben/">Florbetaben</a> </h3> <p>Alzheimer's disease (AD) is the most common type of dementia, which severely impacts the intellectual abilities of a</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/florbetaben/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-neurofibrillary-tangle.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/flucelvax-vaccine-for-protection-against-seasonal-influenza/">Flucelvax Vaccine for Protection Against Seasonal Influenza</a> </h3> <p>Flucelvax, developed by Novartis in association with the US Department of Health and Human Services, is a vaccine that provides protection against seasonal influenza for adult patients aged 18 years and above.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/flucelvax-vaccine-for-protection-against-seasonal-influenza/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-18.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fludase/">Fludase – Experimental Antiviral Drug for Influenza</a> </h3> <p>NexBio, a US start-up biopharmaceutical company that specialises in developing antiviral agents, has pioneered the development of Fludase (DAS181).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fludase/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-influenza.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/flulavalinfluenzavir/">FluLaval Influenza Virus Vaccine</a> </h3> <p>FluLaval is an influenza vaccine that was approved by the US FDA on 23 July 2010, for use on people who are 18 years and</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/flulavalinfluenzavir/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-8.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/flurizan/">Flurizan – Anti-Amyloid Drug for Treatment of Alzheimer’s Disease</a> </h3> <p>Myriad Pharmaceuticals' Flurizan (tarenflurbil) is a selective amyloid lowering agent under development for the treatmen</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/flurizan/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-brain-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/flutiform-fluticasone-proprionate-and-formoterol-fumarate-for-treatment-of-asthma/">Flutiform (fluticasone proprionate and formoterol fumarate) for Treatment of Asthma</a> </h3> <p>Flutiform (fluticasone proprionate and formoterol fumarate) is a combination therapy used for the treatment of asthma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/flutiform-fluticasone-proprionate-and-formoterol-fumarate-for-treatment-of-asthma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-21.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/forxiga-dapagliflozin-for-treatment-of-type-2-diabetes/">Forxiga (dapagliflozin) for Treatment of Type 2 Diabetes</a> </h3> <p>Forxiga® (dapagliflozin) is approved for the treatment of paediatric type 2 diabetes, chronic heart failure and chronic kidney disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/forxiga-dapagliflozin-for-treatment-of-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2014/01/Featured-Image-Forxiga-dapagliflozin-shutterstock_2401535759.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fotivda-tivozanib-for-the-treatment-of-renal-cell-carcinoma/">FOTIVDA (tivozanib) for the Treatment of Renal Cell Carcinoma</a> </h3> <p>FOTIVDA® (tivozanib) is an oral tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC) in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fotivda-tivozanib-for-the-treatment-of-renal-cell-carcinoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/03/Image-1-Fotivda.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fruzaqla-fruquintinib-metastatic-colorectal-cancer/">FRUZAQLA (fruquintinib) for the Treatment of Metastatic Colorectal Cancer, USA</a> </h3> <p>FRUZAQLA® (fruquintinib) is an oral targeted therapy indicated for adult patients with metastatic colorectal cancer (mCRC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fruzaqla-fruquintinib-metastatic-colorectal-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/02/Featured-Image-FRUZAQLA-fruquintinib-for-the-Treatment-of-Metastatic-Colorectal-Cancer.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/fulyzaq-crofelemer-treatment-hiv-aids-associated-diarrhoea/">Fulyzaq (Crofelemer) for the Treatment of HIV / AIDS-Associated Diarrhoea</a> </h3> <p>Fulyzaq (crofelemer) is an anti-infective drug which is derived from a botanical source. It is indicated for the treatment of non-infectious diarrhoea in HIV / AIDS patients who are on anti-retroviral therapy (ART).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/fulyzaq-crofelemer-treatment-hiv-aids-associated-diarrhoea/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-21.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/perampaneltreatmentf/">Fycompa (perampanel) – Treatment for Epilepsy</a> </h3> <p>Fycompa (perampanel / E2007) is an AMPA-type glutamate receptor antagonist indicated for the treatment of epilepsy. It was developed by Japan-based healthcare company Eisai.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/perampaneltreatmentf/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image1-4.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="g" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>G</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/gaboxadol/">Gaboxadol – Investigational Agent</a> </h3> <p>Gaboxadol is a direct-acting gamma-amino butyric acid (GABA)A agonist under development by Danish pharmaceutical company</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/gaboxadol/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/sleep-disorders.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/galafold-migalastat-fabry-disease/">Galafold (migalastat) Indicated for the Treatment of Fabry Disease</a> </h3> <p>Galafold™ (migalastat) is indicated for the treatment of adult patients aged 16 years and older with Fabry disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/galafold-migalastat-fabry-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Galafold.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/galida/">Galida – Dual PPAR</a> </h3> <p>AstraZeneca's, Galida (tesaglitazar) is a dual-acting oral Peroxisome Proliferator-Activated Receptor (PPAR) agonist tha</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/galida/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/image_1-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/gamifant-emapalumab-lzsg/">Gamifant (emapalumab-lzsg) for Primary Haemophagocytic Lymphohistiocytosis</a> </h3> <p>Gamifant® (emapalumab-lzsg) is an interferon-gamma (IFNγ) blocking antibody indicated for the treatment of primary haemophagocytic lymphohistiocytosis (HLH) in paediatric and adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/gamifant-emapalumab-lzsg/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Gamifant.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/gardasil-9-vaccine-hpv/">Gardasil 9 Vaccine for Prevention of Cancers Caused by Human Papillomavirus (HPV)</a> </h3> <p>Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) is indicated for the prevention of cancers caused by some types of human papillomavirus (HPV).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/gardasil-9-vaccine-hpv/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-65.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/gattex-teduglutide-treatment-short-bowel-syndrome/">Gattex (Teduglutide) for Treatment of Short Bowel Syndrome (SBS)</a> </h3> <p>Gattex (teduglutide) is a subcutaneous injection indicated for the treatment of adult patients with short bowel syndrome (SBS). The drug was developed and manufactured by NPS Pharmaceuticals in association with Takeda Pharmaceuticals.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/gattex-teduglutide-treatment-short-bowel-syndrome/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-26.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/gavreto-pralsetinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/">Gavreto (pralsetinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)</a> </h3> <p>Gavreto™ (pralsetinib) is a targeted therapy indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), diagnosed by a US Food and Drug Administration (FDA)-approved test, in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/gavreto-pralsetinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/09/Image-2-Gavreto-pralsetinib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/gazyva-obinutuzumab-for-the-treatment-of-chronic-lymphocytic-leukaemia-cll/">Gazyva (obinutuzumab) for the Treatment of Chronic Lymphocytic Leukaemia (CLL)</a> </h3> <p>Gazyva (obinutuzumab / GA101) is a monoclonal antibody indicated for the treatment of chronic lymphocytic leukaemia (CLL). </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/gazyva-obinutuzumab-for-the-treatment-of-chronic-lymphocytic-leukaemia-cll/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-45.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/gemtesa-vibegron-for-the-treatment-of-overactive-bladder-oab/">GEMTESA for the Treatment of Overactive Bladder, US</a> </h3> <p>GEMTESA’s long-term safety, tolerability, and efficacy in adults with OAB was evaluated in a 40-week Phase III EMPOWUR extension study.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/gemtesa-vibegron-for-the-treatment-of-overactive-bladder-oab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/07/OAB-Feat-Img.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/gilotrif-afatinib-treatment-of-metastatic-non-small-cell-lung-cancer/">Gilotrif (afatinib) for the Treatment of Metastatic Non-Small cell Lung Cancer</a> </h3> <p>Gilotrif (afatinib) is an orally administered drug that is indicated as the first-line treatment for metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/gilotrif-afatinib-treatment-of-metastatic-non-small-cell-lung-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-8.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/givlaari-givosiran/">Givlaari™ (givosiran) for the Treatment of Acute Hepatic Porphyria</a> </h3> <p>Givlaari™ (givosiran) is the first aminolevulinic acid synthase 1 (ALAS1)-targeting RNAi drug indicated for the treatment of acute hepatic porphyria (AHP) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/givlaari-givosiran/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/12/Image-1-Givlaari™.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/glatopa-glatiramer-acetate-injection-multiple-sclerosis/">Glatopa (glatiramer acetate injection) for the Treatment of Multiple Sclerosis</a> </h3> <p>Glatopa (glatiramer acetate injection, formerly M356) is the first substitutable generic drug approved for the treatment of relapsing-remitting multiple sclerosis (RRMS).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/glatopa-glatiramer-acetate-injection-multiple-sclerosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-78.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/gls-5700-dna-vaccine-for-prevention-of-infection-from-zika-virus/">GLS-5700 DNA Vaccine for Prevention of Infection from Zika Virus</a> </h3> <p>GLS-5700 is a synthetic vaccine being developed by Inovio Pharmaceuticals and GeneOne Life Sciences to prevent and treat infections caused by the Zika virus.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/gls-5700-dna-vaccine-for-prevention-of-infection-from-zika-virus/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-large.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/glybera-alipogene-tiparvovec-treatment-lipoprotein-lipase-deficiency-lpld/">Glybera (alipogene tiparvovec) for Treatment of Lipoprotein Lipase Deficiency (LPLD)</a> </h3> <p>Glybera (alipogene tiparvovec) is a gene therapy indicated for the treatment Lipoprotein Lipase Deficiency (LPLD). It was developed by Amsterdam Molecular Therapeutics (AMT), which was acquired by uniQure in April 2012.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/glybera-alipogene-tiparvovec-treatment-lipoprotein-lipase-deficiency-lpld/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-16.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/grnpocforspinalcordi/">GRNOPC1 for spinal-cord injury</a> </h3> <p>GRNOPC1 is an indicative stem cell therapy developed by Geron for the treatment of spinal cord injuries (SCI).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/grnpocforspinalcordi/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-7.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="h" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>H</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/haegarda-for-the-preventive-treatment-of-hereditary-angioedema/">Haegarda for the Preventive Treatment of Hereditary Angioedema</a> </h3> <p>Haegarda® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/haegarda-for-the-preventive-treatment-of-hereditary-angioedema/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-149.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/haiyitan-treatment-non-small-cell-lung-cancer-japan/">Haiyitan for the Treatment of Non-Small Cell Lung Cancer, Japan</a> </h3> <p>The NMPA granted conditional approval for Haiyitan in China for NSCLC patients with METex14 skipping mutations in 2023.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/haiyitan-treatment-non-small-cell-lung-cancer-japan/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/Featured-Image-Haiyitan-Gumarontinib-Hydrate-shutterstock_2239483735.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/halaven-cancer/">Halaven – Treatment of Metastatic Breast Cancer</a> </h3> <p>Halaven is a non-taxane drug developed by Eisai Co. for the treatment of metastatic breast cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/halaven-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-halaven.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/halaven-eribulin-mesylate-treatment-advanced-liposarcoma/">Halaven (eribulin mesylate) for the Treatment of Advanced Liposarcoma</a> </h3> <p>Halaven (eribulin mesylate) is an injectable chemotherapy drug developed by Eisai for the treatment of unresectable or metastatic liposarcoma patients that previously received anthracycline-based chemotherapy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/halaven-eribulin-mesylate-treatment-advanced-liposarcoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-26.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/harvoni-chronic-hepatitis-c/">Harvoni (ledipasvir/sofosbuvir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection</a> </h3> <p>Developed by Gilead Sciences, Harvoni (ledipasvir/sofosbuvir) is the first combination pill approved for the treatment of adult patients with chronic hepatitis C genotype 1 infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/harvoni-chronic-hepatitis-c/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-18.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/hemlibra-emicizumab-kxwh-treatment-haemophilia-inhibitors/">Hemlibra® (emicizumab-kxwh) for the Treatment of Haemophilia A with Inhibitors</a> </h3> <p>Hemlibra® (emicizumab-kxwh) is an antibody indicated to reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/hemlibra-emicizumab-kxwh-treatment-haemophilia-inhibitors/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/2l-image-Hemlibra.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/herzuma-trastuzumab-biosimilar-treatment-breast-gastric-cancers/">Herzuma (trastuzumab biosimilar) for the Treatment of Breast and Gastric Cancers</a> </h3> <p>Herzuma® (trastuzumab biosimilar / CT-P6) is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/herzuma-trastuzumab-biosimilar-treatment-breast-gastric-cancers/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Herzuma.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/hetlioz-tasimelteon-treatment-non-24-hour-sleep-wake-disorder/">Hetlioz (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder</a> </h3> <p>Hetlioz (tasimelteon) is the first and only drug approved in the European Union (EU) for non-24-hour sleep-wake disorder (Non-24).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/hetlioz-tasimelteon-treatment-non-24-hour-sleep-wake-disorder/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-80.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/hizentra-treatment-patients-cidp/">Hizentra for the Treatment of Patients with CIDP</a> </h3> <p>Hizentra® (immune globulin subcutaneous 20% liquid) is a subcutaneous infusion indicated for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/hizentra-treatment-patients-cidp/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Hizentra.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/horizant-treatment-restless-legs-syndrome/">Horizant – Treatment for Restless Legs Syndrome</a> </h3> <p>Horizant is a non-dopaminergic therapy indicated for the treatment of restless legs syndrome (RLS). It was developed by XenoPort and is marketed by GSK in the US.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/horizant-treatment-restless-legs-syndrome/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/humira-adalimumab-ulcerative-colitis/">HUMIRA (adalimumab) for the Treatment of Ulcerative Colitis</a> </h3> <p>HUMIRA is the only subcutaneous therapy approved by the US Food and Drug Administration (FDA) for the treatment of ulcerative colitis in paediatric patients aged five years and above.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/humira-adalimumab-ulcerative-colitis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/03/Image-1-HUMIRA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/humira/">Humira for the Treatment of Hidradenitis Suppurativa</a> </h3> <p>Humira (adalimumab) is a monoclonal antibody indicated for the treatment of more than ten indications, including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa (HS), and uveitis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/humira/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-Image-Humira.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/hycamtin/">Hycamtin – Anti-Tumour Drug for Treatment of Relapsed Small Cell Lung Cancer</a> </h3> <p>Hycamtin is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for relapsed small cell lung cancer (S</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/hycamtin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-xray.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/hydroxychloroquine/">Hydroxychloroquine for Potential Covid-19 Treatment</a> </h3> <p>Hydroxychloroquine, marketed by Sanofi under the trade name Plaquenil, is primarily indicated for the treatment of malaria, discoid and systemic lupus erythematosus, and rheumatoid arthritis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/hydroxychloroquine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/03/Image-1-Hydroxychloroquine.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/hyqvia-chronic-inflammatory-demyelinating-polyneuropathy/">HYQVIA for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy, USA</a> </h3> <p>HYQVIA® can treat primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/hyqvia-chronic-inflammatory-demyelinating-polyneuropathy/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/03/Featured-Image-HYQVIA-for-the-Treatment-of-Chronic-Inflammatory-Demyelinating-Polyneuropathy.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="i" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>I</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ibrance-palbociclib-for-the-treatment-of-metastatic-breast-cancer/">Ibrance (palbociclib) for the Treatment of Metastatic Breast Cancer</a> </h3> <p>Ibrance (palbociclib) is an oral formulation developed by Pfizer for the treatment of metastatic breast cancer in women with disease progression post endocrine therapy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ibrance-palbociclib-for-the-treatment-of-metastatic-breast-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-32.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/iclusig-ponatinib-for-the-treatment-of-chronic-myeloid-leukaemia/">Iclusig (ponatinib) for the Treatment of Chronic Myeloid Leukaemia</a> </h3> <p>Iclusig (ponatinib) is indicated for the treatment of chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ALL). The drug is discovered, developed and marketed by Ariad Pharmaceuticals.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/iclusig-ponatinib-for-the-treatment-of-chronic-myeloid-leukaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-5.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/idelvion-for-the-treatment-of-haemophilia-b/">Idelvion for the Treatment of Haemophilia B</a> </h3> <p>Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) is an injectable formulation developed by CSL Behring, for the treatment of haemophilia B in children and adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/idelvion-for-the-treatment-of-haemophilia-b/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-117.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/idhifa-enasidenib-for-the-treatment-of-acute-myeloid-leukaemia-aml/">Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)</a> </h3> <p>Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/idhifa-enasidenib-for-the-treatment-of-acute-myeloid-leukaemia-aml/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-44.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/idraparinux/">Idraparinux – Investigational Agent for Treatment and Prevention of Thromboembolic Events</a> </h3> <p>The product of a joint development programme between Sanofi-Aventis (formerly Sanofi-Synthelabo) and Organon, Idraparinux is a new addition to the family of anticoagulant drugs.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/idraparinux/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_Artery_Cross_Section.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ilaris-canakinumab-for-the-treatment-of-systemic-juvenile-idiopathic-arthritis/">Ilaris (canakinumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis</a> </h3> <p>Ilaris (canakinumab) is a subcutaneous injection indicated for the treatment of systemic juvenile idiopathic arthritis (SJIA).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ilaris-canakinumab-for-the-treatment-of-systemic-juvenile-idiopathic-arthritis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-30.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nrilloperidone/">Iloperidone – Atypical Antipsychotic for Schizophrenia</a> </h3> <p>Iloperidone is a dual-acting dopamine and serotonin receptor antagonist, developed originally by Titan Pharmaceuticals a</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nrilloperidone/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-brain-cross-section-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/iluvienfordiabeticma/">Iluvien for the Treatment of Diabetic Macular Oedema</a> </h3> <p>Iluvien is indicated for the treatment of diabetic macular oedema, an eye disease that affects the retina.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/iluvienfordiabeticma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-diabetic-retinopathy.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/imbruvica-ibrutinib-for-the-treatment-of-mantle-cell-lymphoma-mcl/">Imbruvica (Ibrutinib) for the Treatment of Mantle Cell Lymphoma (MCL)</a> </h3> <p>Imbruvica (ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor indicated for the treatment of mantle cell lymphoma (MCL) patients that previously received at least one therapy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/imbruvica-ibrutinib-for-the-treatment-of-mantle-cell-lymphoma-mcl/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-46.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/imcivree-setmelanotide-chronic-weight-management/">IMCIVREE (setmelanotide) for Chronic Weight Management in Bardet-Biedl Syndrome Patients, USA</a> </h3> <p>IMCIVREE® (setmelanotide) is the first approved treatment for managing weight in Bardet-Biedl syndrome patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/imcivree-setmelanotide-chronic-weight-management/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/06/Featured-Image-IMCIVREE-setmelanotide-for-Chronic-Weight-Management-in-Bardet-Biedl-Syndrome-Patients-USA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/imdelltra-tarlatamab-extensive-stage-small-cell-lung-cancer-usa/">IMDELLTRA (tarlatamab) for the Treatment of Extensive-Stage Small Cell Lung Cancer, USA</a> </h3> <p>IMDELLTRA™ (tarlatamab) is the first T-cell engager therapy approved to treat extensive-stage small cell lung cancer (ES-SCLC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/imdelltra-tarlatamab-extensive-stage-small-cell-lung-cancer-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/05/Featured-Image-IMDELLTRA-tarlatamab-for-the-Treatment-of-Extensive-Stage-Small-Cell-Lung-Cancer.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/imfinzi-durvalumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/">Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)</a> </h3> <p>Imfinzi™ (durvalumab) is a monoclonal antibody (mAb) indicated for the treatment of metastatic urothelial carcinoma (mUC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/imfinzi-durvalumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-39.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/imlygic-talimogene-laherparepvec-treatment-cutaneous-subcutaneous-nodal-lesions/">Imlygic (talimogene laherparepvec) for the Treatment of Cutaneous, Subcutaneous and Nodal Lesions</a> </h3> <p>Developed by Amgen, Imlygic (talimogene laherparepvec) is the first injectable formulation of altered herpes simplex virus type 1 for the treatment of cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrence after initial surgery.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/imlygic-talimogene-laherparepvec-treatment-cutaneous-subcutaneous-nodal-lesions/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-101.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/inbrija-levodopa-inhalation-powder/">Inbrija for the Treatment of OFF Episodes in Parkinson’s Disease, USA</a> </h3> <p>Inbrija is indicated for OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa medicine.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/inbrija-levodopa-inhalation-powder/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Inbrija.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/incb9471/">INCB9471 – CCR5 Antagonist for Treatment of HIV Infection</a> </h3> <p>Under development by Incyte Corporation, INCB9471 is an experimental small molecule drug indicated for the treatment of</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/incb9471/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-hiv-virus.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/incivek-telaprevir/">Incivek / Telaprevir – Treatment for Chronic Hepatitis C</a> </h3> <p>Incivek (telaprevir) is a protease inhibitor used for treating hepatitis C infections in liver patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/incivek-telaprevir/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-incivek-telaprevir.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/incruse-ellipta-for-the-treatment-chronic-obstructive-pulmonary-disease-copd/">Incruse Ellipta for the Treatment Chronic Obstructive Pulmonary Disease (COPD)</a> </h3> <p>IncruseTM (unmeclidinium) Ellipta is the first approved anticholinergic indicated as a maintenance treatment to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/incruse-ellipta-for-the-treatment-chronic-obstructive-pulmonary-disease-copd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-COPD.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/indinavir-inhibitor/">Indinavir – First-Generation HIV Protease Inhibitor</a> </h3> <p>Merck's Crixivan (indinavir sulphate) is a first-generation HIV-protease inhibitor. Drugs such as indinavir have demonst</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/indinavir-inhibitor/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-indinavir.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/influenza-ah1n1/">Influenza A (H1N1) Monovalent Vaccine by Sanofi Pasteur</a> </h3> <p>Sanofi Pasteur's Influenza A (H1N1) 2009 Monovalent Vaccine for 2009 Influenza A (H1N1) or swine flu is one of the f</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/influenza-ah1n1/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-influenza-h1n1-virus.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ingrezza-valbenazine-for-the-treatment-of-tardive-dyskinesia/">Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia</a> </h3> <p>Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with Tardive dyskinesia (TD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ingrezza-valbenazine-for-the-treatment-of-tardive-dyskinesia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-142.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/inmazeb/">INMAZEB for the Treatment of Zaire Ebolavirus Infection</a> </h3> <p>INMAZEB™ (atoltivimab, maftivimab, and odesivimab) is the first antiviral antibody therapeutics approved for the treatment of Zaire ebolavirus infection in adults and children, including newborns whose mothers tested positive for the infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/inmazeb/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/11/Image-3-Inmazeb.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/inspraeplerenonefort/">Inspra (Eplerenone)</a> </h3> <p>Inspra (eplerenone) is indicated for the treatment of chronic heart failure. It was developed by Pharmacia Corporation,</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/inspraeplerenonefort/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-eplermenone.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/intermezzotreatmentf/">Intermezzo – Treatment for Insomnia</a> </h3> <p>Intermezzo is a formulation of zolpidem that is indicated for the treatment of insomnia or sleeping disorders. The drug</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/intermezzotreatmentf/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Pic-1-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/invega-hafyera-paliperidone-palmitate/">Invega Hafyera (paliperidone palmitate) for the Treatment of Schizophrenia</a> </h3> <p>Invega Hafyera™ (paliperidone palmitate) is a long-acting atypical antipsychotic drug indicated for the treatment of schizophrenia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/invega-hafyera-paliperidone-palmitate/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/09/Featured-Image-INVEGA-HAFYERA-paliperidone-palmitate.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/invega-trinza-paliperidone-palmitate-for-the-treatment-for-schizophrenia/">Invega Trinza (paliperidone palmitate) for the Treatment for Schizophrenia</a> </h3> <p>Invega Trinza (paliperidone palmitate), an atypical antipsychotic, is a three-month injection that is the first, and only, four-times-a-year drug indicated to treat schizophrenia .</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/invega-trinza-paliperidone-palmitate-for-the-treatment-for-schizophrenia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-81.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/invokamet-xr-for-the-treatment-of-type-2-diabetes-in-adults/">Invokamet XR for the Treatment of Type 2 Diabetes in Adults</a> </h3> <p>Developed by Janssen Pharmaceuticals, Invokamet XR (Canagliflozin / Metformin Hydrochloride Extended Release) is indicated for the treatment of Type 2 diabetes in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/invokamet-xr-for-the-treatment-of-type-2-diabetes-in-adults/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-129.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/invokana-canagliflozin-for-the-treatment-of-type-2-diabetes/">Invokana (canagliflozin) for the Treatment of Type 2 Diabetes</a> </h3> <p>Invokana (canagliflozin) is indicated to improve glycemic control in adults with type 2 diabetes, along with diet and exercise. It was first developed by Mitsubishi Tanabe Pharma Corporation in Japan and later licensed to Janssen Pharmaceuticals.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/invokana-canagliflozin-for-the-treatment-of-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-25.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/iomab-b-for-the-treatment-of-refractory-and-relapsed-acute-myeloid-leukaemia/">Iomab-B for the treatment of Refractory and Relapsed Acute Myeloid Leukaemia</a> </h3> <p>Iomab-B is a radio-immunotherapeutic drug developed by Actinium Pharmaceuticals for treatment of refractory and relapsed acute myeloid leukaemia in elderly patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/iomab-b-for-the-treatment-of-refractory-and-relapsed-acute-myeloid-leukaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-112.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/iqirvo-treatment-primary-biliary-cholangitis-us/">Iqirvo for the Treatment of Primary Biliary Cholangitis, US</a> </h3> <p>Iqirvo is available for oral administration as round, orange-coloured, film-coated tablets in a dosage strength of 80mg.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/iqirvo-treatment-primary-biliary-cholangitis-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/09/Featured-Image-Iqirvo-elafibranor-for-the-Treatment-of-PBC-USA-Shutterstock_2317247939.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/istaroxime/">Istaroxime</a> </h3> <p>Istaroxime is an investigational drug for acute decompensated heart failure under development by Debiopharm of Switzerla</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/istaroxime/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-heart-diagram-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/isturisa-osilodrostat/">Isturisa (osilodrostat) for the Treatment of Cushing’s Disease</a> </h3> <p>Isturisa® (osilodrostat) is the first cortisol synthesis inhibitor indicated for the treatment of Cushing's disease in adult patients, who are ineligible or failed pituitary surgery.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/isturisa-osilodrostat/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/03/Image-1-Isturisa.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/iwilfin-treatment-high-risk-neuroblastoma-us/">Iwilfin for the Treatment of High-Risk Neuroblastoma, US</a> </h3> <p>Iwilfin is the first and only oral maintenance therapy for high-risk neuroblastoma approved by the FDA.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/iwilfin-treatment-high-risk-neuroblastoma-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/02/Featured-Image-Iwilfin-eflornithine.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/bmsanticancer/">Ixempra (Ixapebilone) chemotherapeutic agent – New Cancer Therapy</a> </h3> <p>Bristol-Myers Squibb's (BMS) ixabepilone (epothilone B) is a new chemotherapeutic agent that is currently in development</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/bmsanticancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-breast-structure.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ixinity-treatment-haemophilia-b/">Ixinity for Treatment for Haemophilia B</a> </h3> <p>Ixinity (coagulation factor IX (recombinant)) is an intravenous injection containing recombinant human coagulation factor IX that is indicated for the control and prevention of bleeding episodes in patients suffering from haemophilia B.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ixinity-treatment-haemophilia-b/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-79.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/izervay-ga-treatment-us/">Izervay for the Treatment of GA, US</a> </h3> <p>Izervay is available as a clear to slightly opalescent, colourless to slightly yellow solution.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/izervay-ga-treatment-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/08/Featured-Image-Izervay.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="j" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>J</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ruxolitinib-treatmen/">Jakafi (ruxolitinib) – Treatment of Myelofibrosis</a> </h3> <p>Jakafi (ruxolitinib) is an oral janus kinase (JAK) inhibitor indicated for the treatment of myelofibrosis. It was developed by Incyte Corp in collaboration with Novartis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ruxolitinib-treatmen/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-ruxolitinib-treatmen.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/januvia/">Januvia – Treatment of Diabetes Type 2</a> </h3> <p>Januvia (sitagliptin phosphate) is an antihyperglycaemic drug containing an orally active inhibitor of the dipeptidyl pe</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/januvia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-diabetes.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/jardiance-empagliflozin-hfref/">Jardiance (empagliflozin) for the treatment of heart failure with reduced ejection fraction (HFrEF)</a> </h3> <p>Jardiance® (empagliflozin) is an SGLT2 inhibitor indicated to treat heart failure in adults with reduced ejection fraction.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/jardiance-empagliflozin-hfref/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/10/Featured-Image-Jardiance-empagliflozin-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/jardiance-treatment-type-2-diabetes/">Jardiance for the Treatment of Type 2 Diabetes, US</a> </h3> <p>Jardiance is available as a film-coated, pale-yellow-coloured tablet in 10mg and 25mg strengths for oral administration.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/jardiance-treatment-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/01/Jardiance-Feat-img.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/jaypirca-pirtobrutinib-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma-usa/">Jaypirca (pirtobrutinib) for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma, USA</a> </h3> <p>Jaypirca™ is a first-of-a kind BTK inhibitor for the treatment of mantle cell lymphoma in previously treated patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/jaypirca-pirtobrutinib-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/03/Featured-Image-Jaypirca-pirtobrutinib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/jemperli-dostarlimab-gxly/">Jemperli (dostarlimab-gxly) for the Treatment of Advanced Solid Tumours, US</a> </h3> <p>Jemperli is the first anti-PD-1 therapy for the treatment of certain types of endometrial cancer in Europe.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/jemperli-dostarlimab-gxly/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/08/Featured-Image-Jemperli.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/jesduvroq-daprodustat-for-the-treatment-of-anaemia-of-chronic-kidney-disease-on-dialysis-usa/">Jesduvroq (daprodustat) for the Treatment of Anaemia of Chronic Kidney Disease on Dialysis, USA</a> </h3> <p>Jesduvroq (daprodustat) is the first oral treatment for anaemia caused by chronic kidney disease in adults undergoing dialysis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/jesduvroq-daprodustat-for-the-treatment-of-anaemia-of-chronic-kidney-disease-on-dialysis-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/04/Featured-Image-Jesduvroq-daprodustat.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/jetrea-ocriplasmin-for-treatment-of-symptomatic-vitreomacular-adhesion/">Jetrea (ocriplasmin) for Treatment of Symptomatic Vitreomacular Adhesion</a> </h3> <p>Jetrea (ocriplasmin) is a pharmacological agent developed by ThromboGenics, for the treatment of Symptomatic Vitreomacular Adhesion (VMA).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/jetrea-ocriplasmin-for-treatment-of-symptomatic-vitreomacular-adhesion/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-19.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/juluca-dolutegravir-rilpivirine-treatment-hiv-1-infection/">Juluca (Dolutegravir and Rilpivirine) for the Treatment of HIV-1 Infection</a> </h3> <p>Juluca® (Dolutegravir and Rilpivirine) is a two-drug regimen indicated for the maintenance treatment of HIV-1 infection in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/juluca-dolutegravir-rilpivirine-treatment-hiv-1-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Juluca.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/juxtapid-lomitapide-for-the-treatment-of-homozygous-familial-hypercholesterolemia-hofh/">Juxtapid (lomitapide) for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)</a> </h3> <p>Juxtapid (lomitapide) is developed and manufactured by Aegerion Pharmaceuticals for the treatment of patients affected with homozygous familial hypercholesterolemia (HoFH).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/juxtapid-lomitapide-for-the-treatment-of-homozygous-familial-hypercholesterolemia-hofh/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-19.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/jinarc-tolvaptan-adpkd/">JYNARQUE™ (tolvaptan) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)</a> </h3> <p>JYNARQUE™ (tolvaptan) is indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD). </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/jinarc-tolvaptan-adpkd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-74.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/jynneos-vaccine/">JYNNEOS Vaccine for the Prevention of Smallpox and Monkeypox</a> </h3> <p>JYNNEOS™ is a non-replicating vaccine indicated for smallpox and monkeypox disease prevention in adults aged 18 years and older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/jynneos-vaccine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/10/1l-Image-Jynneos.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="k" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>K</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kadcyla-trastuzumab-emtansine-treatment-breast-cancer/">Kadcyla (Trastuzumab Emtansine) for Treatment of Breast Cancer</a> </h3> <p>Kadcyla (trastuzumab emtansine) is an antibody drug conjugate indicated for the treatment of HER2-positive metastatic breast cancer (mBC). The drug has been developed by Genentech (a member of the Roche Group).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kadcyla-trastuzumab-emtansine-treatment-breast-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/dyax-corps-kalbitor/">Kalbitor – Treatment for Hereditary Angioedema</a> </h3> <p>Kalbitor (ecallantide) is a drug developed by US-based Dyax Corp for the treatment of hereditary angioedema (HAE).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/dyax-corps-kalbitor/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-kalibator.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ivacaftor-treatment-for-cystic-fibrosis/">Kalydeco (Ivacaftor) – Treatment for Cystic Fibrosis</a> </h3> <p>Kalydeco (Ivacaftor / VX-770) is a cystic fibrosis transmembrane conductor regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ivacaftor-treatment-for-cystic-fibrosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-formula-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kamrabkedrab-rabies-immunoglobulin-human-for-the-treatment-of-rabies/">KamRAB/KedRAB (rabies immunoglobulin human) for the Treatment of Rabies</a> </h3> <p>KamRAB/KedRAB™ is a human rabies immunoglobulin (HRIG) indicated for the treatment of passive, transient post-exposure prophylaxis (PEP) of rabies infection. The drug was jointly developed by Kamada and Kedrion Biopharma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kamrabkedrab-rabies-immunoglobulin-human-for-the-treatment-of-rabies/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-154.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kanuma-sebelipase-alfa-for-the-treatment-of-lysosomal-acid-lipase-lal-deficiency/">Kanuma (sebelipase alfa) for the Treatment of Lysosomal Acid Lipase Deficiency (LAL-D)</a> </h3> <p>Kanuma™ (sebelipase alfa) is an enzyme replacement therapy (ERT) for the treatment of patients of all ages with lysosomal acid lipase deficiency (LAL-D).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kanuma-sebelipase-alfa-for-the-treatment-of-lysosomal-acid-lipase-lal-deficiency/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-104.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kengreal-cangrelor-for-reducing-thrombotic-events-during-percutaneous-coronary-intervention-pci/">Kengreal (cangrelor) for Reducing Thrombotic Events During Percutaneous Coronary Intervention (PCI)</a> </h3> <p>Kengreal (cangrelor) is the first and only intravenous anti-platelet agent indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing thrombotic events.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kengreal-cangrelor-for-reducing-thrombotic-events-during-percutaneous-coronary-intervention-pci/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-21.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kerendia-finerenone-ckd/">KERENDIA (finerenone) for the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes, USA</a> </h3> <p>KERENDIA® is the first, nonsteroidal mineralocorticoid receptor antagonist for diabetes-related chronic kidney disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kerendia-finerenone-ckd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/07/Featured-Image-KERENDIA-finerenone.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kesimpta-ofatumumab-for-the-treatment-of-relapsing-multiple-sclerosis-rms/">Kesimpta (ofatumumab) for the Treatment of Relapsing Multiple Sclerosis (RMS)</a> </h3> <p>Kesimpta® (ofatumumab) is the first and only self-administered, targeted B-cell therapy indicated for the treatment of patients with relapsing multiple sclerosis (RMS) including clinically isolated syndrome (CIS), relapsing-remitting (RRMS), and active secondary progressive multiple sclerosis (SPMS).</p> </div> <div class="cell large-4"> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/keveyis-treatment-primary-hyperkalemic-hypokalemic-periodic-paralysis/">Keveyis for the Treatment of Primary Hyperkalemic and Hypokalemic Periodic Paralysis</a> </h3> <p>Keveyis (dichlorphenamide) is the first medicine indicated for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, which are a group of rare hereditary disorders that cause occasional episodes of muscle weakness or paralysis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/keveyis-treatment-primary-hyperkalemic-hypokalemic-periodic-paralysis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/Image-1l.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kevzara-sarilumab-for-the-treatment-of-rheumatoid-arthritis/">Kevzara (sarilumab) for the Treatment of Rheumatoid Arthritis</a> </h3> <p>Kevzara® (sarilumab) is a human monoclonal antibody indicated for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kevzara-sarilumab-for-the-treatment-of-rheumatoid-arthritis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-147.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/keytruda-pembrolizumab-melanoma/">Keytruda (pembrolizumab) for the treatment of metastatic melanoma</a> </h3> <p>Keytruda (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) immunotherapy developed by Merck to treat melanoma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/keytruda-pembrolizumab-melanoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/02/Featured-Image-Keytruda-pembrolizumab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kineret-anakinra-for-the-treatment-of-neonatal-onset-multisystem-inflammatory-disease-nomid/">Kineret (anakinra) for the Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)</a> </h3> <p>Kineret (anakinra) is a recombinant protein drug which was originally discovered and developed by Amgen. The drug was later licensed to Swedish Orphan Biovitrum (Sobi) in December 2008.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kineret-anakinra-for-the-treatment-of-neonatal-onset-multisystem-inflammatory-disease-nomid/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-24.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kisqali-ribociclib-for-the-treatment-of-hrher2-metastatic-breast-cancer/">Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer</a> </h3> <p>Formerly known as LEE011, Kisqali® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer in post-menopausal women.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kisqali-ribociclib-for-the-treatment-of-hrher2-metastatic-breast-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-138.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kisunla-donanemab-azbt-early-alzheimers-usa/">Kisunla (donanemab-azbt) for the Treatment of Early Alzheimer’s Disease, USA</a> </h3> <p>Kisunla™ (donanemab-azbt) is an amyloid plaque-targeting therapy, developed by Eli Lilly, to treat early Alzheimer's disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kisunla-donanemab-azbt-early-alzheimers-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/07/Featured-Image-Kisunla-donanemab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/korlym-mifepristone-for-the-treatment-of-endogenous-cushings-syndrome/">Korlym (Mifepristone) for Treatment of Endogenous Cushing’s Syndrome</a> </h3> <p>Korlym (mifepristone) is a glucocorticoid receptor blocker indicated for the control of high blood sugar levels in adult patients suffering from endogenous Cushing's syndrome.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/korlym-mifepristone-for-the-treatment-of-endogenous-cushings-syndrome/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-28.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/korsuva-difelikefalin-ckd/">Korsuva (difelikefalin) for the Treatment of Pruritus Associated with Chronic Kidney Disease</a> </h3> <p>Korsuva (difelikefalin) is the first US FDA-approved treatment for moderate-to-severe pruritus in adult patients on haemodialysis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/korsuva-difelikefalin-ckd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/09/Featured-Image-Korsuva.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/koselugo-selumetinib-for-the-treatment-of-neurofibromatosis-type-1-nf1/">Koselugo (selumetinib) for the Treatment of Neurofibromatosis Type 1 (NF1)</a> </h3> <p>Koselugo® (selumetinib) is the first FDA-approved drug indicated for the treatment of neurofibromatosis type 1 (NFI), a rare and incurable genetic condition, developed and commercialised globally by AstraZeneca and Merck (MSD) under a licensing agreement.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/koselugo-selumetinib-for-the-treatment-of-neurofibromatosis-type-1-nf1/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/04/Image-1-Koselugo.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kovaltry-anti-haemophilic-factor-vii-recombinant-for-the-treatment-of-haemophilia-a/">Kovaltry (Anti-haemophilic Factor VII (Recombinant)) for the Treatment of Haemophilia A</a> </h3> <p>Kovaltry (Anti haemophilic Factor VII (Recombinant)) is developed by Bayer as the treatment for children and adult patients with haemophilia A.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kovaltry-anti-haemophilic-factor-vii-recombinant-for-the-treatment-of-haemophilia-a/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-116.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/krazati-adagrasib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc-usa/">Krazati (adagrasib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC), USA</a> </h3> <p>Krazati™ (adagrasib) is a targeted treatment for advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/krazati-adagrasib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/03/Featured-Image-Krazati-adagrasib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/krx-0401-perifosine/">KRX-0401 Perifosine</a> </h3> <p>KRX-0401 (perifosine) is a potential oral anti-cancer agent that suppresses the pathways associated with the programmed</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/krx-0401-perifosine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-multiple-myleloma.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kymriah-tisagenlecleucel-for-the-treatment-of-acute-lymphoblastic-leukaemia/">Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia, USA</a> </h3> <p>Kymriah (tisagenlecleucel) is the first FDA-approved CAR-T therapy indicated for treating ALL.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kymriah-tisagenlecleucel-for-the-treatment-of-acute-lymphoblastic-leukaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/01/Featured-Image-Kymriah-tisagenlecleucel.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kynmobi-for-the-treatment-of-off-episodes-in-parkinsons-disease/">KYNMOBI for the Treatment of OFF episodes in Parkinson’s Disease, USA</a> </h3> <p>KYNMOBI is the first and only sublingual therapy indicated for the on-demand treatment of OFF episodes in Parkinson's disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kynmobi-for-the-treatment-of-off-episodes-in-parkinsons-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/06/Featured-Image-KYNMOBI-for-the-Treatment-of-OFF-episodes-in-Parkinsons-Disease.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/kyprolis-carfilzomib-for-treatment-of-multiple-myeloma/">Kyprolis (carfilzomib) for Treatment of Multiple Myeloma</a> </h3> <p>Kyprolis (carfilzomib), developed and manufactured by Onyx Pharmaceuticals, is a proteasome inhibitor indicated for the treatment of the patients with multiple myeloma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/kyprolis-carfilzomib-for-treatment-of-multiple-myeloma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-16.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="l" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>L</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lamictal-by-gsk/">Lamictal – Approved Treatment for Epilepsy and Bipolar</a> </h3> <p>Lamictal XR (lamotrigine), developed by GlaxoSmithKline, is an approved treatment for epilepsy and bipolar I disease. Th</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lamictal-by-gsk/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-lamictal-tablets.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lampit-nifurtimox-for-the-treatment-of-chagas-disease/">Lampit (nifurtimox) for the Treatment of Chagas Disease</a> </h3> <p>Lampit® (nifurtimox) is an antiprotozoal medication indicated for the treatment of Chagas disease (American Trypanosomiasis) in paediatric patients from birth to less than 18 years of age and weighing at least 2.5kg.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lampit-nifurtimox-for-the-treatment-of-chagas-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/11/Image-1-Lampit-nifurtimox.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lamzede/">Lamzede (velmanase alfa) to Treat Alpha-Mannosidosis</a> </h3> <p>Lamzede® (velmanase alfa) is one of the first enzyme replacement therapies indicated for the treatment of non-neurological symptoms of patients with mild-to-moderate alpha‑mannosidosis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lamzede/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/Image-1-Lamzede.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lartruvo-olaratumab-for-the-treatment-of-soft-tissue-sarcoma/">Lartruvo (olaratumab) for the Treatment of Soft Tissue Sarcoma</a> </h3> <p>Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma (STS) in adult patients. The drug is available as a 10mg/ml injection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lartruvo-olaratumab-for-the-treatment-of-soft-tissue-sarcoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-128.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/latuda-schizophrenia/">Latuda (lurasidone HCl) for the Treatment of Schizophrenia</a> </h3> <p>Latuda (lurasidone HCl) is indicated for the treatment of schizophrenia. The drug was developed by Sunovion Pharmaceut</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/latuda-schizophrenia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-latuda-schizophrenia.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lenvima-lenvatinib-mesylate-thyroid-cancer/">Lenvima™ (Lenvatinib Mesylate) for the Treatment of Thyroid Cancer</a> </h3> <p>Lenvima™ (lenvatinib mesylate) is a multiple receptor tyrosine kinase (RTK) inhibitor indicated for the treatment of thyroid cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lenvima-lenvatinib-mesylate-thyroid-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-71.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/leqembi-alzheimers-disease/">Leqembi (lecanemab-irmb) for the Treatment of Alzheimer’s Disease, USA</a> </h3> <p>Leqembi™ is the second FDA-approved anti-amyloid antibody for Alzheimer disease, after Biogen’s aducanumab.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/leqembi-alzheimers-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/07/Featured-Image-Leqembi.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/leqvio-hypercholesterolaemia-treatment/">Leqvio for the Treatment of Hypercholesterolaemia, US</a> </h3> <p>Patients need to be administered two maintenance doses of the drug a year via syringe, following an initial dose and another at three months.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/leqvio-hypercholesterolaemia-treatment/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/10/Featured-Image-Leqvio-inclisiran.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lexapro-forest/">Lexapro – Treatment of Major Depressive Disorder in Adolescents</a> </h3> <p>In March 2009, the US Food and Drug Administration (FDA) approved the supplemental new drug application (sNDA) of Forest</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lexapro-forest/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-lexapro.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/libtayo-cemiplimab-rwlc/">Libtayo (cemiplimab-rwlc) for the Treatment of Advanced Non-Small Cell Lung Cancer</a> </h3> <p>Libtayo (cemiplimab-rwlc) is an advanced fully human monoclonal antibody indicated for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients ineligible to undergo curative surgery or radiation therapy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/libtayo-cemiplimab-rwlc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Libtayo.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/licofelone/">Licofelone – Novel Analgesic and Anti-Inflammatory Agent for Osteoarthritis</a> </h3> <p>Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and La</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/licofelone/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/Knee_01.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/linzess-for-the-treatment-of-irritable-bowel-syndrome-with-chronic-idiopathic-constipation/">Linzess (linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation, USA</a> </h3> <p>Linzess (linaclotide) is a guanylate cyclase-C (GC-C) receptor agonist co-developed by AbbVie and Ironwood Pharmaceuticals.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/linzess-for-the-treatment-of-irritable-bowel-syndrome-with-chronic-idiopathic-constipation/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2012/09/Feature-Image-Linzess-linaclotide.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lipaglyn-saroglitazar-treating-type-ii-diabetes/">Lipaglyn (Saroglitazar) for Treating Hypertriglycerdaemia in Type 2 Diabetes, India</a> </h3> <p>Lipaglyn (saroglitazar) is approved for the treatment of hypertriglyceridaemia in type 2 diabetes.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lipaglyn-saroglitazar-treating-type-ii-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/01/Featured-Image-Lipaglyn-Saroglitazar-to-Treat-Hypertriglyceridemia.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lipitor-atorvastatin-cholesterol-lowering-drug/">Lipitor (Atorvastatin) – Treatment for High Cholesterol</a> </h3> <p>Lipitor (Atorvastatin) is a statin class drug indicated for reducing high cholesterol levels in the blood, which helps prevent cardiovascular diseases. It is manufactured by Pfizer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lipitor-atorvastatin-cholesterol-lowering-drug/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-16.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lipitor/">Lipitor / Torcetrapib – Combination Therapy</a> </h3> <p>Under development by Pfizer, torcetrapib is a member of the cholesteryl ester transfer protein (CETP) inhibitor class of</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lipitor/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_Labelled_Human_Heart.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/liptruzet-ezetimibe-and-atorvastatin-for-the-treatment-of-hyperlipidaemia/">Liptruzet (ezetimibe and atorvastatin) for the Treatment of Hyperlipidaemia</a> </h3> <p>Liptruzet (ezetimibe and atorvastatin) is a combination drug indicated to reduce elevated low-density lipoprotein (LDL) cholesterol in patients suffering from hyperlipidaemia disorder.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/liptruzet-ezetimibe-and-atorvastatin-for-the-treatment-of-hyperlipidaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-26.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/liraglutide/">Liraglutide – Next-Generation Antidiabetic Medication</a> </h3> <p>Under development by Novo Nordisk, liraglutide is a member of a new class of antidiabetic medications called GLP-1 analo</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/liraglutide/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/2-diabetes.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/livdelzi-seladelpar-primary-biliary-cholangitis-usa/">Livdelzi (Seladelpar) for the Treatment of Primary Biliary Cholangitis, USA</a> </h3> <p>Livdelzi® (seladelpar) received accelerated approval from the US FDA in August 2024 for treating primary biliary cholangitis.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/livdelzi-seladelpar-primary-biliary-cholangitis-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/09/Featured-Image-Livdelzi-Seladelpar-for-the-Treatment-of-Primary-Biliary-Cholangitis-USA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/livmarli-maralixibat-for-the-treatment-of-cholestatic-pruritus-in-alagille-syndrome/">Livmarli™ (maralixibat) for the Treatment of Cholestatic Pruritus in Alagille Syndrome</a> </h3> <p>Livmarli™ (maralixibat) is the first and only approved treatment for cholestatic pruritus in patients with Alagille syndrome.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/livmarli-maralixibat-for-the-treatment-of-cholestatic-pruritus-in-alagille-syndrome/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/10/Featured-Image-Livmarli.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/livtencity-maribavir-for-the-treatment-of-post-transplant-cytomegalovirus-cmv-infection-usa/">Livtencity (maribavir) for the Treatment of Post-Transplant Cytomegalovirus (CMV) Infection, USA</a> </h3> <p>Livtencity™ is the first and only treatment for post-transplant cytomegalovirus infection in adult and paediatric patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/livtencity-maribavir-for-the-treatment-of-post-transplant-cytomegalovirus-cmv-infection-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/02/Featured-Image-Livtencity-maribavir.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lixisenatide-diabete/">Lixisenatide</a> </h3> <p>Lixisenatide is an investigational glucagon-like peptide (GLP)-1 agonist being developed for the treatment of type 2 d</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lixisenatide-diabete/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-lixisenatide-diabete.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lodoco-colchicine-cardiovascular-disease/">LODOCO (colchicine) for the Treatment of Cardiovascular Disease, USA</a> </h3> <p>LODOCO® (colchicine) is the first FDA-approved anti-inflammatory atheroprotective cardiovascular treatment.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lodoco-colchicine-cardiovascular-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/07/Featured-Image-LODOCO-colchicine-for-the-Treatment-of-Cardiovascular-Disease.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lodotra-treatment-for-rheumatoid-arthritis/">LODOTRA – Treatment for Rheumatoid Arthritis</a> </h3> <p>Lodotra was developed utilising SkyePharma's proprietary GeoClock and GeoMatrix technologies, for which Horizon Pharma holds an exclusive worldwide license for the delivery of corticosteroids.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lodotra-treatment-for-rheumatoid-arthritis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-box.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lokelma-sodium-zirconium-cyclosilicate-treatment-of-hyperkalaemia/">Lokelma (sodium zirconium cyclosilicate) for the Treatment of Adults with Hyperkalaemia</a> </h3> <p>Lokelma is an oral suspension of sodium zirconium cyclosilicate that is indicated for the treatment of patients with hyperkalaemia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lokelma-sodium-zirconium-cyclosilicate-treatment-of-hyperkalaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Lokelma.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lonsurf-trifluridine-tipiracil-refractory-metastatic-colorectal-cancer/">Lonsurf (trifluridine and tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer</a> </h3> <p>Lonsurf is approved for the treatment of patients with advanced metastatic colorectal cancer (mCRC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lonsurf-trifluridine-tipiracil-refractory-metastatic-colorectal-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-92.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/loqtorzi-treatment-nasopharyngeal-carcinoma-us/">Loqtorzi for the Treatment of Nasopharyngeal Carcinoma, US</a> </h3> <p>Loqtorzi is the first and only treatment approved by the FDA for the first-line treatment of nasopharyngeal carcinoma.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/loqtorzi-treatment-nasopharyngeal-carcinoma-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/02/Featurd-Image-Loqtorzi-for-Recurrent-or-Metastatic-Nasopharyngeal-Carcinoma-NPC-US.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lorbrena-lorlatinib/">Lorbrena (lorlatinib) for ALK-Positive Metastatic Non-Small Cell Lung Cancer</a> </h3> <p>Lorbrena® (lorlatinib) is an anaplastic lymphoma kinase (ALK) inhibitor indicated as a second or third-line treatment of advanced non-small cell lung cancer (NSCLC). The drug was discovered and developed by Pfizer.</p> </div> <div class="cell large-4"> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lorcaserin/">Lorcaserin, Investigational Oral Anti-Obesity Drug</a> </h3> <p>Lorcaserin hydrochloride (Lorcaserin) is an investigative oral treatment drug for obesity, and was discovered by Arena P</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lorcaserin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-pills-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lovenox-treatment-deep-vein-thrombosis-us/">Lovenox (Enoxaparin Sodium) – Treatment for Deep Vein Thrombosis (DVT)</a> </h3> <p>Lovenox (enoxaparin sodium) is an anti-thrombotic drug indicated for the treatment of deep vein thrombosis (DVT) and acute ST-segment elevation myocardial infarction (STEMI).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lovenox-treatment-deep-vein-thrombosis-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-7.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lucemyra-lofexidine-management-opioid-withdrawal-symptoms/">Lucemyra (lofexidine) for the Management of Opioid Withdrawal Symptoms</a> </h3> <p>Lucemyra™ (lofexidine) is a non-opioid medication indicated for the mitigation of opioid withdrawal symptoms.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lucemyra-lofexidine-management-opioid-withdrawal-symptoms/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Lucemyra.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lucentis-ranibizumab-for-the-treatment-of-diabetic-macular-edema-dme/">Lucentis (ranibizumab) for the Treatment of Diabetic Macular Edema (DME)</a> </h3> <p>Lucentis (ranibizumab) is a monoclonal antibody indicated for the treatment of diabetic macular edema (DME). The drug is developed by Genentech, a subsidiary of Roche Group.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lucentis-ranibizumab-for-the-treatment-of-diabetic-macular-edema-dme/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-11.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lumakras-sotorasib-nsclc/">LUMAKRAS (sotorasib) for the Treatment of Non-Small Cell Lung Cancer</a> </h3> <p>LUMAKRAS (sotorasib) is approved in the US, United Arab Emirates (UAE), Canada and the UK.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lumakras-sotorasib-nsclc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/02/Featured-Image-LUMAKRAS™-sotorasib-for-the-Treatment-of-Non-Small-Cell-Lung-Cancer.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/moxetumomab-pasudotox-hairy-cell-leukaemia/">Lumoxiti (Moxetumomab pasudotox –tdfk) for the Treatment of Hairy Cell Leukaemia</a> </h3> <p>Lumoxiti (Moxetumomab pasudotox) is an investigational anti-CD22 recombinant immunotoxin developed as a potential treatment for relapsed/refractory hairy cell leukaemia (HCL) patients previously treated with at least two lines of therapy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/moxetumomab-pasudotox-hairy-cell-leukaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Moxetumomab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lupkynis-voclosporin/">LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis, US</a> </h3> <p>LUPKYNIS™ (voclosporin) is a calcineurin-inhibitor immunosuppressant indicated for the treatment of adult patients with active lupus nephritis (LN).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lupkynis-voclosporin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/05/Image-1-LUPKYNIS-voclosporin.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lurasidone/">Lurasidone – Treatment for Schizophrenia and Bipolar Disorder</a> </h3> <p>Lurasidone is an atypical antipsychotic agent developed by Japan's Dainippon Sumitomo Pharma (DSP). The drug is indicat</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lurasidone/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lutathera-lutetium-lu-177-dotatate-treatment-gastroenteropancreatic-neuroendocrine-tumours/">Lutathera (lutetium Lu 177 dotatate) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumours</a> </h3> <p>Lutathera® (lutetium Lu 177 dotatate) is a peptide receptor radionuclide therapy (PRRT) indicated for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lutathera-lutetium-lu-177-dotatate-treatment-gastroenteropancreatic-neuroendocrine-tumours/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/Image-1-Lutathera.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/luxturna-voretigene-neparvovec-treatment-biallelic-rpe65-mutation-associated-retinal-dystrophy/">Luxturna (voretigene neparvovec) for the Treatment of Biallelic RPE65 Mutation-Associated Retinal Dystrophy</a> </h3> <p>LuxturnaTM (voretigene neparvovec) is approved for the treatment of patients with biallelic RPE65 mutation-associated retinal dystrophy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/luxturna-voretigene-neparvovec-treatment-biallelic-rpe65-mutation-associated-retinal-dystrophy/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/elililleyantisycotic/">LY2140023 – Treatment of Schizophrenia</a> </h3> <p>Under development by Eli Lilly, LY2140023 is a novel investigational agent for the treatment of schizophrenia. A member</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/elililleyantisycotic/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-schizo-types.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lybalvi-olanzapine-samidorphan/">Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder</a> </h3> <p>Lybalvi® is a prescription medicine indicated for the treatment of adults with schizophrenia and bipolar I disorder.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lybalvi-olanzapine-samidorphan/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/04/Featured-Image-Lybalvi-olanzapine-and-samidorphan.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lynparza-olaparib-cancer/">Lynparza (olaparib) for the Treatment of BRCA-mutated Advanced Ovarian Cancer</a> </h3> <p>Lynparza (olaparib), discovered and developed by AstraZeneca, is the first PARP inhibitor drug approved for germline BRCA-mutated advanced ovarian cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lynparza-olaparib-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2015/01/Featured-Image-Lynparza-olaparib-for-the-Treatment-of-BRCAgBRCA-mutated-Advanced-Ovarian-Cancer.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/pregabalin/">Lyrica (Pregabalin) for the Treatment of Neuropathic Pain, USA</a> </h3> <p>Lyrica is a 3-substituted analogue of gamma-aminobutyric acid indicated to treat neuropathic pain.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/pregabalin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2003/06/Featured-Image-Lyrica-Pregabalin.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lyumjev/">Lyumjev (insulin lispro-aabc) for the Treatment of Type 1 and Type 2 Diabetes</a> </h3> <p>Lyumjev™ (insulin lispro-aabc) is rapid-acting insulin indicated to enhance glucose control in adults with type 1 and type 2 diabetes.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lyumjev/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/07/Image-1-Lyumjev-insulin-lispro-aabc.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="m" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>M</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/m6g/">M6G, A New Morphine Derivative For Post-Operative Pain Relief</a> </h3> <p>Morphine-6-Glucuronide (M6G) is a new morphine derivative under development by biopharmaceutical company PAION. Developm</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/m6g/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-pharmaceutical-dev.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/maraviroc/">Maraviroc – Therapy for Treatment of HIV Infection</a> </h3> <p>Discovered and developed by researchers at Pfizer, maraviroc is a novel treatment for infection due to the human immunod</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/maraviroc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-aids-virus.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/mavenclad-cladribine-tablets-treatment-relapsing-remitting-multiple-sclerosis/">Mavenclad (cladribine tablets) for the Treatment of Relapsing-Remitting Multiple Sclerosis</a> </h3> <p>Mavenclad™ (cladribine tablets) is a selective immune reconstitution therapy indicated for the treatment of active relapsing multiple sclerosis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/mavenclad-cladribine-tablets-treatment-relapsing-remitting-multiple-sclerosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Mavenclad.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/mavyret-glecaprevirpibrentasvir-for-the-treatment-of-chronic-hepatitis-c/">MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C</a> </h3> <p>MAVYRET™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV) infection across six major genotypes (GT1 to GT6).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/mavyret-glecaprevirpibrentasvir-for-the-treatment-of-chronic-hepatitis-c/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-43.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/mayzent-siponimod/">Mayzent for the Treatment of Multiple Sclerosis, US</a> </h3> <p>The drug has been approved by governmental health departments in the US, Japan, Europe, and Canada.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/mayzent-siponimod/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-Image-Mayzent.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/mekinist-trametinib-treatment-metastatic-melanoma/">Mekinist (Trametinib) – Treatment for Metastatic Melanoma</a> </h3> <p>Mekinist (trametinib) is a mitogen-activated protein kinase (MEK) inhibitor indicated for the treatment of unresectable or metastatic melanoma in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/mekinist-trametinib-treatment-metastatic-melanoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-29.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/menactra-vaccine/">Menactra – Meningococcal Vaccine</a> </h3> <p>Menactra vaccine is developed and manufactured by Sanofi Pasteur, the vaccines division of the Sanofi Aventis Group. The</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/menactra-vaccine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-child-injected.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/menveovaccineforthep/">Menveo vaccine for the prevention of invasive meningococcal disease</a> </h3> <p>Menveo is an active immunisation vaccine indicated for the prevention of invasive meningococcal disease caused by sero</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/menveovaccineforthep/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-11.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/issentress/">Merck Isentress – Emerging Therapy for Treatment of HIV Infection</a> </h3> <p>Under development by Merck & Co, Isentress (raltegravir) is an experimental drug indicated for the treatment of human im</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/issentress/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-aids-virus-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/mirapextreatmentforp/">Mirapex (Pramipexole Dihydrochloride) for the Treatment of Parkinson’s Disease, USA</a> </h3> <p>Mirapex is indicated to treat Parkinson’s disease (PD) symptoms and restless legs syndrome (RLS).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/mirapextreatmentforp/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2010/05/Featured-Image-Mirapex-Pramipexole-dihydrochloride-Treatment-for-Parkinsons-Disease.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/monovisc-sodium-hyaluronate-for-the-treatment-of-osteoarthritis/">Monovisc (sodium hyaluronate) for the Treatment of Osteoarthritis</a> </h3> <p>Monovisc (sodium hyaluronate), indicated for the treatment of Osteoarthritis (OA) of the knee, is the first US Food and Drug Administration (FDA) approved single injection made with hyaluronate from a non-animal source.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/monovisc-sodium-hyaluronate-for-the-treatment-of-osteoarthritis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-52.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/mor103/">MOR103 – Antibody for the Treatment of Rheumatoid Arthritis</a> </h3> <p>MOR103 is a fully human antibody indicated for the treatment of rheumatoid arthritis (RA). The drug is being developed</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/mor103/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image1-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nrimotovizumab/">Motavizumab – New Biological Therapy for RSV Prevention</a> </h3> <p>Developed by MedImmune (now wholly owned by AstraZeneca), motavizumab is an investigational monoclonal antibody (MAb) in</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nrimotovizumab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-respiratory-viruses.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/mounjaro-tirzepatide-type-2-diabetes/">Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA</a> </h3> <p>Mounjaro™ (tirzepatide) is a first-in-class GIP and GLP-1 receptor agonist for treating type 2 diabetes.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/mounjaro-tirzepatide-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/01/Featured-Image-Mounjaro-tirzepatide-for-the-Treatment-of-Type-2-Diabetes.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/movantik-for-the-treatment-of-opioid-induced-constipation/">Movantik for the Treatment of Opioid-Induced Constipation</a> </h3> <p>Movantik™ (naloxegol) is an opioid antagonist therapy indicated for the treatment of opioid-induced constipation in adult patients with chronic, non-cancerous pain.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/movantik-for-the-treatment-of-opioid-induced-constipation/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/09/1l-Image-Movantik.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/dronedarone/">Multaq</a> </h3> <p>Multaq (dronedarone) is a Class III antiarrhythmic drug developed by Sanofi-Aventis (formerly Sanofi-Synthlelabo) for th</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/dronedarone/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_Sanofi_HQ_Full_Bldg.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/myalepta-metreleptin/">Myalepta (metreleptin) for the Treatment of Lipodystrophy</a> </h3> <p>Myalepta® (metreleptin) is a recombinant human leptin analogue indicated to treat complications of congenital or acquired generalised lipodystrophy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/myalepta-metreleptin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-Image-Myalepta.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/mydayis-for-the-treatment-of-attention-deficit-hyperactivity-disorder/">Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder</a> </h3> <p>Mydayis is a CNS stimulant drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 years and above.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/mydayis-for-the-treatment-of-attention-deficit-hyperactivity-disorder/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-40.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/mylinax/">Mylinax – Novel Therapy for the Treatment of</a> </h3> <p>The product of a joint development programme between IVAX Corporation and Serono, Mylinax, a proprietary oral formulatio</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/mylinax/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/Interferon_Beta.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/myobloc-rimabotulinumtoxinb/">Myobloc (rimabotulinumtoxinB) for the Treatment of Chronic Sialorrhea</a> </h3> <p>Myobloc® (rimabotulinumtoxinB) is the first neurotoxin approved for the treatment of chronic sialorrhea in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/myobloc-rimabotulinumtoxinb/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/10/2l-Image-Myobloc.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/myrbetriq-mirabegron-overactive-bladder-japan/">Myrbetriq (Mirabegron) – Treatment for Overactive Bladder (OAB)</a> </h3> <p>Myrbetriq (mirabegron) is a beta-3 adrenergic agonist indicated for the treatment of the overactive bladder (OAB) condition. It was developed by Japan's Astellas Pharma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/myrbetriq-mirabegron-overactive-bladder-japan/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/OABLarge.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="n" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>N</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/namzaric-memantine-donepezil-alzheimers-disease/">Namzaric (Memantine/Donepezil) for the Treatment of Alzheimer’s Disease</a> </h3> <p>Namzaric (memantine/donepezil) is the first fixed-dose combination drug approved for the treatment of moderate and severe Alzheimer's disease in the US.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/namzaric-memantine-donepezil-alzheimers-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-70.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/azd3582/">Naproxcinod (HCT 3012) – COX-Inhibiting Nitric Oxide-Donator</a> </h3> <p>Developed by French pharmaceutical company NicOx, naproxcinod (HCT 3012) is the first in a new class of analgesic and an</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/azd3582/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_Pain_Signal_Chemicals.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/natesto-nasal-gel-for-the-treatment-men-low-testosterone/">Natesto Nasal Gel for the Treatment of Men with Low Testosterone</a> </h3> <p>Natesto (testosterone, formerly known as CompleoTRT) is the only FDA-approved nasal gel for treatment of adult males with conditions associated with deficiency or absence of endogenous testosterone.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/natesto-nasal-gel-for-the-treatment-men-low-testosterone/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-55.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/natpara-parathyroid-hormone-for-the-treatment-of-hypoparathyroidism/">Natpara® (parathyroid hormone) for the Treatment of Hypoparathyroidism</a> </h3> <p>Natpara® (parathyroid hormone), a subcutaneous injection indicated for the treatment of hypoparathyroidism, was discovered and developed by NPS Pharmaceuticals that was acquired by Shire in February 2015.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/natpara-parathyroid-hormone-for-the-treatment-of-hypoparathyroidism/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-72.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nerlynx-neratinib-for-the-treatment-of-breast-cancer/">Nerlynx (neratinib) for the Treatment of Breast Cancer</a> </h3> <p>Nerlynx™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult patients with early stage HER2-overexpressed or amplified breast cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nerlynx-neratinib-for-the-treatment-of-breast-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-152.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nesina-alogliptin-for-the-treatment-of-type-2-diabetes-mellitus/">Nesina (alogliptin) for Treatment of Type 2 Diabetes Mellitus</a> </h3> <p>Nesina (alogliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor developed and marketed by Takeda Pharmaceuticals for the treatment of diabetes 2 mellitus.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nesina-alogliptin-for-the-treatment-of-type-2-diabetes-mellitus/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-24.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nexavar-cancer/">Nexavar for Kidney or Liver Cancer</a> </h3> <p>Nexavar is an oral anti-cancer agent that blocks cell proliferation and tumour angiogenesis. Developed by Bayer Healthcare with Onyx Pharmaceuticals, the drug obstructs the receptor tyrosine kinases – vascular endothelial growth factor receptor (VEGFR) VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR B), KIT, fms-related tyrosine kinase 3 (FLT-3) and RET – along the signalling pathways.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nexavar-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-antic-cancer-agents.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nexium-iv/">Nexium I.V.- Treatment of Gastroesophageal Reflux Disease</a> </h3> <p>Nexium I.V. (intravenous) / esomeprazole sodium is a proton pump inhibitor manufactured and marketed by Astra Zeneca fo</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nexium-iv/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-nexium-iv.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nexletol-heterozygous-familial-hypercholesterolemia/">NEXLETOL (bempedoic acid) for the Treatment of Heterozygous Familial Hypercholesterolemia (HeFH), USA</a> </h3> <p>NEXLETOL® (bempedoic acid) and its combination with ezetimibe NEXLIZET® are oral non-statin cholesterol-lowering drugs.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nexletol-heterozygous-familial-hypercholesterolemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/05/Featured-Image-NEXLETOL-bempedoic-acid-for-the-Treatment-of-Heterozygous-Familial-Hypercholesterolemia-HeFH.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nexviazyme-avalglucosidase-alfa-ngpt/">Nexviazyme (avalglucosidase alfa-ngpt) for the Treatment of Late-onset Pompe Disease</a> </h3> <p>Nexviazyme® (avalglucosidase alfa-ngpt) is a new therapeutic option approved for the treatment of late-onset Pompe disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nexviazyme-avalglucosidase-alfa-ngpt/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/10/Featured-Image-Nexviazyme-avalglucosidase-alfa-ngpt.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/insomnia-treatment/">NG2-73 – A Novel Agent For The Treatment of Insomnia</a> </h3> <p>Under development by specialist pharmaceutical company, Neurogen, NG2-73 is a new, selective gamma-amino butyric acid (G</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/insomnia-treatment/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-sleep-cycle.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ngenla-somatrogon-for-the-treatment-of-paediatric-growth-hormone-deficiency-usa/">NGENLA (somatrogon) for the Treatment of Paediatric Growth Hormone Deficiency, USA</a> </h3> <p>NGENLA® (somatrogon) is a human growth hormone analogue to treat growth failure in children aged three years and older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ngenla-somatrogon-for-the-treatment-of-paediatric-growth-hormone-deficiency-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/03/Featured-Image-NGENLA-somatrogon-for-the-Treatment-of-Paediatric-Growth-Hormone-Deficiency.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nicvaxfornicotineadd/">NicVAX for Nicotine Addiction</a> </h3> <p>NicVAX is an investigational vaccine developed for use as an aid to treat smoking addiction and prevent smoking relaps</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nicvaxfornicotineadd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-5.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/niktimvo-axatilimab-for-treatment-of-cgvhd-us/">NIKTIMVO for the Treatment of cGvHD, US</a> </h3> <p>NIKTIMVO received US FDA approval in August 2024 to treat GvHD.<br /> <br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/niktimvo-axatilimab-for-treatment-of-cgvhd-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/09/Featured-Image-NIKTIMVO-axatilimab-for-the-Treatment-of-cGvHD-USA-Shutterstock_2181578479.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ninlaro-ixazomib-treatment-multiple-myeloma/">Ninlaro (ixazomib) for the Treatment of Multiple Myeloma</a> </h3> <p>Ninlaro (ixazomib) is a proteasome inhibitor indicated for the treatment of multiple myeloma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ninlaro-ixazomib-treatment-multiple-myeloma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-100.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/northera-droxidopa-treatment-symptomatic-neurogenic-orthostatic-hypotension-noh/">Northera (droxidopa) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (NOH)</a> </h3> <p>Northera (droxidopa) is the world’s first approved therapy for symptomatic neurogenic orthostatic hypotension (NOH).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/northera-droxidopa-treatment-symptomatic-neurogenic-orthostatic-hypotension-noh/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-13.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nourianz-istradefylline/">NOURIANZ (istradefylline) for the Treatment of Parkinson’s Disease</a> </h3> <p>NOURIANZ (istradefylline) is indicated as adjunctive therapy to levodopa and carbidopa medications in adult patients with Parkinson’s disease (PD) to treat “off” episodes, caused when existing medications are ineffective and lead to an increase in PD symptoms.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nourianz-istradefylline/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/11/Image-1-Nourianz.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/novavax-vlp-vaccine/">Novavax Trivalent VLP Vaccine for Seasonal Influenza</a> </h3> <p>Novavax's trivalent seasonal influenza virus-like particle (VLP) vaccine was developed to address the need to produce va</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/novavax-vlp-vaccine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-novavax-vlp-vaccine.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/noxafil-posaconazole-for-treatment-of-fungal-infections/">Noxafil (posaconazole) for the Treatment of Fungal Infections</a> </h3> <p>Noxafil (posaconazole) is a triazole antifungal agent indicated for treatment of the prophylaxis of invasive Aspergillus and Candida infections.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/noxafil-posaconazole-for-treatment-of-fungal-infections/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-38.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nucala-mepolizumab-for-the-treatment-of-hypereosinophilic-syndrome-hes/">Nucala (mepolizumab) for the Treatment of Hypereosinophilic Syndrome (HES)</a> </h3> <p>Nucala® (mepolizumab) is the first biologic therapy indicated for the treatment of hypereosinophilic syndrome (HES) in adult and paediatric patients aged 12 years and older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nucala-mepolizumab-for-the-treatment-of-hypereosinophilic-syndrome-hes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/10/Image-1-Nucala-mepolizumab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nuedexta-treatment-pseudobulbar-affect-pba/">Nuedexta for the Treatment of Pseudobulbar Affect (PBA)</a> </h3> <p>Nuedexta (dextromethorphan hydrobromide / quinidine sulfate) is a combination drug indicated for the treatment of pseudobulbar affect (PBA). The drug was developed and manufactured by Avanir Pharmaceuticals.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nuedexta-treatment-pseudobulbar-affect-pba/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-36.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nulibry-fosdenopterin/">Nulibry™ (Fosdenopterin) for the Treatment of Molybdenum Cofactor Deficiency Type A</a> </h3> <p>Nulibry™ (fosdenopterin) is the first and only US Food and Drug Administration (FDA) approved treatment indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nulibry-fosdenopterin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/05/Image-1-Nulibry.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nulojix-kidney/">Nulojix – Treatment for Preventing Acute Organ Rejection Post Kidney Transplantation</a> </h3> <p>Nulojix (Belatacept) was developed by Bristol Myers Squibb and is indicated to prevent the rejection of the organ in p</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nulojix-kidney/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-nulojix-kidney.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nuplazid-pimavanserin-treatment-parkinsons-disease-psychosis-pdp/">Nuplazid (pimavanserin) for the Treatment of Parkinson’s Disease Psychosis (PDP), USA</a> </h3> <p>Nuplazid (pimavanserin) is an atypical antipsychotic drug indicated for the treatment of Parkinson’s disease psychosis (PDP).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nuplazid-pimavanserin-treatment-parkinsons-disease-psychosis-pdp/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-99.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nurtec-rimegepant/">NURTEC (Rimegepant) for the Acute Treatment of Migraine</a> </h3> <p>NURTEC® ODT (rimegepant) is the first migraine medication indicated for both acute and preventive treatment in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nurtec-rimegepant/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/03/Featured-Image-Nurtec-ODT-rimegepant.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nuwiq-anti-haemophilic-factor-recombinant-treatment-haemophilia-a/">Nuwiq, Anti-Haemophilic Factor (recombinant) for the Treatment of Haemophilia A</a> </h3> <p>Nuwiq injection is the first recombinant anti-haemophilic factor (blood coagulation factor VIII) drug indicated for the treatment of patients with haemophilia A.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nuwiq-anti-haemophilic-factor-recombinant-treatment-haemophilia-a/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-91.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nymalize-nimodipine-for-the-treatment-of-subarachnoid-haemorrhage-sah/">Nymalize (nimodipine) for the Treatment of Subarachnoid Haemorrhage (SAH)</a> </h3> <p>Nymalize (nimodipine) is an oral liquid form capsule indicated to improve neurological outcomes in patients suffering from subarachnoid haemorrhage (SAH).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nymalize-nimodipine-for-the-treatment-of-subarachnoid-haemorrhage-sah/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-27.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="o" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>O</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/obizur-anti-haemophilic-factor/">Obizur Antihemophilic Factor (recombinant) for the Treatment of Acquired Haemophilia A</a> </h3> <p>Obizur antihemophilic factor (recombinant) is the first recombinant porcine FVIII indicated for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/obizur-anti-haemophilic-factor/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-46.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ocrevus-ocrelizumab-for-the-treatment-of-multiple-sclerosis/">Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis</a> </h3> <p>Developed by Genentech, Ocrevus (ocrelizumab) is indicated for the treatment of relapsing multiple sclerosis (MS) and primary progressive MS.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ocrevus-ocrelizumab-for-the-treatment-of-multiple-sclerosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-33.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/odomzo-sonidegib-for-the-treatment-of-locally-advanced-basal-cell-carcinoma/">Odomzo (sonidegib) for the Treatment of Locally Advanced Basal Cell Carcinoma</a> </h3> <p>Odomzo® (sonidegib) is an oral, selective smoothened (SMO) inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC). The drug was discovered and developed by Novartis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/odomzo-sonidegib-for-the-treatment-of-locally-advanced-basal-cell-carcinoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-87.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ofev-nintedanib-ipf/">Ofev (nintedanib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)</a> </h3> <p>Discovered and developed by German pharmaceutical company Boehringer Ingelheim, Ofev (nintedanib) is the first and only tyrosine kinase inhibitor (TKI) to receive approval for the treatment of idiopathic pulmonary fibrosis (IPF).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ofev-nintedanib-ipf/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-47.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ogsiveo-treatment-desmoid-tumours-us/">Ogsiveo for the Treatment of Desmoid Tumours, US</a> </h3> <p>The Phase III DeFi clinical trial for Ogsiveo demonstrated both clinically meaningful and statistically significant improvements.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ogsiveo-treatment-desmoid-tumours-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/12/Featured-Image-OGSIVEO-nirogacestat.jpeg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ohtuvayre-chronic-obstructive-pulmonary-disease/">Ohtuvayre (ensifentrine) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD), USA</a> </h3> <p>Ohtuvayre™ (ensifentrine) is a novel, inhaled treatment for adult patients with chronic obstructive pulmonary disease (COPD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ohtuvayre-chronic-obstructive-pulmonary-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/07/Featured-Image-Ohtuvayre-ensifentrine-shutterstock_2251358881.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ojemda-tovorafenib-paediatric-low-grade-glioma/">OJEMDA (tovorafenib) for the Treatment of Paediatric Low-Grade Glioma (pLGG), USA</a> </h3> <p>OJEMDA™ (tovorafenib) is the first and only FDA-approved medicine for children with BRAF fusions or rearrangements. <br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ojemda-tovorafenib-paediatric-low-grade-glioma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/06/Featured-Image-OJEMDA-tovorafenib-for-Treatment-of-Paediatric-Low-Grade-Glioma.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/olcegepant/">Olcegepant – Novel Therapy for Acute Migraine</a> </h3> <p>Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP)</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/olcegepant/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-drugs_migraine.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/olinvyk-oliceridine/">OLINVYK (oliceridine) for the Treatment of Acute Pain</a> </h3> <p>OLINVYK™ (oliceridine) is a new chemical agent indicated for the treatment of acute pain in adults for whom the available treatments are ineffective.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/olinvyk-oliceridine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/08/Image-1-OLINVYK-oliceridine.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/baricitinib-treatment-moderate-severe-rheumatoid-arthritis/">Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis</a> </h3> <p>Olumiant® (baricitinib) is one of the first once-daily oral selective JAK1 and JAK2 inhibitors for the treatment of moderate-to-severe active rheumatoid arthritis (RA).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/baricitinib-treatment-moderate-severe-rheumatoid-arthritis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/04/Featured-Image-OLUMIANT-baricitinib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/olysio-simeprevir-for-the-treatment-of-chronic-hepatitis-c-chc/">Olysio (simeprevir) for the Treatment of Chronic Hepatitis C (CHC)</a> </h3> <p>Olysio (simeprevir) is an antiviral drug indicated for the treatment of chronic hepatitis C (CHC) infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/olysio-simeprevir-for-the-treatment-of-chronic-hepatitis-c-chc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-37.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/omidria-cataract-intraocular-lens-replacement-ilr-procedures/">Omidria™ for Use in Cataract and Other Intraocular Lens Replacement (ILR) Procedures</a> </h3> <p>Omidria (ketorolac and phenylephrine/ OMS302) is the only approved drug for intraocular use to prevent intraoperative miosis and reduce postoperative pain in cataract surgery and other intraocular lens replacement (ILR) procedures.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/omidria-cataract-intraocular-lens-replacement-ilr-procedures/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-39.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/peginesatide-hematide-for-the-treatment-of-anaemia-associated-with-chronic-kidney-disease/">Omontys (peginesatide) – for Treatment of Anaemia Associated with Chronic Kidney Disease</a> </h3> <p>Omontys (peginesatide) is an erythropoiesis-stimulating agent (ESA) developed for the treatment of anaemia associated with chronic kidney disease (CKD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/peginesatide-hematide-for-the-treatment-of-anaemia-associated-with-chronic-kidney-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-bottles.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/omvoh-mirikizumab-mrkz-for-the-treatment-of-active-ulcerative-colitis-usa/">Omvoh (mirikizumab-mrkz) for the Treatment of Active Ulcerative Colitis, USA</a> </h3> <p>Omvoh™ is a biologic treatment approved for moderate to severe active ulcerative colitis (UC) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/omvoh-mirikizumab-mrkz-for-the-treatment-of-active-ulcerative-colitis-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/11/Featured-Image-Omvoh-for-treating-UC-US.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/onbrez-capsules/">Onbrez Capsules – Treatment for Chronic Obstructive Pulmonary Disease</a> </h3> <p>Onbrez capsules are hard capsules developed by Novartis for the treatment of chronic obstructive pulmonary disease (CO</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/onbrez-capsules/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-onbrez-capsules.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/onfi-clobazam-for-the-treatment-of-lennox-gastaut-syndrome-lgs/">Onfi (Clobazam) – Treatment for Lennox-Gastaut Syndrome</a> </h3> <p>Onfi (clobazam) is an antiepileptic drug approved to treat seizures that are associated with Lennox-Gastaut syndrome (LGS) in patients who are aged two years and above.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/onfi-clobazam-for-the-treatment-of-lennox-gastaut-syndrome-lgs/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-onfi-clobazam.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ongentys-opicapone/">ONGENTYS (opicapone) for the Treatment of Parkinson’s Disease</a> </h3> <p>ONGENTYS® (opicapone) is the first and only approved catechol-O-methyltransferase (COMT) inhibitor indicated for the treatment of Parkinson's disease with off episodes, used as an adjunctive treatment to levodopa and carbidopa.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ongentys-opicapone/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/05/Image-1-Ongentys-opicapone.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/onivyde-irinotecan-liposome-injection-treatment-metastatic-pancreatic-cancer/">Onivyde (irinotecan liposome injection) for the Treatment of Metastatic Pancreatic Cancer</a> </h3> <p>Onivyde (MM-398 / irinotecan liposome injection) is an intravenous injection indicated for the treatment of metastatic pancreatic cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/onivyde-irinotecan-liposome-injection-treatment-metastatic-pancreatic-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-95.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/onpattro-for-hereditary-transthyretin-mediated-amyloidosis/">Onpattro (patisiran) for the Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults</a> </h3> <p>Onpattro™ (patisaran) is the first-of-its-kind RNA interference (RNAi)-based drug indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/onpattro-for-hereditary-transthyretin-mediated-amyloidosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Onpattro.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/onureg-azacitidine-for-the-treatment-of-acute-myeloid-leukaemia-aml/">ONUREG (azacitidine) for the Treatment of Acute Myeloid Leukaemia (AML)</a> </h3> <p>ONUREG® (azacitidine) is the first and only US Food and Drug Administration (FDA)-approved drug indicated for the continued treatment of acute myeloid leukaemia (AML) in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/onureg-azacitidine-for-the-treatment-of-acute-myeloid-leukaemia-aml/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/09/Image-2-ONUREG-azacitidine.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/onzetra-xsail-treatment-migraine/">ONZETRA Xsail for the Treatment of Migraine in Adults</a> </h3> <p>ONZETRA Xsail is a Food and Drug Administration (FDA)-approved intranasal dry powder formulation developed by Avanir Pharmaceuticals.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/onzetra-xsail-treatment-migraine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-114.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/opdivo-nivolumab-melanoma/">Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma</a> </h3> <p>Opdivo (nivolumab) is indicated for the treatment of unresectable or metastatic melanoma in patients with a positive BRAF V600 mutation who were previously treated and made progression with Yervoy (ipilimumab).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/opdivo-nivolumab-melanoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-68.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/opdualag-nivolumab-and-relatlimab-rmbw-for-the-treatment-of-unresectable-or-metastatic-melanoma-us/">Opdualag (nivolumab and relatlimab-rmbw) for the Treatment of Unresectable or Metastatic Melanoma, USA</a> </h3> <p>Opdualag™ (nivolumab and relatlimab-rmbw) is indicated for the treatment of unresectable or metastatic melanoma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/opdualag-nivolumab-and-relatlimab-rmbw-for-the-treatment-of-unresectable-or-metastatic-melanoma-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/04/Featured-Image-1-Opdualag-nivolumab-and-relatlimab-rmbw-for-the-Treatment-of-Unresectable-or-Metastatic-Melanoma_US.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/opsumit-macitentan-treatment-pulmonary-arterial-hypertension/">Opsumit (Macitentan) for Treatment of Pulmonary Arterial Hypertension (PAH)</a> </h3> <p>Opsumit (macitentan) is an oral dual endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/opsumit-macitentan-treatment-pulmonary-arterial-hypertension/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-11.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/opzelura-ruxolitinib-treatment-vitiligo-us/">Opzelura (ruxolitinib) for the Treatment of Vitiligo, US</a> </h3> <p>Opzelura (ruxolitinib) is the first and only topical treatment for repigmentation in vitiligo patients to have been approved by the Food and Drug Administration (FDA).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/opzelura-ruxolitinib-treatment-vitiligo-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/03/Featured-Image-Opzelura-ruxolitinib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/oral-lyn/">Oral-Lyn – Oral Spray Formulation of Human Insulin for Types 1 and 2 Diabetes</a> </h3> <p>Oral-Lyn is an oral spray formulation of human insulin indicated for the treatment of type 1 and 2 diabetes. It is being</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/oral-lyn/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-DIAB_SYMP.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/orbactiv-oritavancin-treatment-of-acute-bacterial-skin-skin-structure-infections/">Orbactiv (oritavancin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections</a> </h3> <p>Orbactiv (oritavancin) is the first and only approved antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/orbactiv-oritavancin-treatment-of-acute-bacterial-skin-skin-structure-infections/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-17.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/orenitram-treprostinil-treatment-pulmonary-arterial-hypertension-pah/">Orenitram (treprostinil) for Treatment of Pulmonary Arterial Hypertension (PAH)</a> </h3> <p>Orenitram (treprostinil/UT-15C) is indicated for the treatment of pulmonary arterial hypertension (PAH), in World Health Organisation (WHO) Group I patients, to improve exercise capacity.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/orenitram-treprostinil-treatment-pulmonary-arterial-hypertension-pah/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-48.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/orgovyx-relugolix-advanced-prostate-cancer/">ORGOVYX (relugolix) for the Treatment of Advanced Prostate Cancer</a> </h3> <p>ORGOVYX™ (relugolix) is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/orgovyx-relugolix-advanced-prostate-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/01/Image-1-ORGOVYX-relugolix.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/orilissa-elagolix-treatment-pain-associated-endometriosis/">ORILISSA (elagolix) for the Treatment of Pain Associated with Endometriosis</a> </h3> <p>ORILISSA (elagolix) is an oral gonadotropin-releasing hormone (GnRH) antagonist indicated for the treatment of moderate-to-severe pain associated with endometriosis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/orilissa-elagolix-treatment-pain-associated-endometriosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-ORILISSA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/oritavancin/">Oritavancin – Glycopeptide Antibiotic</a> </h3> <p>Oritavancin is an investigational glycopeptide antibiotic being developed by Targanta Therapeutics for the treatment of</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/oritavancin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-tissue-infections.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/orkambi-lumacaftor-ivacaftor-cystic-fibrosis/">Orkambi (lumacaftor/ivacaftor) for the Treatment of Cystic Fibrosis (CF)</a> </h3> <p>Orkambi (lumacaftor/ivacaftor) is the first approved medicine to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/orkambi-lumacaftor-ivacaftor-cystic-fibrosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-84.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/orladeyo-berotralstat-hereditary-angioedema/">ORLADEYO (berotralstat) for the Treatment of Hereditary Angioedema (HAE), USA</a> </h3> <p>ORLADEYO™ (berotralstat) is the first oral, once-daily preventive therapy indicated for hereditary angioedema (HAE).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/orladeyo-berotralstat-hereditary-angioedema/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/12/Image-1-ORLADEYO-berotralstat.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/orserdu-elacestrant-for-the-treatment-of-advanced-or-metastatic-breast-cancer-usa/">Orserdu (elacestrant) for the Treatment of Advanced or Metastatic Breast Cancer, USA</a> </h3> <p>Orserdu™ is the first endocrine therapy for ESR1-mutated advanced or metastatic breast cancer in more than two decades.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/orserdu-elacestrant-for-the-treatment-of-advanced-or-metastatic-breast-cancer-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/05/Feature-Image-Orserdu-elacestrant.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/osanetant/">Osanetant – Novel Investigational Agent for Treatment of Schizophrenia</a> </h3> <p>Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/osanetant/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/image1-20.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/otezla-apremilast-for-the-treatment-of-active-psoriatic-arthritis/">Otezla (apremilast) for the Treatment of Active Psoriatic Arthritis</a> </h3> <p>Otezla (apremilast), developed by Celgene Corporation, is an inflammatory drug indicated for the treatment of adult patients with active psoriatic arthritis (PsA).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/otezla-apremilast-for-the-treatment-of-active-psoriatic-arthritis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-14.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/oxbryta-voxelotor/">Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease</a> </h3> <p>Oxbryta™ (voxelotor), previously known as GBT440, is the first and only FDA-approved sickle haemoglobin polymerisation inhibitor indicated for the treatment of sickle cell disease (SCD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/oxbryta-voxelotor/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/01/Image-1-Oxbryta-voxelotor.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/oxervate-cenegermin-bkbj/">Oxervate (cenegermin-bkbj) to Treat Neurotrophic Keratitis, US</a> </h3> <p>Oxervate™ (cenegermin-bkbj) is an ophthalmic solution indicated for the treatment of moderate-to-severe neurotrophic keratitis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/oxervate-cenegermin-bkbj/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-Image-Oxervate.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/oxlumo-lumasiran-for-the-treatment-of-primary-hyperoxaluria-type-1-ph1/">OXLUMO (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1)</a> </h3> <p>OXLUMO™ (lumasiran) is the first small interfering ribonucleic acid (RNAi) therapeutics indicated for the treatment of primary hyperoxaluria type 1 (PH1) to reduce urinary oxalate levels in paediatric and adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/oxlumo-lumasiran-for-the-treatment-of-primary-hyperoxaluria-type-1-ph1/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/12/Image-1-OXLUMO-lumasiran.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/oxtellar-xr-for-the-treatment-of-partial-seizures/">Oxtellar XR for the Treatment of Partial Seizures</a> </h3> <p>Oxtellar XR (oxcarbazepine/ SPN-804) is an anti-epileptic drug indicated for the treatment of partial seizures. The drug is developed, manufactured and marketed by Supernus Pharmaceuticals.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/oxtellar-xr-for-the-treatment-of-partial-seizures/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-25.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/oxytrol-oxybutynin-for-the-treatment-of-overactive-bladder-oab-in-women/">Oxytrol (oxybutynin) for the Treatment of Overactive Bladder (OAB) in Women</a> </h3> <p>Oxytrol (oxybutynin) is a transdermal patch indicated for the treatment of overactive bladder in women who have symptoms of urge urinary incontinence, urgency and frequency.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/oxytrol-oxybutynin-for-the-treatment-of-overactive-bladder-oab-in-women/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-29.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ozempic-semaglutide-treatment-type-2-diabetes/">Ozempic (semaglutide) for the Treatment of Type 2 Diabetes</a> </h3> <p>Ozempic® (semaglutide) is a glucagon-like peptide (GLP-1) receptor agonist indicated for the treatment of Type 2 diabetes in adults. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ozempic-semaglutide-treatment-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Ozempic.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="p" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>P</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/padcev-enfortumab-vedotin/">Padcev (enfortumab vedotin) for the Treatment of Urothelial Cancer, USA</a> </h3> <p>Padcev (enfortumab vedotin) is the first Nectin-4-directed antibody-drug conjugate approved to treat urothelial cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/padcev-enfortumab-vedotin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/10/Featured-Image-Padcev-enfortumab-vedotin.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/palynziq-pegvaliase-pqpz-for-the-treatment-of-adults-with-phenylketonuria/">Palynziq (pegvaliase-pqpz) for the Treatment of Phenylketonuria</a> </h3> <p>Palynziq™ (pegvaliase-pqpz) is a subcutaneous infusion indicated for the treatment of adults with phenylketonuria (PKU).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/palynziq-pegvaliase-pqpz-for-the-treatment-of-adults-with-phenylketonuria/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Palynziq.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/pandemrix/">Pandemrix – Adjuvanted H1N1 Influenza Vaccine</a> </h3> <p>Pandemrix is an adjuvanted vaccine used in the prevention of the H1N1 (swine flu) virus infection and has been developed</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/pandemrix/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-flu-vaccine.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/panflu-1/">Panflu.1 – Single-Shot Vaccine Against H1N1 Influenza</a> </h3> <p>Developed by Sinovec Biotech to provide protection against the H1N1 virus, also known as swine flu, Panflu.1 is a single</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/panflu-1/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-electron-micrograph.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/etelcalcetide-calcimimetic-for-the-treatment-of-secondary-hyperparathyroidism-shpt/">Parsabiv™ (etelcalcetide) for the Treatment of Secondary Hyperparathyroidism (SHPT)</a> </h3> <p>Parsabiv™ (etelcalcetide) is an intravenous injectable calcimimetic agent developed by Amgen for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) that were previously treated with haemodialysis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/etelcalcetide-calcimimetic-for-the-treatment-of-secondary-hyperparathyroidism-shpt/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-102.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/paxil/">Paxil – SSRI for the Treatment of Major Depressive Disorders</a> </h3> <p>Paxil (paroxetine hydrochloride) was first developed in 1975 by a Danish company called Ferrosan. During 1980 Ferrosan s</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/paxil/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-gsk.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/paxlovid-nirmatrelvir-ritonavir-covid-19/">Paxlovid (nirmatrelvir and ritonavir) for the Treatment of Covid-19</a> </h3> <p>Paxlovid is the first FDA-approved oral antiviral treatment for mild to moderate Covid-19 in adult and paediatric patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/paxlovid-nirmatrelvir-ritonavir-covid-19/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/02/Featured-Image-Paxlovid-nirmatrelvir-and-ritonavir.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/pemazyre-pemigatinib/">Pemazyre™ (pemigatinib) for the Treatment of Cholangiocarcinoma</a> </h3> <p>Pemazyre™ (pemigatinib) is the first and only US Food and Drug Administration (FDA)-approved kinase inhibitor indicated for the treatment of cholangiocarcinoma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/pemazyre-pemigatinib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/05/Image-1-Pemazyre-pemigatinib-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/penbraya-meningococcal-a-b-c-w-and-y-vaccine-for-the-prevention-of-meningococcal-disease-usa/">PENBRAYA (Meningococcal A, B, C, W, and Y vaccine) for the Prevention of Meningococcal Disease, USA</a> </h3> <p>PENBRAYA™ is the first pentavalent vaccine to protect adolescents against the most common types of meningococcal disease.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/penbraya-meningococcal-a-b-c-w-and-y-vaccine-for-the-prevention-of-meningococcal-disease-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/04/Featured-Image-PENBRAYA-for-the-Prevention-of-Meningococcal-Disease-Shutterstock_1858345222.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/pepaxto-melphalan-flufenamide/">PEPAXTO® (melphalan flufenamide) for the Treatment of Multiple Myeloma</a> </h3> <p>PEPAXTO® (melphalan flufenamide) is a first-in-class peptide-drug conjugate indicated in combination with the glucocorticoid dexamethasone for the treatment of relapsed or refractory (r/r) multiple myeloma in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/pepaxto-melphalan-flufenamide/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/06/Image-1-Pepaxto-1.png" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/pertuzumab/">Pertuzumab – Treatment / Therapy for Breast Cancer</a> </h3> <p>Roche / Genentech's Perjeta (Pertuzumab) is a humanised monoclonal antibody (MAb) to the HER2 receptor for the treatment of advanced breast cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/pertuzumab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-female-breast.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/phenserine/">Phenserine – Next Generation AChE Inhibitor</a> </h3> <p>Axonyx, a US biopharmaceutical company that focuses on treatments for dementia, developed phenserine as a next-generatio</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/phenserine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/cross_section1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/phesgo-treatment-her2-positive-breast-cancer-us/">Phesgo for the Treatment of HER2-Positive Breast Cancer, US</a> </h3> <p>The formulation of Phesgo incorporates Halozyme Therapeutics’ Enhanze drug delivery technology.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/phesgo-treatment-her2-positive-breast-cancer-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/03/Featured-Image-Phesgo-pertuzumab-trastuzumab-and-hyaluronidase-zzxf-for-the-Treatment-of-HER2-Positive-Breast-Cancer.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/piasky-crovalimab-for-the-treatment-of-paroxysmal-nocturnal-haemoglobinuria-pnh/">PiaSky (crovalimab) for the Treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH), USA</a> </h3> <p>PiaSky® (crovalimab), discovered by Chugai, treats paroxysmal nocturnal haemoglobinuria (PNH) in adult and paediatric patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/piasky-crovalimab-for-the-treatment-of-paroxysmal-nocturnal-haemoglobinuria-pnh/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/07/Featured-Image-PiaSky-crovalimab-shutterstock_2449741397.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/pifeltro-treatment-hiv-1-infection/">Pifeltro (doravirine) for the Treatment of HIV-1 Infection</a> </h3> <p>Pifeltro (doravirine) is indicated for the treatment of adult patients with Human Immunodeficiency Virus-1 (HIV-1) infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/pifeltro-treatment-hiv-1-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-image-Pifeltro-doravirine.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/piqray-alpelisib/">Piqray (alpelisib) for the Treatment of Advanced Breast Cancer</a> </h3> <p>Piqray® (alpelisib) is a kinase inhibitor indicated for the treatment of hormone receptor (HR) positive or HER2-negative advanced breast cancer with PIK3CA mutation in men and post-menopausal women.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/piqray-alpelisib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-Image-Piqray.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/pirfenidone-treatment-for-idiopathic-pulmonary-fibrosis/">Pirfenidone – Treatment for Idiopathic Pulmonary Fibrosis</a> </h3> <p>Pirfenidone is a drug indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a disease that causes scarring and thickening of lungs.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/pirfenidone-treatment-for-idiopathic-pulmonary-fibrosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-structure.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/plavix-treatment-acute-coronary-syndrome/">Plavix (Clopidogrel Bisulfate) – Treatment for Acute Coronary Syndrome</a> </h3> <p>Plavix (clopidogrel bisulfate) is a thienopyridine class inhibitor indicated for the treatment of acute coronary syndrome (ACS).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/plavix-treatment-acute-coronary-syndrome/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-4.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/plectasin/">Plectasin NZ2114 – Novel Microbial Agent</a> </h3> <p>Under development by Novozymes A/S, the Danish biotechnology company, plectasin NZ2114 is a novel antimicrobial peptide.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/plectasin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-lab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/plegridy-peginterferon-beta-1a/">Plegridy (peginterferon beta-1a) for the Treatment of Relapsing Multiple Sclerosis (RMS)</a> </h3> <p>Plegridy (peginterferon beta-1a) is the only pegylated beta interferon approved for the treatment of relapsing multiple sclerosis (RMS). The drug was discovered and developed by Biogen Idec.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/plegridy-peginterferon-beta-1a/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-63.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/pluvicto-metastatic-prostate-cancer/">Pluvicto for the treatment of metastatic castration-resistant prostate cancer</a> </h3> <p>Pluvicto™ is the first FDA-approved targeted radioligand therapy for PSMA+ metastatic, castration-resistant prostate cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/pluvicto-metastatic-prostate-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/05/Featured-Image-Pluvicto.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/polivy-polatuzumab-vedotin/">Polivy (polatuzumab vedotin) for the Treatment of Diffuse Large B-cell Lymphoma</a> </h3> <p>Polivy™ (polatuzumab vedotin-piiq) is an antibody-drug conjugate indicated for the third-line treatment of adults with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/polivy-polatuzumab-vedotin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-Image-Polivy.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/pomalyst-pomalidomide-treatment-multiple-myeloma/">Pomalyst (Pomalidomide) for the Treatment of Multiple Myeloma</a> </h3> <p>Pomalyst (pomalidomide) is an anti-angiogenic drug developed by Celgene Corporation for the treatment of multiple myeloma in patients who have received two prior therapies.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/pomalyst-pomalidomide-treatment-multiple-myeloma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ponvory-ponesimod-for-the-treatment-of-multiple-sclerosis/">PONVORY (ponesimod) for the Treatment of Multiple Sclerosis</a> </h3> <p>PONVORY™ (ponesimod) is an oral disease-modifying therapy approved for the treatment of adult patients with relapsing forms of multiple sclerosis (MS).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ponvory-ponesimod-for-the-treatment-of-multiple-sclerosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/04/Image-2-PONVORY.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/portrazza-necitumumab-for-the-treatment-of-metastatic-squamous-non-small-cell-lung-cancer-nsclc/">Portrazza (necitumumab) for the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)</a> </h3> <p>Portrazza (necitumumab) is a recombinant human lgG1 monoclonal antibody developed by Eli Lilly, for the treatment of metastatic squamous non-small cell lung cancer (NSCLC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/portrazza-necitumumab-for-the-treatment-of-metastatic-squamous-non-small-cell-lung-cancer-nsclc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-103.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/posluma-prostate-cancer/">POSLUMA (flotufolastat F 18) PET Imaging Agent for Prostate Cancer, USA</a> </h3> <p>POSLUMA® is the first FDA-approved radio-hybrid PSMA-targeted agent for PET imaging of prostate cancer in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/posluma-prostate-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/08/Featured-Image-POSLUMA-Flotufolastat-F-18-Injection.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/poteligeo-mogamulizumab/">Poteligeo for the Treatment of Mycosis Fungoides and Sezary Syndrome</a> </h3> <p>Poteligeo® (mogamulizumab-kpkc) is a monoclonal antibody (mAb) indicated for the treatment of mycosis fungoides and Sézary syndrome in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/poteligeo-mogamulizumab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Poteligeo-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/pradaxa/">Pradaxa (dabigatran etexilate) – Oral Direct Thrombin Inhibitor</a> </h3> <p>Pradaxa (dabigatran etexilate) is an oral anticoagulant under development by Boehringer Ingelheim. Its primary indicatio</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/pradaxa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-human-heart-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/praluent-alirocumab-for-the-treatment-of-hypercholesterolemia/">Praluent (alirocumab) for the Treatment of Hypercholesterolemia</a> </h3> <p>Praluent (alirocumab) is an investigational therapy injection intended for the treatment of patients with hypercholesterolemia.</p> </div> <div class="cell large-4"> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/prasugrel/">Prasugrel, Investigational Antiplatelet Agent by Daiichi Sankyo and Lilly</a> </h3> <p>Originally discovered by Sankyo and Ube Industries, prasugrel is now the product of a co-development programme between D</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/prasugrel/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-heart-diagram.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/prexige/">Prexige – COX-2 Inhibitor</a> </h3> <p>Prexige (lumiracoxib) is an innovative COX-2 inhibitor developed by Novartis for the relief of pain and inflammation ass</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/prexige/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_Pain_Signal_Chemicals-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/prezcobix-darunavircobicistat-for-the-treatment-of-hiv-1/">Prezcobix™ (darunavir/cobicistat) for the Treatment of HIV-1</a> </h3> <p>Prezcobix™ (darunavir / cobicistat), discovered and developed by Janssen Therapeutics, is a fixed-dose antiretroviral combination tablet indicated for the treatment of human immunodeficiency virus (HIV-1) infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/prezcobix-darunavircobicistat-for-the-treatment-of-hiv-1/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-19.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/priorix-mmr-vaccine/">PRIORIX for the Prevention of Measles, Mumps and Rubella, USA</a> </h3> <p>The PRIORIX vaccine is approved for the prevention of measles, mumps and rubella (MMR) in people aged 12 months and older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/priorix-mmr-vaccine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/08/Featured-Image-Priorix-for-Prevention-of-Measles-Mumps-and-Rubella-US.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/procysbi-cysteamine-bitartrate-for-the-treatment-of-nephropathic-cystinosis/">Procysbi (cysteamine bitartrate) for the Treatment of Nephropathic Cystinosis</a> </h3> <p>Procysbi (cysteamine bitartrate) is a delayed-release capsule indicated for the treatment of nephropathic cystinosis. The drug was discovered and developed by Raptor Pharmaceutical (Raptor).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/procysbi-cysteamine-bitartrate-for-the-treatment-of-nephropathic-cystinosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-28.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/denosumab/">Prolia (Denosumab) – Therapy for Prevention and Treatment of Osteoporosis</a> </h3> <p>Amgen's prolia (denosumab) is a biological therapy developed for the prevention and treatment of osteoporosis and other</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/denosumab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-bone-structure.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/promacta-eltrombopag-treatment-severe-aplastic-anaemia-saa/">Promacta (eltrombopag) for the Treatment of Severe Aplastic Anaemia (SAA)</a> </h3> <p>Promacta (eltrombopag) is the first-in-class treatment indicated for patients with severe aplastic anaemia (SAA) immunosuppressive therapy (IST) was proven ineffective for.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/promacta-eltrombopag-treatment-severe-aplastic-anaemia-saa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-44.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/provenge-for-the-treatment-of-advanced-prostate-cancer/">Provenge – Treatment for Advanced Prostate Cancer</a> </h3> <p>Provenge (sipuleucel-T) is an autologous cellular immunotherapy used intravenously in the form of infusion for the treatment of men with advanced prostate cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/provenge-for-the-treatment-of-advanced-prostate-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-intravenous.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/psi7977fortreatmento/">PSI-7977 for Treatment of Chronic Hepatitis C</a> </h3> <p>PSI-7977 is indicated for the treatment of chronic Hepatitis C-virus (HCV) infection. The investigational drug is being</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/psi7977fortreatmento/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-9.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="q" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>Q</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/qalsody-tofersen-amyotrophic-lateral-sclerosis-europe/">QALSODY (tofersen) for the Treatment of Amyotrophic Lateral Sclerosis, Europe</a> </h3> <p>QALSODY® (tofersen) is the first therapy approved for a rare, genetic form of amyotrophic lateral sclerosis (ALS).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/qalsody-tofersen-amyotrophic-lateral-sclerosis-europe/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/07/Featured-Image-QALSODY-tofersen-shutterstock_1969483819.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/qinlock-ripretinib/">QINLOCK (ripretinib) for the Treatment of Gastrointestinal Stromal Tumour</a> </h3> <p>QINLOCK™ (ripretinib) is indicated as a fourth-line treatment for advanced gastrointestinal stromal tumour (GIST) in adult patients who have completed previous treatment with three or more kinase inhibitors, including imatinib.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/qinlock-ripretinib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/06/Image-1-QINLOCK-ripretinib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/qtern-dapagliflozin-and-saxagliptin-for-the-treatment-of-type-2-diabetes/">Qtern (dapagliflozin and saxagliptin) for the Treatment of Type 2 Diabetes</a> </h3> <p>Qtern (dapagliflozin and saxagliptin) is a combination drug with sodium/glucose cotransporter (SGLT) 2 and dipeptidyl peptidase 4 (DPP-4) inhibitors indicated for the treatment of type 2 diabetes.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/qtern-dapagliflozin-and-saxagliptin-for-the-treatment-of-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Qtern.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/quillivant-xr-methylphenidate-attention-deficit-hyperactivity-disorder-adhd/">Quillivant XR (methylphenidate) for Treatment of Attention Deficit Hyperactivity Disorder (ADHD)</a> </h3> <p>Quillivant XR (methylphenidate) is a psychostimulant drug indicated for Attention Deficit Hyperactivity Disorder (ADHD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/quillivant-xr-methylphenidate-attention-deficit-hyperactivity-disorder-adhd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-18.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/quizartinib-acute-myeloid-leukemia/">Quizartinib Indicated for the Treatment of FLT3-ITD AML</a> </h3> <p>Quizartinib is an investigational oral selective FLT3 inhibitor being developed for the treatment of adult patients with acute myeloid leukaemia (AML) having FLT3 internal tandem duplication (ITD) mutation.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/quizartinib-acute-myeloid-leukemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Quizartinib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/quviviq-daridorexant-insomnia/">QUVIVIQ (daridorexant) for the Treatment of Insomnia, USA</a> </h3> <p>QUVIVIQ™ (daridorexant) is a new treatment option developed by Idorsia Pharmaceuticals for adult patients with insomnia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/quviviq-daridorexant-insomnia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/09/Featured-Image-QUVIVIQ-daridorexant-to-Treat-Insomnia.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="r" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>R</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rad001/">RAD001 – Anti-Cancer Therapy, Anti-neoplastic agent by Novartis</a> </h3> <p>Afinitor (everolimus), formerly known as RAD001, is a macrolide antibiotic derived from rapamycin that is being investig</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rad001/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-solid-tumour.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/radicava-edaravone-for-the-treatment-of-amyotrophic-lateral-sclerosis-als/">Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)</a> </h3> <p>Radicava™ (edaravone) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/radicava-edaravone-for-the-treatment-of-amyotrophic-lateral-sclerosis-als/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-143.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rapamune-sirolimus-treatment-lymphangioleiomyomatosis-lam/">Rapamune (sirolimus) for the Treatment of Lymphangioleiomyomatosis (LAM)</a> </h3> <p>Rapamune (sirolimus), an immunosuppressive agent, is the first approved medicine in the US for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that affects the lungs, kidneys and the lymphatic system.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rapamune-sirolimus-treatment-lymphangioleiomyomatosis-lam/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-83.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/peramivir/">Rapiacta (peramivir) – Neuraminidase Inhibitor for Treatment of Influenza</a> </h3> <p>Rapiacta (peramivir) as is a neuraminidase inhibitor discovered and developed by BioCryst Pharmaceuticals for the treatm</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/peramivir/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-peramivir.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rasagiline-parkinsons-disease/">Rasagiline – Second-Generation MAO-B Inhibitor for the Treatment of Parkinson’s Disease</a> </h3> <p>Azilect® (rasagiline) is a monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease (PD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rasagiline-parkinsons-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2012/04/Featured-Image-Azilect-rasagiline-for-the-Treatment-of-Parkinsons-Disease.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rasilez/">Rasilez – Innovative Treatment for Hypertension</a> </h3> <p>The product of a joint development programme between Swiss companies Speedel and Novartis, Rasilez (aliskiren) is an ora</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rasilez/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-hyperglycaemia-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ravicti-glycerol-phenylbutyrate-for-treatment-of-urea-cycle-disorders-ucd/">Ravicti (glycerol phenylbutyrate) for Treatment of Urea Cycle Disorders (UCD)</a> </h3> <p>Ravicti (glycerol phenylbutyrate) is indicated for the treatment of Urea Cycle Disorders (UCD) in adults and paediatric patients aged two and above.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ravicti-glycerol-phenylbutyrate-for-treatment-of-urea-cycle-disorders-ucd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-23.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/reblozyl-luspatercept-aamt/">REBLOZYL for the Treatment of Anaemia Associated with Beta-Thalassemia, US</a> </h3> <p>REBLOZYL is a first-in-class treatment for patients affected by conditions influenced by anaemia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/reblozyl-luspatercept-aamt/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/11/Featured-Image-Reblozyl.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/regen-cov-casirivimab-imdevimab/">REGEN-COV (Casirivimab with Imdevimab) for the Treatment of Mild to Moderate Covid-19</a> </h3> <p>REGEN-COV™ (casirivimab with imdevimab) is an investigational monoclonal antibody cocktail authorised for the treatment of mild to moderate Covid-19 in adults and paediatric patients aged 12 years and older who are infected with SARS-COV-2 and are at high risk of progression to severe Covid-19.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/regen-cov-casirivimab-imdevimab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/05/Image-1-REGEN-COV-Casirivimab-with-Imdevimab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/relyvrio-sodium-phenylbutyrate-taurursodiol/">Relyvrio (sodium phenylbutyrate/taurursodiol) to Treat Amyotrophic Lateral Sclerosis, USA</a> </h3> <p>Relyvrio is an oral, fixed-dose combination therapy for amyotrophic lateral sclerosis (ALS) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/relyvrio-sodium-phenylbutyrate-taurursodiol/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/01/Featured-Image-Relyvrio-.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/drug-rember/">Rember – Novel Therapy for Alzheimer’s Disease</a> </h3> <p>Rember (methylthioninium chloride) is a potential disease-modifying therapy for Alzheimer's disease that is under develo</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/drug-rember/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-alois-alzheimer.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/remdesivir/">Remdesivir for Potential Treatment of Covid-19</a> </h3> <p>Remdesivir is an investigational antiviral drug being developed by Gilead Sciences for the treatment of COVID-19, a coronavirus disease, and Ebola virus infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/remdesivir/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/03/Image-1-Remdesivir.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/repatha-evolocumab-treatment-heterozygous-homozygous-familial-hypercholesterolemia/">Repatha for the Treatment of Heterozygous and Homozygous Familial Hypercholesterolaemia, US</a> </h3> <p>The FDA approved Repatha in December 2017 to help prevent heart attacks, strokes, and coronary revascularisations.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/repatha-evolocumab-treatment-heterozygous-homozygous-familial-hypercholesterolemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/04/Featured-Image-Repatha-evolocumab-for-the-Treatment-of-Heterozygous-and-Homozygous-Familial-Hypercholesterolaemia.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/restanza/">Restanza</a> </h3> <p>Restanza (cethromycin) is a second-generation ketolide, once-a-day oral antibiotic that is under review for approval by</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/restanza/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-streptococcus-pneumoniae.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/retevmo-selpercatinib/">Retevmo (selpercatinib) for the Treatment of RET-Driven Cancers</a> </h3> <p>Retevmo™ (selpercatinib) is the first therapy approved for the treatment of three rearranged during transfection (RET)-driven cancer indications.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/retevmo-selpercatinib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/05/Image-1-Retevmo-selpercatinib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/pfizersrevatio/">Revatio (Sildenafil) – Treatment for Pulmonary Arterial Hypertension</a> </h3> <p>Revatio is an approved formulation developed by Pfizer for the treatment of pulmonary arterial hypertension. The drug w</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/pfizersrevatio/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-1-19.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/revcovi/">Revcovi for the Treatment of ADA-SCID</a> </h3> <p>Revcovi (elapegademase-lvlr) is a PEGylated recombinant adenosine deaminase (rADA) enzyme indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in paediatric and adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/revcovi/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/Image-1-Revcovi-for-ADA-SCID.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/revlimid-lenalidomide-treatment-mantle-cell-lymphoma/">Revlimid (Lenalidomide) for the Treatment of Mantle Cell Lymphoma (MCL)</a> </h3> <p>Revlimid (lenalidomide) oral capsules are indicated for the treatment of Mantle Cell Lymphoma (MCL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/revlimid-lenalidomide-treatment-mantle-cell-lymphoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-39.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rexulti-brexpiprazole-treatment-major-depressive-disorder-schizophrenia/">Rexulti (Brexpiprazole) for the Treatment of Major Depressive Disorder (MDD) and Schizophrenia</a> </h3> <p>Rexulti (brexpiprazole) is a newly-discovered psychotropic compound indicated as an add-on therapy for major depressive disorder (MDD) and as a treatment for schizophrenia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rexulti-brexpiprazole-treatment-major-depressive-disorder-schizophrenia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-85.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rezdiffra-treatment-nash-us/">Rezdiffra for the Treatment of Noncirrhotic Non-alcoholic Steatohepatitis, US</a> </h3> <p>Rezdiffra is the first FDA-approved medication to treat NASH.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rezdiffra-treatment-nash-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/04/Featured-Image-Rezdiffra-resmetirom.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rezular/">Rezular – Oral Treatment for IBS</a> </h3> <p>Developed by AGI Therapeutics, Rezular (arverapamil) is an orally administered triple-action intestinal regulator indica</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rezular/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-human-gi-tract.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rezurock-belumosudil-cgvhd/">REZUROCK™ (belumosudil) for the Treatment of Chronic Graft-Versus-Host Disease</a> </h3> <p>REZUROCK™ (belumosudil) is an oral kinase inhibitor indicated for the treatment of chronic graft-versus-host disease (cGVHD) in patients aged 12 years and older who have received at least two failed previous lines of alternative systemic therapy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rezurock-belumosudil-cgvhd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/08/Featured-Image-REZUROCK.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/riastap-treatment-congenital-fibrinogen-deficiency/">RiaSTAP – Treatment for Congenital Fibrinogen Deficiency (CFD)</a> </h3> <p>CSL Behring's RiaSTAP is a lyophilised fibrinogen concentrate targeted at the treatment of congenital fibrinogen deficiency (CFD). It can also be used for the treatment of afibrinogenemia and hypofibrinogenemia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/riastap-treatment-congenital-fibrinogen-deficiency/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-8.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rifapantinefortuberc/">Rifapentine</a> </h3> <p>Rifapentine is an antibiotic drug developed by Sanofi-aventis for treating tuberculosis (TB). It is marketed under the</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rifapantinefortuberc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-tuberculosis-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rinvoq-upadacitinib-for-the-treatment-of-active-crohns-disease-usa/">Rinvoq (upadacitinib) for the Treatment of Active Crohn’s Disease, USA</a> </h3> <p>Rinvoq is approved in the US and Europe for active Crohn’s disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rinvoq-upadacitinib-for-the-treatment-of-active-crohns-disease-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/05/Featured-Image-Rinvoq.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rituxan-treatment/">Rituxan for the Treatment of Non-Hodgkin’s Lymphoma, US</a> </h3> <p>Rituxan was developed by Biogen Idec, a biotechnology company based in the US, together with the copromotion partner Genentech.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rituxan-treatment/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2011/03/Featured-Image-Rituxan-rituximab-for-the-Treatment-of-Non-Hodgkins-Lymphoma-Shutterstock_2368117205.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rixubis-coagulation-factor-ix-recombinant-for-the-treatment-of-haemophilia-b/">Rixubis (coagulation factor IX (recombinant)) for the Treatment of Haemophilia B</a> </h3> <p>Rixubis [coagulation factor IX (recombinant)] is indicated for the control and prevention of bleeding episodes and perioperative management in the treatment of adult patients suffering from haemophilia B.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rixubis-coagulation-factor-ix-recombinant-for-the-treatment-of-haemophilia-b/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-47.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rozlytrek-entrectinib/">Rozlytrek (entrectinib) for the Treatment of Solid Cancerous Tumours</a> </h3> <p>Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced solid tumours in adult and paediatric patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rozlytrek-entrectinib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-Image-Rozlytrek.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rubraca-rucaparib-for-the-treatment-of-advanced-ovarian-cancer/">Rubraca (rucaparib) for the Treatment of Advanced Ovarian Cancer</a> </h3> <p>Poly adenosine diphosphate ribose polymerase (PARP) inhibitor Rubraca® (rucaparib) is indicated for the treatment of breast cancer susceptibility gene (BRCA) mutation-linked advanced ovarian cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rubraca-rucaparib-for-the-treatment-of-advanced-ovarian-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-131.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ruconest-treatment-hereditary-angioedema-hae/">Ruconest for Treatment of Hereditary Angioedema (HAE)</a> </h3> <p>Ruconest (C1 Esterase Inhibitor [Recombinant]) is a recombinant approved for treatment of acute angioedema attacks in patients suffering from hereditary angioedema (HAE).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ruconest-treatment-hereditary-angioedema-hae/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-16.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rukobia-fostemsavir-for-the-treatment-of-hiv/">Rukobia (fostemsavir) for the Treatment of HIV</a> </h3> <p>Rukobia (fostemsavir) is an antiretroviral drug, developed by ViiV Healthcare, for the treatment of HIV-1 infection in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rukobia-fostemsavir-for-the-treatment-of-hiv/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/07/Image-1-Rukobia.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ag7088/">Rupintrivir (AG7088)</a> </h3> <p>Agouron Pharmaceuticals, a subsidiary of Pfizer, has pioneered the development of rupintrivir (AG7088), an experimental treatment for the common cold.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ag7088/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_influenza_00271.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ruzurgi-amifampridine/">Ruzurgi (amifampridine) for the Treatment of LEMS</a> </h3> <p>Ruzurgi® (amifampridine) is approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in paediatric patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ruzurgi-amifampridine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/05/Featured-Image-Ruzurgi-amifampridine-for-the-Treatment-of-LEMS-USA.jpeg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rybelsus/">Rybelsus (Semaglutide) for the Treatment of Type 2 Diabetes</a> </h3> <p>Rybelsus® (semaglutide) is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rybelsus/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/02/Image-1-Rybelsus.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rybrevant-nsclc/">RYBREVANT (amivantamab-vmjw) for the Treatment of Non-Small Cell Lung Cancer</a> </h3> <p>Rybrevant (amivantamab-vmjw) is the first fully-human bispecific antibody indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has advanced on or after platinum-based chemotherapy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rybrevant-nsclc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/07/Image-1-Rybrevant-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rydapt-midostaurin-for-the-treatment-of-acute-myeloid-leukaemia-and-systemic-mastocytosis/">Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis</a> </h3> <p>Rydapt® (midostaurin) is a multi-targeted inhibitor of multiple kinases including FMS-like tyrosine kinase 3 mutation-positive (FLT3+) and KIT approved for the treatment of acute myeloid leukaemia (AML) and three types of advanced systemic mastocytosis (SM) indications.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rydapt-midostaurin-for-the-treatment-of-acute-myeloid-leukaemia-and-systemic-mastocytosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-38.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rylaze-asparaginase/">Rylaze™ (asparaginase erwinia chrysanthemi (recombinant) rywn)</a> </h3> <p>Rylaze (asparaginase erwinia chrysanthemi (recombinant) rywn), formerly known as JZP458, is an asparagine-specific enzyme approved for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in certain adult and paediatric patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rylaze-asparaginase/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/07/Featured-Image-Rylaze.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rystiggo-rozanolixizumab-noli-generalised-myasthenia-gravis-usa/">RYSTIGGO (rozanolixizumab-noli) for the Treatment of Generalised Myasthenia Gravis, USA</a> </h3> <p>RYSTIGGO® is the first FDA-approved therapy for generalised myasthenia gravis with anti-AChR or anti-MuSK positive antibody.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rystiggo-rozanolixizumab-noli-generalised-myasthenia-gravis-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/01/Featured-Image-RYSTIGGO-rozanolixizumab-noli-for-the-Treatment-of-Generalised-Myasthenia-Gravis.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rytelo-treatment-mds/">RYTELO for the Treatment of Myelodysplastic Syndromes, US</a> </h3> <p>The vial is available in 47mg and 188mg dosage strengths.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rytelo-treatment-mds/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/06/Featured-Image-RYTELO-imetelstat-shutterstock_1999345856.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="s" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>S</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sabril-vigabatrin-partial-seizures-infantile-spasms/">Sabril (Vigabatrin) – Treatment for Refractory Complex Partial Seizures and IS</a> </h3> <p>Sabril (vigabatrin) is an antiepileptic drug indicated for the treatment of refractory complex partial seizures (CPS) and infantile spasms (IS). It was developed by Ovation Pharmaceuticals, which was later acquired by Lundbeck.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sabril-vigabatrin-partial-seizures-infantile-spasms/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-8.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/saphnelo-anifrolumab-fnia/">Saphnelo (Anifrolumab-fnia) for the Treatment of Systemic Lupus Erythematosus</a> </h3> <p>Saphnelo is the only novel therapy approved for systemic lupus erythematosus (SLE) in more than a decade.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/saphnelo-anifrolumab-fnia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/08/Featured-Image-Anifrolumab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sarclisa-isatuximab-irfc/">Sarclisa (isatuximab) for the Treatment of Multiple Myeloma, USA</a> </h3> <p>Sarclisa® is the first approved anti-CD38 therapy along with standard-of-care treatment to treat newly diagnosed multiple myeloma. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sarclisa-isatuximab-irfc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/09/Featured-Image-Sarclisa-isatuximab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sativex/">Sativex (Nabiximols) for the Treatment of Multiple Sclerosis, Europe</a> </h3> <p>Sativex®, also known as Nabiximols, is indicated to treat spasticity due to multiple sclerosis and cancer pain.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sativex/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2003/06/Featured-Image-Sativex-delta-9-tetrahydrocannabinol-and-cannabidiol-for-the-Treatment-of-Multiple-Sclerosis.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/saxagliptin/">Saxagliptin – Treatment for Type 2 Diabetes</a> </h3> <p>The product of a joint development programme between AstraZeneca and Bristol-Myers Squibb, saxagliptin is a member of a</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/saxagliptin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-hyperglycaemia.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/saxenda-liraglutide-obesity/">Saxenda (liraglutide) for the Treatment of Obesity, US</a> </h3> <p>Saxenda is a GLP-1 receptor agonist to treat obesity in adolescents with a 60kg body weight and an initial BMI of 30kg/m².</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/saxenda-liraglutide-obesity/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/09/Featured-Image-Saxenda-liraglutide-for-the-Treatment-of-Obesity.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/scemblix-asciminib-chronic-myeloid-leukaemia/">Scemblix (asciminib) for the Treatment of Chronic Myeloid Leukaemia</a> </h3> <p>Scemblix (asciminib) is a first-in-class STAMP inhibitor indicated for treating chronic myeloid leukaemia (CML) in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/scemblix-asciminib-chronic-myeloid-leukaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/Image-1-Scemblix-asciminib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/secuado-asenapine/">Secuado (asenapine) for the Treatment of Schizophrenia</a> </h3> <p>Secuado® (asenapine) is an atypical anti-psychotic drug approved for the treatment of schizophrenia in adult patients. It is the first drug approved as transdermal patch formulation for schizophrenia treatment in the US.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/secuado-asenapine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/10/1l-Image-Secuado.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/nalmefene-falcoholde/">Selincro (nalmefene) – Treatment for Alcohol Dependence</a> </h3> <p>Selincro (nalmefene) is an injected drug for the treatment of alcohol dependence.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/nalmefene-falcoholde/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-13.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/semagacestat/">Semagacestat – Gamma Secretase Inhibitor for Alzheimer’s Disease</a> </h3> <p>Semagacestat (LY-450139) was a gamma secretase inhibitor being developed as a treatment for Alzheimer's disease by Eli</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/semagacestat/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-alzheimers-disease.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/seroquel-treatment/">Seroquel – Treatment for Major Depressive Disorder (MDD)</a> </h3> <p>Seroquel (quetiapine fumarate) is an anti-psychotic drug indicated as an add-on treatment for patients suffering from</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/seroquel-treatment/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-seroquel-treatment.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/treatmentofchronicly/">SF1126 –</a> </h3> <p>SF1126 is indicated for treating chronic lymphocytic leukaemia (CLL). The drug is being developed by US-based Semafore</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/treatmentofchronicly/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-treatment-of-chronicly.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/shingrix-herpes-zoster-subunit-vaccine-prevention-shingles/">Shingrix (herpes zoster subunit vaccine) for the Prevention of Shingles</a> </h3> <p>Shingrix is a recombinant subunit shingles vaccine that was discovered and developed by GlaxoSmithKline (GSK).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/shingrix-herpes-zoster-subunit-vaccine-prevention-shingles/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Shingrix.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/signifor-pasireotide-treatment-cushings-disease/">Signifor (Pasireotide) – Treatment for Cushing’s Disease</a> </h3> <p>Signifor (SOM230 / Pasireotide) is a somatostatin analogue indicated for the treatment of patients with Cushing's disease for whom surgery has failed. The drug is developed and manufactured by Novartis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/signifor-pasireotide-treatment-cushings-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-9.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/siklos-hydroxyurea-treatment-children-sickle-cell-anaemia/">Siklos (hydroxyurea) for the Treatment of Children with Sickle Cell Anaemia</a> </h3> <p>Siklos® is an orally administered tablet form of hydroxyurea that is indicated for the treatment of sickle-cell anaemia in paediatric patients aged two years and older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/siklos-hydroxyurea-treatment-children-sickle-cell-anaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Siklos.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/silenor-doxepin-insomnia/">Silenor (doxepin) for the Treatment of Insomnia</a> </h3> <p>Silenor (doxepin) is a tricyclic antidepressant indicated for the treatment of insomnia. It was developed by Somaxon Pharmaceuticals.<br /> In March 2010, the US Food and Drug Administration (FDA) approved Silenor for the treatment of insomnia characterised by difficulty with sleep maintenance.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/silenor-doxepin-insomnia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-12.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/simbrinza-brinzolamidebrimonidine-tartrate-for-the-reduction-of-elevated-intraocular-pressure/">Simbrinza (brinzolamide/brimonidine tartrate) for the Reduction of Elevated Intraocular Pressure</a> </h3> <p>Simbrinza (brinzolamide/brimonidine tartrate) is a carbonic anhydrase inhibitor developed by Alcon, a division of Novartis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/simbrinza-brinzolamidebrimonidine-tartrate-for-the-reduction-of-elevated-intraocular-pressure/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-6.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/simponi-golimumab-treatment-ulcerative-colitis/">Simponi (Golimumab) – Treatment for Ulcerative Colitis (UC)</a> </h3> <p>Simponi (golimumab) is a subcutaneous injection for the treatment of adult patients living with ulcerative colitis (UC). The drug was discovered and developed by Janssen Biotech.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/simponi-golimumab-treatment-ulcerative-colitis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-33.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/simponi-aria-golimumab/">SIMPONI ARIA (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)</a> </h3> <p>SIMPONI ARIA® (golimumab) is a fully human anti-tumour necrosis factor (TNF) alpha monoclonal antibody.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/simponi-aria-golimumab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/10/Image-1-SIMPONI-ARIA-golimumab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sirturo-bedaquiline-for-treatment-of-pulmonary-multi-drug-resistant-tuberculosis-tb/">Sirturo (bedaquiline) for Treatment of Pulmonary Multi-Drug Resistant Tuberculosis (TB)</a> </h3> <p>Sirturo (bedaquiline) was developed by Janssen Therapeutics, a division of Janssen Products. It is indicated for the treatment of multi-drug resistant tuberculosis (MDR-TB).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sirturo-bedaquiline-for-treatment-of-pulmonary-multi-drug-resistant-tuberculosis-tb/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-22.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sitavig-acyclovir-treatment-herpes-labialis/">Sitavig (Acyclovir) – Treatment for Herpes Labialis</a> </h3> <p>Sitavig (acyclovir) is a muco-adhesive buccal tablet indicated for the treatment of recurring Herpes Labialis. The drug is manufactured and marketed by BioAlliance Pharma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sitavig-acyclovir-treatment-herpes-labialis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-7.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sivextro-treatment-acute-bacterial-skin-skin-structure-infections/">Sivextro for Treatment of Acute Bacterial Skin and Skin Structure Infections</a> </h3> <p>Sivextro (tedizolid phosphate) is an oxazolidinone class antibacterial drug indicated for treatment of adult patients infected with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sivextro-treatment-acute-bacterial-skin-skin-structure-infections/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-56.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/skyrizi-risankizumab-plaque-psoriasis/">Skyrizi (risankizumab-rzaa) for the Treatment of Plaque Psoriasis, USA</a> </h3> <p>Skyrizi® is an interleukin-23 inhibitor indicated to treat plaque psoriasis, active psoriatic arthritis and Crohn’s disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/skyrizi-risankizumab-plaque-psoriasis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/07/Featured-Image-Skyrizi-risankizumab-rzaa-for-the-Treatment-of-Plaque-Psoriasis.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sohonos-palovarotene-for-the-treatment-of-fibrodysplasia-ossificans-progressiva-fop-usa/">Sohonos (palovarotene) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP), USA</a> </h3> <p>Sohonos, developed by Ipsen, is the first and only approved treatment for patients with fibrodysplasia ossificans progressiva.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sohonos-palovarotene-for-the-treatment-of-fibrodysplasia-ossificans-progressiva-fop-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/11/Featured-Image-Sohonos-for-the-treatment-of-fibrodysplasia-ossificans-progressiva.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/soliqua-10033-for-the-treatment-of-type-2-diabetes/">Soliqua 100/33 for the Treatment of Type 2 Diabetes</a> </h3> <p>Developed by Sanofi, Soliqua 100/33 (insulin glargine & Lixisenatide injection) is indicated for the treatment of Type 2 diabetes.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/soliqua-10033-for-the-treatment-of-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-35.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/soliris-eculizumab-pnh-ahus/">Soliris (Eculizumab) for the Treatment of Generalised Myasthenia Gravis (gMG), USA</a> </h3> <p>Soliris® (eculizumab) is the first targeted therapy approved for paediatric patients with gMG in Europe.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/soliris-eculizumab-pnh-ahus/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/09/Featured-Image-Soliris-Eculizumab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/solithera-solithromycin-for-the-treatment-of-community-acquired-bacterial-pneumonia/">Solithera (solithromycin) for the Treatment of Community-Acquired Bacterial Pneumonia</a> </h3> <p>Solithera (solithromycin) is a next-generation macrolide antibiotic developed by Cempra as a treatment for community-acquired bacterial pneumonia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/solithera-solithromycin-for-the-treatment-of-community-acquired-bacterial-pneumonia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-122.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/solosec-secnidazole-bacterial-vaginosis-trichomoniasis/">Solosec (secnidazole) for the Treatment of Bacterial Vaginosis and Trichomoniasis</a> </h3> <p>Solosec® (secnidazole) is a next-generation antibiotic indicated for the treatment of bacterial vaginosis and trichomoniasis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/solosec-secnidazole-bacterial-vaginosis-trichomoniasis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/04/Featured-Image-Solosec-secnidazole.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/inpefa-sotagliflozin-hf-treatment-us/">Sotagliflozin for the Treatment of Heart Failure, US</a> </h3> <p>Sotagliflozin is a once-daily oral drug indicated to reduce the risk of cardiovascular death in adults.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/inpefa-sotagliflozin-hf-treatment-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/06/Featured-Image-INPEFA-sotagliflozin-for-Treatment-of-Heart-Failure.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sotyktu-deucravacitinib-plaque-psoriasis/">Sotyktu (deucravacitinib) to Treat Moderate to Severe Plaque Psoriasis, USA</a> </h3> <p>Sotyktu (deucravacitinib) is the first oral TYK2 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sotyktu-deucravacitinib-plaque-psoriasis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/09/Featured-Image-Sotyktu™-deucravacitinib-to-Treat-Moderate-to-Severe-Plaque-Psoriasis.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sovaldi-sofosbuvir-treatment-chronic-hepatitis-c-infection/">Sovaldi (sofosbuvir) for the Treatment of Chronic Hepatitis C Infection</a> </h3> <p>Sovaldi (sofosbuvir), developed by Gilead Sciences (Gilead), is an oral nucleotide analog inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sovaldi-sofosbuvir-treatment-chronic-hepatitis-c-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-33.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/spevigo-spesolimab-gpp/">Spevigo (Spesolimab-sbzo) to Treat Generalised Pustular Psoriasis Flares, USA</a> </h3> <p>Spevigo (spesolimab-sbzo) is the first approved treatment for generalised pustular psoriasis flares in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/spevigo-spesolimab-gpp/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/02/Featured-Image-Spevigospesolimab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/spinraza-nusinersen-for-the-treatment-of-spinal-muscular-atrophy-sma/">SPINRAZA for the Treatment of Spinal Muscular Atrophy, US</a> </h3> <p>SPINRAZA is available as a clear, colourless solution of 12mg/5ml dosage strength.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/spinraza-nusinersen-for-the-treatment-of-spinal-muscular-atrophy-sma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2017/01/SPINRAZA-Feat-Img.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/spiriva-treatment-for-chronic-obstructive-pulmonary-disease/">Spiriva – Treatment for Chronic Obstructive Pulmonary Disease</a> </h3> <p>Spiriva is an anticholinergic drug targeted at chronic obstructive pulmonary disease (COPD). It contains tiotropium bromide as the active ingredient.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/spiriva-treatment-for-chronic-obstructive-pulmonary-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image1-5.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/spritam-levetiracetam-epilepsy/">Spritam (levetiracetam) for the Treatment of Epilepsy</a> </h3> <p>Spritam (levetiracetam) is an adjunctive therapy indicated for the treatment of seizures in patients with epilepsy, the fourth most common neurological disorder affecting people of all age groups.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/spritam-levetiracetam-epilepsy/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-89.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/steglatro-ertugliflozin-treatment-type-2-diabetes/">Steglatro (ertugliflozin) for the Treatment of Type 2 Diabetes</a> </h3> <p>Steglatro™ (ertugliflozin) is a combination drug indicated for the improvement of glycaemic control in adult patients with Type 2 diabetes mellitus.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/steglatro-ertugliflozin-treatment-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/Image-1-Steglatro.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/stelara-treatment-moderate-severe-crohns-disease/">Stelara for the Treatment of Moderate to Severe Crohn’s Disease, US</a> </h3> <p>Stelara was approved for the treatment of US adult patients with moderately to severely active UC in 2019 by the FDA.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/stelara-treatment-moderate-severe-crohns-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2016/11/Stelara-Feat-Img.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/stimufend-pegfilgrastim-fpgk-febrile-neutropenia/">Stimufend (pegfilgrastim-fpgk) for the Treatment of Febrile Neutropenia, USA</a> </h3> <p>Stimufend® (pegfilgrastim-fpgk) is a biosimilar to Neulasta® for use in patients at risk for febrile neutropenia.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/stimufend-pegfilgrastim-fpgk-febrile-neutropenia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/07/Featured-Image-Stimufend®-pegfilgrastim-fpgk_Europe.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/stimuvax/">Stimuvax – Investigational Therapeutic Cancer Vaccine</a> </h3> <p>Stimuvax, formerly known as BLP25 liposome vaccine (L-BLP25), is an investigational therapeutic vaccine being developed to provide immunity against the cancer cells that over express Mucin 1 (MUC-1), a glycoprotein antigen</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/stimuvax/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-stimuvax.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/stiolto-respimat-for-the-treatment-of-chronic-obstructive-pulmonary-disease-copd/">Stiolto Respimat for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)</a> </h3> <p>Stiolto Respimat (tiotropium bromide and olodaterol), an oral inhalation spray indicated for the treatment of chronic obstructive pulmonary disease (COPD), is manufactured by Boehringer Ingelheim Pharmaceuticals, the US subsidiary of Boehringer Ingelheim Corp.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/stiolto-respimat-for-the-treatment-of-chronic-obstructive-pulmonary-disease-copd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-82.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/stivarga-regorafenib-metastatic-colorectal-cancer-bayer/">Stivarga (Regorafenib) for Treating Metastatic Colorectal Cancer (mCRC)</a> </h3> <p>Stivarga (Regorafenib) is an oral multikinase inhibitor developed by Bayer HealthCare for the treatment of metastatic colorectal cancer (mCRC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/stivarga-regorafenib-metastatic-colorectal-cancer-bayer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-14.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/strensiq-asfotase-alfa-hypophosphatasia/">Strensiq (asfotase alfa) for the Treatment of Hypophosphatasia</a> </h3> <p>Strensiq (asfotase alfa) is the first enzyme replacement therapy (ERT) approved in the US for the treatment of perinatal / infantile and juvenile-onset hypophosphatasia (HPP), which is a life-threatening and ultra-rare metabolic disorder.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/strensiq-asfotase-alfa-hypophosphatasia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-96.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/stribild-a-single-tablet-regimen-for-the-treatment-of-hiv-1/">Stribild – A Single Tablet Regimen for the Treatment of HIV-1</a> </h3> <p>Stribild is a combination of four compounds; elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The drug is indicated for the treatment of HIV-1 infection in adults who have never received antiretroviral treatment for the disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/stribild-a-single-tablet-regimen-for-the-treatment-of-hiv-1/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-4.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/striverdi-respimat-for-the-maintenance-treatment-of-copd/">Striverdi Respimat for the Maintenance Treatment of COPD</a> </h3> <p>Striverdi Respimat (olodaterol) is an inhalation spray indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and / or emphysema.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/striverdi-respimat-for-the-maintenance-treatment-of-copd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-59.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sublocade-treatment-opioid-use-disorder/">Sublocade™ for the Treatment of Opioid Use Disorder</a> </h3> <p>Sublocade™ (buprenorphine extended-release) is a partial agonist indicated for the treatment of moderate-to-severe opioid use disorder (OUD) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sublocade-treatment-opioid-use-disorder/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Sublocade.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sun-101eflow-for-the-treatment-of-chronic-obstructive-pulmonary-disease/">SUN-101/eFlow for the Treatment of Chronic Obstructive Pulmonary Disease</a> </h3> <p>SUN-101 (Glycopyrrolate) is an inhalation solution developed by Sunovion Pharmaceuticals as a treatment for patients with moderate to severe chronic obstructive pulmonary disease (COPD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sun-101eflow-for-the-treatment-of-chronic-obstructive-pulmonary-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-123.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sunlenca-lenacapavir-hiv-1/">Sunlenca (Lenacapavir) for the Treatment of HIV-1 Infection, USA</a> </h3> <p>Sunlenca (lenacapavir) is a first-in-class, long-acting HIV capsid inhibitor approved for the treatment of HIV-1 infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sunlenca-lenacapavir-hiv-1/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/01/Featured-Image-Sunlenca-lenacapavir.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/surfaxin-lucinactant-prevention-respiratory-distress-syndrome-rds-infants/">Surfaxin (Lucinactant) – Treatment for Preventing Infant RDS</a> </h3> <p>Surfaxin (Lucinactant) is a non-pyrogenic pulmonary surfactant used for the prevention of respiratory distress syndrome (RDS) in premature infants.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/surfaxin-lucinactant-prevention-respiratory-distress-syndrome-rds-infants/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-17.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sustiva-efavirenz-hiv-infected-paediatric-patients/">Sustiva (Efavirenz) – Treatment for HIV-1 Infected Paediatric Patients</a> </h3> <p>Sustiva (efavirenz) is an antiretroviral indicated for the treatment of paediatric patients with the HIV-1 infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sustiva-efavirenz-hiv-infected-paediatric-patients/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-35.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/susvimo-ranibizumab-namd/">Susvimo (ranibizumab) for Treating Wet Age‑related Macular Degeneration</a> </h3> <p>Susvimo™ (ranibizumab) is a VEGF inhibitor indicated for the treatment of neovascular age-related macular degeneration (nAMD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/susvimo-ranibizumab-namd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/Featured-Image-Susvim-ranibizumab.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sutent-sunitinib-malate-treatment-pancreatic-neuroendocrine-tumours/">Sutent (Sunitinib Malate) – Treatment for Pancreatic Neuroendocrine Tumours</a> </h3> <p>Sutent (sunitinib malate) is an oral multikinase inhibitor which is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumours (NET).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sutent-sunitinib-malate-treatment-pancreatic-neuroendocrine-tumours/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sycrest-asenapine-treatment-bipolar-i-disorder/">Sycrest (asenapine) – Treatment for Bipolar I Disorder</a> </h3> <p>Sycrest (asenapine) is an antipsychotic medicine indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder. The drug was developed by Merck.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sycrest-asenapine-treatment-bipolar-i-disorder/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-9.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/syfovre-pegcetacoplan-treatment-geographic-atrophy-usa/">Syfovre (pegcetacoplan) for the Treatment of Geographic Atrophy, USA</a> </h3> <p>Syfovre™ is the first FDA-approved treatment for geographic atrophy, an advanced form of age-related macular degeneration.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/syfovre-pegcetacoplan-treatment-geographic-atrophy-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/04/Feature-Image-Syfovre-pegcetacoplan.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/sylvant-siltuximab-for-the-treatment-of-multicentric-castlemans-disease-mcd/">Sylvant (siltuximab) for the Treatment of Multicentric Castleman’s Disease</a> </h3> <p>Sylvant (siltuximab) is indicated for the treatment of patients with multi-centric Castleman’s disease (MCD) in the US.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/sylvant-siltuximab-for-the-treatment-of-multicentric-castlemans-disease-mcd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2018/07/1l-Image.jpeg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/symbicort-budesonide-and-formoterol-for-the-treatment-of-asthma/">Symbicort (budesonide and formoterol) for the Treatment of Asthma</a> </h3> <p>Symbicort is a combination drug comprising an inhaled corticosteroid and a long-acting bronchodilator to treat asthma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/symbicort-budesonide-and-formoterol-for-the-treatment-of-asthma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2017/02/Feature-Image-Symbicort.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/symdeko-tezacaftor-ivacaftor-ivacaftor-treatment-cystic-fibrosis/">Symdeko (tezacaftor/ivacaftor and ivacaftor) for the Treatment of Cystic Fibrosis</a> </h3> <p>Symdeko™ (tezacaftor/ivacaftor and ivacaftor) is a combination drug indicated for the treatment of cystic fibrosis (CF) in people aged 12 years and above.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/symdeko-tezacaftor-ivacaftor-ivacaftor-treatment-cystic-fibrosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Symdeko-pack.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/synribo-omacetaxine-mepesuccinate-for-treatment-of-chronic-myeloid-leukaemia-cml/">Synribo (Omacetaxine Mepesuccinate) for Treating Chronic Myeloid Leukaemia</a> </h3> <p>Synribo (Omacetaxine Mepesuccinate) is a subcutaneously injected drug developed by Teva Oncology, a division of Teva Pharmaceutical Industries, based in the US. The drug is indicated for the treatment of patients with chronic myelogenous leukaemia (CML) in both chronic and accelerated phases.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/synribo-omacetaxine-mepesuccinate-for-treatment-of-chronic-myeloid-leukaemia-cml/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-17.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="t" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>T</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/t705/">T-705 – Antiviral Drug for Influenza by Toyama Chemical of Japan</a> </h3> <p>T-705 is a novel oral agent indicated for the treatment of influenza that is under development by Toyama Chemical of Jap</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/t705/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-influenza-virus.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tabrecta-capmatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/">Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)</a> </h3> <p>Tabrecta™ (capmatinib) is the first US Food and Drug Administration (FDA)-approved therapy for the treatment of adult patients diagnosed with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that results in mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tabrecta-capmatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/07/Image-2-TABRECTA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tafinlar-dabrafenib-treatment-metastatic-melanoma/">Tafinlar (Dabrafenib) – Treatment for Metastatic Melanoma</a> </h3> <p>Tafinlar (dabrafenib) is a single-agent oral treatment indicated for the treatment of unresectable or metastatic melanoma in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tafinlar-dabrafenib-treatment-metastatic-melanoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-30.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tagrisso-osimertinib-for-the-treatment-of-egfr-mutation-in-non-small-cell-lung-cancer/">Tagrisso (osimertinib) For the Treatment of EGFR mutation in Non-Small Cell Lung Cancer</a> </h3> <p>Tagrisso (osimertinib) is a once-daily tablet developed by AstraZeneca for the treatment of metastatic epidermal growth factor receptor (EGFR) T790M mutation associated with non-small cell lung cancer (NSCLC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tagrisso-osimertinib-for-the-treatment-of-egfr-mutation-in-non-small-cell-lung-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-119.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/takhzyro-lanadelumab-flyo-prevention-hereditary-angioedema/">Takhzyro (lanadelumab-flyo) for the Prevention of Hereditary Angioedema</a> </h3> <p>Takhzyro (lanadelumab-flyo) is indicated for the preventive treatment of hereditary angioedema (HAE) in patients aged 12 years and older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/takhzyro-lanadelumab-flyo-prevention-hereditary-angioedema/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-Takhzyro.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/taltz/">Taltz (ixekizumab) for the Treatment of Non-Radiographic Axial Spondyloarthritis</a> </h3> <p>Taltz® (ixekizumab) is the first humanised interleukin (IL)-17A antagonist therapy approved for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective inflammation signs.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/taltz/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/06/Image-1-Taltz.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/talvey-treatment-multiple-myeloma-us/">TALVEY for the Treatment of Multiple Myeloma, US</a> </h3> <p>The US FDA granted accelerated approval to TALVEY in August 2023.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/talvey-treatment-multiple-myeloma-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/02/Featured-Image-TALVEY-talquetamab-for-the-Treatment-of-Relapsed-or-Refractory-Multiple-Myeloma.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/talzenna-talazoparib/">Talzenna (talazoparib) for the Treatment of Advanced Breast Cancer</a> </h3> <p>Talzenna™ (talazoparib) is an inhibitor of the poly adenosine diphosphate (ADP) ribose polymerase (PARP) enzyme that is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) negative breast cancer in adult patients with the BRCA-mutated (gBRCAm) gene.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/talzenna-talazoparib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Talzenna.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tamiflu/">Tamiflu – Oral Anti-Viral Treatment Agent</a> </h3> <p>Tamiflu or oseltamivir is a prescription drug used for prophylaxis and treatment of flu caused by influenza virus types A (H1N1) and B.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tamiflu/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-tamiflu.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tanzeum-albiglutide-for-treatment-of-type-2-diabetes/">Tanzeum (albiglutide) for Treatment of Type 2 Diabetes</a> </h3> <p>Tanzeum (albiglutide), developed by GlaxoSmithKline (GSK), is a GLP-1 receptor agonist indicated for treatment of type 2 diabetes.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tanzeum-albiglutide-for-treatment-of-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-53.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/taranabant/">Taranabant CB1 Receptor Inverse Agonist for Management of Obe</a> </h3> <p>Taranabant is a highly selective cannabinoid-1 (CB1) receptor inverse agonist developed by Merck & Co for the treatment</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/taranabant/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-per-cent-obese.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tarceva/">Tarceva Small Molecule EGFR-Tyrosine Kinase Inhibitor for Cancer</a> </h3> <p>Tarceva (erlotinib) is an oral anti-cancer drug developed by OSI Pharmaceuticals, Genentech and Roche. It is a member of</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tarceva/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_Ultra_High_Throughput_scr.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tarpeyo-treatment-igan-us/">TARPEYO for the Treatment of IgAN, US</a> </h3> <p>TARPEYO is the first and only FDA-approved therapy to reduce the loss of kidney function in adults with primary IgAN.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tarpeyo-treatment-igan-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/01/Featured-Image-TARPEYO-budesonide-.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tasigniaforchronicmy/">Tasigna (Nilotinib)</a> </h3> <p>Tasigna (nilotinib) is indicated for treating Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML). Th</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tasigniaforchronicmy/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-01.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tavalisse-fostamatinib-disodium-hexahydrate-treatment-chronic-immune-thrombocytopenia/">TAVALISSE (fostamatinib disodium hexahydrate) for the Treatment of Chronic Immune Thrombocytopenia</a> </h3> <p>TAVALISSE™ is a twice-daily regimen indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tavalisse-fostamatinib-disodium-hexahydrate-treatment-chronic-immune-thrombocytopenia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-TAVALISSE.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tavneos-avacopan-anca-associated-vasculitis/">Tavneos (avacopan) for the Treatment of ANCA-Associated Vasculitis</a> </h3> <p>Tavneos (avacopan) is the first FDA-approved oral selective complement 5a receptor inhibitor drug for ANCA-associated vasculitis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tavneos-avacopan-anca-associated-vasculitis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/Featured-Image-TAVNEOS-avacopan-900x506-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tazverik-tazemetostat/">Tazverik (tazemetostat) for the Treatment of Epithelioid Sarcoma</a> </h3> <p>Tazverik is the first approved treatment for metastatic/locally advanced epithelioid sarcoma in patients aged 16 years and older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tazverik-tazemetostat/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/01/Image-1-Tazverik.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tb402/">TB402 – Treatment of VTE and AF</a> </h3> <p>The product of a co-development programme between ThromboGenics, a Belgian biotechnology company, and BioInvent Internat</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tb402/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-anticoagulant.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tbria-calcitonin-salmon-treatment-postmenopausal-osteoporosis/">TBRIA (calcitonin-salmon) for the Treatment of Postmenopausal Osteoporosis</a> </h3> <p>TBRIA (calcitonin-salmon [rDNA origin] delayed release tablet) is the first oral recombinant salmon calcitonin, developed by Tarsa Therapeutics, for the treatment of postmenopausal osteoporosis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tbria-calcitonin-salmon-treatment-postmenopausal-osteoporosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-98.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tecartus-brexucabtagene-autoleucel/">Tecartus (brexucabtagene autoleucel) for the Treatment of Mantle Cell Lymphoma (MCL)</a> </h3> <p>Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19) chimeric antigen receptor (CAR) T-cell therapy is the first and only approved cell-based gene therapy for the treatment of mantle cell lymphoma (MCL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tecartus-brexucabtagene-autoleucel/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/08/Image-1-Tecartus.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tecelra-afamitresgene-autoleucel-synovial-sarcoma-usa/">TECELRA (afamitresgene autoleucel) for the Treatment of Synovial Sarcoma, USA</a> </h3> <p>TECELRA® (afamitresgene autoleucel) is the first novel treatment option for individuals with synovial sarcoma in more than ten years.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tecelra-afamitresgene-autoleucel-synovial-sarcoma-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/Featured-Image-TECELRA-afamitresgene-autoleucel-for-the-Treatment-of-Metastatic-Synovial-Sarcoma_USA-Shutterstock_2149388383.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tecentriq-atezolizumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/">Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)</a> </h3> <p>Tecentriq® (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tecentriq-atezolizumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-146.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ms-treatment/">Tecfidera (Dimethyl Fumarate), Treatment for Relapsing-Remitting Multiple Sclerosis (RRMS)</a> </h3> <p>Tecfidera (BG-12/Dimethyl Fumarate) is a first-line oral treatment indicated for patients with relapsing-remitting multiple sclerosis (RRMS). The drug was developed by Biogen Idec.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ms-treatment/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-ms-treatment.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/technivie-ombitasvir-paritaprevir-ritonavir-treatment-genotype-4-chronic-hepatitis-c/">Technivie (Ombitasvir, Paritaprevir, Ritonavir) for the Treatment of Genotype 4 Chronic Hepatitis C</a> </h3> <p>Technivie (ombitasvir, paritaprevir and ritonavir) is the first direct-acting antiviral drug approved for the treatment of genotype 4 (GT4) chronic hepatitis C virus (HCV) infection in the US.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/technivie-ombitasvir-paritaprevir-ritonavir-treatment-genotype-4-chronic-hepatitis-c/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-22.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tegsedi-inotersen-for-the-treatment-of-hattr/">Tegsedi for the Treatment of Polyneuropathy of hATTR Amyloidosis</a> </h3> <p>Tegsedi™ (inotersen) is an anti-sense oligonucleotide indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tegsedi-inotersen-for-the-treatment-of-hattr/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Tegsedi.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/telbivudine/">Telbivudine – Investigational Drug</a> </h3> <p>The product of a joint collaborative programme between Idenix Pharmaceuticals and Novartis Pharma, telbivudine (oral L-d</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/telbivudine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Formula.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tepmetko-tepotinib-non-small-cell-lung-cancer/">Tepmetko (tepotinib) for the Treatment of Non-Small Cell Lung Cancer</a> </h3> <p>Tepmetko (tepotinib) is an oral kinase inhibitor approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). It is the first and only US Food and Drug Administration (FDA) approved mesenchymal-epithelial transition (MET) inhibitor with once-daily oral dosing.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tepmetko-tepotinib-non-small-cell-lung-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/04/Image-1-TEPMETKO.png" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/terlivaz-terlipressin-hrs/">Terlivaz (terlipressin) for the Treatment of Hepatorenal Syndrome (HRS), USA</a> </h3> <p>Terlivaz (terlipressin) is the first and only approved treatment of hepatorenal syndrome (HRS) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/terlivaz-terlipressin-hrs/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/01/Featured-Image-1-Terlivaz-terlipressin-002.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tesmilifene/">Tesmilifene – Chemopotentiator for Cancer</a> </h3> <p>Tesmilifene is a small molecule chemopotentiator under development by YM BioSciences, a Candian pharmaceutical company t</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tesmilifene/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_Tumour_resistance.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tesofensine/">Tesofensine Anti-Obesity Medication</a> </h3> <p>Under development by NeuroSearch, a Danish pharmaceutical company, tesofensine is a novel treatment for obesity. A serot</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tesofensine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-eating-process.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tezspire-tezepelumab-ekko-for-the-treatment-of-severe-asthma-usa/">Tezspire (tezepelumab-ekko) for the Treatment of Severe Asthma, USA</a> </h3> <p>Tezspire (tezepelumab-ekko) is the first and only biologic indicated as an add-on maintenance treatment for severe asthma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tezspire-tezepelumab-ekko-for-the-treatment-of-severe-asthma-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/02/Featured-Image-Tezspire-tezepelumab-ekko-for-the-Treatment-of-Severe-Asthma.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tibsovo-ivosidenib-indicated-relapsed-refractory-acute-myeloid-leukaemia/">TIBSOVO (ivosidenib) for Treating Relapsed or Refractory AML and Advanced Cholangiocarcinoma, US</a> </h3> <p>TIBSOVO® (ivosidenib) is the first approved targeted therapy for patients with IDH1-mutated advanced cholangiocarcinoma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tibsovo-ivosidenib-indicated-relapsed-refractory-acute-myeloid-leukaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2018/10/Image-1-TIBSOVO-ivosidenib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tiglutik-riluzole-treatment-amyotrophic-lateral-sclerosis/">TIGLUTIK (Riluzole) for the Treatment of Amyotrophic Lateral Sclerosis</a> </h3> <p>TIGLUTIK (Riluzole) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tiglutik-riluzole-treatment-amyotrophic-lateral-sclerosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-TIGLUTIK-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tivdak-tisotumab-vedotin-tftv/">Tivdak (tisotumab vedotin-tftv) for the Treatment of Recurrent or Metastatic Cervical Cancer</a> </h3> <p>Tivdak (tisotumab vedotin-tftv) is the first and only approved antibody-drug conjugate to treat adults with cervical cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tivdak-tisotumab-vedotin-tftv/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/11/Featured-Image-TIVDAK-tisotumab-vedotin-tftv.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tivicay-dolutegravir-treatment-hiv-1-infection/">Tivicay (Dolutegravir) for the Treatment of HIV-1 Infection</a> </h3> <p>Tivicay (dolutegravir) is an integrase inhibitor indicated for the treatment of the HIV-1 infection in adults and children aged 12 years and above.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tivicay-dolutegravir-treatment-hiv-1-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-37.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tivorbex-indomethacin-for-the-treatment-of-acute-pain/">Tivorbex (indomethacin) for the Treatment of Acute Pain</a> </h3> <p>Tivorbex (indomethacin) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of mild to moderate acute pain in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tivorbex-indomethacin-for-the-treatment-of-acute-pain/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-50.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/toujeo-treatment-type-1-type-2-diabetes/">Toujeo for the Treatment of Type 1 and Type 2 Diabetes</a> </h3> <p>Toujeo (insulin glargine [rDNA origin]) is an insulin injection approved for the treatment of type 1 and type 2 diabetes to improve glycaemic control in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/toujeo-treatment-type-1-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-76.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/cardiooral/">TRA-SCH-530348</a> </h3> <p>TRA-SCH 530348 is an oral antiplatelet drug under development by Schering-Plough for the treatment and prevention of ath</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/cardiooral/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-human-heart.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tradjenta-diabetes/">Tradjenta Indicated for the Treatment of Type II Diabetes</a> </h3> <p>Linagliptin (BI-1356), which is being marketed under the trade name Tradjenta®, is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor drug for the treatment of type 2 diabetes.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tradjenta-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-linagliptin.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/translarna-ataluren-for-the-treatment-of-nonsense-mutation-duchenne-muscular-dystrophy-nmdmd/">Translarna (ataluren) for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)</a> </h3> <p>Translarna™ (ataluren) is a protein restoration therapy indicated for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The drug was developed by PTC Therapeutics.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/translarna-ataluren-for-the-treatment-of-nonsense-mutation-duchenne-muscular-dystrophy-nmdmd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-139.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/trastuzumabforadvanc/">Trastuzumab –</a> </h3> <p>Trastuzumab, indicated for the treatment of recurrent gastric cancer with a high concentration of HER2 (human epiderma</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/trastuzumabforadvanc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-4.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tremfya-guselkumab-for-the-treatment-of-plaque-psoriasis/">Tremfya (guselkumab) for the Treatment of Plaque Psoriasis</a> </h3> <p>Tremfya™ (guselkumab) is a biologic approved for the treatment moderate-to-severe plaque psoriasis in adults. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tremfya-guselkumab-for-the-treatment-of-plaque-psoriasis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-150.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tresiba-insulin-degludec-for-the-treatment-of-type-1-and-type-2-diabetes/">Tresiba (insulin degludec) for the Treatment of Type 1 and Type 2 Diabetes, USA</a> </h3> <p>Novo Nordisk’s Tresiba® (insulin degludec) is indicated for the treatment of Type 1 and Type 2 diabetes. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tresiba-insulin-degludec-for-the-treatment-of-type-1-and-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2017/03/Featured_Image-_Tresiba_insulin_degludec_for_the_Treatment_of_Type_1_and_Type_2_Diabetes1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tretten-for-the-treatment-of-congenital-factor-xiii-deficiency/">Tretten for the Treatment of Congenital Factor XIII Deficiency</a> </h3> <p>Tretten is the world’s first recombinant treatment available for the prevention of bleeding in adults and children suffering from congenital factor XIII (FXIII) A-subunit deficiency.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tretten-for-the-treatment-of-congenital-factor-xiii-deficiency/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-35.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/trexima/">Treximet – Next-Generation Treatment for Migraine</a> </h3> <p>The product of a joint development programme between US drug development company Pozen and GSK, Treximet is a novel comb</p> </div> <div class="cell large-4"> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/trikafta/">TRIKAFTA (elexacaftor, ivacaftor and tezacaftor) for the Treatment of Cystic Fibrosis</a> </h3> <p>TRIKAFTA is the first triple combination therapy containing elexacaftor, ivacaftor, and tezacaftor indicated for the treatment of cystic fibrosis (CF) in people aged 12 years and above and having a F508del mutation and one minimal function mutation.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/trikafta/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/10/1l-Image-TRIKAFTA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/triumeq-dolutegravirabacavirlamivudine-for-the-treatment-of-hiv/">Triumeq (dolutegravir/abacavir/lamivudine) for the Treatment of HIV</a> </h3> <p>Triumeq (dolutegravir/abacavir/lamivudine) is an investigational drug indicated for the treatment of adult and adolescent patients (minimum age of 12 years and with a minimum weight of 40kg) affected with Human Immunodeficiency Virus (HIV).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/triumeq-dolutegravirabacavirlamivudine-for-the-treatment-of-hiv/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-42.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/trobalt-potiga/">Trobalt / Potiga – Treatment for Partial-Onset Seizure</a> </h3> <p>Trobalt (ezogabine / retigabine) is indicated for the treatment of partial-onset epileptic seizures in patients aged more than 18 years old.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/trobalt-potiga/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-trobalt-potiga.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/trodelvy-sacituzumab-govitecan/">Trodelvy (sacituzumab govitecan) for the Treatment of Advanced Triple-Negative Breast Cancer</a> </h3> <p>Gilead’s Trodelvy is indicated for the treatment of locally advanced or metastatic breast cancer and urothelial cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/trodelvy-sacituzumab-govitecan/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/05/Featured-Image-Trodelvy-sacituzumab-govitecan.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/trofinetide-for-the-treatment-of-rett-syndrome-us/">Trofinetide for the Treatment of Rett Syndrome, US</a> </h3> <p>Daybue is the first and only drug approved for the treatment of Rett syndrome, a rare neurodevelopmental disorder.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/trofinetide-for-the-treatment-of-rett-syndrome-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/06/Featured-Image_Daybue.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/trogarzo-ibalizumab-uiyk-treatment-multidrug-resistant-hiv-1-infection/">Trogarzo (ibalizumab-uiyk) for the Treatment of Multidrug-Resistant HIV-1 Infection</a> </h3> <p>Trogarzo™ is indicated for the treatment of multidrug-resistant HIV-1 infection in heavily treatment-experienced patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/trogarzo-ibalizumab-uiyk-treatment-multidrug-resistant-hiv-1-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-image-Trogarzo.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/trulance-plecanatide-for-the-treatment-of-adults-with-chronic-idiopathic-constipation-cic/">Trulance™ (Plecanatide) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC)</a> </h3> <p>Trulance™ (Plecanatide) is a guanylate cyclase-C (GC-C) agonist indicated for the treatment of adult patients with chronic idiopathic constipation (CIC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/trulance-plecanatide-for-the-treatment-of-adults-with-chronic-idiopathic-constipation-cic/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-133.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/trulicity-type-2-diabetes/">Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes</a> </h3> <p>Trulicity (dulaglutide) is a glucagon-like peptide 1 receptor agonist (GLP-1 agonist) indicated for the treatment of adults with type 2 diabetes. The drug was discovered and developed by Eli Lilly and Company.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/trulicity-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-62.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/trumenba-vaccine-for-prevention-of-meningococcal-meningitis-b-disease/">Trumenba Vaccine for Prevention of Meningococcal Meningitis B Disease</a> </h3> <p>Trumenba is a vaccine licenced in the US for the prevention of invasive meningococcal meningitis B in adolescents and young adults between ten and 25 years.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/trumenba-vaccine-for-prevention-of-meningococcal-meningitis-b-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-48.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/truqap-capivasertib-breast-cancer/">TRUQAP (capivasertib) for the Treatment of Breast Cancer, USA</a> </h3> <p>TRUQAP™ (capivasertib) in combination with Faslodex® (fulvestrant) is indicated for the treatment of breast cancer in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/truqap-capivasertib-breast-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/06/Featured-Image-TRUQAP-capivasertib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/truseltiq-infigratinib-cholangiocarcinoma/">TRUSELTIQ™ (infigratinib) for the Treatment of Cholangiocarcinoma</a> </h3> <p>TRUSELTIQ™ (infigratinib) is an oral kinase inhibitor indicated for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor II (FGFR2) fusion in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/truseltiq-infigratinib-cholangiocarcinoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/06/Image-1-TRUSELTIQ.png" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/truvada-prevention-hiv/">Truvada – Antiretroviral Treatment to Prevent HIV</a> </h3> <p>Truvada (emtricitabine and tenofovir disoproxil fumarate) is an antiretroviral indicated for preventing or reducing the risk of acquiring HIV-1.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/truvada-prevention-hiv/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-7.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/truxima-rituximab-for-the-treatment-of-cancer/">Truxima (rituximab) for the Treatment of Cancer</a> </h3> <p>ruxima™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well as granulomatosis with polyangiitis and microscopic polyangiitis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/truxima-rituximab-for-the-treatment-of-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-148.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tudorza-pressair-aclidinium-bromide-inhalation-powder-for-long-term-treatment-of-copd/">Tudorza™ Pressair™ (aclidinium bromide inhalation powder) for Long-term Treatment of COPD</a> </h3> <p>Tudorza Pressair (aclidinium bromide inhalation powder) is an anticholinergic drug indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It was developed by Forest Laboratories in collaboration with Spanish company Almirall.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tudorza-pressair-aclidinium-bromide-inhalation-powder-for-long-term-treatment-of-copd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-11.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tukysa-tucatinib-for-the-treatment-of-her2-positive-breast-cancer/">TUKYSA™ (tucatinib) for the treatment of HER2-Positive Breast Cancer</a> </h3> <p>TUKYSA™ (tucatinib) is the first HER-2 tyrosine kinase inhibitor approved in combination with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tukysa-tucatinib-for-the-treatment-of-her2-positive-breast-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/04/Image-1-TUKYSA-tucatinib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tygacil/">Tygacil – Broad-Spectrum Antibiotic for Empiric</a> </h3> <p>Developed by Wyeth Pharmaceuticals, Tygacil (tigecycline) is the first in a new class of antibiotics, the glycylcyclines</p> </div> <div class="cell large-4"> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/lapatinib/">Tykerb – Dual Tyrosine Kinase Inhibitor</a> </h3> <p>Tykerb (lapatinib ditosylate) is an epidermal growth factor receptor (EGFR) and ErbB-2 (Her2/neu) dual tyrosine kinase i</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/lapatinib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/ERB_Receptor.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tyrvaya-varenicline-dry-eye-disease/">Tyrvaya (varenicline) for the Treatment of Dry Eye Disease</a> </h3> <p>Tyrvaya (varenicline) is the first and only nasal spray approved by the FDA for the treatment of dry eye disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tyrvaya-varenicline-dry-eye-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/11/Featured-Image-Tyrvaya-varenicline.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/antegren/">Tysabri – Therapeutic Monoclonal Antibody (Mab) for the Treatment of Multiple Sclerosis</a> </h3> <p>The product of a joint development programme between by Elan Pharmaceuticals and Biogen, Tysabri (natalizumab) is a huma</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/antegren/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/Human_Brain01.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="u" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>U</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/uceris-budesonide-treatment-ulcerative-colitis-us/">Uceris (Budesonide) for Treating Ulcerative Colitis</a> </h3> <p>Uceris (budesonide) is glucocorticoid receptor that is indicated for the treatment of ulcerative colitis. It is developed by US-based biopharmaceutical company Santarus, in collaboration with Cosmo Technologies.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/uceris-budesonide-treatment-ulcerative-colitis-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-23.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ukoniq-umbralisib/">UKONIQ™ (umbralisib) for the Treatment of Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)</a> </h3> <p>UKONIQ™ (umbralisib) is the first and only oral, dual inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon, indicated for the treatment of previously treated relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL) in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ukoniq-umbralisib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/02/Image-1-UKONIQ™-Umbralisib.png" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ultomiris-ravulizumab-cwvz/">Ultomiris (ravulizumab-cwvz) for Paroxysmal Nocturnal Haemoglobinuria</a> </h3> <p>Ultomiris™ (ravulizumab-cwvz) is a complement inhibitor drug approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ultomiris-ravulizumab-cwvz/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/01/Featured-Image-Ultomiris-ravulizumab-cwvz-for-Paroxysmal-Nocturnal-Haemoglobinuria.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ultresa-treatment-exocrine-pancreatic-insufficiency/">Ultresa – Treatment for Exocrine Pancreatic Insufficiency (EPI)</a> </h3> <p>Aptalis Pharma's Ultresa is indicated for the treatment of exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis or other conditions. It was approved by the US Food and Drug Administration.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ultresa-treatment-exocrine-pancreatic-insufficiency/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-6.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ustekinumab/">Ustekinumab, Treatment for Plaque Psoriasis by Centocor and Janssen-Cilag</a> </h3> <p>Ustekinumab (CNTO 1275), a human anti-interleukin 12 (IL-12) and anti-interleukin 23 (IL-23) monoclonal antibody (MAb),</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ustekinumab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-ustekinumab.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="v" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>V</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/v1512/">V1512 (melevodopa/carbidopa) for the Treatment of Parkinson’s Disease, Italy</a> </h3> <p>V1512 (melevodopa/carbidopa) is an effervescent tablet formulation for the treatment of Parkinson's disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/v1512/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2006/10/Featured-Image-V1512-Sirio.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vabysmo-faricimab-svoa-namd-dme/">Vabysmo (faricimab-svoa) for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema</a> </h3> <p>Vabysmo™ (faricimab-svoa) is the first injectable eye medicine approved for two conditions, nAMD and DME, simultaneously.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vabysmo-faricimab-svoa-namd-dme/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/03/Featured-Image-Vabysmo-faricimab-svoa.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/valtorcitabine/">Valtorcitabine – Combination Drug Therapy for Chronic Hepatitis B</a> </h3> <p>In partnership with Novartis Pharma, Idenix Pharmaceuticals is developing valtorcitabine (L-deoxycytidine) as part of a</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/valtorcitabine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-hbv-infections.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vanflyta-quizartinib-treatment-acute-myeloid-leukaemia/">VANFLYTA (quizartinib) for the Treatment of Acute Myeloid Leukaemia, USA</a> </h3> <p>VANFLYTA® (quizartinib) is the first and only FLT3 inhibitor indicated to treat newly diagnosed acute myeloid leukaemia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vanflyta-quizartinib-treatment-acute-myeloid-leukaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/09/Featured-Image-VANFLYTA-quizartinib-for-the-Treatment-of-Acute-Myeloid-Leukemia_Japan.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/varithena-polidocanol-injectable-foam-for-the-treatment-of-varicose-veins/">Varithena (Polidocanol Injectable Foam) for the Treatment of Varicose Veins</a> </h3> <p>Varithena (Polidocanol Injectable Foam) is injectable foam indicated for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/varithena-polidocanol-injectable-foam-for-the-treatment-of-varicose-veins/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-34.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/varizig-immune-globulin-human-treatment-chickenpox/">VariZIG (Varicella Zoster Immune Globulin Human) for the Treatment of Chickenpox</a> </h3> <p>VariZIG (Varicella Zoster Immune Globulin Human) is an antibody drug that is indicated for the post-exposure prevention of chickenpox in immunocompromised children, newborns and pregnant women. It was developed by Cangene Corporation, a Canada-based company.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/varizig-immune-globulin-human-treatment-chickenpox/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-22.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/veletri-epoprostenol-pulmonary-arterial-hypertension-pah/">Veletri (epoprostenol) for the Treatment of Pulmonary Arterial Hypertension (PAH)</a> </h3> <p>Veletri (epoprostenol) is an eicosanoid indicated for controlling functions in the body such as blood pressure and muscle contractions. It was originally developed by GeneraMedix.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/veletri-epoprostenol-pulmonary-arterial-hypertension-pah/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-10.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/velphoro-for-the-treatment-of-hyperphosphatemia-in-chronic-kidney-disease-patients-on-dialysis/">Velphoro for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis</a> </h3> <p>Velphoro (sucroferric oxyhydroxide / PA21) is an iron-based Ca-free phosphate binder for treating Hyperphosphatemia in Chronic Kidney Disease (CKD) patients on dialysis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/velphoro-for-the-treatment-of-hyperphosphatemia-in-chronic-kidney-disease-patients-on-dialysis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-12.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection/">Vemlidy (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection</a> </h3> <p>Developed by Gilead Sciences, Vemlidy (tenofovir alafenamide) is indicated for treatment of hepatitis B (HBV) virus infection with compensated liver disease in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-34.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/venclexta-venetoclax-for-the-treatment-of-chronic-lymphocytic-leukaemia/">Venclexta (Venetoclax) for the Treatment of Chronic Lymphocytic Leukaemia</a> </h3> <p>Venclexta (Venetoclax) is an oral formulation developed by AbbVie in collaboration with Genentech and Roche, for the treatment of chronic lymphocytic leukaemia patients with 17p deletion.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/venclexta-venetoclax-for-the-treatment-of-chronic-lymphocytic-leukaemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-120.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/veopoz-chaple-disease-us/">Veopoz for the Treatment of Chaple Disease, US</a> </h3> <p>Veopoz received FDA approval for the treatment of PLE in August 2023.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/veopoz-chaple-disease-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/03/Featured-Image_Veopoz.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/veozah-fezolinetant-vasomotor-symptoms-menopause-usa/">VEOZAH (fezolinetant) to Treat Vasomotor Symptoms Due to Menopause, USA</a> </h3> <p>VEOZAH™ (fezolinetant) is an FDA-approved nonhormonal treatment for vasomotor symptoms (VMS) due to menopause.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/veozah-fezolinetant-vasomotor-symptoms-menopause-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/06/Featured-Image-VEOZAH-fezolinetant-to-Treat-Vasomotor-Symptoms-Due-to-Menopause.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/verquvo-vericiguat-heart-failure/">VERQUVO (vericiguat) for the Treatment of Heart Failure with Reduced Ejection Fraction, USA</a> </h3> <p>Verquvo (vericiguat) is the first soluble guanylate cyclase (sGC) stimulator approved to treat heart failure.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/verquvo-vericiguat-heart-failure/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2021/02/Image-1-VERQUVO-vericiguat.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/verzenio-abemaciclib-treatment-metastatic-breast-cancer/">Verzenio (abemaciclib) for the Treatment of Metastatic Breast Cancer</a> </h3> <p>Verzenio (abemaciclib) is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor indicated for the treatment of women with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/verzenio-abemaciclib-treatment-metastatic-breast-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/solifenacin/">Vesicare – Oral Selective Muscarinic Receptor</a> </h3> <p>Vesicare (solifenacin succinate) is an oral selective muscarinic receptor antagonist developed by Yamanouchi, Japan's th</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/solifenacin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/image_1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/viberzi-eluxadoline-for-the-treatment-of-irritable-bowel-syndrome-with-diarrhoea-ibs-d/">Viberzi (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhoea (IBS-D)</a> </h3> <p>Viberzi (eluxadoline), an oral tablet developed by Actavis, is indicated for the treatment of adults suffering from irritable bowel syndrome with diarrhoea (IBS-D).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/viberzi-eluxadoline-for-the-treatment-of-irritable-bowel-syndrome-with-diarrhoea-ibs-d/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-20.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/viekirax-exviera/">Viekirax and Exviera for the Treatment of Chronic Hepatitis C Virus Infection</a> </h3> <p>Viekirax (ombitasvir / paritaprevir / ritonavir) and Exviera (dasabuvir) is indicated for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection and compensated cirrhosis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/viekirax-exviera/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-66.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/viibryd-treatmentofm/">Viibryd – Treatment for Major Depressive Disorder</a> </h3> <p>Viibryd (Vilazodone) is an antidepressant manufactured for the treatment of adults with major depressive disorder (MDD). T</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/viibryd-treatmentofm/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-14.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vildagliptin/">Vildagliptin Oral Antidiabetic Agent – For The Treatment of Type 2 Diabetes</a> </h3> <p>Novartis' Galvus (vildagliptin) is a member of a new class of oral antidiabetic agents known as dipeptidyl peptidase IV</p> </div> <div class="cell large-4"> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/viltepso-viltolarsen/">VILTEPSO (viltolarsen) for the Treatment of Duchenne Muscular Dystrophy (DMD)</a> </h3> <p>VILTEPSO™ (viltolarsen) is an antisense oligonucleotide drug indicated to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder, in patients with a confirmed DMD gene mutation that is vulnerable to exon 53 skipping therapy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/viltepso-viltolarsen/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/09/Image-1-VILTEPSO-viltolarsen.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vimizim-elosulfase-alfa-treatment-patients-morquio-a-syndrome/">Vimizim (elosulfase alfa) for Treating Morquio A Syndrome</a> </h3> <p>Vimizim (elosulfase alfa / BMN 110) is an enzyme replacement therapy (ERT) for treating patients with Morquio A syndrome (MPS IVA).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vimizim-elosulfase-alfa-treatment-patients-morquio-a-syndrome/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-36.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vimpat-lacosamide/">VIMPAT (lacosamide) for the Treatment of Primary Generalised Tonic-Clonic Seizures (PGTCS)</a> </h3> <p>VIMPAT® (lacosamide) is a federally-controlled drug (CV) indicated as a supplementary therapy for the treatment of primary generalised tonic-clonic seizures (PGTCS) in patients aged four years and older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vimpat-lacosamide/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/11/Image-2-Vimpat-Lacosamide.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vitrakvi-larotrectinib-advanced-solid-tumours/">Vitrakvi (larotrectinib) for Advanced Solid Tumours with NTRK Gene Fusion</a> </h3> <p>Vitrakvi® (larotrectinib) is an oral tyrosine kinase (TRK) inhibitor indicated for the treatment of advanced solid tumours in adult and paediatric patients with neurotrophic receptor tyrosine kinase (NTRK) gene fusion.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vitrakvi-larotrectinib-advanced-solid-tumours/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Vitrakvi.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vivjoa-oteseconazole-vulvovaginal-candidiasis/">VIVJOA (oteseconazole) to Treat Recurrent Vulvovaginal Candidiasis, USA</a> </h3> <p>VIVJOA is the first and only FDA-approved drug for the treatment of recurrent vulvovaginal candidiasis (RVVC) in females.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vivjoa-oteseconazole-vulvovaginal-candidiasis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/08/Featured-Image-Vivjoa-oteseconazole-to-Treat-Recurrent-Vulvovaginal-Candidiasis-RVVC-in-Females_USA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vizimpro-dacomitinib/">Vizimpro (dacomitinib) for the Treatment of Non-Small Cell Lung Cancer</a> </h3> <p>Vizimpro® (dacomitinib) is a kinase inhibitor indicated for the treatment of EGFR-positive advanced non-small cell lung cancer (NSCLC) patients diagnosed with exon 19 deletion or exon 21 L858R substitution mutations.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vizimpro-dacomitinib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Vizimpro.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/volasertib-treatment-acute-myeloid-leukaemia-aml/">Volasertib for Treatment of Acute Myeloid Leukaemia (AML)</a> </h3> <p>Volasertib (BI 6727) is a selective and potent polo-like kinase (Plk) inhibitor currently being investigated for the treatment of patients with acute myeloid leukaemia (AML).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/volasertib-treatment-acute-myeloid-leukaemia-aml/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-43.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vonjo-pacritinib-myelofibrosis/">VONJO (pacritinib) to Treat Myelofibrosis, USA</a> </h3> <p>VONJO (pacritinib) is the first oral kinase inhibitor approved for the treatment of myelofibrosis and thrombocytopaenia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vonjo-pacritinib-myelofibrosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/08/Featured-Image-VONJO-pacritinib-to-Treat-Myelofibrosis-US.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/voquezna-vonoprazan-h-pylori-infection/">VOQUEZNA (vonoprazan) for the Treatment of Helicobacter Pylori Infection, USA</a> </h3> <p>VOQUEZNA is a co-packaged medicine containing vonoprazan with antibiotics for the treatment of H pylori infection.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/voquezna-vonoprazan-h-pylori-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/07/Featured-Image-VOQUEZNA-vonoprazan-for-Treatment-of-Helicobacter-pylori-Infection-in-Adults-US.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/voranigo-vorasidenib-grade-2-idh-mutant-glioma-usa/">VORANIGO (vorasidenib) for the Treatment of Grade 2 IDH-mutant Glioma, USA</a> </h3> <p>VORANIGO® (vorasidenib) is the first FDA-approved targeted therapy for Grade 2 isocitrate dehydrogenase (IDH)-mutant glioma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/voranigo-vorasidenib-grade-2-idh-mutant-glioma-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/08/Featured-Image-VORANIGOvorasidenib-for-the-Treatment-of-Grade-2-IDH-mutant-Glioma_USA-Shutterstock_2028110009.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/voraxaze-glucarpidase-for-the-treatment-of-toxic-plasma-methotrexate-concentrations/">Voraxaze (glucarpidase) for the Treatment of Toxic Plasma Methotrexate Concentrations</a> </h3> <p>Voraxaze (glucarpidase) is an antidote indicated for the treatment of plasma methotrexate (MTX) toxicity in patients with delayed elimination of methotrexate due to kidney dysfunction.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/voraxaze-glucarpidase-for-the-treatment-of-toxic-plasma-methotrexate-concentrations/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-20.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/voreloxin/">Voreloxin, Anti-Cancer Quinolone Derivative</a> </h3> <p>Voreloxin is a quinolone derivative being investigated for the treatment of various cancers. The drug is being develop</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/voreloxin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-1-21.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vosaroxin-treatment/">Vosaroxin – Treatment for Myeloid Leukaemia</a> </h3> <p>Vosaroxin is a first-in-class anticancer quinolone derivative (AQD) under development by Sunesis Pharmaceuticals for th</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vosaroxin-treatment/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-vosaroxin-treatment.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vosevi-for-the-retreatment-of-chronic-hepatitis-c-virus-infection/">Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection</a> </h3> <p>Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vosevi-for-the-retreatment-of-chronic-hepatitis-c-virus-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-151.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/votrient-renal-cell-cancer-soft-tissue-sarcoma/">Votrient – Treatment for Renal Cell Cancer and Soft Tissue Sarcoma</a> </h3> <p>GlaxoSmithKline's (GSK's) Votrient drug is an approved medication for the treatment of renal cell cancer (RCC). The RRC treatment drug has conditional marketing authorisation in the European Union (EU).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/votrient-renal-cell-cancer-soft-tissue-sarcoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/VotrientLARGE.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vowst-faecal-microbiota-recurrent-clostridioides/">VOWST (faecal microbiota spores, live-brpk) for the Prevention of Recurrent Clostridioides difficile Infection, USA</a> </h3> <p>VOWST™ is the first and only FDA-approved orally administered microbiota-based therapy to prevent the recurrence of CDI.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vowst-faecal-microbiota-recurrent-clostridioides/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/07/Feature-Image-VOWST.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/voxzogo-vosoritide-achondroplasia-usa/">VOXZOGO (vosoritide) for the Treatment of Achondroplasia and Open Epiphyses, USA</a> </h3> <p>VOXZOGO (vosoritide) is the first approved therapeutic treatment for achondroplasia and epiphyses.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/voxzogo-vosoritide-achondroplasia-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/07/Featured-Image-VOXZOGO-vosoritide-a-Prescription-Medicine-for-Achondroplasia-and-Open-Epiphyses-USA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vraylar-cariprazine-for-the-treatment-of-bipolar-disorder-and-schizophrenia/">Vraylar (cariprazine) for the Treatment of Bipolar Disorder and Schizophrenia</a> </h3> <p>Designed for specific mood disorders, Vraylar (cariprazine) is approved for bipolar disorder, schizophrenia and major depressive disorder.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vraylar-cariprazine-for-the-treatment-of-bipolar-disorder-and-schizophrenia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/05/1l-image-94.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vtama-tapinarof-for-the-treatment-of-plaque-psoriasis/">Vtama (tapinarof) for the Treatment of Plaque Psoriasis</a> </h3> <p>Vtama® (tapinarof) is a steroid-free, topical treatment option for mild to severe plaque psoriasis in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vtama-tapinarof-for-the-treatment-of-plaque-psoriasis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/06/Featured-Image-Vtama.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vuity-pilocarpine-hci-for-the-treatment-of-presbyopia-usa/">Vuity (pilocarpine HCI) for the Treatment of Presbyopia, USA</a> </h3> <p>Vuity (pilocarpine HCl) eye drop is the first-of-its-kind FDA-approved treatment for age-related blurry presbyopia in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vuity-pilocarpine-hci-for-the-treatment-of-presbyopia-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/02/Featured-Image-Vuity-pilocarpine-HCI.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vumerity-diroximel-fumarate/">VUMERITY (diroximel fumarate) for the Treatment of Multiple Sclerosis</a> </h3> <p>VUMERITY™ (diroximel fumarate), previously known as ALKS 8700, is a novel oral formulation indicated for the treatment of relapsing forms of multiple sclerosis (MS).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vumerity-diroximel-fumarate/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/11/1l-Image-Vumerity.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vyloy-zolbetuximab-gastric-cancer-japan/">VYLOY (zolbetuximab) for the Treatment of Gastric Cancer, Japan</a> </h3> <p>VYLOY™ (zolbetuximab) is the first and only CLDN18.2-targeted therapy approved for the treatment of gastric cancer. <br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vyloy-zolbetuximab-gastric-cancer-japan/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/09/Featured-Image-VYLOY-zolbetuximab-for-Treatment-of-Gastric-Cancer-Japan-Shutterstock_2475962827.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vyndaqel-tafamidis-for-the-treatment-of-transthyretin-familial-amyloid-polyneuropathy/">Vyndaqel (Tafamidis) – Treatment for Transthyretin Familial Amyloid Polyneuropathy</a> </h3> <p>Vyndaqel (tafamidis meglumine) is a first-in-class transthyretin stabiliser indicated for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vyndaqel-tafamidis-for-the-treatment-of-transthyretin-familial-amyloid-polyneuropathy/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2012/01/1l-Image-Vyndaqel.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vyvanse-lisdexamfetamine/">Vyvanse® (lisdexamfetamine) for the Treatment of Binge-Eating Disorder</a> </h3> <p>Vyvanse® (lisdexamfetamine dimesylate) is a central nervous system (CNS) stimulant indicated for the treatment of moderate-to-severe binge-eating disorder and attention deficit hyperactivity disorder (ADHD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vyvanse-lisdexamfetamine/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/09/1l-Image-Vyvanse.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/vyvgart-efgartigimod-alfa-fcab-for-the-treatment-of-generalised-myasthenia-gravis-usa/">VYVGART (efgartigimod alfa fcab) for the Treatment of Generalised Myasthenia Gravis, USA</a> </h3> <p>Developed by argenx, VYVGART is approved in the US, Europe, Japan, China and Israel.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/vyvgart-efgartigimod-alfa-fcab-for-the-treatment-of-generalised-myasthenia-gravis-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/09/Featured-Image-Vyvgart-Hytrulo-efgartigimod-alfa-and-hyaluronidase-qvfc-for-the-Treatment-of-generalized-Myasthenia-Gravis.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="w" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>W</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/wainua-eplontersen-for-the-treatment-of-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis-usa/">WAINUA (eplontersen) for the Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis, USA</a> </h3> <p>WAINUA™ (eplontersen) is the only medicine for managing transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), allowing self-administration through an auto-injector. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/wainua-eplontersen-for-the-treatment-of-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/01/Featured-Image-Wainua-eplontersen-for-the-Treatment-of-Polyneuropathy-of-Hereditary-Transthyretin-Mediated-Amyloidosis.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/wakix-pitolisant-for-the-treatment-of-cataplexy-with-narcolepsy/">WAKIX (pitolisant) for the Treatment of Cataplexy with Narcolepsy</a> </h3> <p>WAKIX® (pitolisant) is the first and only non-scheduled medication indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adult patients with narcolepsy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/wakix-pitolisant-for-the-treatment-of-cataplexy-with-narcolepsy/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/10/Image-1-WAKIX-pitolisant.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/wegovy-semaglutide-weight-management/">Wegovy for the Treatment of Chronic Weight Management, US</a> </h3> <p>The FDA approved semaglutide under the brand name Wegovy for chronic weight management in adults in June 2021.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/wegovy-semaglutide-weight-management/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/09/Featured-Image-Wegovy-semaglutide.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/wilatevonwillebrandd/">Wilate, von Willebrand Factor/Coagulation Factor Concentrate</a> </h3> <p>Wilate is a von Willebrand Factor/Coagulation Factor VIII (vWF/FVIII) concentrate developed for the treatment of von W</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/wilatevonwillebrandd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-23.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/winrevair-sotatercept-treatment-pulmonary-arterial-hypertension-usa/">Winrevair (Sotatercept) for the Treatment of Pulmonary Arterial Hypertension, USA</a> </h3> <p>Winrevair (sotatercept) is a breakthrough biologic treatment for the rare and progressive pulmonary arterial hypertension (PAH). <br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/winrevair-sotatercept-treatment-pulmonary-arterial-hypertension-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/04/Featured-Image-Winrevair-sotatercept.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="x" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>X</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xadago-safinamide-for-the-treatment-of-parkinsons-disease-pd/">Xadago (safinamide) for the Treatment of Parkinson’s Disease (PD)</a> </h3> <p>Xadago® (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xadago-safinamide-for-the-treatment-of-parkinsons-disease-pd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-140.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xalkori-treatment-for-nonsmall-cell-lung-cancer/">Xalkori – Treatment for Non-Small Cell Lung Cancer</a> </h3> <p>The FDA approved Xalkori for the treatment of metastatic Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer in August 2011.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xalkori-treatment-for-nonsmall-cell-lung-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Xalkori.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xarelto/">Xarelto: Investigational Agent for Treatment and Prevention of Thromboembolic Events</a> </h3> <p>The product of a joint development programme between Bayer and Johnson & Johnson, Xarelto (rivaroxaban) is a new oral anticoagulant. It is indicated for the primary prevention and treatment of venous thromboembolism (VTE) following orthopaedic surgery. Clinical trials are also ongoing to evaluate Xarelto (rivaroxaban) for stroke prevention in patients with atrial fibrillation and acute coronary syndrome.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xarelto/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-human-heart-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/tofacitinib/">Xeljanz (tofacitinib) – Treatment for Rheumatoid Arthritis</a> </h3> <p>Xeljanz (tofacitinib) is a janus kinase (JAK) 3 inhibitor developed by Pfizer as a treatment for the symptoms of rheumatoid arthritis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/tofacitinib/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-tofacitinib.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xeljanz-xr-tofacitinib-citrate-modified-release-tablets-for-the-treatment-of-rheumatoid-arthritis/">Xeljanz XR (tofacitinib citrate) Modified Release Tablets For the Treatment of Rheumatoid Arthritis</a> </h3> <p>Xeljanz XR (tofacitinib citrate) is an 11mg once-daily oral JAK inhibitor developed by Pfizer for the treatment of moderate to severe Rheumatoid Arthritis (RA).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xeljanz-xr-tofacitinib-citrate-modified-release-tablets-for-the-treatment-of-rheumatoid-arthritis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-109.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/rochexeloda/">Xeloda – Treatment for Metastatic Colorectal Cancer</a> </h3> <p>Xeloda is an approved oral drug developed by F. Hoffmann-La Roche (Roche) for treating metastatic colorectal cancer and</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/rochexeloda/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-xeloda.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xenpozyme-olipudase-alfa-asmd/">Xenpozyme (olipudase alfa) to Treat Acid Sphingomyelinase Deficiency (ASMD), Europe</a> </h3> <p>Xenpozyme is the first enzyme replacement therapy for acid sphingomyelinase deficiency approved in Japan and Europe.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xenpozyme-olipudase-alfa-asmd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/08/Featured-Image-Xenpozyme-olipudase-alfa-to-Treat-Acid-Sphingomyelinase-Deficiency-ASMD-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xgeva-cancer/">Xgeva (Denosumab) for the Prevention of Metastatic Bone Cancer</a> </h3> <p>Xgeva (denosumab) is a preventive medicine developed by Amgen to check the spread of cancer to the bones.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xgeva-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-xgeva-cancer.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xhance-fluticasone-propionate-treatment-nasal-polyps/">Xhance™ (fluticasone propionate) for the Treatment of Nasal Polyps</a> </h3> <p>Xhance™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xhance-fluticasone-propionate-treatment-nasal-polyps/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/2l-image-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xiaflexdupuytens/">Xiaflex for Treatment of Dupuytren’s Contracture / Peyronie’s Disease</a> </h3> <p>Xiaflex is the first drug indicated for treating Dupuytren's contracture. The drug was developed by Auxilium Pharmaceuticals in collaboration with BioSpecifics Technologies.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xiaflexdupuytens/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/xiaflex-1.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xiidra-lifitegrast-ophthalmic-solution-for-the-treatment-of-dry-eye-disease/">Xiidra (lifitegrast ophthalmic solution) for the Treatment of Dry Eye Disease</a> </h3> <p>Xiidra lifitegrast ophthalmic solution is a twice-a-day eye drop solution developed by Shire as a treatment for the signs and symptoms of dry eye disease in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xiidra-lifitegrast-ophthalmic-solution-for-the-treatment-of-dry-eye-disease/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-29.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xipere-triamcinolone-acetonide-macular-oedema/">Xipere (triamcinolone acetonide) for the Treatment of Macular Oedema Associated with Uveitis</a> </h3> <p>Xipere™ is the first and only FDA-approved therapy for suprachoroidal use to treat macular oedema associated with uveitis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xipere-triamcinolone-acetonide-macular-oedema/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/Featured-Image-Xipere-triamcinolone-acetonide.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xl184-thyroidcancer/">XL184</a> </h3> <p>XL184 (cabozantinib) is an indicator to inhibit tumour growth, angiogenesis and metastasis.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xl184-thyroidcancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Image-1-12.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xofigo-radium-223-dichloride-for-the-treatment-of-prostate-cancer-with-bone-metastases/">Xofigo (Radium 223 dichloride) for the Treatment of Prostate Cancer with Bone Metastases</a> </h3> <p>Xofigo (radium 223 dichloride) is an intravenous radiotherapeutic drug indicated for the treatment of patients suffering from prostate cancer with bone metastases.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xofigo-radium-223-dichloride-for-the-treatment-of-prostate-cancer-with-bone-metastases/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-32.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xolair/">Xolair – Biological Therapy</a> </h3> <p>The product of a joint development programme between Tanox, Genentech and Novartis, Xolair (omalizumab) is a recombinant</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xolair/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1_labelling_packaging_03065.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xolremdi-mavorixafor-whim-syndrome-usa/">XOLREMDI (mavorixafor) for the Treatment of WHIM Syndrome, USA</a> </h3> <p>XOLREMDI™ (mavorixafor) is the first approved therapy specifically indicated to treat patients with WHIM syndrome.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xolremdi-mavorixafor-whim-syndrome-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/05/Featured-Image-XOLREMDI-mavorixafor-for-the-Treatment-of-WHIM-Syndrome-shutterstock_1510758878.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xospata-gilteritinib-aml/">Xospata (gilteritinib) for Acute Myeloid Leukaemia with FLT3 Mutation</a> </h3> <p>Xospata® (gilteritinib) is a feline McDonough sarcoma (FMS) like tyrosine kinase 3 (FLT3) inhibitor indicated for the treatment of relapsed or refractory acute myeloid leukaemia (AML) with FLT3 mutation in adult patients.</p> </div> <div class="cell large-4"> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xpovio/">XPOVIO (selinexor) for the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)</a> </h3> <p>XPOVIO® (selinexor) is the only single-agent oral therapy indicated for the treatment of patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xpovio/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/07/Image-1-XPOVIO-selinexor-2.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xtandi-enzalutamide-metastatic-castration-resistant-prostate-cancer/">Xtandi (enzalutamide) for Treatment of Metastatic Castration-Resistant Prostate Cancer</a> </h3> <p>Xtandi (enzalutamide) is an androgen receptor inhibitor indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xtandi-enzalutamide-metastatic-castration-resistant-prostate-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-15.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xultophy-10036-for-the-treatment-of-type-2-diabetes/">Xultophy 100/3.6 for the Treatment of Type 2 Diabetes</a> </h3> <p>Developed by Novo Nordisk, Xultophy 100/3.6 is indicated for the treatment of type 2 diabetes.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xultophy-10036-for-the-treatment-of-type-2-diabetes/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/xultophy-1L.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/xywav-calcium-magnesium-potassium-and-sodium-oxybates-for-the-treatment-of-cataplexy-and-narcolepsy-usa/">XYWAV (calcium, magnesium, potassium, and sodium oxybates) for the Treatment of Cataplexy and Narcolepsy, USA</a> </h3> <p>Jazz Pharmaceuticals’ XYWAV™ (calcium, magnesium, potassium, and sodium oxybates) is the first US Food and Drug Administration (FDA) approved medicine indicated for the treatment of cataplexy and excessive daytime sleepiness (EDS) associated with narcolepsy in over 15 years.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/xywav-calcium-magnesium-potassium-and-sodium-oxybates-for-the-treatment-of-cataplexy-and-narcolepsy-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/08/Image-1-Xywav.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="y" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>Y</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/yervoy-ipilimumab/">Yervoy (Ipilimumab) – Therapy for Treatment of Metastatic Melanoma</a> </h3> <p>Yervoy is a monoclonal antibody drug indicated for treating metastatic melanoma. The drug was developed by Bristol-Myers</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/yervoy-ipilimumab/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-yervoy.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/yescarta-axicabtagene-ciloleucel-treatment-large-b-cell-lymphoma/">Yescarta (axicabtagene ciloleucel) for the Treatment of Large B-Cell Lymphoma</a> </h3> <p>Yescarta™ (axicabtagene ciloleucel) is one of the first chimeric antigen receptor T cell (CAR T) therapies indicated for the treatment of relapsed / refractory large B-cell lymphoma in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/yescarta-axicabtagene-ciloleucel-treatment-large-b-cell-lymphoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/2l-image-Yescarta.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/yupelri-revefenacin/">Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease</a> </h3> <p>Yupelri™ (revefenacin) is a long-acting muscarinic antagonist (LAMA) indicated as a maintenance treatment for chronic obtrusive pulmonary disease (COPD) in adult patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/yupelri-revefenacin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Yupelri.jpg" alt=""> </a> </figure> </div> </div> </li> </section> <section id="z" class="common-head"> <div class="capital-sign smedium-2 u-mb-3"> <h4>Z</h4> </div> <ul class="gdm-article-list"> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zactima/">Zactima – Tyrosine Kinase Inhibitor</a> </h3> <p>Zactima (vandetanib) is an orally available tyrosine kinase inhibitor (TKI) developed by AstraZeneca for the treatment o</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zactima/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-Labelled_Lungs.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zaltrap-ziv-aflibercept-for-the-treatment-of-metastatic-colorectal-cancer/">Zaltrap (ziv-aflibercept) for the Treatment of Metastatic Colorectal Cancer</a> </h3> <p>Zaltrap (ziv-aflibercept) is a recombinant fusion protein indicated for the treatment of metastatic colorectal cancer (mCRC). It was developed by Sanofi-Aventis in collaboration with Regeneron Pharmaceuticals.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zaltrap-ziv-aflibercept-for-the-treatment-of-metastatic-colorectal-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-13.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zegerid/">Zegerid – Proton Pump Inhibitor for Treatment of Heartburn</a> </h3> <p>Zegerid is a proton pump inhibitor (PPI) comprising omeprazole, a leading prescription acid that reduces heartburn and s</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zegerid/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-gastoesophageal-deseases.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zejula-niraparib-for-the-treatment-of-ovarian-cancer/">Zejula (niraparib) for the Treatment of Ovarian Cancer</a> </h3> <p>Zejula™ (niraparib) is a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor approved for the treatment of adult patients with ovarian cancer.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zejula-niraparib-for-the-treatment-of-ovarian-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-141.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zelboraf-vemurafenib-tablets-treatment-for-metastatic-melanoma/">Zelboraf (vemurafenib) Tablets – Treatment for Metastatic Melanoma</a> </h3> <p>Zelboraf is indicated for the treatment of metastatic melanoma and Erdheim-Chester disease. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zelboraf-vemurafenib-tablets-treatment-for-metastatic-melanoma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-drug.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zepatier-treatment-chronic-hepatitis-c-genotype-1-and-4-infection/">Zepatier for the Treatment of Chronic Hepatitis C Genotype 1 and 4 Infection</a> </h3> <p>Zepatier is a once-daily oral medicine comprising 50mg of non-structural protein 5A (NS5A) replication complex inhibitor elbasvir and 100mg of NS3/4A protease inhibitor grazoprevir. </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zepatier-treatment-chronic-hepatitis-c-genotype-1-and-4-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-108.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zeposia-ozanimod/">ZEPOSIA (Ozanimod) for the Treatment of Multiple Sclerosis</a> </h3> <p>ZEPOSIA® (Ozanimod) is the only FDA approved sphingosine-1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zeposia-ozanimod/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/04/Image-1-ZEPOSIA-Ozanimod-.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zepzelca-lurbinectedin/">Zepzelca (lurbinectedin) for the Treatment of Small Cell Lung Cancer</a> </h3> <p>Zepzelca™ (lurbinectedin) is a prescription medicine indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zepzelca-lurbinectedin/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/06/Image-1-Zepzelca-lurbinectedin.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ceftolozanetazobactam-treatment-gram-negative-bacterial-infections/">Zerbaxa (ceftolozane/tazobactam) for the Treatment of Gram-negative Bacterial Infections</a> </h3> <p>Zerbaxa (ceftolozane/tazobactam) is an antibiotic developed and marketed by Merck (formerly Cubist Pharmaceuticals (Cubist)), for the treatment of infections caused by gram-negative bacteria.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ceftolozanetazobactam-treatment-gram-negative-bacterial-infections/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Zerbaxa-vial.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zilretta-triamcinolone-acetonide-extended-release-injectable-suspension-treatment-osteoarthritis-knee-pain/">Zilretta (triamcinolone acetonide extended-release injectable suspension) for the Treatment of Osteoarthritis Knee Pain</a> </h3> <p>Zilretta™ (triamcinolone acetonide extended-release injectable suspension) is a US Food and Drug Administration (FDA) approved extended-release intra-articular therapy indicated for the treatment of osteoarthritis knee pain.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zilretta-triamcinolone-acetonide-extended-release-injectable-suspension-treatment-osteoarthritis-knee-pain/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/2l-image-Zilretta.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zinbryta-daclizumab-for-the-treatment-of-multiple-sclerosis/">Zinbryta (daclizumab) for the Treatment of Multiple Sclerosis</a> </h3> <p>Zinbryta (daclizumab) is an injectable formulation jointly developed by Biogen and Abbive for the treatment of relapsing forms of multiple sclerosis (MS) in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zinbryta-daclizumab-for-the-treatment-of-multiple-sclerosis/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-118.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zinforo-ceftaroline-fosamil-for-the-treatment-of-complicated-skin-and-soft-tissue-infections/">Zinforo (ceftaroline fosamil) for the Treatment of Complicated Skin and Soft Tissue Infections</a> </h3> <p>Zinforo (ceftaroline fosamil) is a new intravenous cephalosporin antibiotic indicated for the treatment of serious skin infections or community-acquired pneumonia.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zinforo-ceftaroline-fosamil-for-the-treatment-of-complicated-skin-and-soft-tissue-infections/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-13.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zinplava-bezlotoxumab-for-the-treatment-of-clostridium-difficile-infection/">Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection</a> </h3> <p>Zinplava (bezlotoxumab) is an injectable solution developed by Merck indicated for the treatment of clostridium difficile infection (CDI) in adult patients who are already receiving anti-bacterial drug treatment.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zinplava-bezlotoxumab-for-the-treatment-of-clostridium-difficile-infection/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/injection-1L.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zioptan-elevated-intraocular-pressure-iop/">Zioptan for the Reduction of Elevated Intraocular Pressure (IOP)</a> </h3> <p>Zioptan (tafluprost ophthalmic solution) was developed by Santen Pharmaceutical in collaboration with Merck. The drug is indicated for the reduction of elevated intraocular pressure (IOP). In February 2012, Zioptan received approval for the reduction of IOP in patients suffering from ocular hypertension or open-angle glaucoma.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zioptan-elevated-intraocular-pressure-iop/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-3.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zohydro-hydrocodone-bitartrate-for-treatment-of-chronic-pain/">Zohydro (Hydrocodone Bitartrate) for the Treatment of Chronic Pain</a> </h3> <p>Zohydro (hydrocodone) is a single-entity oral drug indicated for the treatment of chronic pain. San Diego-based pharmaceutical company Zogenix developed and commercialised the drug in the US.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zohydro-hydrocodone-bitartrate-for-treatment-of-chronic-pain/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-4.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zokinvy-lonafarnib-for-the-treatment-of-progeria-usa/">Zokinvy (lonafarnib) for the Treatment of Progeria, USA</a> </h3> <p>Zokinvy (lonafarnib) is the first approved therapy for the group of ultra-rare genetic diseases collectively known as progeria.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zokinvy-lonafarnib-for-the-treatment-of-progeria-usa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/06/Featured-Image-Zokinvy.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zolgensma/">Zolgensma for the Treatment of Spinal Muscular Atrophy</a> </h3> <p>Zolgensma® (onasemnogene abeparvovec-xioi) is a one-time gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in paediatric patients.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zolgensma/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-Image-Zolgensma.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zometa-preventing-bone-complications-cancer/">Zometa for Preventing Bone Cancer Complications</a> </h3> <p>Zometa is a bone resorption inhibitor indicated for the treatment of bone complications in patients with advanced cancer. It has several anticancer properties.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zometa-preventing-bone-complications-cancer/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-5.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zonegran-zonisamide-treatment-epilepsy/">Zonegran (Zonisamide) for the Treatment of Epilepsy</a> </h3> <p>Zonegran (Zonisamide) is an anti-epileptic drug indicated for the treatment of partial seizures in adults with epilepsy with or without secondary generalisation.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zonegran-zonisamide-treatment-epilepsy/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-10.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zontivity-vorapaxar-for-the-reduction-of-thrombotic-cardiovascular-events/">Zontivity (vorapaxar) for the Reduction of Thrombotic Cardiovascular Events</a> </h3> <p>Zontivity (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of heart attack or peripheral arterial disease (PAD).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zontivity-vorapaxar-for-the-reduction-of-thrombotic-cardiovascular-events/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-54.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zorvolex-diclofenac-for-the-treatment-of-acute-pain/">Zorvolex (diclofenac) for the Treatment of AcutePain</a> </h3> <p>Zorvolex (diclofenac) is a nonsteroidal anti-inflammatory drug currently indicated for the treatment of mild to moderate acute pain in adults.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zorvolex-diclofenac-for-the-treatment-of-acute-pain/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-32.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/ztalmy-seizures-cdd/">ZTALMY (ganaxolone) for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder, USA</a> </h3> <p>ZTALMY® is the first FDA-approved therapy for seizures due to CDLK5 deficiency disorder in patients aged two years and older. <br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/ztalmy-seizures-cdd/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/08/Featured-Image-ZTALMY-ganaxolone-for-the-Treatment-of-Seizures-Due-to-CDKL5-Deficiency-Disorder-USA.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zubsolv-buprenorphine-naloxone-opioid-dependence/">Zubsolv (Buprenorphine and Naloxone) – Maintenance Treatment for Opioid Dependence</a> </h3> <p>Zubsolv (buprenorphine and naloxone) is a sublingual tablet indicated as maintenance treatment for people suffering from opioid dependence.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zubsolv-buprenorphine-naloxone-opioid-dependence/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-image-31.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/anticancerdrug/">Zybrestat – Vascular Disrupting Agent and Cancer Therapy</a> </h3> <p>Zybrestat is a vascular disrupting agent (VDA) indicated for the treatment of anaplastic thyroid cancer and, potentially</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/anticancerdrug/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-combrestatin.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zydelig-idelalisib-for-the-treatment-of-three-b-cell-blood-cancers/">Zydelig (idelalisib) for the Treatment of Three B-cell Blood Cancers</a> </h3> <p>Zydelig (idelalisib) is a phosphoinositide 3-kinase (PI3K) delta inhibitor and is used for the treatment of three B-cell blood cancers: relapsed chronic lymphocytic leukaemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zydelig-idelalisib-for-the-treatment-of-three-b-cell-blood-cancers/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-image-58.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zykadia-ceritinib-treatment-metastatic-non-small-cell-lung-cancer-nsclc/">Zykadia (Ceritinib) for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)</a> </h3> <p>Zykadia (Ceritinib / LDK378) is an inhibitor of anaplastic lymphoma kinase (ALK) indicated for treatment of non-small cell lung cancer (NSCLC).</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zykadia-ceritinib-treatment-metastatic-non-small-cell-lung-cancer-nsclc/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1l-Image-Zycadia.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zynteglo-beta-thalassemia/">Zynteglo for the Treatment of Transfusion-Dependent Beta-thalassemia</a> </h3> <p>Zynteglo™ is a gene therapy indicated for the treatment of transfusion-dependent beta (β)-thalassemia (TDT) in patients aged 12 years and older.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zynteglo-beta-thalassemia/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/08/1l-Image-Zynteglo.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zynyz-treatment-mcc-us/">Zynyz for the Treatment of Merkel Cell Carcinoma, US</a> </h3> <p>The drug holds orphan drug designation by the FDA for the treatment of anal cancer.<br /> </p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zynyz-treatment-mcc-us/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2023/07/Featured-Image-ZYNYZ-retifanlimab-dlwr-for-Treatment-of-Merkel-cell-carcinoma.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/zyprexa/">Zyprexa – Schizophrenia treatment</a> </h3> <p>Zyprexa (olanzapine) belongs to a newer group of antipsychotic medications called atypical antipsychotics and is widely</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/zyprexa/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-zyprexa.jpg" alt=""> </a> </figure> </div> </div> </li> <li> <div class="grid-x"> <div class="cell large-8 article-text"> <h3><a href="https://www.clinicaltrialsarena.com/projects/drug_abiateronecance/">Zytiga (abiraterone acetate) – Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)</a> </h3> <p>Developed by Coughar Biotechnology, abiraterone acetate (CB7630) was discovered by the UK Institute for Cancer Research.</p> </div> <div class="cell large-4"> <figure> <a href="https://www.clinicaltrialsarena.com/projects/drug_abiateronecance/"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/1-gleason-grade.jpg" alt=""> </a> </figure> </div> </div> </li> </section> </div> </section> </div> </div> </div> </section> <div class="scrollTopBtn"> <a href="#top"> <img src="https://www.mining-technology.com//wp-content/themes/goodlife-wp-B2B/assets/img/icon_arrow.png" class="white"> <img src="https://www.mining-technology.com//wp-content/themes/goodlife-wp-B2B/assets/img/icon_arrow_purple.png" class="purple"> </a> </div> </main> <script> var x, i, j, l, ll, selElmnt, a, b, c; /* Look for any elements with the class "custom-select": */ x = document.getElementsByClassName("custom-select"); l = x.length; for (i = 0; i < l; i++) { selElmnt = x[i].getElementsByTagName("select")[0]; ll = selElmnt.length; /* For each element, create a new DIV that will act as the selected item: */ a = document.createElement("DIV"); a.setAttribute("class", "select-selected"); a.innerHTML = selElmnt.options[selElmnt.selectedIndex].innerHTML; x[i].appendChild(a); /* For each element, create a new DIV that will contain the option list: */ b = document.createElement("DIV"); b.setAttribute("class", "select-items select-hide"); for (j = 1; j < ll; j++) { /* For each option in the original select element, create a new DIV that will act as an option item: */ c = document.createElement("DIV"); c.innerHTML = selElmnt.options[j].innerHTML; c.addEventListener("click", function (e) { /* When an item is clicked, update the original select box, and the selected item: */ var y, i, k, s, h, sl, yl; s = this.parentNode.parentNode.getElementsByTagName("select")[0]; sl = s.length; h = this.parentNode.previousSibling; for (i = 0; i < sl; i++) { if (s.options[i].innerHTML == this.innerHTML) { s.selectedIndex = i; h.innerHTML = this.innerHTML; y = this.parentNode.getElementsByClassName("same-as-selected"); yl = y.length; for (k = 0; k < yl; k++) { y[k].removeAttribute("class"); } this.setAttribute("class", "same-as-selected"); break; } } h.click(); s.dispatchEvent(new Event('change')); }); b.appendChild(c); } x[i].appendChild(b); a.addEventListener("click", function (e) { /* When the select box is clicked, close any other select boxes, and open/close the current select box: */ e.stopPropagation(); closeAllSelect(this); this.nextSibling.classList.toggle("select-hide"); this.classList.toggle("select-arrow-active"); }); } function closeAllSelect(elmnt) { /* A function that will close all select boxes in the document, except the current select box: */ var x, y, i, xl, yl, arrNo = []; x = document.getElementsByClassName("select-items"); y = document.getElementsByClassName("select-selected"); xl = x.length; yl = y.length; for (i = 0; i < yl; i++) { if (elmnt == y[i]) { arrNo.push(i) } else { y[i].classList.remove("select-arrow-active"); } } for (i = 0; i < xl; i++) { if (arrNo.indexOf(i)) { x[i].classList.add("select-hide"); } } } /* If the user clicks anywhere outside the select box, then close all select boxes: */ document.addEventListener("click", closeAllSelect); </script> <script> jQuery('select').on('change', function() { jQuery('#project-az').html('<div class="thb-loading-bottom" id="loader"></div>'); var selectedSector1 = jQuery("#filter-region").val(); var selectedreg1 = jQuery("#filter-categories").val(); var selectedSort1 = jQuery("#filter-sort-by").val(); var ajaxurl = "https://www.clinicaltrialsarena.com/wp-admin/admin-ajax.php"; jQuery.ajax({ type: 'post', url: ajaxurl, data: { "action": "project_search", sector: selectedreg1, region: selectedSector1, sort: selectedSort1, posttype: 'projects', }, success: function (data) { if (data) { jQuery('#project-az').find('#loader').remove(); jQuery('#project-az').html(data); } jQuery('a[href*="#"]').on('click', function (e) { e.preventDefault() jQuery('html, body').animate({ scrollTop: jQuery(jQuery(this).attr('href')).offset().top, }, 500, 'linear' ) }) } }); }); jQuery(document).ready(function () { jQuery(".myInput").on("keyup", function () { var value = jQuery(this).val().toLowerCase(); jQuery(".u-mb-3").filter(function () { jQuery(this).toggle(jQuery(this).text().toLowerCase().indexOf(value) > -1); jQuery('.common-head div.smedium-2').toggle(jQuery(this).text().toLowerCase() .indexOf(value) > -1); }); }); }); jQuery('a[href*="#"]').on('click', function (e) { e.preventDefault() jQuery('html, body').animate({ scrollTop: jQuery(jQuery(this).attr('href')).offset().top, }, 500, 'linear' ) }) </script>  <footer id="footer" class="footer-container grid-x"> <div class="footer-wrapper grid-x"> <div class="main-footer-col medium-6"> <img src="https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2018/06/ClinicalTrialsArena_footer.png" alt="ClinicalTrials" data-displayname="Clinical Trials Arena" class="footer-logo"> <p class="footer-excerpt"> Hard data and deep insights on clinical trials strategy & operations</p> <div class="share"> <div class="share__list"> <a href="https://www.linkedin.com/company/clinical-trials-arena" target="_blank" class="share__link icon-linkedin" title=""> <img src="/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/linkedin_icon_w.svg"> </a> <a href="https://twitter.com/TrialsArena" target="_blank" class="share__link icon-twitter" title=""> <img src="/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/twitter_icon_w.svg"> </a> <a href="https://www.facebook.com/globaldataplc/" target="_blank" class="share__link icon-facebook" title=""> <img src="/code/wp-content/themes/goodlife-wp-B2B/assets/img/icons/facebook_icon_w.svg"> </a> </div> </div> </div> <div class="footer-cols grid-x medium-5"> <nav class="footer-nav medium-6"> <ul class="footer-nav-list"><li id="menu-item-168850" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-168850"><a href="https://www.clinicaltrialsarena.com/about-us-online/">About us</a></li> <li id="menu-item-168856" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-168856"><a href="https://www.clinicaltrialsarena.com/advertise-with-us/">Advertise with us</a></li> <li id="menu-item-175193" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-175193"><a href="https://www.clinicaltrialsarena.com/license-our-content/">License our content</a></li> <li id="menu-item-168839" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-168839"><a href="https://www.clinicaltrialsarena.com/contact-us/">Contact us</a></li> <li id="menu-item-168840" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-168840"><a href="https://www.clinicaltrialsarena.com/editorial-standards/">Editorial approach</a></li> <li id="menu-item-168851" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-168851"><a href="https://www.clinicaltrialsarena.com/all-newsletters/">Newsletters</a></li> <li id="menu-item-168852" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-168852"><a href="https://www.verdictmediastrategies.com/">Our marketing solution</a></li> </ul> </nav> <div class="copyright-col medium-6"> <ul class=""><li id="menu-item-168853" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-168853"><a href="https://www.globaldata.com/privacy-policy/" class="c-nav-hamburger-menu__link">Privacy policy</a></li> <li id="menu-item-168854" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-168854"><a href="https://www.globaldata.com/terms-conditions/" class="c-nav-hamburger-menu__link">Terms and conditions</a></li> <li id="menu-item-181480" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-181480"><a href="https://www.clinicaltrialsarena.com/sitemap/" class="c-nav-hamburger-menu__link">Sitemap</a></li> </ul> <p class="footer-tag-line"> Powered by <a href="https://www.globaldata.com" target="_blank"><img class="c-footer__tag-line-img" src="/code/wp-content/themes/goodlife-wp-B2B/assets/images/verdict-logo-w.png" alt="Pharma Tech Logo"></a> </p> <p class="footer-copyright">© Verdict Media Limited 2025</p> </div> </div> </div> </footer> <script type='text/javascript' src='https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/custom_newsletter.js?ver=1.6'> </script> <script type='text/javascript' src='https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/subscribe.js?ver=1.4'> </script> <script type='text/javascript' src='https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/report.js?ver=1.0'> </script>  <script type="text/javascript" id="hs-script-loader" async defer src="//js-eu1.hs-scripts.com/26632421.js?businessUnitId=15641589"></script>  <script> function setCookie(cname, cvalue, exdays) { var d = new Date(); d.setTime(d.getTime() + (exdays*24*60*60*1000)); var expires = "expires="+ d.toUTCString(); document.cookie = cname + "=" + cvalue + ";" + expires + ";path=/"; } function getCookie(cname) { var name = cname + "="; var decodedCookie = decodeURIComponent(document.cookie); var ca = decodedCookie.split(';'); for(var i = 0; i <ca.length; i++) { var c = ca[i]; while (c.charAt(0) == ' ') { c = c.substring(1); } if (c.indexOf(name) == 0) { return c.substring(name.length, c.length); } } return ""; } permutive.once('Clearbit', function(clearbit){ if((clearbit.properties.company)!= null){ var company_id = clearbit.properties.company.id; } else{ var company_id = 'NA'; } permutive.segment(23691, function(result){ if (result && getCookie('globaldata_report') !== "shown") { jQuery('#globaldata_report').css('display','block'); setCookie('globaldata_report', 'shown', 7) permutive.track('ipTarget', { company:company_id, target_reason: "Globaldata", content: "Download a free 10 page preview of our Mergers & Acquisitions in TMT – Thematic Research 2019 Report", content_type: "targeted popup", content_url: "https://www.verdict.co.uk/download-a-free-10-page-preview-of-our-mergers-acquisitions-in-tmt-thematic-research-2019-report/" }) } }); permutive.segment(24097, function(result){ if (result && getCookie('corporate_meed') !== "shown") { jQuery('#corporate_meed').css('display','block'); setCookie('corporate_meed', 'shown', 7) permutive.track('ipTarget', { company:company_id, target_reason: "CorporateHealthAndWellness", content: "Why we believe workplace health and wellness is important", content_type: "targeted popup", content_url: "https://www.corporatehealthandwellness.meed.com/why-we-believe-workplace-health-and-wellness-is-important/" }) } }); permutive.segment(33716, function(result){ if (result && getCookie('oracle_meed') !== "shown") { jQuery('#oracle_meed').css('display','block'); setCookie('oracle_meed', 'shown', 7) permutive.track('ipTarget', { company:company_id, target_reason: "Orcale", content: "Q&A with Baraq Hadi: Vice President Middle East, Oracle Construction and Engineering", content_type: "targeted popup", content_url: "https://innovation.meed.com/qa-with-baraq-hadi-vice-president-middle-east-oracle-construction-and-engineering/" }) } }); permutive.segment(40190, function(result){ if (result && getCookie('Smartstream') !== "shown") { jQuery('#Smartstream').css('display','block'); setCookie('Smartstream', 'shown', 7) permutive.track('ipTarget', { company:company_id, target_reason: "Smartstream", content: "Fit for the future, whatever it looks like", content_type: "targeted popup", content_url: "https://www.verdict.co.uk/private-banker-international/future-banking-technology/fit-for-the-future-whatever-it-looks-like/" }) } }); permutive.segment(30918, function(result){ if (result && getCookie('target-novotech') !== "shown") { jQuery('#target-novotech').css('display','block'); setCookie('target-novotech', 'shown', 1) permutive.track('ipTarget', { company:company_id, target_reason: "Accelerating Clinical Trials", content: "Clinical Trial Continuity in Asia-Pacific during the COVID-19 pandemic", content_type: "targeted popup", content_url: "https://www.pharmaceutical-technology.com/sponsored/clinical-trial-continuity-in-asia-pacific-during-the-covid-19-pandemic/" }) } }); permutive.segment(21482, function(result){ if (result && getCookie('target-normet') !== "shown") { jQuery('#target-normet').css('display','block'); setCookie('target-normet', 'shown', 1) permutive.track('ipTarget', { company:company_id, target_reason: "Normet", content: "A sneak peek into Canada’s largest transit expansion", content_type: "targeted popup", content_url: "https://www.mining-technology.com/future-of-mining/a-sneak-peek-into-canadas-largest-transit-expansion" }) } }); permutive.segment(33196, function(result){ if (result && getCookie('target-sandvik') !== "shown") { jQuery('#target-sandvik').css('display','block'); setCookie('target-sandvik', 'shown', 1) permutive.track('ipTarget', { company:company_id, target_reason: "Sandvik", content: "Precision wire for vascular therapy: How EXERA® rises to the challenge", content_type: "targeted popup", content_url: "https://www.medicaldevice-network.com/precision-medical-wire/precision-wire-for-vascular-therapy-how-exera-rises-to-the-challenge" }) } }); }) </script> <script> jQuery( document ).ready(function() { function vmsnewTargetpopup(p1,p2,p3){ if( p1 != null && p2 !== null ) { jQuery.ajax({ type: "POST", url: "https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/target_modal.php", dataType: "html", data: { "segmentid": p1, "blogid": p2, }, success: function(data){ if( data.indexOf("false_partner") >= 0 ){ return false; //setCookie("target-"+p1+"_"+'22', 'shown', 1); }else{ jQuery(p3).html(data); //setCookie("target-"+p1+"_"+'22', 'shown', 1); } } }); } } var per_loop =1; permutive.segment(2491, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(2491); if(per_loop==1){ vmsnewTargetpopup(2491, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(2491, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(2491, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(199290, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(199290); if(per_loop==1){ vmsnewTargetpopup(199290, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(199290, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(199290, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(190006, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(190006); if(per_loop==1){ vmsnewTargetpopup(190006, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(190006, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(190006, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(155983, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(155983); if(per_loop==1){ vmsnewTargetpopup(155983, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(155983, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(155983, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(58279, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(58279); if(per_loop==1){ vmsnewTargetpopup(58279, 7, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(58279, 7,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(58279, 7, '#resultnew_third'); } per_loop++; } } }); permutive.segment(164848, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(164848); if(per_loop==1){ vmsnewTargetpopup(164848, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(164848, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(164848, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(141355, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(141355); if(per_loop==1){ vmsnewTargetpopup(141355, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(141355, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(141355, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(187960, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(187960); if(per_loop==1){ vmsnewTargetpopup(187960, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(187960, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(187960, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(164191, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(164191); if(per_loop==1){ vmsnewTargetpopup(164191, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(164191, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(164191, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(199185, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(199185); if(per_loop==1){ vmsnewTargetpopup(199185, 30, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(199185, 30,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(199185, 30, '#resultnew_third'); } per_loop++; } } }); permutive.segment(88696, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(88696); if(per_loop==1){ vmsnewTargetpopup(88696, 26, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(88696, 26,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(88696, 26, '#resultnew_third'); } per_loop++; } } }); permutive.segment(126060, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(126060); if(per_loop==1){ vmsnewTargetpopup(126060, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(126060, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(126060, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(131507, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(131507); if(per_loop==1){ vmsnewTargetpopup(131507, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(131507, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(131507, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(162272, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(162272); if(per_loop==1){ vmsnewTargetpopup(162272, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(162272, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(162272, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(39494, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(39494); if(per_loop==1){ vmsnewTargetpopup(39494, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(39494, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(39494, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(172149, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(172149); if(per_loop==1){ vmsnewTargetpopup(172149, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(172149, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(172149, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(61894, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(61894); if(per_loop==1){ vmsnewTargetpopup(61894, 24, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(61894, 24,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(61894, 24, '#resultnew_third'); } per_loop++; } } }); permutive.segment(195099, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(195099); if(per_loop==1){ vmsnewTargetpopup(195099, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(195099, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(195099, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(187960, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(187960); if(per_loop==1){ vmsnewTargetpopup(187960, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(187960, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(187960, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(33196, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(33196); if(per_loop==1){ vmsnewTargetpopup(33196, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(33196, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(33196, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(47155, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(47155); if(per_loop==1){ vmsnewTargetpopup(47155, 26, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(47155, 26,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(47155, 26, '#resultnew_third'); } per_loop++; } } }); permutive.segment(216341, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(216341); if(per_loop==1){ vmsnewTargetpopup(216341, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(216341, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(216341, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(106931, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(106931); if(per_loop==1){ vmsnewTargetpopup(106931, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(106931, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(106931, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(207295, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(207295); if(per_loop==1){ vmsnewTargetpopup(207295, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(207295, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(207295, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(106166, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(106166); if(per_loop==1){ vmsnewTargetpopup(106166, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(106166, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(106166, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(126060, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(126060); if(per_loop==1){ vmsnewTargetpopup(126060, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(126060, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(126060, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(218878, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(218878); if(per_loop==1){ vmsnewTargetpopup(218878, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(218878, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(218878, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(176648, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(176648); if(per_loop==1){ vmsnewTargetpopup(176648, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(176648, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(176648, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(83486, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(83486); if(per_loop==1){ vmsnewTargetpopup(83486, 17, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(83486, 17,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(83486, 17, '#resultnew_third'); } per_loop++; } } }); permutive.segment(98259, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(98259); if(per_loop==1){ vmsnewTargetpopup(98259, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(98259, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(98259, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(126060, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(126060); if(per_loop==1){ vmsnewTargetpopup(126060, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(126060, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(126060, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(126060, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(126060); if(per_loop==1){ vmsnewTargetpopup(126060, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(126060, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(126060, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(178673, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(178673); if(per_loop==1){ vmsnewTargetpopup(178673, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(178673, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(178673, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(99632, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(99632); if(per_loop==1){ vmsnewTargetpopup(99632, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(99632, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(99632, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(199243, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(199243); if(per_loop==1){ vmsnewTargetpopup(199243, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(199243, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(199243, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(189369, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(189369); if(per_loop==1){ vmsnewTargetpopup(189369, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(189369, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(189369, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(103918, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(103918); if(per_loop==1){ vmsnewTargetpopup(103918, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(103918, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(103918, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(39494, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(39494); if(per_loop==1){ vmsnewTargetpopup(39494, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(39494, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(39494, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(39494, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(39494); if(per_loop==1){ vmsnewTargetpopup(39494, 24, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(39494, 24,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(39494, 24, '#resultnew_third'); } per_loop++; } } }); permutive.segment(187596, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(187596); if(per_loop==1){ vmsnewTargetpopup(187596, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(187596, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(187596, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(126060, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(126060); if(per_loop==1){ vmsnewTargetpopup(126060, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(126060, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(126060, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(176357, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(176357); if(per_loop==1){ vmsnewTargetpopup(176357, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(176357, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(176357, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(126060, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(126060); if(per_loop==1){ vmsnewTargetpopup(126060, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(126060, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(126060, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(71444, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(71444); if(per_loop==1){ vmsnewTargetpopup(71444, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(71444, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(71444, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(81525, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(81525); if(per_loop==1){ vmsnewTargetpopup(81525, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(81525, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(81525, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(104754, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(104754); if(per_loop==1){ vmsnewTargetpopup(104754, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(104754, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(104754, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(44460, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(44460); if(per_loop==1){ vmsnewTargetpopup(44460, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(44460, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(44460, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(185678, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(185678); if(per_loop==1){ vmsnewTargetpopup(185678, 2, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(185678, 2,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(185678, 2, '#resultnew_third'); } per_loop++; } } }); permutive.segment(209867, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(209867); if(per_loop==1){ vmsnewTargetpopup(209867, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(209867, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(209867, 22, '#resultnew_third'); } per_loop++; } } }); permutive.segment(193412, function(result){ if(per_loop<4){ if (result) { console.log(result); //console.log(193412); if(per_loop==1){ vmsnewTargetpopup(193412, 22, '#resultnew'); }if(per_loop==2){ vmsnewTargetpopup(193412, 22,'#resultnew_secondary'); }if(per_loop==3){ vmsnewTargetpopup(193412, 22, '#resultnew_third'); } per_loop++; } } }); }); </script>  <script> document.addEventListener("DOMContentLoaded", function(event) { let preFooter = document.createElement('div'); preFooter.className= 'pre-footer-subscribe'; preFooter.innerHTML = ` <a class="pre-footer-subscribe__all-newsletters" href="https://www.clinicaltrialsarena.com/all-newsletters"> <img src='https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/images/eye.svg' alt=''> <span class="text">View all newsletters</span> <span class="icon-chevron-right"></span> </a> <div class="pre-footer-subscribe__click" onclick="showPopUp('newsletter')"> <figure class="pre-footer-subscribe__figure"> <div class="lines"></div> </figure> <span class="text"> Receive our newsletter - data, insights and analysis delivered to you <span class="icon-chevron-right"></span></span> </div> ` var cfooterExist = document.getElementsByClassName('c-footer'); if (cfooterExist.length > 0) { document.querySelector('footer.c-footer').before(preFooter); } }) </script>   <script src="https://platform.twitter.com/oct.js" type="text/javascript"></script> <script type="text/javascript">if(typeof twttr !== undefined) twttr.conversion.trackPid('ocdmp', { tw_sale_amount: 0, tw_order_quantity: 0 });</script> <noscript> <img height="1" width="1" style="display:none;" alt="" src="https://analytics.twitter.com/i/adsct?txn_id=ocdmp&p_id=Twitter&tw_sale_amount=0&tw_order_quantity=0" /> <img height="1" width="1" style="display:none;" alt="" src="//t.co/i/adsct?txn_id=ocdmp&p_id=Twitter&tw_sale_amount=0&tw_order_quantity=0" /> </noscript>  <script type="text/javascript" id="Sgpolls0-js-extra"> /* <![CDATA[ */ var Sgpolls = {"ajax_url":"https:\/\/www.clinicaltrialsarena.com\/wp-admin\/admin-ajax.php","polls":["https:\/\/survey.alchemer.eu\/s3\/90803853\/Pharma-CTA-Poll-120-Potential-price-impact-of-BIOSECURE-Act-on-biosimilars","https:\/\/survey.alchemer.eu\/s3\/90803855\/Pharma-CTA-Poll-121-Future-leader-in-biosimilars-production","https:\/\/survey.alchemer.eu\/s3\/90768699\/Technology-Poll-28-Data-center-hosting-vendors-in-your-organization","https:\/\/survey.alchemer.eu\/s3\/90786849\/Pharma-CTA-Poll-117-Challenges-of-integrating-genomics-in-pharma","https:\/\/survey.alchemer.eu\/s3\/90803850\/Pharma-CTA-Poll-119-Impact-of-Inflation-Reduction-Act-on-biosimilar-prices"],"options":{"title":false,"source":false,"userid":0,"usersid":"","time":false},"css":"@import \"https:\/\/live-b2b-gdm-figaro1.pantheonsite.io\/wp-content\/themes\/goodlife-wp-B2B\/assets\/scss\/main.css\"","jsOptions":{"jspollsSeparate":"1","jspollsOrder":null,"jspollsCalc":"1"}}; /* ]]> */ </script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/plugins/sgpolls/assets/iframeResizer.min.js?ver=2.0.c..2092851416" id="Sgpolls0-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/plugins/sgpolls/assets/parent.js?ver=2.0.c..2092851416" id="Sgpolls1-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/plugins/verdict-tracking//js/permutiveData.js?ver=1.0.5" id="crb-permutive-data-js"></script> <script type="text/javascript" id="nsmgscampaigns-js-extra"> /* <![CDATA[ */ var nsmgscampaigns = {"ajaxurl":"https:\/\/www.clinicaltrialsarena.com\/wp-admin\/admin-ajax.php","nonce":"daac371dcb"}; /* ]]> */ </script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/plugins/nsmg-campaigns/assets/public/js/main.js?ver=2.7#defer" id="nsmgscampaigns-js"></script> <script type="text/javascript" src="https://www.google.com/recaptcha/api.js?ver=1.0" id="ha-recaptcha-js"></script> <script type="text/javascript" src="https://cdn.jsdelivr.net/npm/swiper@8/swiper-bundle.min.js" id="Swiper-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/swiper.js?ver=5.127" id="gdm-b2b-swiper-script-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/sep-22-ui.js?ver=2.0.3" id="sep-22-redesign-ui-script-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/catfish.js?ver=1.5" id="catfish-script-js"></script> <script type="text/javascript" src="https://cdn.plyr.io/3.6.3/plyr.polyfilled.js?ver=3.6.3" id="plyr-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-includes/js/underscore.min.js?ver=1.13.7" id="underscore-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp/assets/js/vendor.min.js?ver=4.6.0" id="thb-vendor-js"></script> <script type="text/javascript" id="thb-app-js-extra"> /* <![CDATA[ */ var themeajax = {"url":"https:\/\/www.clinicaltrialsarena.com\/wp-admin\/admin-ajax.php","l10n":{"loading":"Loading ...","nomore":"No More Posts"},"settings":{"viai_publisher_id":"431861828953521","thb_custom_video_player":"on"}}; /* ]]> */ </script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp/assets/js/app.min.js?ver=4.6.0" id="thb-app-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/plugins/storefronts-gd/assets/js/app.js?ver=5.8.6" id="main-js-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/collapseToggler.js?ver=1.1.0" id="Collapse-toggler-js-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/collapsible.js?ver=1.7.8" id="Collapse-js-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/modal.js?ver=1.7.9" id="Modal-js-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/plugins/storefronts-gd/assets/vendor/swiper/swiper.js?ver=6.8.3" id="Swiper-js-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/plugins/storefronts-gd/assets/js/swiper.js?ver=5.127" id="gdm-slider-js-js"></script> <script data-cfasync="false" type="text/javascript" data-parsely-site="clinicaltrialsarena.com" src="https://cdn.parsely.com/keys/clinicaltrialsarena.com/p.js?ver=2.6.1" id="parsely-cfg"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/jquery.min.js?ver=6.7.1" id="jquery_latest-js"></script> <script type="text/javascript" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/detect-private-browsing.js?ver=6.7.1" id="detect_browsing-js"></script> <aside id="thb-login" class="mfp-hide thb-login-form light"> <ul> <li class="lost"><a href="#" class="always">Lost Password</a> <span class="back">Back ⟶</span></li> <li><a href="#" class="active">Login</a></li> <li><a href="#">Register</a></li> </ul> <div class="thb-overflow-container"> <div class="thb-form-container"> <div class="thb-lost"> <form id="thb_lost_form" action="https://www.clinicaltrialsarena.com/" method="post"> <div class="thb-errors lost-errors"></div> <div class="form-field"> <input class="form-control required " name="thb_user_or_email" id="thb_user_or_email" type="text" placeholder="Username or E-mail" /> </div> <div class="form-field"> <input type="hidden" name="action" value="thb_reset_password"/> <button class="btn " type="submit">Get new password</button> </div> <input type="hidden" id="password-security" name="password-security" value="34871db096" /><input type="hidden" name="_wp_http_referer" value="/projects-a-z/" /> </form> </div> <div class="thb-login"> <form id="thb_login_form" action="https://www.clinicaltrialsarena.com/" method="post"> <div class="thb-errors login-errors"></div> <div class="form-field"> <input class="form-control required " name="thb_user_login" type="text" placeholder="Username" autocomplete="off" /> </div> <div class="form-field"> <input class="form-control required " name="thb_user_pass" id="thb_user_pass" type="password" placeholder="Password"> </div> <div class="form-field"> <a href="#" class="lost_password">Lost Password?</a> </div> <div class="form-field last"> <input type="hidden" name="action" value="thb_login_member"/> <button class="btn " type="submit">Login</button> </div> <input type="hidden" id="login-security" name="login-security" value="34871db096" /><input type="hidden" name="_wp_http_referer" value="/projects-a-z/" /> </form> </div> <div class="thb-register"> <div class="alert alert-warning">Registration is disabled.</div> </div> </div> </div> </aside> <div class="hide"> <svg class="comment_icon" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" width="13px" height="13px" viewBox="0 0 13 13" enable-background="new 0 0 13 13" xml:space="preserve"> <path id="comment_icon" d="M12.7,0H0.3C0.134,0,0,0.128,0,0.286v9.143c0,0.157,0.134,0.286,0.3,0.286h2.1v3c0,0.105,0.061,0.201,0.159,0.252 C2.603,12.988,2.651,13,2.7,13c0.058,0,0.116-0.016,0.167-0.048l3.524-3.237H12.7c0.165,0,0.3-0.129,0.3-0.286V0.286 C13,0.128,12.865,0,12.7,0z"/> </svg> </div> <script type="text/javascript"> var elem = document.getElementById("framecovid"); function openFullscreen() { if (elem.requestFullscreen) { elem.requestFullscreen(); } else if (elem.mozRequestFullScreen) { /* Firefox */ elem.mozRequestFullScreen(); } else if (elem.webkitRequestFullscreen) { /* Chrome, Safari & Opera */ elem.webkitRequestFullscreen(); } else if (elem.msRequestFullscreen) { /* IE/Edge */ elem.msRequestFullscreen(); } } </script> <style> .covidspreaddata{ font-size: 16px; padding: 6px 14px; color: #18a1cd; font-weight: normal; font-family: Roboto,sans-serif; } .covidspreaddata:hover{ cursor: pointer; } </style> <script> function addParam() { for (var e = ["www.clinicaltrialsarena.com", "pantheonsite.io"], n = ["scalar", "pid", "sid", "utm_source", "utm_medium", "utm_content", "utm_campaign"], t = document.querySelectorAll("a"), o = 0; o < t.length; o++) for (var a = 0; a < e.length; a++) t[o].href.indexOf(e[a]) > -1 && -1 === t[o].href.indexOf("#") && window.location.href.indexOf("?") > -1 && (t[o].href = i(t[o].href)); function i(e) { e = -1 === e.indexOf("?") ? e + "?" : e + "&"; for (var t = [], o = 0; o < n.length; o++) r(n[o]) && t.push(n[o] + "=" + r(n[o])); if( e.indexOf("utm_") == -1) { var a = e + t.join("&"); } return (a = a.replace(/&$/, "")).replace(/\?$/, "") } function r(e) { if (e = new RegExp("[?&]" + encodeURIComponent(e) + "=([^&]*)").exec(window.location.search)) return decodeURIComponent(e[1]) } } jQuery( document ).ready(function() { addParam(); }); jQuery('.c-company-header__links-toggle-button, .c-company-header__form-toggle-button, .menu-item-type-custom .c-nav-featured__menu-item-link, .btn-custom, .page-template-template-aboutus-magazine .c-tabs-nav__tab').click(function(event) { // This will prevent the default action of the anchor event.preventDefault(); // Failing the above, you could use this, however the above is recommended return false; }); jQuery('.single-storefronts .c-tabs-nav__tab, .page-template-template-aboutus-online .c-tabs-nav__tab, .page-template-template-aboutus-magazine .c-tabs-nav__tab').on('click', function(){ jQuery('html,body').stop().animate({ scrollTop: jQuery( jQuery(this).attr('href') ).offset().top - jQuery('.x-navbar').height() },700 ,'swing'); }); </script> <script type="text/javascript"> jQuery( document ).ready(function() { window._uxa = window._uxa || []; var cname1='pageType:'; var cvalue1="projects- archive page"; window._uxa.push(['setCustomVariable', 1, cname1, cvalue1]); var cname2 = 'pageCategory:'; var cvalue2 =""; window._uxa.push(['setCustomVariable', 2, cname2, cvalue2]); var cname3 = 'region:'; var cvalue3 ="North America"; window._uxa.push(['setCustomVariable', 3, cname3, cvalue3]); var cname4 = 'sector:'; var cname5='reporting:' var cvalue5 =""; window._uxa.push(['setCustomVariable', 5, cname5, cvalue5]); }); // we don't need this anymore // jQuery(document).ready(function(){ // jQuery('#Sgpollsputhere').css('height', jQuery(window).height()-30); // jQuery(window).resize(function(){ // jQuery('#Sgpollsputhere').css('height', jQuery(window).height()-30); // }); // }); </script>  <script type="text/javascript" id="hs-script-loader" async defer src="//js-eu1.hs-scripts.com/26632421.js?businessUnitId=15641589"></script>    <script type="module" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/modules.js?ver=1.006"></script> <script type="module" src="https://www.clinicaltrialsarena.com/wp-content/themes/goodlife-wp-B2B/assets/js/index.js?ver=1.2"></script> <script type='text/javascript' src='https://www.google.com/recaptcha/api.js?ver=1.0' id='ha-recaptcha-js'></script> <script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","licenseKey":"NRJS-7b82eb47d05ddffd6c6","applicationID":"1250398555","transactionName":"MVAAZkoFWEBSURIKWwgaI1FMDVldHEIHBFFLQQdfSAhXR1ZBSxNGCV8HUUxJV0k=","queueTime":0,"applicationTime":8410,"atts":"HRcDEAIfS04=","errorBeacon":"bam.nr-data.net","agent":""}</script></body> </html>

CINXE.COM

Projects A-Z - Clinical Trials Arena